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INTRODUCTION 
 
Vascular surgery patients are at increased risk for developing adverse cardiac events, such as 
myocardial ischemia or infarction, associated with postoperative morbidity and mortality.1 
Perioperative cardiac complications, therefore, remain an area of clinical interest and concern in 
patients undergoing vascular surgery. Importantly, it has been demonstrated that the great 
majority of cardiac events in vascular surgery patients are asymptomatic.2 The high frequency of 
perioperative cardiac complications reflects the high prevalence of underlying coronary artery 
disease.3 Surgical procedures can be classified to be associated with low-risk (<1%), 
intermediate-risk (1-5%), or high-risk (>5%) for the development of perioperative cardiac 
complications. Open lower extremity revascularization and open aortic procedures are 
considered high-risk surgery. Carotid surgery and endovascular aortic aneurysm repair are 
considered to have intermediate cardiac risk.4-5 
 
Over the years, perioperative risk assessment has evolved significantly in order to 
detect surgical patients with myocardium at risk due to coronary artery disease. Several risk 
indices have been developed to identify patients at risk, of which the Revised Cardiac Risk 
index is currently widely used. Cardiac risk factors imbedded in the Revised Cardiac Risk index 
are (i) ischemic heart disease, (ii) symptomatic heart failure, (iii) cerebrovascular disease, (iv) 
insulin dependent diabetes mellitus, (v) renal dysfunction, and (vi) high-risk surgery.6 However, 
preoperative risk stratification for adverse cardiac outcome using traditional cardiac risk indices 
is considered suboptimal, indicating the necessity to improve cardiac evaluation before 
surgery.7-8  
 
 
OUTLINE OF THE THESIS  
 
Part I: Left ventricular function  
These days, the physician needs to inform the patient about his or her perioperative risk. When 
preoperative risk stratification with, for instance, the use of the Revised Cardiac Risk index 
identifies the patient to have an increased cardiac risk, additional cardiac testing to diagnose or 
exclude coronary artery disease is warranted. In Chapter 2, tests most frequently used in 
preoperative cardiac risk stratification are discussed and recommendations provided in most 
recent perioperative guidelines are summarized.9-10   
 
Echocardiography is a well-established imaging technique in the detection and 
quantification of coronary artery disease. With the use of cardiac echo, regional and global wall 
motion abnormalities representing ischemic and infarcted regions of the myocardium supplied 
by a stenotic coronary artery, can be detected. Chapter 3 describes the role of 
echocardiography in the detection of coronary artery disease. 
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Coronary artery disease is the aetiology of heart failure in 60 to 70% of patients, 
predominantly in the elderly population.11-12 Whereas the term heart failure describes a clinical 
syndrome characterized by shortness of breath and exercise intolerance, left ventricular (LV) 
dysfunction describes the impaired mechanical properties of the left ventricle. Asymptomatic 
LV dysfunction is considered a precursor of symptomatic heart failure, associated with high 
mortality.13 Hypertrophy of the myocardium is associated with abnormal relaxation of the left 
ventricle causing diastolic LV dysfunction. In addition, dilatation of the left ventricle is 
associated with systolic LV dysfunction with an impaired LV ejection fraction.14 The prevalence 
of asymptomatic systolic LV dysfunction and symptomatic heart failure in vascular surgery 
patients and pharmacological treatment according to the ‘European Society of Cardiology’ 
guidelines for the diagnosis and treatment of acute and chronic heart failure 13 is evaluated in 
Chapter 4. In addition, the prognostic implications of asymptomatic LV dysfunction towards 
30-day cardiovascular events and long-term mortality and its relation with chronic obstructive 
pulmonary disease and high-sensitive C-reactive protein are described in Chapters 5, 6, and 7.  
 
 Although the pathophysiology of perioperative myocardial ischemia or infarction is 
not entirely clear, it is well accepted that coronary plaque rupture is an important cause, similar 
to the nonsurgical setting. The location of the cardiac event is difficult to foresee, because of 
unpredictable plaque rupture of non-significant, vulnerable coronary artery lesions. In Chapter 
8, the relation and reproducibility of (i) ischemic LV territories assessed with dobutamine 
echocardiography before surgery with (ii) new wall motion abnormalities observed with 
transesophageal echocardiography performed during surgery was examined.    
 
The echo community has put a lot of efforts in guidelines and standardization of LV 
function assessment. However, echocardiographic assessment of systolic LV function is often 
performed subjectively, which is increasingly considered suboptimal. In Chapter 9, automated 
assessment of LV volumes and function using three dimensional speckle tracking ultrasound is 
discussed.  
 
Part II: Asymptomatic atherosclerosis in patients with symptomatic peripheral arterial 
disease  
The heart is an organ with a high metabolic demand and requires a continuous high level of 
myocardial oxygen-supply. During surgery, high catecholamine production is responsible for 
vasoconstriction and hemodynamic stress,15 associated with an increased oxygen-demand of the 
myocardium. Perioperative myocardial damage may occur when the increased oxygen-demand 
is not met by an adequate increase of oxygen-supply.16 Chapter 10 provides an overview of 
literature addressing perioperative myocardial damage in vascular surgery patients.  
 
As the population age increases, the prevalence of atherosclerotic disease and its 
associated adverse outcomes will increase. The process of established atherosclerosis is not 
limited to a single arterial location. In Chapter 11, (i) the prevalence and number of affected 
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vascular beds and (ii) the prognostic implications of polyvascular disease on short- and long-
term outcome is evaluated in vascular surgery patients with symptomatic peripheral arterial 
disease.  
 
Cardiac risk factors, as summarized in the Revised Cardiac Risk index, have been 
identified as independent predictors of perioperative cardiovascular events. However, a more 
direct marker of the underlying atherosclerotic disease may be of predictive value as well, in 
addition to conventional cardiac risk indices. A correlation between (i) an increased 
intimamedia thickness of the common carotid artery and (ii) cardiac risk factors and coronary 
atherosclerosis has been demonstrated,17 however, limited information is available in vascular 
surgery patients. In addition, the ankle-brachial index is a simple noninvasive test to screen 
patients with suspected peripheral arterial disease. A resting low ankle-brachial index (<0.90) 
has been demonstrated to improve risk prediction for cardiovascular mortality and major 
nonfatal myocardial infarction (nonsurgical setting), even beyond the risk prediction properties 
using cardiac risk scores.18 However, the predictive value of asymptomatic low ankle-brachial 
index in patients undergoing carotid- or abdominal aortic surgery is less well understood. In 
Chapters 12, 13, and 14, the separate and combined prognostic values of an increased 
intimamedia thickness of the common carotid artery (>1.25 mm) and low ankle-brachial index 
(<0.90) towards postoperative outcome of vascular surgery patients is evaluated.  
 
The metabolic syndrome is the concurrence of multiple metabolic abnormalities such 
as (i) abdominal obesity and abnormal (ii) triglycerides, (iii) high density lipoprotein cholesterol, 
(iv) blood pressure, and (v) fasting glucose. Metabolic syndrome was primarily developed as a 
predictor of cardiovascular disease in the healthy population. The prevalence of the metabolic 
syndrome in patients with occlusive or aneurysmatic peripheral arterial disease and its long-term 
predictive value is discussed in Chapter 15.  
 
N-terminal pro-B-type natriuretic peptide is synthesized in the ventricular 
myocardium in response to ventricular wall stress, such as in heart failure and coronary artery 
disease.19 Although, it has been suggested that measurement of N-terminal pro-B-type 
natriuretic peptide levels might improve preoperative cardiac risk stratification for surgical 
patients, several conditions might influence this prognostic value, including anemia. Chapter 
16 evaluates whether anemia confounds the prognostic value of N-terminal pro-B-type 
natriuretic peptide for predicting 30-day cardiac events in patients undergoing vascular surgery. 
 
 Abdominal aortic aneurysms are often asymptomatic and diagnosed at time of 
(impending) rupture, which leads to a dramatic increase of morbidity and mortality. In 
Chapter 17, the diagnostic accuracy of a new portable ultrasound scanner, developed for 
automatic abdominal aortic aneurysm detection, is evaluated.  
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Part III: Prevention and treatment 
In order to reduce the incidence of cardiac complications during vascular surgery, two strategies 
can be considered: (i) pharmacological treatment with i.e. β-blockers and (ii) prophylactic 
coronary revascularization. An extended and detailed overview of leading observational studies, 
randomized, controlled trials and guidelines addressing the value of these risk-reducing 
strategies before vascular surgery is provided in Chapter 18.  
 
Early surgery after coronary stent placement is associated with in-stent thrombosis or 
bleeding complications. This might explain the lack of perioperative benefit derived from 
preoperative coronary revascularization in order to improve immediate postoperative 
outcome.20 Long-term outcome of the randomized, controlled Dutch Echocardiographic 
Cardiac Risk Evaluation Applying Stress Echocardiography-V trial is analysed in Chapter 19, to 
assess if there is a long-term effect of prophylactic revascularization in high-risk vascular 
surgery patients.  
 
 The prevention of cardiac complications vs. the risk of severe bleeding complications 
creates a double-edged sword on the timing of surgery and the antiplatelet regimen. Current 
guidelines from the ‘American College of Cardiology/American Heart Association' recommend 
postponing noncardiac surgery for ≥6 weeks after bare metal stent placement and 1 year after 
drug-eluting stent placement, however, much debate has ensued about these intervals.9 In 
Chapter 20, the relation between (i) the interval to noncardiac surgery after percutaneous 
coronary intervention and (ii) the occurrence of perioperative major adverse cardiovascular 
events, is addressed.  
 
 In the nonsurgical setting, β-blockers are widely used for the prevention and 
treatment of coronary heart disease and heart failure, both important determinants of 
perioperative cardiovascular complications. Factors that may relate to the effectiveness of β-
blocker therapy are the patients underlying cardiac risk factors and variations in treatment 
protocols, such as (i) β-blocker type, (ii) β-blocker dose, and (iii) timing of β-blocker initiation 
before surgery. However, the duration of β-blocker treatment before surgery and its effect on 
cardiovascular outcome has not been evaluated yet in a cohort of vascular surgery patients. 
Timing of β-blocker initiation and its influence on preoperative heart rate, preoperative high-
sensitive C-reactive protein levels, and postoperative outcome in vascular surgery patients is 
outlined in Chapter 21. 
 
 In Chapter 22, a brief overview is provided regarding two important randomized, 
controlled trials evaluating the protective value of β-blockers: (i) the Dutch Echocardiographic 
Cardiac Risk Evaluation Applying Stress Echocardiography-1 trial,21 and (ii) the multi-centre 
Perioperative Ischemic Evaluation-trial.22  
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ABSTRACT 
 
During noncardiac surgery, patients may be at risk for developing cardiac events, related to 
underlying coronary artery disease. Therefore, perioperative cardiac complications remain an 
area of clinical interest and concern in patients undergoing noncardiac surgery. Over the years, 
perioperative risk assessment has evolved significantly to detect surgical patients with 
myocardium at risk due to the coronary artery disease. In addition, many efforts have been 
made to reduce the cardiac risk of patients undergoing noncardiac surgery. The present review 
article will focus on the definition of high cardiac risk surgery and patients related cardiac risk 
factors will be discussed. In addition, the preoperative cardiac tests available to detect patients 
with coronary artery disease and strategies to reduce perioperative cardiac risk, as 
recommended in most recent perioperative guidelines, will be outlined.  
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INTRODUCTION 
 
Perioperative cardiac complications remain an area of clinical interest and concern in patients 
undergoing noncardiac surgery. Worldwide, major noncardiac surgery is performed in 230 
million patients annually. It is suspected that approximately 1% (2,300,000 patients) suffer 
perioperative myocardial infarction with a cardiovascular mortality rate around 0.3% (690,000 
patients).1 The high frequency of perioperative cardiac complications reflects the high 
prevalence of underlying coronary artery disease.2 The highest incidence of perioperative 
myocardial infarction is within the first three days after surgery.3 Over the years, perioperative 
risk assessment has evolved significantly to detect surgical patients with myocardium at risk 
due to coronary artery disease. In addition, many efforts have been made to reduce the cardiac 
risk of patients undergoing noncardiac surgery. This review article will focus on (i) the 
definition of high cardiac risk surgery, (ii) patients-related cardiac risk factors, (iii) preoperative 
cardiac tests available to detect patients with coronary artery disease, and (iv) strategies to 
reduce perioperative cardiac risk. 
 
 
DEFINING HIGH CARDIAC RISK SURGERY 
 
Patient-related factors are more important than surgery-related factors in the prediction of 
cardiac risk during noncardiac surgery. However, to cardiac risk stratify patients undergoing 
elective noncardiac surgery, knowledge of the clinician regarding the cardiac risk related to 
surgery is inevitable. Cardiac risk imbedded in surgical interventions can differ depending on 
the magnitude, duration, location, blood loss, and fluid shifts related to the specific procedure.4 
In 2005, Boersma et al.5 developed a model to risk stratify surgical procedures based on the 
occurrence of 30-day cardiac death and myocardial infarction. Surgical procedures were 
classified low-risk (<1%), intermediate-risk (1 to 5%), or high-risk (>5%) for the development 
of 30-day adverse cardiac outcome. An overview of surgical procedures and the cardiac risk 
estimated is provided in Table 1. High-risk surgery is considered to be lower extremity 
revascularization and open aortic aneurysm or stenosis repair. Endovascular aortic aneurysm 
repair is considered to have intermediate cardiac risk because it is associated with reduced 
myocardial stress and the need for lower fluid administration compared with open abdominal 
aortic aneurysm repair.6, 7 Interestingly, patients undergoing laparoscopic surgery should be 
evaluated similar to patients undergoing open surgery, because the cardiac stress evoked during 
these surgical procedures is similar.4 Laparoscopic surgery is associated with increased intra-
abdominal pressure and reduced venous return due to the pneumoperitoneum used during 
these procedures, leading to lower cardiac output and increased systemic vascular resistance.4  
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Table 1 Cardiac risk associated with noncardiac surgery 
Low-risk surgery 
 
(<1%) 
Intermediate-risk surgery 
 
(1-5%) 
High-risk surgery 
 
(>5%) 
breast abdominal open aortic 
dental carotid, PTA and EVAR peripheral vascular 
endocrien hip and spine  
eye head and Neck  
gynaecology neurological  
knee transplantation  
urologic (minor) urologic (major)  
Percutaneous transluminal angioplasty (PTA), endovascular aneurysm repair (EVAR). 
 
 
PATIENTS RELATED CARDIAC RISK FACTORS 
 
Adequate risk stratification of patients undergoing noncardiac surgery is of utmost importance 
to identify patients at risk for perioperative cardiac events. Over the years, several cardiac risk 
indices have been developed to identify those patients at risk. In 1977, Goldman et al.8 
developed the first multifactorial risk index specifically for cardiac complications in a large 
surgical population. The risk index included nine independent risk factors for cardiac 
complications and was subsequently modified by Detsky et al.9 in 1986. In 1999, Lee et al.10 
modified the original Goldman index into the Revised Cardiac Risk (RCR) index, nowadays 
widely used and considered to be the best available cardiac risk index for patients undergoing 
noncardiac surgery. Cardiac risk factors imbedded in the RCR index include (i) ischemic heart 
disease, (ii) congestive heart failure, (iii) cerebrovascular disease, (iv) insulin dependent diabetes 
mellitus, (v) renal dysfunction, and (vi) high-risk surgery. Based on the presence of none, 1, 2, 
or ≥3 risk factors, the occurrence of major cardiac complications was estimated in a validation 
cohort of 1,422 patients. Patients with one to two risk factors were considered to be at 
intermediate risk (0.9 to 7%) for the development of major cardiac complications and patients 
with ≥3 risk factors were considered to be at high risk (11%), as demonstrated in Figure 1. The 
inclusion of high-risk surgery in the RCR index underlines the importance of knowledge of the 
clinician regarding the cardiac risk related to specific surgical procedures.  
 
The predictive value of the RCR index towards cardiovascular mortality has been 
validated in a cohort study performed by Boersma et al.5 including more than 100,000 patients. 
In this study, published in 2005, it is demonstrated that the prediction of cardiovascular 
mortality in noncardiac surgery could be improved by adding the risk factor of age greater than 
70 years and a more detailed classification of type of surgical procedure (low-, intermediate-
low, intermediate-high and high-risk surgery). C-statistic improved from 0.63 in the RCR index 
to 0.85 in the Erasmus Cardiac Risk index.5 
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Figure 1: Revised Cardiac Risk index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREOPERATIVE CARDIAC TESTING 
 
These days, the doctor needs to adequately inform the patient about his or her perioperative 
risk. When preoperative risk stratification with the use of the RCR index identifies the patients 
to have an increased cardiac risk, additional cardiac testing is warranted. However, testing is, 
only recommended if the test results will influence perioperative management.11 Consequences 
of testing may include (i) changing the surgical procedure, (ii) initiation of pharmacological 
treatment to reduce the risk of perioperative complications, (iii) postponing surgery to 
optimally treat the patient first or, (iv) cancelling surgery. Tools for preoperative cardiac 
evaluation of patients undergoing noncardiac surgery are (i) rest 12-lead electrocardiography, 
(ii) resting echocardiography, (iii) noninvasive stress testing, (iv) coronary angiography and, (v) 
biomarkers.  
 
Commonly used cardiac stress tests are (i) exercise electrocardiography, (ii) exercise or 
pharmacological-induced stress echocardiography, and (iii) nuclear imaging. Regardless of the 
technique used, resting images are recorded first and serve as a baseline for comparison with 
stress images obtained during peak stress or immediately after exercise.12 The additional value 
of both rest and stress testing in cardiac risk stratification of patients undergoing noncardiac 
surgery will be outlined in the following paragraphs, including recommendations provided in 
most recent ‘American College of Cardiology / American Heart Association’ (ACC/AHA) and 
‘European Society of Cardiology’ (ESC) perioperative guidelines.   
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Electrocardiography 
Twelve-lead electrocardiography is widely used for cardiac evaluation, both in the surgical and 
nonsurgical setting. Left ventricular hypertrophy, nonspecific ST-T wave changes, and 
pathological Q-waves are associated with a reduced long-term prognosis in the general 
population.13 Multiple studies have evaluated and confirmed the associations between the 
presence of rest 12-lead electrocardiogram abnormalities before surgery and adverse 
postoperative cardiac outcome.14-16  
 
Recommendations for preoperative rest 12-lead electrocardiography (ACC/AHA and 
ESC recommendations) are provided in Table 2.4, 11 In addition to Table 2, ACC/AHA 
guidelines recommend preoperative rest 12-lead electrocardiography in patients with ≥1 RCR 
factors undergoing high-risk surgery, as well as in patients with (i) known coronary heart 
disease, (ii) peripheral arterial disease, or (iii) cerebrovascular disease undergoing intermediate-
risk surgery. In addition, preoperative rest 12-lead electrocardiography is not indicated in 
asymptomatic patients undergoing low-risk surgery.11 In ESC guidelines, standard preoperative 
evaluation with rest 12-lead electrocardiography is recommended in all patients undergoing 
intermediate- or high-risk surgery, except for patients with 0 RCR factors undergoing 
intermediate-risk surgery, in which rest 12-lead electrocardiography may be considered (Table 
2).4  
 
 
Table 2 
Recommendations on rest electrocardiography before 
noncardiac surgery 
Surgery Revised Cardiac 
Risk factors 
 
Low-risk Intermediate-risk High-risk 
 ACC/AHA GUIDELINES 
0* not recommended 
(III B) 
 is reasonable 
(IIa B) 
1-2**  may be reasonable 
(IIb B) 
recommended 
(1 B) 
≥3***  may be reasonable 
(IIb B) 
recommended 
(1 B) 
 ESC GUIDELINES 
0* not recommended 
(III B) 
may be considered 
(IIb B) 
recommended 
(1 B) 
1-2** should be considered 
(IIa B) 
recommended 
(1 B) 
recommended 
(1 B) 
≥3*** should be considered 
(IIa B) 
recommended 
(1 B) 
recommended 
(1 B) 
* low cardiac risk, ** intermediate cardiac risk, *** high cardiac risk. American College of Cardiology /American Heart 
Accociation (ACC/AHH), European Society of Cardiology (ESC). 
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Several exercise stress tests are available for perioperative risk assessment to detect 
myocardial ischemia and identify coronary artery disease. The most commonly used stress test 
is treadmill or cycle electrocardiography, which is considered to induce the most physiological 
form of stress. This test provides an estimate of the functional capacity and hemodynamic 
response of the patient and detects myocardial ischemia by ST-segment changes. The criterion 
of exercise-induced ischemia detected with stress electrocardiography is generally accepted as 
an ST segment depression ≥1 mm.17 Studies have shown a positive association between 
electrocardiographic responses and cardiovascular mortality in patients with ≥3 RCR factors 
without symptoms of coronary artery disease.18, 19 Compared with other stress tests, such as 
stress echocardiography or nuclear imaging, exercise electrocardiography has shown reasonable 
sensitivity and specificity to predict perioperative cardiac complications.20 Exercise 
electrocardiography is widely available at relatively low costs and should therefore be 
considered as a preoperative diagnostic tool in patients with ≥3 RCR factors undergoing 
noncardiac surgery. The recommendations (ACC/AHA and ECS) towards preoperative stress 
testing (i.e. exercise electrocardiography, stress echocardiography or nuclear imaging) are 
provided in Table 3.4, 11 In both AHA/ACC and ESC guidelines, preoperative noninvasive 
stress testing is recommended in patients with an active cardiac condition before proceeding 
with noncardiac surgery. In addition, preoperative stress testing should only be performed if the 
results derived from the test are likely to influence perioperative cardiac management.  
 
Echocardiography 
Echocardiography is a well-established imaging technique in the detection and quantification 
of coronary artery disease. Regional and global wall motion abnormalities represent ischemic 
and infarcted myocardial regions supplied by a stenotic coronary artery. ACC/AHA guidelines 
state that it is reasonable to perform preoperative noninvasive evaluation of left ventricular 
function (i.e. with rest echocardiography) in patients with (i) dyspnea of unknown origin or (ii) 
current or prior heart failure experiencing worsening of dyspnea (class IIa recommendation, 
level of evidence C [IIa C]). Reassessment of left ventricular function is not well established in 
clinically stable patients with previously documented cardiomyopathy [IIIb C].11 In ESC 
guidelines it is stated that rest echocardiography should be considered in all patients 
undergoing high-risk surgery [IIIa C].4 However, routine rest echocardiography for the 
assessment of left ventricular function in asymptomatic patients is not recommended in 
ACC/AHA or ESC perioperative guidelines.4 11 
 
Recently, Flu et al. evaluated more than 1,000 vascular surgery patients with standard 
preoperative rest echocardiography, irrespectively of the presence of heart failure symptoms. 
Diastolic and/or systolic left ventricular dysfunction was present in half of the patients, of 
which 80% was asymptomatic.21 In open vascular surgery patients, both asymptomatic systolic 
and isolated diastolic left ventricular dysfunction were associated with 30-day cardiovascular 
events and long-term cardiovascular mortality. In addition, almost one third of the patients 
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Table 3 
Recommendations on stress testing before  
noncardiac surgery 
Surgery Revised Cardiac 
Risk factors 
 
Low-risk Intermediate-risk High-risk 
 ACC/AHA GUIDELINES 
0* not useful 
(III C) 
not useful 
(III C) 
 
1-2** not useful 
(III C) 
may be considered 
(IIb B)**** 
may be considered 
(IIb B)****** 
≥3*** not useful 
(III C) 
may be considered 
(IIb B)**** 
is reasonable  
IIa B**** 
 ESC GUIDELINES 
0* not recommended 
(III C) 
may be considered 
(IIb C) 
may be considered 
(IIb B) 
1-2** not recommended 
(III C) 
may be considered 
(IIb C) 
may be considered 
(IIb B) 
≥3*** not recommended 
(III C) 
may be considered 
(IIb C) 
recommended 
(1C) 
* low cardiac risk, ** intermediate cardiac risk, *** high cardiac risk, **** poor functional capacity of <4 metabolic 
equivalents,***** good functional capacity of ≥4 metabolic equivalents. American College of Cardiology /American Heart 
Accociation (ACC/AHH), European Society of Cardiology (ESC). 
 
with asymptomatic left ventricular dysfunction did not receive pharmacological treatment as 
recommended. The authors concluded that routine preoperative evaluation of left ventricular 
function with rest echocardiography could reveal patients with asymptomatic left ventricular 
dysfunction eligible for pharmacological treatment.21 Another recent study performed by 
Matyal et al. studied 313 vascular surgery patients with intraoperative transesophageal 
echocardiography and found isolated diastolic left ventricular dysfunction to be a predictor of 
adverse cardiovascular outcome.22  
 
Due to physiological stress during surgery, the myocardial oxygen-demand is 
increased and therefore demand-ischemia may occur in patients with a coronary artery stenosis. 
Echocardiography during stress, evoked with treadmill/bicycle exercise or pharmacologically 
induced stress, can (i) detect reversible ischemia, (ii) distinguish reversible ischemia from 
scarred myocardium, and (iii) identify the myocardial region at risk. When physiological stress 
induces myocardial ischemia, echocardiography permits wall motion analysis. The images are 
analyzed using a model with 17-segments assigned to one of the three major coronary arteries. 
Wall motion and wall thickness are scored in each myocardial segment on a four-point scale. 
Test results are considered positive when wall motion or wall thickness deteriorates by one 
grade or more in any segment 23.  
 
In treadmill echocardiography, images must be taken immediately after the exercise is 
performed. However, wall contraction abnormalities can recover very rapidly and persist only 
for several minutes. Therefore, treadmill echocardiography can miss resolved wall contraction 
abnormalities. This may lead to false-negative results affecting the sensitivity of treadmill 
echocardiography to detect ischemia. The overall sensitivity of exercise echocardiography has 
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been reported to range from 76 to 89%, and sensitivity is greater with more high-grade 
coronary disease.24, 25 Meta-analyses performed by Noguchi et al. and Kwok et al.24, 25 
demonstrated exercise stress echocardiography to have a specificity of 84 and 89%, 
respectively.  
 
Another important limitation of exercise echocardiography is the frequently limited 
exercise capacity of elderly patients undergoing noncardiac surgery, due to the presence of (i) 
claudication, (ii) arthrosis, or (iii) chronic obstructive pulmonary disease. Therefore, 
nonphysiological stress tests, such as dobutamine or dipyridamole echocardiography, are used 
in patients with limited exercise capacity. A recent meta-analysis performed in nonsurgical 
patients by Picano et al, analysed five studies addressing the diagnostic accuracy of dobutamine 
vs. dipyridamole stress echocardiography. They noted dipyridamole and dobutamine to have 
similar accuracy, sensitivity, and specificity for the detection coronary artery disease.26 In 
patients undergoing vascular surgery, many reports demonstrated that pharmacological stress 
echocardiography predicts perioperative events.27-30 The negative predictive value of 
pharmacological stress echocardiography is high, however, the positive predictive value is 
lower. Kertai et al. reported a weighted sensitivity of 85% (95%-CI: 74 to 97%) and a specificity 
of 70% (95%-CI: 62 to 79%) for dobutamine stress echocardiography, in 850 patients included 
in eight studies.20  
 
Nuclear imaging 
Since their introduction in the early 1970s, positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) have been widely used as a diagnostic tool in 
the detection of coronary artery disease. The detection of coronary artery disease is based on a 
difference in myocardial uptake of radiotracers caused by an altered blood-flow distribution 
through the left ventricular myocardium. These perfusion abnormalities can be explained by 
insufficient coronary blood-flow, caused by coronary artery stenosis.31, 32 Husmann et al. 
evaluated the diagnostic accuracy of PET (13N-ammonia-PET) and SPECT (201-TICI-SPECT 
and MIBI-SPECT) imaging using coronary angiography as the standard of reference. Positron 
emission tomography imaging showed a higher sensitivity for locating coronary artery stenosis 
compared with SPECT (95 and 77%, respectively), however no difference in specificity was 
found (84% in both groups). In the detection of ischemia, the specificity of PET was 91% 
compared with 74% for SPECT.33 
 
A meta-analysis by Shaw et al. identified the results of 10 articles describing the use of 
dipyridamole-thallium-201 nuclear imaging in vascular surgery patients during a 10-year period. 
The occurrence of cardiac death and nonfatal myocardial infarction was correlated with 
reversible defects detected with thallium-201 nuclear imaging. Cardiac event rates were low in 
patients without a history of coronary artery disease, compared with: (i) patients with coronary 
artery disease and a normal or fixed defect pattern and (ii) patients with ≥1 thallium-201 
redistribution abnormalities (1.0% [N=176], 4,8% [N=83] and 18,6% [N=97], p = 0,0001, 
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respectively).34 Boucher et al. evaluated 49 patients scheduled for peripheral vascular surgery 
and performed dipyridamole-thallium imaging preoperatively. Half of the patients with 
thallium redistribution had cardiac events, whereas no events occurred in patients with a 
normal scan or with nonreversible defects only.35  
 
Studies indicate that nuclear imaging is highly sensitive in predicting cardiac 
complications, however the positive predictive value remains less satisfactory. A meta-analysis 
conducted by Kertai et al. reported a sensitivity of 83% (95%-CI: 77 to 89%) and a much lower 
specificity of 47% (95%-CI: 41 to 57%) for thalium-201 nuclear imaging to predict 
perioperative cardiac events.20 Although nuclear imaging demonstrated lower diagnostic 
accuracy compared with dobutamine stress echocardiography, they concluded that nuclear 
imaging is a valuable test for cardiac risk assessment, especially in patients with 
contraindications to dobutamine stress echocardiography. Beattie et al. concluded that 
dobutamine stress echocardiography has a superior negative predictive value in preoperative 
cardiac risk assessment compared with nuclear imaging.36 Their meta-analysis identified 75 
studies addressing preoperative noninvasive testing, including 25 nuclear imaging and 50 
dobutamine stress echocardiography studies involving vascular surgery patients over a 20 year 
period. They demonstrated that the likelihood ratio of a postoperative cardiac event was higher 
for dobutamine stress echocardiography (likelihood ratio: 4.09, 95%-CI: 3.21 to 6.56, p = 
0.001) compared with nuclear imaging (likelihood ratio: 1.83, 95%-CI: 1.59 to 2.1. p = 0.001).37  
 
Coronary angiography 
Coronary angiography is a well-established invasive diagnostic procedure for cardiac evaluation 
of nonsurgical patients; however there is lack of information focusing on the efficacy of 
coronary angiography in patients scheduled for noncardiac surgery. Both ACC/AHA and ESC 
guidelines suggest that indications for preoperative coronary angiography are similar to 
angiography indications in the nonsurgical setting. Indications for coronary angiography 
constitute of active cardiac conditions such as (i) unstable angina, (ii) decompensated heart 
failure, (iii) significant arrhythmias, and (iv) severe valvular disease.4, 11 The central question 
following coronary angiography is whether or not a patient should receive coronary 
revascularization before noncardiac surgery. This important topic will be discussed in the 
paragraph addressing the ‘clinical implications’. 
 
Biomarkers 
In patients scheduled for noncardiac surgery, a biomarker associated with adverse cardiac 
events, could be useful to indentify patients who might benefit from (i) additional cardiac 
testing or (ii) therapeutic interventions. Brain natriuretic peptide (BNP) and its inactive 
precursor N-terminal proBNP (NT-proBNP) are synthesized by cardiomyocytes in response 
to elevated ventricular wall stress or ischemia.38, 39 Brain natriuretic peptide and NT-proBNP 
are therefore associated with cardiac pathologies such as (i) left ventricular dysfunction, (ii) 
valvular heart disease, and (iii) acute coronary syndromes. N-terminal proBNP can be 
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measured in plasma using automated immunoassays and is increasingly used as a screening test 
to identify patients with heart failure.40 Recently, two meta-analyses demonstrated that elevated 
preoperative NT-proBNP measurements have the potential to identify surgical patients at 
increased risk for adverse postoperative cardiovascular events.41,42 Routine biomarker sampling 
is not recommended (III C), however ESC guidelines state that NT-proBNP and BNP 
measurements should be considered for obtaining prognostic information in patients with ≥3 
RCR factors.4 
 
It is estimated that of the 230 million patients undergoing major surgery annually, 
approximately 1% (2,300,000 patients) suffer perioperative myocardial infarction with a 
cardiovascular mortality rate around 0.3% (690,000 patients).1 Importantly, the incidence of 
asymptomatic perioperative myocardial damage is suspected to be as high as 20% in patients 
undergoing high-risk surgery.43 In addition, the highest incidence of perioperative myocardial 
infarction is within the first three days after surgery.3 Cardiac troponin T and I biomarkers are 
used to diagnose myocardial infarction and provide prognostic information, complementary to 
other indicators of cardiac risk, such as (i) electrocardiographic alterations and (ii) left 
ventricular function. In order to detect asymptomatic myocardial infarction in vascular surgery 
patients, routine assessment of cardiac troponin release and continuous electrocardiogram 
monitoring is required during the first postoperative days. Perioperative guidelines do not 
provide recommendations for standard troponin T measurements. However, the prevalence of 
asymptomatic myocardial infarction in patients undergoing high-risk surgery could indicate 
that troponin T measurements could be useful in these subjects.  
 
 
CLINICAL IMPLICATIONS 
 
In preoperative evaluation of patients with possible coronary artery disease, it is of utmost 
importance to define high-risk surgery and to address patient-related cardiac risk factors. An 
algorithm, including patients and surgery related cardiac risk, is demonstrated in Figure 2, 
summarizing the appropriate courses of action to prevent perioperative cardiac events in 
patients undergoing noncardiac surgery. Noncardiac surgery can proceed without a delay in 
asymptomatic patients with 0 to 2 RCR factors. In addition, noncardiac surgery should not be 
delayed in asymptomatic patients with ≥3 RCR factors undergoing low- or intermediate-risk 
surgery. However, appropriate pharmacological treatment with statins and β-blockers should be 
initiated as indicated in perioperative guidelines.4, 11, 44   
 
 
 
 
 
 
 30 
Figure 2: Detection nd management of coronary artery disease in patients undergoing noncardiac 
surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a:  ACC/AHA guidelines recommend statin initiation in:  
1) patients with 0 RCR factors undergoing high-risk surgery [IIa B] 
2) patients with 1-2 RCR factors undergoing intermediate- [IIb C] or high-risk surgery [IIa B] 
3) patients with ≥3 RCR factors undergoing intermediate- [IIb C] or high-risk surgery [IIa B] 
ESC guidelines recommend statin initiation in:  
4) patients with 0 RCR factors undergoing low-, intermediate- [IIa B], or high-risk surgery [I B]   
5) patients with 1-2 RCR factors undergoing low-, intermediate- [IIa B], or high-risk surgery [I B] 
6) patients with ≥3 RCR factors undergoing low, intermediate- [IIa B], or high-risk surgery [I B] 
 
b:  ACC/AHA guidelines recommend β-initiation and titration in: 
1) patients with 1-2 RCR factors undergoing intermediate- [IIa B] or high-risk surgery [IIa C] 
2) patients with ≥3 RCR factors undergoing intermediate- [IIa B] or high-risk surgery [IIa C] 
ESC guidelines recommend β-initiation and titration in: 
3) patients with 0 RCR factors undergoing intermediate- [IIb B] or high-risk surgery [I B] 
4) patients with 1-2 RCR factors undergoing low- [IIb B], intermediate- [IIa B], or high-risk surgery [I B] 
5) patients with ≥3 RCR factors undergoing low- [IIb B], intermediate- [IIa B], or high-risk surgery [I B] 
 
American College of Cardiology /American Heart Accociation (ACC/AHH), European Society of Cardiology (ESC, 
Revised Cardiac Risk (RCR). 
 31 
Preoperative stress testing is recommended (i) in patients with ≥3 RCR factors 
undergoing high-risk surgery or (ii) in patients with stable coronary artery disease. In patients 
with a positive stress test demonstrating mild ischemia, noncardiac surgery should be 
postponed at least 30 days to initiate and optimize preoperative pharmacological treatment with 
statins and β-blockers. Patients with (i) a positive stress test demonstrating severe ischemia or 
(ii) unstable angina pectoris should receive coronary angiography before surgery and, if needed, 
revascularization should be performed.  
 
Most recent ESC guidelines state that prophylactic revascularization may be 
considered in patients with ≥3 RCR factors and proven ischemic heart disease [IIb B], however 
not in patients with 1 to 2 [III B] or none [III C] RCR factors. In patients with unstable angina 
pectoris, prophylactic revascularization is recommended before elective noncardiac surgery [I 
A].4 ACC/AHA guidelines provide a Class I Level of evidence A recommendation for 
prophylactic revascularization before elective noncardiac surgery in patients with stable angina 
who have (i) significant left main coronary artery stenosis, (ii) three-vessel disease, (iii) two-
vessel disease in combination with significant proximal left anterior descending stenosis + left 
ventricular ejection fraction <50% or ischemia during noninvasive testing, (iv) unstable angina 
pectoris or non-ST elevation myocardial infarction and (v) acute ST elevation myocardial 
infarction.11 In addition, it is stated that the usefulness of prophylactic revascularization is not 
well established for high-risk (dobutamine stress echocardiogram with wall motion 
abnormalities in ≥5 segments) or low-risk ischemic patients (wall motion abnormalities in up to 
4 segments).11  
 
Both ACC/AHA and ESC guidelines provide the following recommendations for 
noncardiac surgery after revascularization. In patients with previous coronary stenting, a time 
window to surgery of at least 6 weeks for bare metal stents and 1 year for drug-eluting stents is 
recommended. After coronary artery bypass grafting, noncardiac surgery should be postponed 
at least 1 month. In patients who underwent coronary angiography without stent placement, 
noncardiac surgery should be postponed at least 2 weeks.4, 44 Continuing (single or dual)-
antiplatelet therapy in the perioperative period should be considered in patients with coronary 
artery disease, during the time frame that requires antiplatelet therapy. In patients who require 
temporary interruption of antiplatelet therapy, ESC guidelines recommend that treatment 
should be stopped at least 5 days before surgery and be resumed 24 hours after surgery, when 
adequate haemostasis is achieved.4, 11 
 
 
CONCLUSION 
 
Perioperative risk stratification has evolved over the years to detect patients with possible 
coronary artery disease at risk for perioperative and postoperative adverse cardiac events. 
Models incorporating patient-related cardiac risk factors and the classification of low-, 
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intermediate- or high-risk surgery form the basis of preoperative risk stratification and guide the 
clinician when to initiate medical treatment strategies (statins, β-blocker titration) to reduce the 
risk for cardiac events. In patients with ≥3 RCR factors, stress testing or coronary angiography 
is needed to address if surgery should be postponed in order to (i) optimize medical treatment 
or (ii) perform coronary revascularization. Recently it is demonstrated that high-risk surgery is 
accompanied with a high prevalence of asymptomatic left ventricular dysfunction, reflecting the 
need for evaluation of possible coronary artery disease. In preoperative risk stratification, 
incorporating biomarkers (i.e. BNP) or rest echocardiography could be argued and regarded as 
an interesting research topic in the years lying ahead.   
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ABSTRACT 
 
Coronary artery stenosis causes an imbalance between myocardial oxygen-supply and demand, 
leading to myocardial ischemia and infarction. Echocardiography is a well-established imaging 
technique in the detection and quantification of coronary artery disease. Regional and global 
wall motion abnormalities represent ischemic and infarcted myocardial regions supplied by a 
stenotic coronary vessel. With the use of stress echocardiography (exercise, dobutamine or 
dipyridamole), reversible ischemia can be distinguished from irreversible myocardial infarction. 
Contrast enhancement exerts beneficial effects in identifying the endocardial border of the left 
ventricle cavity, allowing a more subtle assessment of myocardial perfusion and contractility. 
LV dysfunction is a major predictor of mortality after myocardial infarction, may be manifest 
as LV enlargement and reduced ejection fraction. Echocardiography plays a pivotal role in the 
detection of CAD complications, including infarct expansion, mitral valve regurgitation, 
ventricular wall rupture, right ventricle infarction and pericardial effusion. Technical 
developments such as tissue Doppler, strain rate imaging and speckle tracking will further 
improve the quantitation of echocardiography. 
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INTRODUCTION 
 
Coronary artery stenosis causes an imbalance between myocardial oxygen-supply and demand, 
leading to myocardial ischemia and infarction. Echocardiography is a well-established imaging 
technique in the detection and quantification of coronary artery disease (CAD). Regional and 
global wall motion abnormalities represent ischemic and infarcted myocardial regions supplied 
by a stenotic coronary vessel. With the use of stress echocardiography (exercise, dobutamine, 
or dipyridamole), reversible ischemia can be distinguished from irreversible myocardial 
infarction (MI). Contrast enhancement exerts beneficial effects in identifying the endocardial 
border of the left ventricle (LV) cavity, allowing a more subtle assessment of myocardial 
perfusion and contractility. Left ventricular dysfunction is a major predictor of mortality after 
MI and may be manifest as LV enlargement and reduced ejection fraction. Echocardiography 
plays a pivotal role in the detection of CAD complications, including infarct expansion, mitral 
valve regurgitation, ventricular wall rupture, right ventricle infarction, and pericardial effusion. 
Technical developments such as tissue Doppler, strain rate imaging, and speckle tracking will 
further improve the quantitation of echocardiography. 
 
Edler and Hertz introduced echocardiography in 1954 with the publication of their 
milestone paper ‘The use of ultrasonic reflectoscope for continuous recordings of the 
movements of heart valves’.1 Echocardiography has developed to be an established 
noninvasive imaging technique widely available for cardiovascular investigation. With the 
introduction of M-mode and two-dimensional (2D) ultrasound, pivotal information about the 
anatomy of the heart could be obtained, including cardiac valves, ventricular wall, tumours and 
masses. The introduction of Doppler ultrasound made it possible to perform flow-related 
measurements providing information about cardiac function such as diastolic and systolic 
ventricular function. Without directly visualizing (most of) the coronary arteries, 
echocardiography has proven to be an excellent diagnostic tool in the detection and 
quantification of CAD.  
 
 
CORONARY ARTERY DISEASE: PATHOPHYSIOLOGY 
 
The heart, an active metabolic organ, requires a high level of oxygen-supply. Due to the high 
metabolic demand of the heart, the myocardium is susceptible to ischemia and infarction. The 
progression of coronary atherosclerosis causes a gradual reduction in vascular cross-sectional 
area, which leads to coronary artery stenosis/occlusion and causes a critical flow reduction to 
the myocardium. An imbalance between myocardial oxygen-supply and demand will lead to 
ischemia, followed by (i) metabolic changes, (ii) regional wall contraction alterations, and, at a 
later stage (iii) ECG changes, (iv) global LV dysfunction and (v) chest pain, described in the 
“classic ischemic cascade”. Thus when the ischemic cascade is triggered, it causes myocardial 
dysfunction with ischemia present as (i) wall motion abnormalities alone (‘super-silent’ 
 38 
ischemia), (ii) wall motion abnormalities with ST segment alterations (‘silent’ ischemia), and (iii) 
wall motion abnormalities and symptoms of angina pectoris with or without ECG changes 
(symptomatic ischemia).2 Not all patients follow the reassuring paradigm proposed in the 
‘classic ischemic cascade’. ECG changes in combination with chest pain may occur in patients 
without wall contraction alterations detectable with echocardiography, a process called the 
‘alternative ischemic cascade’.3 Explanations for this apparent paradox could be a reduction in 
coronary flow reserve, not detectible as regional or global wall contraction alterations, but as 
local perfusion defects,4 as well as subendocardial ischemia with preservation of overall 
segmental function due to the intact subepicardium. 
 
Figure 1: End-systolic freeze-frames showing left anterior descendens territory (apical septum, lateral, 
inferior and anterior walls) subendocardial perfusion abnormalities, after opacification of the remaining 
muscle and persisting up to five beats post flash. The accompanying loops show no inducible wall motion 
abnormalities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myocardial ischemia generally occurs at the time of occlusion when decreased blood 
flow is associated with low adenosine triphosphate (ATP) production and contractile failure 
secondary to a decreased energy supply.  Five myocardial outcomes are possible during or after 
a coronary occlusion: (i) normal structure and function, (ii) myocardial ischemia, (iii) stunned 
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myocardium, (iv) myocardial hibernation, and (v) MI. After a coronary occlusion, normal 
structure and function of the myocardium is maintained when myocardial perfusion is 
preserved due to the presence of collateral vessels. The subendocardium is the most 
functionally active myocardial layer with the lowest perfusion reserve and, therefore, the 
greatest vulnerability to ischemia and infarction.5, 6 Myocardial ischemia starts in the 
endocardium and may lead to a non-transmural MI (non-Q-wave MI). Because less severe 
ischemia does not lead to irreversible damage, myocytes become damaged (but not necrotic) 
and maintain viability. The myocardium becomes stunned (reduction or absence of normal 
contractility) after a coronary occlusion has been relieved. Myocardial dysfunction due to 
stunning (i) can persist in the absence of irreversible damage and despite restoration of a 
normal coronary flow, (ii) can last weeks to months after normal perfusion has been recovered, 
and (ii) often lies adjacent to an infarcted necrotic myocardial segment.7, 8 After prolonged 
coronary occlusion (4-6 h), myocardial necrosis progresses from endocardium to epicardium in 
a wave-front. If perfusion is reinstituted, an incomplete (non-transmural) MI results, but if not, 
a complete (transmural, or ‘Q-wave’) MI will occur.9, 10 In necrotic myocardium, the local 
capillary network becomes thrombosed and occluded, leading to irreversible damage of 
membrane integrity, glycolytic or mitochondrial function, and absence of contractile potential. 
Changes in myocardial function and perfusion can be detected by echocardiography as global 
systolic and diastolic LV dysfunction, regional wall motion and wall thickening abnormalities, 
and LV perfusion defects.11 (Figure 1).  
 
 
ECHOCARDIOGRAPHY DETECTING CORONARY ARTERY DISEASE 
 
Regional wall motion assessment 
 
Rest echocardiography 
In the early 1970s, M-mode recordings were used to assess wall motion of the LV; however, 
2D imaging has replaced M-mode echocardiography for evaluation of global and regional wall 
motion. With 2D echocardiography, ischemic segmental wall motion abnormalities can be 
detected in patients with CAD. Visual assessment (‘eyeball approach’) categorizes wall motion 
as being normal or abnormal on the basis of degree of endocardial excursion (which is subject 
to tethering and translational motion), thickening, the timing of motion and the shape of the 
LV. Timing is particularly important, and accurate wall motion assessment requires frame-by-
frame review to overcome the limited temporal resolution of the human eye.12 Wall motion 
abnormalities are characterized as hypokinetic, akinetic, or dyskinetic, and changes in LV shape 
are important and often neglected (Figure 2). Normally the endocardium thickens during 
systole; however ischemic myocardium shows different patterns of wall thickening or even 
thinning during systole as shown in Table 1 and Figure 3A-B.  
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Table 1 Regional systolic wall function 
Normal 
 
1 normal inward  
systolic motion 
4-10 mm systolic thickening - double thickness 
Mild hypokinesia 
 
2 mildly reduced inward  
systolic motion 
mildly reduced systolic thickening - delayed 
Severe hypokinesia 
 
2.5 severely reduced inward  
systolic motion 
severely reduced systolic thickening - delayed 
Akinesia 
 
3 absent inward  
systolic motion 
absent systolic thickening 
Dyskinesia 
 
4 abnormal outward  
systolic motion 
systolic thinning 
Aneurysmal 
 
5 abnormal shape  
at rest 
systolic thinning 
 
 
Although there is tremendous variability in the coronary artery blood supply to the 
myocardium, a model with 17-segments assigned to one of the three major coronary arteries is 
recommended for visual interpretation of regional LV wall motion abnormalities (Figure 4). 
Unfortunately, the true apical cap is rarely visualised by echo,  so some investigators continue 
to use the 16-segment model.13 Therefore, individual myocardial segments can be assigned to 
one of the three major coronary arteries with recognition that there is anatomic variability. 
Wall motion abnormalities at rest may represent scar tissue (caused by transmural MI), 
hibernation or myocardial stunning (viable myocardium with a reduction or absence of 
contractility).  Ischemic myocardial segments can have a normal or abnormal function at rest 
with development of wall motion abnormalities during exercise or stress. In general, wall 
motion and wall thickening abnormalities show the highest specificity in the determination of 
CAD, representing the ‘classic ischemic cascade’. Myocardial perfusion is the most sensitive 
indicator for CAD, as it includes the ‘alternative ischemic cascade’. Two dimensional 
echocardiography in combination with a contrast agent (further discussed in the section on 
contrast enhanced echocardiography) provides a means of recognition of subendocardial 
hypoperfusion with high spatial resolution. The combination of perfusion and wall motion 
affords a simple method to predict functional recovery of dysfunctional segments after 
revascularization by evaluating end-diastolic wall thickness and perfusion abnormalities, as 
shown in Table 2.14 
 
Table 2 Likelihood of functional recovery after revascularization 
End-diastolic wall thickness  >11, perfusion + 
 
highest likelihood of recovery 
End-diastolic wall thickness  >11, perfusion - 
 
high likelihood of recovery 
End-diastolic wall thickness  <11, perfusion + 
 
intermediate likelihood of recovery 
End-diastolic wall thickness  <11, perfusion - 
 
low likelihood of recovery 
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Figure 3A: End-systolic freeze-frames showing left anterior descendens territory infarction without wall 
thinning (arrows) in two and three dimensional images (below). Accompanying loops show no inducible 
ischemia. 
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Figure 3B: End-systolic freeze-frames showing infarction in the left anterior descendens territory with 
wall thinning (yellow arrows), as well as left circumflexus territory (white arrows) and right coronary 
artery territory akinesis (blue arrows). Accompanying loops show no inducible ischemia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stress echocardiography  
During exercise or stress, the myocardial oxygen-demand is increased and demand ischemia 
occurs in patients with a coronary artery stenosis. Stress testing can detect reversible ischemia, 
distinguish ischemia and viability from scar, and identify regions supplied by a specific 
coronary vessel. When stress testing induces ischemia, it permits wall motion analysis during 
stress with the use of treadmill and bicycle exercise or pharmacologically induced stress. 
Regardless of the technique used, rest images are recorded first and serve as a baseline for 
comparison 15 with stress images obtained during peak stress or immediately after exercise. The 
images are analysed using a segmental model. Wall motion and wall thickness is scored in each 
myocardial segment on a 4-point scale, and test results are considered positive when wall 
motion or wall thickness deteriorates by one grade or more in any segment.16 During stress 
testing, five different ventricular wall motion response patterns can be observed: (i) 
normokinesis or normal systolic wall motion, (ii) hyperkinesis or increased inward systolic wall 
movement, (iii) hypokinesis or reduced inward systolic wall movement, (iv) akinesis or no 
systolic wall movement and, (v) dyskinesis or outward systolic wall movement. Necrotic 
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myocardium can be akinetic or dyskinetic at rest. Akinetic and dyskinetic myocardium could be 
viable as well, and assessing the ventricular wall motion response to stress can make a 
distinction between viable and necrotic tissue. Although hypokinetic myocardium is sometimes 
labelled as viable, it may not necessarily show improvement after revascularization, for 
instance, when hypokinesis is caused by subendocardial scar. In the normal response to stress, 
normokinetic wall segments remain normokinetic during stress or becomes hyperkinetic. 
During an ischemic response, wall segments become hypokinetic, akinetic, or dyskinetic during 
stress (Figure 5A-C). In a necrotic response, wall segments that are akinetic or dyskinetic at rest 
will remain akinetic or dyskinetic during stress. A viable response is seen when hypokinetic, 
akinetic, or dyskinetic segments show improved contractility during stress (Table 3). 
Hibernating myocardium is identified when improved contractility at low stress rate is followed 
by reduced contractility at high stress rate, i.e., the biphasic response.17 Stunned myocardium 
shows sustained improvement of myocardial contraction at both low and high stress rates. 
Because hibernating myocardium improves after revascularization, separating hibernating from 
stunning myocardium is of great clinical importance. The three most common stressors used in 
stress echocardiography are (i) exercise, (ii) dobutamine, and (iii) dipyridamole.  
 
Exercise stress testing 
Exercise testing can be subdivided into treadmill and bicycle testing. Scanning during exercise 
can be performed but it is difficult. Therefore, images must be taken immediately after the 
exercise is performed, and echocardiographic examination must be completed within 1-2 min. 
When exercise is terminated, myocardial oxygen-demand gradually declines with recovery of 
reversible wall motion abnormalities. New or increased wall motion abnormalities can persist 
up to 30 min postexercise, demonstrating stunned myocardium depending on the severity and 
extent of the underlying CAD. Stunning is often induced by treadmill testing.18 However, when 
wall motion recovers very rapidly and persists only for several minutes, treadmill testing can 
miss resolved wall motion abnormalities. This may lead to false negative results affecting the 
sensitivity of the test in detecting ischemia. Bicycle exercise is performed in upright and supine 
position and permits echocardiographic examination during exercise. With the patient in the 
supine posture, it is possible to record images from multiple views during graded exercise. In 
the upright posture, imaging is generally limited to either apical or subcostal views. The overall 
sensitivity of exercise echocardiography has been reported to range from 76 to 89%, and 
sensitivity is greater with more high-grade coronary disease.19, 20  However, although 
angiographic comparison is respected as a common metric for the assessment of the accuracy 
of these tests, it should be remembered that the angiogram is imperfect because the severity of 
diffuse narrowing can be underestimated and because this anatomic test ignores the 
contribution of vascular function to perfusion, even in the context of normal conduit vessels.   
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Figure 5A-B: The spectrum of ischemic wall motion responses to stress. Probable angina in a 61-year-old 
man with multiple risk factors. Normal rest electrocardiogram. Exercise test showed no chest pain, 1 mm 
ST depression, submaximal heart rate (79%), seven MET ex capacity. Noncontrast and left ventricle 
opacification images (see loops) show questionable inferoseptal hypokinesis. Use of destruction- 
replenishment imaging to examine myocardial perfusion shows inferior (A) and apical perfusion defects 
(B).   
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Figure 5C: Coronary angiography showed significant 70% distal right coronary artery and 60% mid left 
coronary artery. 
 
 
 
 
Table 3 Wall motion response to stress 
Rest Stress Diagnosis 
Normal hypokinesia 
 
 
normal 
hyperkinesia 
hypokinesia 
normal 
normal 
nontransmural infarction 
Normal hypokinesia hypokinesia  
akninesia  
dyskinesia 
ischemia 
ischemia 
ischemia 
Akinesia normal 
hypokinesia 
viable 
viable 
Akinesia akninesia necrosis 
Dyskinesia dyskinesia necrosis 
 
 
Pharmacological stress testing 
Although exercise testing is more physiologic than pharmacologic stress, it is not feasible in 
many situations. Out of five patients referred for stress, one will not exercise and one will 
exercise submaximally.21 For instance, patients with peripheral vascular disease are unable to 
exercise maximally, so with a pharmacologic stress, echocardiography serves as a good 
alternative in these patients. Pharmacologic stress testing is performed during the infusion of 
dobutamine or dipyridamole. These two stressors induce ischemia through different 
hemodynamic mechanisms. Dobutamine stimulates adrenoreceptors, thereby increasing 
ventricular contractility and myocardial oxygen-demand during stress testing.22 Dipyridamole 
exerts vasodilatory properties by stimulating adrenaline receptors – although steal phenomena 
are commonly cited, experimental evidence suggests that ischaemia is more likely caused by 
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tachycardia and hypotension in the setting of reduced subendocardial flow reserve.23 Although 
dipyridamole is often cited as the stressor of preference in the assessment of myocardial 
perfusion and dobutamine may be preferred to assess regional wall motion abnormalities, 
either can be used for each purpose. Dobutamine infusion increases myocardial oxygen-
demand through positive chronotropic and inotropic effects and impairs myocardial oxygen-
supply by shortening diastole. These effects result in myocardial ischemia and systolic 
dysfunction in myocardial regions supplied by critically stenotic arteries.  
 
Performing these tests requires careful patient monitoring, access to antidotes to 
stress agents, and the presence of an experienced physician. A graded dobutamine infusion 
starting at 5 µg/kg/min and increasing at 5 min stage to 10, 20, 30 and 40 µg/kg/min is the 
standard for dobutamine stress echocardiography. To assess myocardial viability, a thorough 
evaluation at rest is important (Figure 6A) followed by multiple low-dose stages – in most 
cases, the study should progress to peak dose dobutamine to check for ischemia (Figure 6B-C). 
The recommended protocol for dipyridamole echocardiography includes continuous 
echocardiographic monitoring during a two-stage infusion. The first stage consists of 0.56 
mg/kg dipyridamole over 4 min. Monitoring continues for 4 min, and if there is no clinical 
effect, an additional 0.28 mg/kg is infused over 2 min. Aminophylline (240 mg i.v.) should be 
available for use in case of an adverse events related to dipyridamole. Adenosine can be used in 
a similar manner and is typically infused at a maximum dose of 140 mg/min during imaging.24 
Patients undergoing pharmacological stress testing often take β-blockers, which may limit 
heart-rate response and influence the sensitivity of the test to detect CAD. In both dobutamine 
and dipyridamole echocardiography, atropine can be added after the second stage to increase 
heart rate and improve sensitivity.25, 26 Atropine should be used at the minimum effective dose 
and administered in 0.25 mg increments every 60 s until the desired heart response is seen.   
 
Side effects and contraindications 
There are few contraindications (e.g., severe aortic stenosis), and side effects (e.g., MI, death, 
arrhythmia) associated with physical exercise are uncommon. Pharmacological stress testing 
with dobutamine and dipyridamole is considered to be a safe test that is generally well 
tolerated. Major complications such as MI, death, and bronchospasm occur in ~1:1000. 
Potential side effects of pharmacological stress testing are transient arrhythmias and 
hemodynamic abnormalities, which resolve rapidly after cessation of the infusion. Dobutamine 
is contraindicated in patients with current ventricular or atrial arrhythmias and moderate-to-
severe hypertension (defined as diastolic blood pressure above 110 mmHg). Stress 
echocardiography with dipyridamole is contraindicated in patients with high-grade heart block, 
bronchospasm, unstable carotid disease, and patients receiving theophylline treatment.24 
Minor, self-limiting side effects such as chest pain, nausea and headache can occur infrequently 
during dipyridamole infusion. 
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Figure 6A: Rest echocardiogram (end-systolic images) showing left ventricular enlargement and rest wall 
motion abnormalities with preserved wall thickness in the anteroseptum, septum, and apex. The bull’s eye 
display shows reduced longitudinal shortening in these areas (numbers correspond to regional strain; 
normal strain is approximately 18%). 
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Figure 6B and C: End-systolic images at rest, low, peak dose, and recovery in the apical four-chamber 
view. The apical and mid-septal akinetic area does not change at low dose and therefore suggests a 
nonviabile area. The apical lateral wall improves at peak stress, indicating nontransmural infarction (B). 
End-systolic images at rest, low, peak dose, and recovery in the apical two-chamber view. The apical 
inferior akinetic area thickens at the 10 mcg dose, but does not deteriorate, denoting a nontransmural 
infarction. The antero-apical wall deteriorates at peak stress, indicating ischemia (C). 
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Comparison of diagnostic and prognostic performance of exercise and pharmacological stress testing 
The results from multiple meta-analyses comparing exercise, dobutamine and, dipyridamole 
stress testing are shown in Table 4. A recent meta-analysis conducted by Picano et al, analysed 
five studies regarding the diagnostic accuracy of dobutamine vs. dipyridamole stress 
echocardiography. They noted dipyridamole and dobutamine to have similar accuracy (87%, 
95%-CI: 83 to 90%, vs. 84%, 95%-CI: 80 to 88%, p = 0.48), sensitivity (85%, 95%-CI: 80 to 
89%, vs. 86%, 95%-CI: 78 to 91%, p = 0.81), and specificity (89%, 95%-CI: 82 to 94% vs. 
86%, 95%-CI: 75 to 89%, p = 0.15) for the detection CAD.27  These conclusions are in line 
with other meta-analyses, shown in Table 4, generally concluding that stress echocardiography 
shows a higher specificity than sensitivity.19, 20, 27-29 A higher sensitivity than specificity is seen 
in a meta-analysis performed by Bax et al, in which low-dose dobutamine was administered in 
the assessment of myocardial viability, as shown in Table 4.30 The prognostic performance of 
dobutamine stress echocardiography in the prediction of postoperative cardiac events is 
outlined in Table 4.31 
 
Sensitivity and specificity relate to correct identification or exclusion of A. significant coronary stenoses (criteria vary from 50 
to 70% in different trials), B. recovery of regional function after revascularization, and C. perioperative cardiac events. a Low 
dose dobutamine, b in women and c cardiac events. Coronary artery disease (CAD), cardiovascular events (CE), 
dipyridamole (Dip), dobutamine (Dob), exercise (Exe). 
 
 
 
 
Table 4 Accuracy of stress echocardiography 
 
Meta-analyses 
 
Year 
 
Studies 
 
Outcome 
 
Sensitivity (%) 
 
Specificity (%) 
  
 
 
 
Exe Dob Dip Exe Dob Dip 
A. Diagnostic performance of stress echocardiography 
Picano et al. 2008 5 CAD - 85 86 - 92 87 
Noguchi et al. 2005 164 CAD 83 80 71 84 85 92 
Kim et al. 2001 60 CAD - 80 70 - 84 93 
Picano et al. 2000 12 CAD - 77 71 - 87 93 
Kwok et al.a 1999 3 CAD 76 - - 89 - - 
B. Viability assessment of  stress echocardiography 
Schinkel et al. 2007 41 viability - 80 - - 78 - 
Bax et al.b 2001 28 viability - 82 - - 79 - 
C. Prognostic performance of stress echocardiography 
Kertai et al.c 2003 12 postoperative  
CE 
- 85 74 - 70 86 
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Comparison of stress testing with other noninvasive imaging techniques 
Stress echocardiography has the advantage to be a safe, widely available, noninvasive technique, 
feasible in almost all circumstances at low cost. Furthermore, pharmacological stress 
echocardiography is a reliable method for diagnosing CAD in patients with a cardiac 
pacemaker, whereas for instance, exercise myocardial SPECT may show false positive results in 
pacemaker patients.32 However, image quality is negatively affected by obstructive lung disease, 
chest deformation, and obesity. During peak stress, the image quality is negatively affected by 
an increased heart rate and breathing artifact. Furthermore; mechanical tethering, defined as 
decreased contractility of noninfarcted regions adjacent to infarcted regions, may lead to an 
overestimation of the extent of an infarcted region.33, 34 Finally, the accuracy of stress 
echocardiography is dependent on operator experience. A meta-analysis conducted by Beattie et 
al. analyzed the predictive value of pharmacological stress testing in predicting perioperative 
cardiac events, compared with thallium myocardial perfusion scintigraphy. This report included 
25 studies (3,373 patients) of mainly dobutamine and several dipyridamole stress 
echocardiography. The likelihood ratio of a perioperative event with a positive stress 
echocardiogram was 4.09 (95%-CI: 3.21 to 6.56) compared with 1.83 (95%-CI: 1.59 to 2.10) in 
patients undergoing thallium myocardial perfusion scintigraphy.35 Table 5 shows various meta-
analyses comparing sensitivity and specificity of pharmacological stress testing in detecting 
CAD28, 31 and functional improvement after revascularization.30, 36. The cost differential 
between noninvasive tests for coronary disease is summarized in Figure 7. The following 
guidelines (Table 6) have been described in the 2008 ACC/AHA guidelines concerning the 
appropriateness criteria for stress echocardiography with or without contrast enhancement.16 
These criteria are also in agreement with ESC guidelines.  
 
Figure 7. Relative costs of  stress testing procedures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacological (Pharm), single photon emission computed tomography (SPECT). 
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Table 5 Accuracy of various stress tests 
Meta-analyses 
 
Studies 
 
Outcome 
 
Sens (%) 
 
Spec (%) 
Performance in detecting coronary artery disease and predicting cardiac events 
Kim et al.  
 Dipyridamole stress echo 20 CAD 70 93 
 MPS, dipyridamole SPECT 21 CAD 89 65 
 Dobutamine stress echo  40 CAD 80 84 
 MPS, dobutamine SPECT 14 CAD 82 75 
Kertai et al. 
 Dobutamine stress echo 8 perioperative CE 85 70 
 Dipyridamole stress echo 4 perioperative CE 74 86 
 MPS, Tl-201 23 perioperative CE 83 49 
 Exercise electrocardiography 7 perioperative CE 74 69 
Performance in predicting functional improvement after revascularization 
Bax et al. 
 Dobutamine stress echo a 28 functional recovery 82 79 
 MPS, Tl-201 (rest-redistribution) 22 contractile function 86 59 
 MPS Tl-201 (reinjection) 11 contractile function 88 50 
 MPS, Tc-99m labelled (nitrates) 13 functional recovery 79 58 
 MPS, Tc-99m labelled (no nitrates) 7 functional recovery 81 66 
 MPS, PET 18-FDG 20 contractile function 93 58 
Schinkel et al. 
 Dobutamine stress echo 41 regional wall function 82 80 
 MPS, Tl-201 (rest-redistribution) 28 regional wall function 87 56 
 MPS, Tl-201 (reinjection) 343 regional wall function 87 50 
 MPS, Tc-99m labelled  25 regional wall function 83 65 
 MPS, PET 18-FDG 24 regional wall function 92 63 
 MRI 13 regional wall function 84 63 
a Low dose. 18-Fluorodeoxyglucose (18-FDG), coronary artery disease (CAD), cardiovascular events (CE), myocardial 
perfusion scintigraphy (MPS), magnetic resonance imaging (MRI), positron emission tomography (PET), sensitivity (Sens), 
specificity (Spec), single photon emission computed tomography (SPECT). 
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Coronary artery disease (CAD), chronic heart disease (CHD), electrocardiogram (ECG), left ventricular (LV). 
 
 
Contrast-enhanced echocardiography 
Stress echocardiography is widely used for the detection of inducible ischemia and regional 
wall motion abnormalities. Analyzing regional wall motion abnormalities relies on the 
identification of the endocardial border of the LV cavity. Image quality can be severely 
impaired in patients with obstructive lung disease, obesity, and chest wall deformities resulting 
in suboptimal acoustic windows. Furthermore, an increase in heart rate and breathing artifacts 
due to hyperventilation causes difficulties in identifying the endocardial border of the LV 
cavity and interpreting the stress images. Since the first report in 1968, contrast has become an 
indispensable tool for cardiovascular imaging.37 The development and usage of ultrasound 
contrast agents have shown to be beneficial in assessing the endocardial border of the LV 
cavity, and, therefore, exert a beneficial effect in analyzing myocardial contractility and 
Table 6 Appropriateness criteria for stress echocardiography 
Evaluation of chest pain syndrome or anginal equivalent 
- Low pretest probability of CAD 
- ECG interpretable and able to exercise 
inappropriate 
- Low pretest probability of CAD 
- ECG un-interpretable or unable to exercise 
appropriate 
- Intermediate pretest probability of CAD 
- ECG interpretable and able to exercise 
appropriate 
- Intermediate pretest probability of CAD 
- ECG un-interpretable or unable to exercise 
appropriate 
- High pretest probability of CAD 
- Regardless of ECG interpretability and ability to exercise 
appropriate 
- Prior stress ECG is un-interpretable or equivocal appropriate 
General patient populations 
- Low CHD risk (Framingham risk criteria)     
- Moderate CHD risk (Framingham risk criteria) 
inappropriate 
- High CHD risk (Framingham risk criteria)    indeterminate 
Acute chest pain 
- Intermediate pretest probability of CAD 
- ECG; no dynamic ST changes and serial cardiac enzymes negative 
appropriate 
- High pretest probability of CAD 
- ECG; ST elevation 
inappropriate 
New-onset/diagnosed heart failure with chest pain syndrome or anginal equivalent 
- Intermediate pretest probability of CAD 
- Normal LV systolic function 
appropriate 
- LV systolic function indeterminate 
Ischemic cardiomyopathy, assessment of viability/ischemia 
- Known CAD on catheterization 
- In a patient eligible for revascularization  
appropriate 
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perfusion. Left ventricular opacification has shown to improve (i) image quality, (ii) percentage 
of wall segments visualized and (iii) confidence of interpretation of wall motion abnormalities 
both at rest and during peak stress.38 The contrast agents used are suspensions of 
microbubbles, which have the same size as red blood cells and are filled with perfluorocarbon 
gas. Because of the availability of sensitive contrast imaging technologies, only small dosages of 
contrast (0.1 to 0.3 mL) are needed to obtain enhanced images. The accuracy of end-diastolic 
wall thickness measurements is improved as well and, can be used, in combination with 
perfusion abnormalities, to predict recovery of function after revascularization.14 Contrast-
enhanced echocardiography allows visualization of subtle wall motion abnormalities that are 
difficult to detect with normal echocardiography. Furthermore, the observation of subtle wall 
motion abnormalities can be confirmed with the identification of perfusion abnormalities. 
Finally, contrast-enhanced echocardiography can visualize regional perfusion abnormalities 
before contractile abnormalities evolve, potentially identifying CAD at an earlier stage. 
Contrast perfusion imaging has proven to be a valuable tool for the detection of myocardial 
viability. Increased brightness is observed in normally perfused myocardial segments, due to 
contrast enhancement.39, 40 Myocardial viability can be expressed as contrast intensity and 
myocardial replenishment, assessed after 10-15 cardiac cycles after a destructive pulse. Fully 
replenished myocardium with homogeneous contrast intensity indicates the presence of 
myocardial viability.41, 42 (Figure 8)  
 
The use of contrast in association with exercise and pharmacologic stress 
echocardiography improves the visualization of wall motion when this is technically difficult, 
but is not recommended for all studies. The detection of perfusion abnormalities is an ‘off 
label’ use of contrast that is feasible but technically challenging.  The development of new 
contrast agents will be needed in order to move this to mainstream use (Table 7).  
 
 
 
 
 
 
 
 
 
 
Table 7 Contrast use 
Use of contrast with stress echo 
- Routine use of contrast 
- All segments visualized on non-contrast images 
inappropriate 
- Selective use of contrast 
- Two or more contiguous segments are not seen on noncontrast images 
appropriate 
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Figure 8: Rest and myocardial contrast echocardiography in a 65-year-old man after late presentation 
myocardial infarction. Despite regional wall motion abnormalities in the inferior wall, perfusion is 
preserved, (myocardial contrast marked by arrows) suggesting viability.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GLOBAL WALL MOTION ASSESSMENT 
 
Heart failure, a clinical syndrome in which the ability of the ventricles to fill with or eject blood 
is impaired, is a major predictor of mortality after MI. Often, this is transient due to 
spontaneous recovery in the coronary care unit or after coronary revascularization, but may 
progress to chronic heart failure.43 Coronary artery disease is the most common cause of 
myocardial disease, being the initial cause in 70% of patients with predominantly systolic heart 
failure.44, 45 
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  Rest echocardiography is pivotal in the recognition of systolic heart failure, which is 
associated with progressive chamber dilation and eccentric remodeling.46 Left ventricular 
ejection fraction (the fraction of blood ejected out of the LV during one heartbeat) has a 
number of limitations, including sensitivity to hemodynamic setting, but has the advantage of 
being a simple numerical parameter that has been linked to outcome and decision making. In 
patients with LV dysfunction without heart failure, regional wall motion scoring may be more 
sensitive than ejection fraction, which may be preserved by compensatory hyperkinesis. 
Subclinical LV dysfunction describes the situation of apparently normal LV function where 
sensitive indices such as strain are abnormal, or where LV contractile reserve is reduced. The 
latter reflects the response to stress, which usually involves a reduction of LV volumes and an 
increment of LV ejection fraction.   
 
Echocardiographic assessment of global systolic LV function is often performed 
subjectively, but this is increasingly considered suboptimal. This approach is dependent on the 
eye of an experienced observer and is misleading in situations of (i) irregular heart rhythm, (ii) 
very large or small LV size, and (iii) extreme heart rates.47, 48 The most common method for 
the quantitation of LV volumes is the modified Simpson’s rule, a technique that requires 
imaging in apical, 4- or 2-chamber views. First the endocardial border has to be outlined in 
end-diastole and end-systole, and the LV cavity is divided into a series of disks of equal height 
along its long axis. When the central axis of the LV cavity is defined and the endocardial 
border is identified, the volume of each disk can be automatically defined. Each disk volume is 
calculated as disk area x height (height defined as the total length of the LV long axis divided 
by the number of disks). The surface area of each disk is determined from the diameter of the 
ventricle at that point. The ventricular volume is calculated by summing the disk volumes, 
which are equally spaced along the LV long axis. Once the LV volumes have been measured, 
LV ejection fraction can be calculated as (LV end systolic volume – LV end diastolic volume) x 
100/ LV end diastolic volume.49 In more than 15% of patients examined with ultrasound, poor 
ultrasonic windows preclude optimal visualization of the endocardial border,50 despite the use 
of tissue harmonic imaging. In this situation, the use of LV opacification with contrast-
enhanced echocardiography will improve endocardial border definition.51, 52 Contrast-enhanced 
echocardiography has also been shown to improve the assessment of LV volumes and LV 
ejection fraction.53, 54 The use of contrast may also facilitate 3D assessment, which appears to 
be the most reproducible and accurate (but not yet the most robust) echocardiographic means 
of LV volume assessment. The development of real-time 3D imaging has simplified and 
shortened the process of acquisition and calculation of 3D measurements, to the extent that 
this is not feasible for routine echocardiography (Figure 9). 
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Figure 9: Four steps for the use of three dimensional echo for left ventricular volume and ejection 
fraction assessment in the postinfarct heart. (A) Defining landmarks at the base and apex of the left 
ventricle in end-diastole and end-systole. (B) Selection of imaging planes - we use twelve imaging planes, 
especially in irregularly shaped hearts. (C) Contours are defined automatically but commonly require 
revision. (D) Display of the volumes and the ejection fraction using a time volume curve.  
 
 
DETECTION OF CORONARY ARTERY DISEASE COMPLICATIONS 
 
In-hospital mortality caused by acute MI is mainly due to circulatory failure resulting from 
severe LV dysfunction or mechanical complications of MI. These complications of acute MI 
can be visualized and diagnosed using 2D echocardiography. In the following paragraphs we 
will discuss mechanical complications caused by acute MI, such as: (i) infarct expansion leading 
to LV aneurysm and possible thrombus formation (ii) mitral regurgitation, (iii) ventricular wall 
rupture, (iv) right ventricular infarction, and (v) pericardial effusion. These mechanical 
complications can occur in the setting of a well-preserved LV function. Accurate diagnostics 
with the use of echocardiography will guide proper treatment in often life threatening 
situations.  
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Infarct expansion 
Infarct expansion represents acute thinning of the ventricular wall occurring 24-72 h after the 
occurrence of a transmural (Q-wave) MI. The expansion area consists of necrotic myocardial 
tissue with disruption of cells leading to a 50% reduction of wall thickness (i.e., 4-6 mm 
compared with the normal 10-11 mm) in the affected region.55 Infarct expansion is an 
important precursor for the development of LV aneurysm.56 A true ventricular aneurysm is 
characterized by disturbance of diastolic shape and thinning of the LV wall, usually due to 
transmural MI; more than 85% are localized in the apical and antero-septal walls.57 Alteration 
of normal LV contraction and filling properties can result in congestive heart failure, and more 
than 50% of patients with true LV aneurysms develop mural thrombi.58 In contrast, pseudo-
aneurysms form when free wall rupture is contained by overlying adjacent pericardium (see 
below).59 Ventricular thrombi are most commonly localized in the antero-apical segments and 
should be visualized in more than one echocardiographic view, preferably from different 
transducer positions. Thrombus protrusion and mobility can be identified with 2D echo and 
are associated with risk of embolization.60-62 The use of contrast-enhanced echocardiography 
can improve the diagnostic accuracy of 2D echocardiography in situations of suboptimal 
acoustic windows leading to poor image quality (Figure 10).  
 
 
Figure 10:  Value of left ventricular opacification in the detection of left ventricular mural thrombus. 
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Mitral valve regurgitation 
Ischemic mitral valve regurgitation (MR) most often occurs in the setting of an inferior MI. The 
incidence of MR is 38% in patients with inferior MI compared with 10% of patients with an 
anterior MI.63 Ischemic MR occurs due to papillary muscle rupture, dysfunction or 
displacement (Figure 11). Functional MR may also arise from LV dilatation, sphericity, annular 
dilatation, or papillary muscle dyssynchrony. Papillary muscle displacement is mostly caused by 
chronic ischemic heart disease, whereas papillary muscle rupture is associated with the acute 
phase of MI. Mild-to-moderate MR is common in the early phase after an acute MI and often 
decreases or resolves after reverse remodeling. Severe acute MR caused by papillary muscle 
rupture is a rare but life-threatening situation, which accounts for approximately 5% of acute 
MI deaths and (unlike other complications) is not necessarily associated with a large infarct. 
Predominantly, the postero-medial papillary muscle is involved, because its blood supply is 
primarily derived from the posterior descending coronary artery.64 Colour flow Doppler 
echocardiography is the standard diagnostic tool for detecting MR, but a high level of clinical 
suspicion may be needed, as the usual semiquantitative measure of MR severity (based on jet 
size in relation to the left atrium) 65 can be misleading. This is because rapid increment in left 
atrial pressure due to severe MR may cause pressure equalization and limit flow. A marked 
systolic expansion of the left atrium and flail or incomplete closure of the mitral valve are 
important correlative findings. Incomplete closure caused by a posterior flail leaflet usually 
leads to an anterior directed eccentric jet.  
 
 
Figure 11: Typical ischemic mitral valve regurgitation due to papillary muscle displacement (note the same 
location of the posterior wall in end-diastole (A) and end-systole (B). This causes tethering of the 
posterior mitral leaflet with posteriorly directed mitral valve regurgitation (C). 
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Ventricular wall rupture 
Unlike papillary muscle rupture, ventricular wall rupture is noted in anterior and inferior MI, in 
the same frequency and generally preceded by infarct expansion. Free wall rupture has been 
reported to complicate 4 to 24% of acute MI.66-69 Septal wall rupture is associated with anterior 
MI and the defect is most commonly found in the apical septum (Figure 12) and contrasts with 
inferior MI where septal rupture occurs at the base of the heart. The characteristic 
echocardiographic findings are a distinct break in the septal contour and the detection of 
turbulent flow directed from the LV to the in the differential diagnosis of right ventricular 
infarction and dysfunction associated right ventricular cavity. Right ventricular dilatation due to 
shunt should be considered with inferior MI.70 Contrast echocardiography is useful for the 
detection of cardiovascular shunts.71 Risk factors for postinfarction LV free wall rupture 
include: (i) age > 60 years, (ii) female gender, (iii) preexisting hypertension, (iv) absence of LV 
hypertrophy, (v) first MI, and (vi) midventricular or lateral wall transmural MIs.72 The majority 
of ruptures occur within the first week after MI, and suspicious features on echocardiography 
include (i) thinning and delineation of the free wall, (ii) pseudo-aneurysm, and (iii) accumulation 
of pericardial fluid suggestive for pericardial effusion or cardiac tamponade. Although 
echocardiography is considered the diagnostic tool of choice, in most cases free wall rupture 
will lead to instant death (Figure 13). 
 
Figure 1: Multiplanar reconstruction of an apical VSD showing defect diameter (arrow) in the four 
chamber view (A), defect circumference in a modified two-chamber view (B) where it is seen “en face”, a 
short-axis cut through the defect (C) and a 3D display (D). The color map (E) shows the left-right shunt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left ventricle (LV), right-ventricle (RV), ventricular septum defect (VSD).   
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Right ventricular infarction 
Right ventricular MI is strongly associated with inferior MI caused by a proximal occlusion of 
the right coronary artery. Right ventricular dilation may cause tricuspid annulus dilation 
resulting in acute tricuspid insufficiency.72 Wall motion abnormalities can be best visualized in 
subcostal and parasternal short-axis views.  
 
 
Figure 13: Contained apical rupture following antero-apical infarction. The contraction front map display 
derived from the 3D dataset (A) shows akinesis of the anteroseptal, anterior, and anterolateral walls 
(colored blue). The 2D images (B) show a contained rupture (white arrow) at the apex, confirmed on the 
3D images (C). 
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Pericardial effusion 
Pericardial effusion can be seen as an echo-free space surrounding the heart, which does not 
extend posterior to the descending aorta (unlike pleural effusion). Inflammation might be an 
important cause for post-ischemic pericardial effusion.73 However, large amount of pericardial 
fluid with a hemorrhagic appearance is suggestive for myocardial rupture. 
 
 
ADVANTAGES AND LIMITATIONS OF ECHOCARDIOGRAPHY 
 
In comparison with other noninvasive cardiac imaging procedures, such as nuclear cardiology, 
cardiac computed tomography (CT), and magnetic resonance imaging (MRI), 2D 
echocardiography has some limitations and advantages. As already noted, the impairment of 
image quality in patients with obstructive lung disease, obesity, and chest wall deformities can 
be minimized by use of echocardiographic contrast agents, albeit at additional cost.74 Increases 
in heart rate and hyperventilation may cause difficulties in the analysis of echocardiographic 
images. Two-dimensional echocardiography has the advantage of being (i) safe (i.e., no 
radiation or ionizing substances required), (ii) widely available, (iii) noninvasive, and (iv) 
feasible in almost all circumstances at low cost (Figure 14).75 Cardiac MRI has the ability to 
provide information about cardiac anatomy, function and perfusion simultaneously and has a 
superior spatial resolution to 2D echocardiography. However, cardiac MRI has a lower  
 
 
Figure 14: Costs of  cardiac imaging procedures relative to echo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Computed tomography (CT),  magnetic resonance imaging (MRI), positron emission tomography (PET), single photon 
emission computed tomography (SPECT). 
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temporal  resolution (which is a problem for flow measurement, especially diastology), usually 
requires breath-holding sequences during data acquisition, and is relatively expensive and less 
available than echocardiography. According to the 2008 Appropriateness Criteria for Stress 
Echocardiography, the use of stress echocardiography and SPECT nuclear imaging show 
similar bodies of evidence to support their use for ischemia detection.16 Nuclear cardiology 
(e.g., PET and SPECT imaging) has the advantages of (i) higher sensitivity, (ii) higher technical 
success rate, and (iii) better accuracy when multiple resting left wall abnormalities are present, 
compared with echocardiography. The following advantages are in favor of echocardiography: 
(i) higher specificity, (ii) higher versatility, and (iii) greater convenience.76 The ability to directly 
visualize the coronary arteries with coronary CT represents a major shift from the functional 
assessment of CAD to an anatomic evaluation. The ramifications of this on revascularization 
decisions and cost-effectiveness are unexplored. Apart from the requirements for breath-
holding sequences and bradycardia (<65 beats/min), CT is less versatile in the assessment of 
wall motion abnormalities, ventricular function, valve abnormalities, and pericardial disease. 
 
 
FUTURE DEVELOPMENTS OF ECHOCARDIOGRAPHY 
 
There are unifying attractions in the application of new echocardiographic technologies to 
improve the quantitation of echocardiography. Ejection fraction is a widely used parameter in 
decision making, and the reliability of 2D ejection fraction is tenuous when the implications of 
this measurement (e.g., implantable defibrillator insertion) are considered. The use of contrast 
has been shown to improve reliability of these measurements,53 and 3D ejection fraction may 
also be attractive. Likewise, although LV volumes are known to be a powerful prognosticator, 
the reliability of these measurements with 2D echocardiography is limited, and 3D imaging has 
been shown to produce analogous measures to MRI.77 The interpretation of regional function 
(including stress echocardiography) is the most challenging aspect of echocardiography, as well 
as the most difficult to quantify. Recent developments in tissue Doppler, strain rate imaging 
and speckle tracking echocardiography may prove useful for this purpose. The contribution of 
tissue Doppler in ischemic heart disease is limited by its lack of site specificity, which makes its 
measurements susceptible to translation and tethering problems.78 In contrast, strain 
measurements are specific to location, and strain rate in particular has been used to facilitate 
the identification of viable myocardium.79 The use of deformation analysis to facilitate the 
recognition of ischemia is problematic – tissue-velocity based strain may be limited by signal 
noise, and the tracking process for speckle strain is challenging at high heart rates. Further 
technical developments will facilitate the clinical adoption of these techniques.  
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CONCLUSION 
 
Echocardiography is central in the evaluation and management of the patient with ischemic 
heart disease. Although the imaging choices for the evaluation of ischemic heart disease have 
expanded over the last few years, echocardiography remains the initial test in most settings. 
The utility of echo will likely be increased by a number of new developments.   
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ABSTRACT 
 
Aims This study evaluated the prevalence of left ventricular (LV) dysfunction in vascular 
surgery patients and pharmacological treatment, according guidelinesof the European Society 
of Cardiology (ESC). 
 
Methods Echocardiography was performed preoperatively in 1,005 consecutive patients. Left 
ventricular ejection fraction (LVEF) ≤50% defined systolic LV dysfunction. Diastolic LV 
dysfunction was diagnosed based on E/A-ratio, pulmonary vein flow, and deceleration time. 
Optimal pharmacological treatment to improve LV function was considered as: (i) angiotensin-
blocking agent (ACE-I/ABR) in patients with LVEF ≤40%, (ii) ACE-I/ABR, and β-blocker in 
patients with LVEF ≤40% + heart failure symptoms or previous myocardial infarction; and 
(iii) a diuretic in patients with symptomatic heart failure, regardless of LVEF.   
 
Results Left ventricular dysfunction was present in 506 patients (50%), of whom 209 (41%) 
had asymptomatic diastolic LV dysfunction, 194 (39%) had asymptomatic systolic LV 
dysfunction, and 103 (20%) had symptomatic heart failure. Treatment with ACE-I/ABR 
and/or β-blocker could be initiated/improved in 67 (34%) of the 199 patients with 
(a)symptomatic LVEF ≤40%. A diuretic could be initiated in 32 patients (31%) with 
symptomatic heart failure (regardless of LVEF). 
 
Conclusion This study demonstrated a high prevalence of LV dysfunction in vascular surgery 
patients and under-utilization of ESC recommended pharmacological treatment. Standard 
preoperative evaluation of LV function could be argued based on our results to reduce this 
observed care gap. 
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INTRODUCTION 
 
Patients undergoing vascular surgery are known to be at increased risk of perioperative 
complications due to frequently underlying (a)symptomatic coronary artery disease. Coronary 
artery disease is the aetiology of heart failure in 60 to 70% of patients, predominantly in the 
elderly population.1, 2 Coupled to the growing prevalence of heart failure and the elderly 
population, is the increase in surgical procedures. In addition, many invasive surgical 
interventions (such as major vascular surgery) are increasingly performed in elderly patients. 
Worldwide, about 100 million adults undergo noncardiac surgery annually and by the year 2020 
the number of patients eligible for surgery will increase by 25%, with the largest group of 
patients aged >65 years.3  
 
Considerable improvements have been made in the treatment of heart failure. 
Guidelines of the European Society of Cardiology (ESC) recommend treatment with 
angiotensin-converting enzyme inhibitors (ACE-I) in patients with systolic left ventricular (LV) 
dysfunction, defined as LV ejection fraction (LVEF) ≤40%,  irrespective of the presence of 
heart failure symptoms to improve ventricular function.4 An angiotensin-receptor blocker 
(ARB) is recommended in case of ACE-I intolerance.4 Patients with asymptomatic systolic LV 
dysfunction and a myocardial infarction (MI) in past history are recommended to receive a β-
blocker as well. A diuretic is recommended next to these agents in patients with symptomatic 
heart failure.4  
 
The aim of the current study was to evaluate (i) the prevalence and pharmacological 
treatment for asymptomatic systolic LV dysfunction or symptomatic heart failure, according to 
the ESC guidelines, in the vascular surgery population and (ii) the impact of treatment on late 
outcome.  
 
 
METHODS 
 
Study population and baseline characteristics 
The patient population consisted of 1,005 consecutive vascular surgery patients at the Erasmus 
Medical Center (Rotterdam, the Netherlands) during the period between 2002 and 2008. The 
study was approved by the hospital’s ethics committee and performed with the informed 
consent of all patients. A detailed history was obtained from every patient and clinical data 
included: age, gender, ischemic heart disease (history of angina pectoris, coronary 
revascularization, or myocardial infarction),  cerebrovascular disease (history of ischemic or 
hemorrhagic stroke), renal dysfunction (serum creatinine >2.0 mg/dL), diabetes mellitus 
(fasting blood glucose ≥7.0 mmol/L or requirement for anti-diabetic medication), hypertension 
(blood pressure ≥140/90 mmHg in non-diabetics and ≥130/80 mmHg in diabetics or 
requirement for antihypertensive medication), dyslipoproteinemia (low-density lipoprotein 
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cholesterol >3,50 mmol/L or requirement of lipid-lowering medication), and chronic 
obstructive pulmonary disease. 
 
Left ventricular dysfunction 
Preoperatively, transthoracic echocardiography was performed in all patients using a handheld 
Acuson Cypress Ultrasound System (7V3c transducer). Standard images were obtained at rest 
with the patient in the left lateral decubitus position as recommended.5 Left ventricular end-
systolic and end-diastolic volumes were determined and LVEF was calculated using the biplane 
Simpson’s technique.6 Systolic (S) and diastolic (D) pulmonary vein flow, deceleration time, 
and mitral inflow E/A ratios of peak velocities (at early rapid filling E and late filling due to 
atrial contraction A) were determined in apical 4-chamber view as recommended 7.  An LVEF 
≤50% was defined as reduced and an LVEF ≤40% was eligible for pharmacological 
treatment.4 Diastolic LV dysfunction was confirmed in patients with E/A-ratio <0.8 or >2.8 
Abnormal pulmonary vein flow (S/D <1) was used to distinguish normal and pseudo-normal 
diastolic LV function in patients with E/A-ratio between 0.8 and 2.9 Deceleration time >220 
or <140 ms defined diastolic LV dysfunction in patients with atrial fibrillation.9 Patients with 
both systolic and diastolic LV dysfunction were classified as systolic LV dysfunction. The 
presence of LV dysfunction in combination with heart failure symptoms (shortness of breath, 
fatigue, exercise intolerance, signs of fluid retention)4 defined symptomatic heart failure. Two 
experienced investigators performed off-line assessments of the obtained ultrasound images. 
When there was disagreement between the two assessors, a third investigator viewed the 
images without knowledge of the previous assessment and a majority decision was reached.  
 
European Society of Cardiology treatment recommendations  
During the first preoperative visit to the outpatient clinic, the use of the prescription 
medications was recorded and included ACE-Is, ARBs, β-blockers, diuretics, statins, aspirin, 
oral anticoagulants, and nitrates. In the current study, the following ESC treatment 
recommendations were used:  (i) treatment of  all patients with an LVEF ≤40% with at least 
ACE-I/ARB, (ii) treatment of patients with an LVEF ≤40% and a history of myocardial 
infarction with ACE-I/ARB and a β-blocker, (iii) treatment of heart failure symptoms with a 
diuretic, regardless of LVEF, and (iv) treatment of LVEF ≤40% in combination with heart 
failure symptoms with ACE-I/ARB in combination with a β-blocker and diuretic.   
 
Contraindications for ACE-I/ARB were confirmed in patients with known ACE-
I/ARB intolerance, history of angio-oedema, bilateral renal artery stenosis, serum potassium 
concentration >5.0 mmol/L, serum creatinine >2.5 mg/dL, and severe aortic stenosis.4 
Contraindications for β-blocker treatment were confirmed in patients with known β-blocker 
intolerance, sinus bradycardia <50 beats per minute, second- or third degree heart block, sick 
sinus syndrome, or asthma.4 In addition, contraindication for diuretic treatment was confirmed 
in patients with known diuretic intolerance, renal failure, clinical signs of hypovolemia or 
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dehydration, serum potassium concentration <3.5 mmol/L, serum magnesium concentration 
<1.2 mmol/L, or serum sodium concentration <135 mmol/L.4  
 
Follow-up 
Long-term mortality was assessed by approaching the municipal civil registries. Survival status 
and medication use was completed by approaching the referring physician. All surviving 
patients received a mailed questionnaire (80% response rate) addressing medication use. 
Medication use in patients who died or patients who did not respond the questionnaire, was 
completed by approaching the referring physician. Mean follow-up was 2.2 ± 1.8 years.  
 
Statistical analysis 
Dichotomous data are presented as numbers and percentages and categorical data are 
compared using the χ2 test. The continuous variables age, blood pressure, and heart rate are 
described as means ± standard deviation (SD) and compared using ANOVA. The relation 
between ACE-I/ARB use in patients with an LVEF ≤40% and long-term mortality was 
evaluated with Cox regression analyses with propensity score adjustment for treatment with 
ACE-I/ARB. Multivariate analyses were adjusted for demographics (age and gender), 
cardiovascular risk factors (ischemic heart disease, cerebrovascular disease, renal dysfunction, 
diabetes mellitus, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, 
and smoking status) and medication use (β-blockers, statins, and aspirin). We report (crude and 
adjusted) hazard ratios with their 95% confidence interval. For all tests, a p-value <0.05 (two-
sided) was considered significant. All analyses were performed using SPSS version 15.0 
statistical software (SPSS, Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
Baseline characteristics 
The baseline study population consisted of 1,005 vascular surgery patients, of which the 
majority were males (77%) and the mean age was 67 (SD ± 10) years. Patients with LV 
dysfunction were older and more often male compared with patients with normal LV function. 
In addition, LV dysfunction was associated with ischemic heart disease, renal dysfunction, 
hypertension, and chronic obstructive pulmonary disease (Table 1).  
 
Prevalence of left ventricular dysfunction 
Left–ventricular dysfunction was diagnosed in 506 (50%) patients (Figure 1), of which 403 
(80%) patients had asymptomatic LV dysfunction and 103 (20%) patients had symptomatic 
heart failure. Of the patients with asymptomatic LV dysfunction, 209 (52%) had asymptomatic 
isolated diastolic LV dysfunction and 194 (48%) had asymptomatic systolic LV dysfunction. In 
total, 130 (67%) patients with asymptomatic systolic LV dysfunction had an LVEF ≤40% 
(Figure 2). In this group, a medical history of myocardial infarction could be appointed as a 
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cause of LV dysfunction in 63 (49%) patients. In addition, valvular stenosis and/or 
regurgitation could be appointed in 33 (25%) patients as a possible cause of LV dysfunction.  
 
Of the 103 patients with symptomatic heart failure, 72 (70%) patients had NYHA II, 
28 (27%) patients had NYHA III, and 3 (3%) patients had NYHA IV. In addition, 69 (67%) 
patients had an LVEF ≤40%. In this group, a medical history of myocardial infarction could 
be appointed as a cause of LV dysfunction in 52 (75%) patients. In addition, valvular stenosis 
and/or regurgitation could be appointed in 10 (15%) patients as a possible cause of LV 
dysfunction.  
 
Left-ventriccular (LV), standard deviation (SD). 
 
 
Figure 1: Prevalence of left ventricular dysfunction in patients undergoing vascular surgery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left ventricular (LV), left ventricular ejection fraction (LVEF). 
Table 1 Baseline characteristics according to left ventricular function  
Normal LV  
function 
LV  
dysfunction 
p- 
value  
[N=499] [N=506]  
Demographics 
 
   
  Age in years (± SD) 65 (11) 70 (10) <0.01 
  Male (%)    363 (73) 406 (80) 0.005 
Medical history (%)    
  Ischemic heart disease   165 (33) 265 (52) <0.01 
  Cerebrovascular disease 169 (34) 184 (36) 0.407 
  Renal dysfunction 61 (12) 114 (23) <0.01 
  Diabetes mellitus 98 (20) 117 (23) 0.178 
  Hypertension 294 (59) 364 (72) <0.01 
  Hypercholesterolemia 233 (47) 249 (49) 0.425 
  Chronic obstructive pulmonary disease 145 (29) 222 (44) <0.01 
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Figure 2: Distribution of the different types of left ventricular dysfunction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deceleration time (DT), left ventricular (LV), left ventricular ejection fraction (LVEF). 
 
 
Pharmacological treatment at first presentation  
Medication use was recorded during the first presentation at the outpatient clinic. Most 
frequently, we observed the use of (i) statins (N=527 or 52%), (ii) aspirin (N=430 or 43%) (iii) 
β-blockers (N=366 or 36%), (iv) ACE-I (N=310 or 31%), (v) diuretics (N=253 or 25%), (vi) 
oral anticoagulants (N=164 or 16%), (vii) ARB (N=144 or 14%), and (viii) nitrates (N=101 or 
10%). Medication use stratified according to LV function is demonstrated in Table 2. The use 
of ACE-I, ARB, β-blockers, diuretics, oral anticoagulants, and nitrates was associated with LV 
dysfunction.  
 
Table 2 
Medication use stratified according to left ventricular function at first 
presentation to the outpatient clinic 
 
MEDICATION  
USE (%) 
 
Normal 
LV 
function 
Diastolic LV 
dysfunction 
(LVEF >50%) 
Systolic LV 
dysfunction 
(LVEF ≥50%) 
Symptomatic 
heart 
failure 
p 
for 
trend 
 [N=499] [N=209] [N=194] [N=103]  
ACE-I 129 (26) 65 (31) 63 (33) 53 (52) <0.001 
ARB 67 (13) 28 (13) 28 (14) 21 (20) 0.005 
β-blockers 138 (28) 80 (38) 81 (42) 67 (65) <0.001 
Diuretics  95 (19) 54 (26) 57 (29) 47 (46) <0.001 
Statins  249 (50) 108 (52) 114 (59) 564 (54) 0.433 
Aspirin  165 (33) 83 (40) 102 (53) 80 (78) <0.001 
Oral anticoagulants 61 (12) 35 (17) 41 (21) 27 (26) <0.001 
Nitrates  32 (6) 19 (9) 20 (10) 30 (29) <0.001 
Angiotensin-converting enzyme inhibitor (ACE-I), angiotensin-receptor blocker (ARB), left ventricular (LV). 
 74 
Pharmacological treatment to improve left ventricular function 
As demonstrated in Table 3, 71 patients with an LVEF ≤40% and NYHA = 1 did not have a 
myocardial infarction in their past history. Of these patients, 31 (44%) patients received no 
treatment and 25 (35%) patients received optimal treatment with ACE-I/ARB to improve LV 
function. In addition, 128 patients with an LVEF ≤40% did have a myocardial infarction in 
their past history and/or had current NYHA ≥2. Of these patients, 31 (24%) patients received 
no treatment and 52 (41%) patients received optimal treatment with ACE-I/ARB in 
combination with a β-blocker to improve LV function. Of the patients who received no or 
suboptimal treatment to improve LV function, 55 (28%) patients had a contraindication to 
ACE-I/ARB and/or β-blockers. Therefore, pharmacological treatment to improve LV function 
could be initiated or improved in 67 (34%) of the patients with an LVEF ≤40%.      
 
Table 3 
Treatment with angiotensin blocking agents and β-blockers to 
improve left ventricular function in patients with left ventricular 
ejection fraction ≤40% 
 
LVEF ≤40% 
 
No previous MI 
and 
current NYHA 1
 a
 
Previous MI 
and/or 
current NYHA ≥2 
b
 
  [N=71] [N=128] 
ACE-I/ARB - β-blocker  -         (%) 31 (44) 31 (24) 
ACE-I/ARB + β-blocker  - (%) 17 (24) 24 (19) 
ACE-I/ARB - β-blocker + (%) 15 (21) 21 (16) 
ACE-I/ARB + β-blocker + (%) 8 (11) 52 (41) 
Optimal treatment  (%) 25 (35) 52 (41) 
Suboptimal treatment contraindication: no (%) 9 (13) 24 (19) 
 contraindication: yes (%) 6 (9) 20 (16) 
No treatment contraindication: no (%) 18 (25) 16 (12) 
 contraindication: yes (%) 13 (18) 15 (12) 
a Treatment for LV function should at least contain ACE-I/ARB, b  Treatment for left ventricular function should at least 
contain an ABA in combination with β-blocker. Angiotensin-converting enzyme inhibitor (ACE-I), angiotensin-receptor 
blocker (ARB), left ventricular ejection fraction (LVEF), myocardial infarction (MI), New York Heart Association 
(NYHA). 
 
Pharmacological treatment to reduce heart failure symptoms 
In total 103 patients had heart failure symptoms with a severity of NYHA class 2 or more 
during the first presentation at the outpatient clinic (Table 4). Of these, 47 (46%) patients 
received a diuretic. After adjustment for contraindications, initiation of diuretic treatment was 
possible in 32 (31%) of the patients. In addition, of the patients with an LVEF ≤40% and heart 
failure symptoms NYHA ≥2 (N=68), 20 (29%) patients received optimal treatment with ACE-
I/ARB in combination with a β-blocker and a diuretic. Of the patients who received no or 
suboptimal treatment to reduce heart failure symptoms, 29 (43%) patients had a 
contraindication to ACE-I/ARB, β-blockers or diuretics. Pharmacological treatment to reduce 
heart failure symptoms could therefore be initiated or improved in 19 (28%) patients with and 
an LVEF ≤40% and heart failure symptoms NYHA ≥2. 
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Table 4 
Treatment with diuretics for symptom relief in patients with 
symptomatic heart failure 
 
NYHA ≥2 
 
LVEF ≤40% 
 
LVEF >40% 
 [N=68] [N=35] 
Diuretic  (%) 34 (50) 13 (37) 
No diuretic contraindication: no (%) 18 (26) 14 (40) 
 contraindication: yes (%) 16 (34) 8 (23) 
Left ventricular ejection fraction (LVEF), New York Heart Association (NYHA). 
 
Pharmacological treatment at time of discharge 
In total, 199 patients with an LVEF ≤40% were recommended to receive at least ACE-I/ARB 
treatment to improve their LV function. Of these patients, 139 (70%) patients were treated 
with an ACE-I/ARB, and 187 (94%) patients with a β-blocker at time of discharge. 
Multivariate analyses demonstrated that ACE-I/ARB treatment was independently associated 
with a reduced risk of long-term mortality (HR  0.53, 95%-CI: 0.33 to 0.87).  
 
 
DISCUSSION 
 
We have found that LV dysfunction was present in around half of the patients undergoing 
vascular surgery and the majority (80%) of LV dysfunction was asymptomatic. Of the patients 
with asymptomatic LV dysfunction, around half the patients had asymptomatic systolic LV 
dysfunction. In addition, we found that in approximately one-third of the patients with LV 
dysfunction (asymptomatic or symptomatic), pharmacological treatment, as recommended in 
ESC guidelines, could be initiated or improved.  
 
In countries represented by the ESC, the prevalence of LV dysfunction is suspected 
to be around 4% in the general population. In septo- and octogenarians, the prevalence is 
between 10 and 20%.4 In our sub-population, of patients undergoing vascular surgery (mean 
age 67 years), we found a prevalence of LV dysfunction of around 50%. With respect to 
adherence of ESC recommendations, the EuroHeart Failure Survey provided information on 
the state of implementation of the guidelines.10 The following prescription rates in patients 
with an LVEF <40% were reported: (i) ACE-I: 80%, (ii) ARB: 6%, (iii) β-blocker: 49%, and 
(iv) diuretics: 88%.10 Drechsler et al. assessed pharmacological treatment in 747 patients with 
symptomatic heart failure (LVEF ≤40%) and found that 84% received ACE-I, 72% received 
ACE-I + β-blocker, and 38% received ACE-I + β-blocker + diuretic.11  
 
The above-mentioned studies included patients with symptomatic heart failure and 
concluded that there is insufficient adherence to the ESC guidelines. All patients included in 
the present study received routine preoperative echocardiography, which allowed the 
evaluation of asymptomatic LVEF ≤40% as well. We found that half of the patients with 
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symptomatic LVEF ≤40% and one-third of patients with symptomatic diastolic LV 
dysfunction received a diuretic. In addition, less than one-third of the patients with 
symptomatic LVEF ≤40% received an ACE-I/ARB + β-blocker + a diuretic. Therefore, we 
found that optimal treatment for symptomatic heart failure was lower in our vascular surgery 
population, compared with the population described by Drechsler et al.11 Understandably, the 
under-use of ACE-I/ARB and β-blockers was more pronounced in patients with 
asymptomatic LVEF ≤40%. 
 
Peripheral arterial disease patients have a three- to six-fold increased risk for 
cardiovascular mortality, compared with patients without peripheral arterial disease.12, 13 There 
is growing awareness of the systemic vascular risk of patients with peripheral arterial disease. 
However, the Reduction of Atherothrombosis for Continued Health registry demonstrated 
that peripheral arterial disease patients do not receive adequate risk factor control, compared 
with individuals with coronary artery or cerebrovascular disease. In addition, it demonstrated 
that improved risk factor control is associated with a positive impact on 1 year cardiovascular 
event rates.14, 15 
 
In the latest ESC perioperative guidelines, heart failure symptoms are a well-
acknowledged risk factor for cardiac events.16 In addition, preoperative cardiac risk indices 
identify symptomatic heart failure to be an important risk factor.17-19 Asymptomatic LV 
dysfunction is considered a precursor of symptomatic heart failure, which is associated with 
high mortality.4 Currently, routine echocardiography is not recommended for preoperative 
evaluation of LV function. However, echocardiography may be performed in asymptomatic 
patients undergoing high-risk surgery, such as vascular surgery.16 We found that one out of 
four vascular surgery patients were eligible for pharmacological treatment of LV dysfunction,4 
and more than half of these patients appeared to be asymptomatic. With more routine use of 
preoperative echocardiography in vascular surgery patients, pharmacological treatment of 
asymptomatic LV dysfunction could be improved.  
 
Based on cost-effectiveness considerations, preoperative echocardiography might not 
be applicable for all vascular surgery patients. However, these days biochemical markers such 
as N-terminal pro-B-type natriuretic peptide, are increasingly used to detect or exclude LV 
dysfunction.20 Therefore, standard measurements of this biochemical marker may play an 
important role in detecting asymptomatic LV dysfunction in vascular surgery patients. In 
patients with increased levels of N-terminal pro-B-type natriuretic peptide, LV dysfunction 
could be confirmed with echocardiography.   
 
Potential limitations of these data merit consideration. First, although we included 
1,005 patients, the sample size eligible for ESC recommended treatment was relatively small. 
Second, although experienced investigators performed off-line assessments of the ultrasound 
images, we cannot rule out interobserver variability to have had minor influence on our results. 
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Third, the evaluation of diastolic LV function was limited, not including E/E’ ratio, 
isovolumetric relaxation time, or Tissue Doppler Imaging. Finally, our population consisted of 
patients referred to a tertiary referral center and may not fully represent the general vascular 
surgery population. 
 
In conclusion, the current study demonstrates that one-third of vascular surgery 
patients with LV dysfunction do not receive optimal pharmacological treatment, as 
recommended in ESC guidelines. More routine use of echocardiography before vascular 
surgery could reduce the observed care gap in vascular surgery patients, with subsequent 
initiation of ESC recommended pharmacological treatment and thereby improve late outcome.  
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ABSTRACT 
 
Background The prognostic value of heart failure symptoms on postoperative outcome is 
well acknowledged in the American College of Cardiology/American Heart Association and 
European Society of Cardiology perioperative guidelines. However, the prognostic value of 
asymptomatic left ventricular (LV) dysfunction remains unknown. This study evaluated the 
prognostic implications of asymptomatic LV dysfunction, assessed with routine preoperative 
echocardiography, in vascular surgery patients.  
 
Methods Echocardiography was performed preoperatively in 1,005 consecutive vascular 
surgery patients. Systolic LV dysfunction was defined as LV ejection fraction <50%. Isolated 
diastolic LV dysfunction was diagnosed based on the ratio of mitral peak velocity of early 
filling (E) to mitral peak velocity of late filling (A), pulmonary vein flow, and deceleration time. 
Troponin T measurements and electrocardiograms were performed routinely before and after 
surgery. Study endpoints were 30-day cardiovascular events and long-term cardiovascular 
mortality. Multivariate regression analyses evaluated the relation between LV function and 
cardiovascular outcome.  
 
Results Left ventricular dysfunction was diagnosed in 506 (50%) patients, of which 80% was 
asymptomatic. In open vascular surgery (N=649), both asymptomatic systolic and isolated 
diastolic LV dysfunction were associated with 30-day cardiovascular events (OR 2.3, 95%-CI: 
1.4 to 3.6 and OR 1.8, 95%-CI: 1.1 to 2.9) and long-term cardiovascular mortality (HR 4.6, 
95%-CI: 2.4 to 8.5 and HR 3.0, 95%-CI: 1.5 to 6.0). In endovascular surgery (N=356), only 
symptomatic heart failure was associated with 30-day cardiovascular events (OR 1.8, 95%-CI: 
1.1 to 2.9) and long-term cardiovascular mortality (HR 10.3, 95%-CI: 5.4 to 19.3).  
 
Conclusions This study demonstrated that asymptomatic LV dysfunction is predictive for 30-
day and long-term cardiovascular outcome in open vascular surgery patients. These data 
suggest that preoperative risk stratification should not solely include heart failure symptoms, 
but that routine preoperative echocardiography might be considered for risk stratification of 
patients undergoing open vascular surgery. 
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INTRODUCTION 
 
Worldwide, about 100 million adults undergo noncardiac surgery every year,1 and by the year 
2020 this number will increase by 25%.2 The risk of adverse perioperative cardiovascular 
events after vascular surgery is particularly high compared with other noncardiac surgeries.3 
Although ischemic heart disease is acknowledged to be the most important risk factor for 
cardiovascular events after noncardiac surgery, several studies indicate that symptomatic heart 
failure is equally important.4-6,  In the general population the prevalence of symptomatic heart 
failure is estimated to be around 2 to 3% and increases with age, with a prevalence estimated 
between 10 to 20% in septo- and octogenarians.7 Whereas the term heart failure describes a 
clinical syndrome, left ventricular (LV) dysfunction describes the impaired mechanical 
properties of the left ventricle. Asymptomatic LV dysfunction is considered a precursor of 
symptomatic heart failure, associated with high mortality.7 The prevalence of patients with 
asymptomatic LV dysfunction and symptomatic heart failure is assumed to be similar.8 
 
In the most recent American College of Cardiology/American Heart Association 
(AHA) and European Society of Cardiology (ESC) perioperative guidelines,3, 9 the prognostic 
value of symptomatic heart failure on postoperative outcome is well acknowledged. However, 
the prognostic implications of asymptomatic LV dysfunction remains unknown. Routine 
perioperative evaluation of LV function is not recommended in ACC/AHA perioperative 
guidelines (Class III, Level of Evidence: C).9 Additionally, LV assessment with rest 
echocardiography is not recommended in ESC perioperative guidelines (Class III, Level of 
Evidence: C) for asymptomatic patients.3  
 
The present study was conducted to evaluate the impact of asymptomatic isolated 
diastolic and asymptomatic systolic LV dysfunction, objectified with routine preoperative 
echocardiography, on postoperative outcome of patients undergoing open or endovascular 
surgery.  
 
 
MATERIAL AND METHODS 
 
Study population 
The study population has previously been described and consisted of 1,005 consecutive 
vascular surgery patients undergoing elective (open or endovascular) lower extremity artery, 
carotid artery or abdominal aorta repair.10 This prospective cohort study was performed at the 
Erasmus Medical Center in Rotterdam, the Netherlands, during the period between 2002 and 
2008. The study was approved by the hospital’s ethics committee and performed with informed 
consent of all patients.  
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Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Cardiac history was assessed 
and ischemic heart disease was defined as a history of angina pectoris, coronary 
revascularization, or myocardial infarction. Additional clinical data included age, gender, blood 
pressure, heart rate, cerebrovascular disease (history of ischemic or hemorrhagic stroke), renal 
dysfunction (serum creatinine >2 mg/dL), diabetes mellitus (fasting blood glucose ≥126 
mg/dL or requirement of anti-diabetic medication), hypertension (blood pressure ≥140/90 
mmHg in non-diabetics and ≥130/80 mmHg in diabetics,11 or requirement of antihypertensive 
medication), hypercholesterolemia (low density lipoprotein cholesterol ≥135 mg/dL or 
requirement of lipid-lowering medication), chronic obstructive pulmonary disease (according to 
the Global Initiative on Obstructive Lung Diseases classification), and smoking status. Finally, 
the use of β-blockers, statins, aspirin, oral anticoagulants, angiotensin-converting enzyme 
inhibitors, angiotensin-receptor blockers, diuretics, and nitrates was recorded.  
 
Echocardiography 
Preoperatively, transthoracic echocardiography was performed in all patients using a portable 
Acuson Cypress Ultrasound System (Acuson, A Siemens Company, Mountain View, CA) with 
a 3V2C transducer (3.0/3.5/2.5/2.0 MHz) for adult cardiac evaluation. Standard parasternal 
and apical two- and four-chamber views were obtained during rest with the patient in the left 
lateral decubitus position as recommended.12 Left ventricular end-systolic and end-diastolic 
volumes were determined and LV ejection fraction was calculated using the biplane Simpson’s 
technique,13 with an inter- and intraobserver variability of 9 to 12% and 6%, respectively.14 
Systolic (S) and diastolic (D) pulmonary vein flow, deceleration time and ratio of mitral peak 
velocity of early filling (E) to mitral peak velocity of late filling (A) were determined in apical 4-
chamber. Echocardiographic data were used for research purposes and not for clinical 
management.  
 
Definition of left ventricular dysfunction  
Left ventricular ejection fraction <50%, both with and without accompanying diastolic 
dysfunction, defined systolic LV dysfunction.7 Diastolic LV dysfunction was confirmed in 
patients with E/A-ratio <0.8 (impaired relaxation) or >2 (restrictive relaxation).15 Abnormal 
pulmonary vein flow (S/D <1) was used to distinguish normal and pseudo-normal diastolic 
LV function in patients with E/A-ratio between 0.8 and 2.16 Deceleration time >220 ms 
(impaired relaxation) or <140 ms (restrictive relaxation) defined diastolic LV dysfunction in 
patients with atrial fibrillation.16 Diastolic LV dysfunction, in the presence of an LV ejection 
fraction ≥50%, defined asymptomatic isolated diastolic dysfunction. The presence of LV 
dysfunction in combination with heart failure symptoms (shortness of breath, fatigue, exercise 
intolerance, signs of fluid retention) defined symptomatic heart failure.7 Two experienced 
investigators performed off-line assessments of the obtained ultrasound images. When there 
was disagreement between the two assessors, a third investigator viewed the images without 
knowledge of the previous assessment and a majority decision was reached.  
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Study outcomes 
Serial electrocardiograms and troponin T measurements were obtained from all patients before 
surgery, postoperatively on day 1, 3, 7 and before discharge. Study endpoints were 30-day 
cardiovascular (CV) events (defined as myocardial ischemia, myocardial infarction and CV 
mortality) and long-term CV mortality. Myocardial ischemia was present in patients with 
normal preoperative and elevated (>0.03 ng/mL) troponin T levels postoperatively.17 Elevated 
troponin T levels in combination with electrocardiographic changes (new onset ST-T changes 
and pathological Q waves) defined myocardial infarction.18 Troponin T level was measured 
using a whole blood rapid test (TropT version 2, Roche Diagnostics, Mannheim, Germany). 
Patients with elevated troponin T levels before surgery were not included in the study. Patients 
were subjected to a follow-up visit with one of the study investigators 30 days post surgery and 
for those patients who did not attend, the referring physician was approached. In patients still 
admitted or re-admitted at the Erasmus MC, 30-day follow-up was completed using the 
Erasmus MC medical records.  
 
 Long-term mortality was assessed by approaching the municipal civil registries. 
Cause of death was ascertained by examining death certificates and otherwise by reviewing 
medical records. Cause of death was classified as either cardiovascular or noncardiovascular 
death. Cardiovascular death was defined as any death with a cerebro-cardiovascular 
complication as the primary or secondary cause and included death following myocardial 
infarction, serious cardiac arrhythmias (defined as the presence of a sustained cardiac rhythm 
disturbance that required urgent medical intervention), congestive heart failure, stroke 
(cerebrovascular event or transient ischemic attack), and surgery related bleeding complications 
(only a postoperative cause of death). Sudden unexpected death was classified as a 
cardiovascular death. Cause of death was separately assessed by two authors. In the absence of 
consensus, a third investigator assessed the cause of death and a majority decision was reached. 
Follow-up was completed in all patients.  
 
Statistical analysis 
Continuous variables are described as means ± standard deviation (SD) and dichotomous data 
as numbers and percentages. Continuous data were compared using ANOVA for trend and 
categorical data using the linear by linear association. The prognostic value of LV dysfunction 
towards 30-day and long-term follow-up was evaluated with logistic and Cox regression 
analyses, respectively. Multivariate analyses were primarily adjusted for covariates (age, sex, 
ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus, 
hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, and smoking 
status) prospectively locked into the model based on the clinical knowledge and belief that 
these factors might (i) contribute to the study outcomes and (ii) confound the association 
between the primary echo predictors and the study outcomes. Secondary adjustments were 
done in a step-wise fashion and these analyses were adjusted for medication use (β-blockers, 
statins, aspirin, oral anticoagulants, angiotensin-converting enzyme inhibitors, angiotensin-
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receptor blockers, diuretics, and nitrates) on top of the covariates used in the primary 
regression model, (crude and adjusted) odds and hazard ratios with their 95% confidence 
interval (95%-CI) were reported. For all tests, a p-value <0.05 (two-sided) was considered 
significant. Cumulative long-term survival was determined by the Kaplan-Meier method. All 
analyses were performed using SPSS version 15.0 statistical software (SPSS, Inc., Chicago, IL, 
USA).  
 
 
RESULTS 
 
Patients population 
A total of 1,005 patients undergoing open vascular (N=649 or 65%) or endovascular (N=356 
or 35%) surgery were included in the study. Of the open vascular surgery patients; 148 patients 
(23%)  underwent carotid artery repair, 249 patients (38%) underwent abdominal aorta repair, 
and 252 patients (39%) underwent lower extremity artery repair. In comparison, of the 
endovascular patients; 90 patients (25%) underwent carotid artery repair, 162 patients (46%) 
underwent abdominal aorta repair, and 104 patients (29%) underwent lower extremity artery 
repair. All patients undergoing open vascular surgery had general anesthesia and 56 (35%) of 
the patients undergoing endovascular aortic repair had general anesthesia. General anesthesia 
was not provided for the percutaneous procedures.  
 
The majority of patients were men (77%) and the mean age was 67 ±10 years. Mean 
follow-up was 2.2 ± 1.8 years (range 3 to 79 months). Left ventricular dysfunction was 
diagnosed in 506 (50%) patients. Of the patients with LV dysfunction, 403 (80%) patients had 
asymptomatic LV dysfunction and 103 (20%) had symptomatic heart failure. Of the patients 
with asymptomatic LV dysfunction, 209 (52%) had asymptomatic isolated diastolic LV 
dysfunction and 194 (48%) had asymptomatic systolic LV dysfunction. Of the 103 patients 
with symptomatic heart failure, 72/70% patients had New York Heart Association Class II, 
28/27% patients had New York Heart Association Class III (12 patients had signs of fluid 
retention objectified as peripheral oedema) and 3/3% patients had New York Heart 
Association Class IV, with signs of pulmonary oedema objectified with physical examination. 
 
Baseline characteristics 
Clinical parameters are shown in Table 1. Patients with LV dysfunction were older and had 
higher incidence of ischemic heart disease, renal dysfunction, hypertension, chronic obstructive 
pulmonary disease and had higher resting heart rate compared with patients with normal LV 
function. In addition, patients with LV dysfunction more often received β-blockers, oral 
anticoagulants, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, 
diuretics and nitrates. Patients with asymptomatic systolic LV dysfunction or symptomatic 
heart failure were more often male. A higher number of patients with symptomatic heart 
failure underwent open surgery compared with the other groups. 
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Table 1 Baseline characteristics according to left ventricular function 
 
Normal 
LV 
function 
Asymptomatic 
isolated 
diastolic LV 
dysfunction 
Asymptomatic 
systolic 
LV 
dysfunction 
 
Symptomatic 
heart 
failure 
 
p 
for 
trend 
 
[N=499] [N=209] [N=194] [N=103]  
Demographics (mean ± SD) 
 
    
Age  65 (11) 70 (10) 70 (8) 70 (10) <0.001 
Male (%)   363 (73) 154 (74) 168 (87) 84 (82) 0.001 
Systolic blood pressure  141 (24) 142 (24) 141 (26) 135 (23) 0.111 
Diastolic blood pressure  79 (12) 80 (12) 79 (12) 77 (12) 0.199 
Heart rate  70 (13) 73 (13) 73 (15) 72 (15) 0.012 
Medical history (%)      
Ischemic heart disease  165 (33) 83 (40) 102 (53) 80 (78) <0.001 
Cerebrovascular disease  169 (34) 83 (40) 76 (39) 25 (24) 0.603 
Renal dysfunction  62 (12) 34 (16) 41 (21) 42 (41) <0.001 
Diabetes mellitus   141 (28) 62 (30) 64 (33) 30 (29) 0.698 
Hypertension   294 (59) 153 (73) 135 (70) 76 (74) <0.001 
Hypercholesterolemia  303 (65) 131 (65) 114 (60) 61 (63) 0.729 
COPD  100 (20) 49 (23) 50 (26) 32 (31) <0.001 
Smoker, current  225 (45) 85 (41) 69 (36) 41 (40) 0.046 
Surgery type (%)      
Open 320 (64) 129 (62) 118 (61) 82 (80) 0.102 
  Lower extremity  131 (26) 42 (21) 43 (22) 36 (35) 0.926 
  Abdominal aorta  110 (22) 51 (24) 48 (25) 40 (39) 0.100 
  Carotid artery  79 (16) 36 (17) 27 (14) 6 (6) 0.062 
Endovascular 179 (36) 80 (38) 76 (39) 21 (20) 0.102 
  Lower extremity   61 (12) 22 (10) 16 (8) 5 (5) 0.179 
  Abdominal aorta  71 (14) 40 (19) 37 (19) 14 (14) 0.065 
  Carotid artery  47 (10) 18 (9) 23 (12) 2 (1) 0.633 
Medication (%)      
β-blockers  368 (74) 161 (77) 162 (84) 87 (84) 0.001 
Statins  352 (71) 145 (70) 149 (77) 72 (70) 0.433 
Aspirin  303 (61) 110 (53) 114 (60) 61 (59) 0.578 
Oral anticoagulants   61 (12) 35 (17) 41 (21) 27 (26) <0.001 
ACE inhibitors   129 (26) 65 (31) 63 (33) 53 (52) <0.001 
ARB  49 (13) 29 (14) 36 (19) 23 (22) 0.011 
Diuretics 95 (19) 54 (26) 56 (29) 49 (48) <0.001 
Nitrates   32 (6) 19 (9) 20 (10) 30 (29) <0.001 
Angiotensin-converting enzyme (ACE), angiotensin-receptor blocker (ARB), chronic obstructive pulmonary disease 
(COPD), left ventricular (LV), standard deviation (SD). 
 
 
Thirty-day outcome 
During 30-day follow-up, 172 (17%) patients had a nonfatal myocardial event of whom 131 
(76%) patients had myocardial ischemia and 41 (24%) patients had myocardial infarction. In 
total, 51 (10%) patients with normal LV function had a 30-day CV event, compared with 38 
(18%) patients with asymptomatic isolated diastolic LV dysfunction, 44 (23%) patients with 
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asymptomatic systolic LV dysfunction and 50 (49%) patients with symptomatic heart failure (p 
< 0.001, Table 2). Multivariate analyses, in patients undergoing open surgery, demonstrated that 
asymptomatic isolated diastolic LV dysfunction, asymptomatic systolic LV dysfunction, and 
symptomatic heart failure were all associated with 30-day CV events with odds ratios of 1.8 
(95%-CI: 1.1 to 2.9), 2.3 (95%-CI: 1.4 to 3.6) and 6.8 (95%-CI: 4.0 to 11.6), respectively (Table 
3). Other risk factors associated with 30-day CV events were age, ischemic heart disease, renal 
dysfunction, and chronic obstructive pulmonary disease with odds ratios of 1.8 (95%-CI: 1.0 to 
1.1), 1.7 (95%-CI: 1.1 to 2.6), 3.9 (95%-CI: 2.2 to 7.1), and 1.8 (95%-CI: 1.2 to 2.6), 
respectively. Multivariate analyses, in patients undergoing endovascular surgery, demonstrated 
that symptomatic heart failure was associated with 30-day CV events with an odds ratio of 9.3 
(95%-CI: 2.3 to 37.7) (Table 4). For both types of surgical procedures, additional adjustment 
for medication use (β-blockers, statins, angiotensin-converting enzyme inhibitors, angiotensin-
receptor blockers, and diuretics) did not change the prognostic value of LV dysfunction 
towards 30-day outcome. 
 
 
Table 2 Left ventricular function and postoperative outcome 
 
Normal 
LV 
function 
Asymptomatic 
isolated 
diastolic LV 
dysfunction 
Asymptomatic 
systolic 
LV 
dysfunction 
 
Symptomatic 
heart 
failure 
 
 
p- 
value 
 
[N=499] [N=209] [N=194] [N=103]  
30-day (%) 
 
 
 
       
  Cardiovascular events  
Rocedures 
51 (10) 38 (18) 44 (23) 50 (49) <0.001 
  Myocardial damage 50 (10) 36 (17) 41 (21) 45 (44) <0.001 
  Cardiovascular 
mortality  
2 (0) 4 (2) 7 (4) 11 (11) <0.001 
  All-cause mortality   6 (1) 5 (2) 7 (4) 11 (11) <0.001 
Long-term (%)         
  Cardiovascular 
mortality  
15 (3) 21 (10) 31 (16) 40 (39) <0.001 
  All-cause mortality  54 (11) 31 (15) 38 (20) 41 (40) <0.001 
Left ventricular (LV) 
 
 
Long-term outcome 
During long-term follow-up, 164 (16%) patients died. The study endpoint long-term CV 
mortality was reached in 107 (11%) patients. In total, 15 (3%) patients with normal LV 
function died due to CV causes, compared with 21 (10%) patients with asymptomatic isolated 
diastolic LV dysfunction, 31 (16%) patients with asymptomatic systolic LV dysfunction, and 40 
(39%) patients with symptomatic heart failure (p < 0.001, Table 2).  
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Figure 1:  Left ventricular function and long-term survival after vascular surgery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Left ventricular (LV). 
 
 
Table 3 
Association between left ventricular function and postoperative 
outcome: open vascular surgery 
   Univariate Multivariate 
30-day CV events N (%) OR [95%-CI] OR [95%-CI] 
  Normal LV function  
 
44/320 
44/320 
(14) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
30/129 
 
(23) 2.0 1.2-3.1 1.8 1.1-2.9 
  Systolic LV dysfunction  
 
36/118 
 
(31) 2.6 1.7-4.0 2.3 1.4-3.6 
  Symptomatic heart failure 44/82 (54) 8.3 5.1-13.4 6.8 4.0-11.6 
Long-term CV mortality N (%) HR [95%-CI] HR [95%-CI] 
  Normal LV function  
 
8/320 (3) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
14/129 
 
(11) 3.5 1.8-6.8 3.0 1.5-6.0 
  Systolic LV dysfunction  
 
23/118 
 
(20) 5.2 2.8-9.7 4.6 2.4-8.5 
  Symptomatic heart failure 31/82 (38) 13.6 7.5-24.6 10.3 5.4-19.3 
Long-term all-cause mortality N (%) HR [95%-CI] HR [95%-CI] 
  Normal LV function  
 
37/320 (12) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
20/129 
 
(16) 1.5 0.9-2.3 1.4 0.9-2.1 
  Systolic LV dysfunction  
 
28/118 
 
(24) 1.8 1.2-2.7 1.7 1.1-2.5 
  Symptomatic heart failure 32/82 (39) 3.9 2.6-5.8 3.1 2.0-4.8 
 Multivariate analysis adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes 
mellitus, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, and smoking. Cardiovascular (CV), 
confidence interval (CI), hazard ratio (HR), left ventricular (LV), odds ratio (OR). 
 
 
Cumulative survival for all patients is shown in Figure 1 (log rank p < 0.001). Of the patients 
with LV dysfunction who reached the study endpoint long-term CV mortality, 48 patients 
(52%) demonstrated myocardial ischemia or infarction during 30-day follow-up. Multivariate 
analyses, in patients undergoing open vascular surgery, demonstrated that asymptomatic 
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isolated diastolic LV dysfunction, asymptomatic systolic LV dysfunction and symptomatic 
heart failure were all associated with long-term CV mortality with hazard ratios of 3.0 (95%-CI: 
1.5 to 6.0), 4.6 (95%-CI: 2.4 to 8.5) and 10.3 (95%-CI: 5.4 to 19.3), respectively (Table 3).  
 
 
Table 4 
Association between left ventricular function and postoperative 
outcome: endovascular surgery 
   Univariate Multivariate 
30-day CV events N (%) OR [95%-CI] OR [95%-CI] 
  Normal LV function  
 
7/179 
44/320 
(4) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
8/80 
 
(10) 2.7 0.9-7.8 2.2 0.7-6.9 
  Systolic LV dysfunction  
 
8/76 
 
(11) 2.9 1.0-8.6 2.5 0.8-7.8 
  Symptomatic heart failure 6/21 (29) 9.8 2.9-33.0 9.3 2.3-37.7 
Long-term CV mortality N (%) HR [95%-CI] HR [95%-CI] 
  Normal LV function  
 
7/179 (4) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
7/80 
 
(9) 2.2 0.8-6.4 1.7 0.5-5.3 
  Systolic LV dysfunction  
 
8/76 
 
(11) 2.4 0.8-6.5 2.2 0.8-6.6 
  Symptomatic heart failure 9/21 (43) 14.5 5.4-39.1 11.4 3.7-35.6 
Long-term all-cause mortality N (%) HR [95%-CI] HR [95%-CI] 
  Normal LV function  
 
17/179 (10) 1.0  1.0  
  Isolated diastolic LV dysfunction  
 
11/80 
 
(14) 1.5 0.7-3.2 1.2 0.5-2.7 
  Systolic LV dysfunction  
 
10/76 
 
(13) 1.3 0.6-2.9 1.2 0.5-2.9 
  Symptomatic heart failure 9/21 (43) 6.1 2.7-13.8 5.1 1.9-13.3 
 Multivariate analysis adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes 
mellitus, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, and smoking. Cardiovascular (CV), 
confidence interval (CI), hazard ratio (HR), left ventricular (LV), odds ratio (OR). 
 
 
Other risk factors associated with long-term CV mortality were age, ischemic heart 
disease, renal dysfunction, and smoking with hazard ratios of 1.1 (95%-CI: 1.1 to 1.2), 1.6 
(95%-CI: 1.1 to 2.8), 2.5 (95%-CI: 1.3 to 5.1) and 2.0 (95%-CI: 1.2 to 3.1), respectively. 
Multivariate analyses, in patients undergoing endovascular surgery, demonstrated that 
symptomatic heart failure was associated with long-term CV mortality with a hazard ratio of 
11.4 (95%-CI: 3.7 to 35.6) (Table 4). For both types of surgical procedures, additional 
adjustment for medication use did not change the prognostic value of LV dysfunction towards 
long-term outcome.   
 
 
DISCUSSION 
 
The present study demonstrated that open vascular surgery patients with asymptomatic 
isolated diastolic- or systolic LV dysfunction, were at increased risk for 30-day CV events and 
long-term CV mortality. In endovascular surgery patients, only symptomatic heart failure was 
associated with an increased risk for 30-day CV events and long-term CV mortality. In 
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ACC/AHA and ESC guidelines, symptoms of heart failure are acknowledged to be an 
important predictor of postoperative outcome.  However, our data suggest that asymptomatic 
LV dysfunction should be imbedded in preoperative risk stratification of vascular surgery 
patients, as well.   
 
Left ventricular dysfunction is caused by neuro-hormonal responses activated by 
cardiac injury or an increased hemodynamic load. These responses are known to induce (i) 
sympathetic stimulation, (ii) salt and water retention, and (iii) vasoconstriction.19, 20 Although 
these responses are initially adaptive, they become maladaptive over time, due to a process 
called LV remodelling. This process leads to (i) LV hypertrophy (concentric remodelling) 
associated with diastolic LV dysfunction or (ii) LV dilatation (eccentric remodelling) associated 
with systolic LV dysfunction.21 During surgery, high catecholamine production is responsible 
for vasoconstriction and hemodynamic stress.2 Surgical stress and perioperative fluid 
administration increases LV pre- and afterload, making patients with systolic LV dysfunction 
susceptible for perioperative myocardial damage.22 During surgery there is an increased 
oxygen-demand and patients with coronary artery stenosis are at increased risk for 
perioperative myocardial damage, due to a mismatch between oxygen-supply and demand.3, 23 
Patients with diastolic LV dysfunction have a reduced coronary flow reserve, making them 
susceptible to perioperative myocardial damage as well.21 In addition, concentric remodelling 
causes a reduction of LV compliance, making LV filling dependent upon blood volume 
contributed by LV preload. Perioperative LV preload reductions can result in tachycardia with 
concomitant reduction of coronary perfusion, leading to myocardial damage.24  
 
Episodes of perioperative myocardial damage are most often silent and therefore 
patients often remain untreated, which might contribute to an increased risk of long-term CV 
mortality.25, 26 We have found that approximately three out of four patients with perioperative 
damage had LV dysfunction. In line with previous studies, we have found that endovascular 
surgery was associated with a reduced incidence of perioperative myocardial damage, 
compared with open surgery, possibly explained by reduced myocardial stress and the need for 
lower fluid administration during endovascular procedures.27, 28 In addition, one should keep in 
mind that carotid surgery is associated with lower cardiac risk compared with abdominal 
aneurysm repair and lower extremity revascularization.  
 
Myocardial perfusion scintigraphy and pharmacological stress echocardiography are 
known to accurately stratify patients at risk for perioperative myocardial damage.29-31 In 
addition, the presence of wall motion abnormalities at rest has predictive value for the 
development of perioperative cardiac events as well.31 Until now, studies addressing the impact 
of heart failure in surgical patients mainly focused on symptomatic patients with a reduced LV 
ejection fraction.5, 23, 32, 33 A retrospective study conducted by Xu-Cai et al. evaluated the impact 
of symptomatic heart failure with a preserved LV ejection fraction, demonstrating an increased 
risk for long-term mortality. However no increased risk for perioperative mortality was 
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observed.34 Recently, Maytal et al. studied 313 vascular surgery patients and found diastolic LV 
dysfunction to be a predictor of adverse CV outcome, however, systolic LV dysfunction was 
not.35 Several differences between the study conducted by Maytal et al. and the present study 
that might explain the different outcome regarding the impact of systolic LV dysfunction on 
CV outcome, such as: (i) subanalysing open vs. endovascular surgery, (ii) troponin T 
measurements obtained routinely or when clinically indicated, (iii) definition of the LV 
function groups, and (iv) follow-up duration. To our knowledge, the present study is the first 
to demonstrate that asymptomatic LV dysfunction (diastolic and systolic) is associated with an 
increased risk for adverse CV outcome of open vascular surgery patients.  
 
In the most recent ACC/AHA and ESC perioperative guidelines,3, 9 the prognostic 
value of symptoms of heart failure on postoperative outcome is well acknowledged and 
incorporated into the decision process with regard to proceeding directly to surgery. In 
addition, preoperative cardiac risk indices incorporate symptomatic heart failure as an 
important risk factor.4, 6, 36 To define surgical patients at ‘high risk’ for developing adverse CV 
events, one point should be assigned to patients with (a medical history of) current symptoms 
of heart failure, next to other risk factors such as ischemic heart disease, cerebrovascular 
disease, renal dysfunction, diabetes mellitus or high-risk surgery. To prevent an 
underestimation of the ‘cardiac risk burden’ of vascular surgery patients, our data suggest that 
asymptomatic LV dysfunction should be imbedded in these risk indices as well. 
 
Our results indicate that asymptomatic LV dysfunction is not associated with 
increased risk for 30-day CV events and long-term CV mortality in endovascular surgery 
patients. An explanation could lie in the fact that endovascular surgery is associated with 
reduced myocardial stress compared with open vascular surgery.27, 28 The detection of 
asymptomatic LV dysfunction with routine preoperative echocardiography could, therefore, 
add valuable information in the decision making between open and endovascular surgery.    
 
Biochemical markers, such as N-terminal pro-B-type natriuretic peptide, are 
increasingly used in the detection and exclusion of heart failure, 37 and have proven to predict 
poor outcome after vascular surgery.38 Standard measurements of this biochemical marker may 
play an important role to detect asymptomatic LV dysfunction in vascular surgery patients, 
regardless of the presence of heart failure symptoms. However, the diagnostic value of 
natriuretic peptides in asymptomatic patients at risk for diastolic or systolic LV dysfunction is 
controversial. In a recent study conducted by Luers et al, plasma levels of natriuretic peptides 
significantly increased with a decreasing ejection fraction and with a severe degree of diastolic 
dysfunction.39 Therefore, the authors suggest that high-risk individuals may be screened most 
efficiently by using a score system, incorporating clinical data and N-terminal pro-B-type 
natriuretic peptide. In vascular surgery patients, future studies are needed to evaluate the value 
of B-type natriuretic peptides vs. echocardiography to detect LV dysfunction in patients with 
or without heart failure symptoms. In 2003 Grayburn et al. proposed to shift the paradigm 
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from preoperative noninvasive risk stratification to therapy.40 Routine preoperative evaluation 
of LV function could reveal patients with asymptomatic LV dysfunction eligible for 
pharmacological treatment. Before surgery, low-dose β-blockade could be considered, titrated 
to obtain a heart rate between 60-70 beats per minute.41 In addition, initiation of angiotensin 
blockers could be considered after surgery.42 
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent the 
general vascular surgery population scheduled. Second, although two experienced investigators 
performed an off-line assessment of ultrasound images, we cannot rule out interobserver 
variability to have had a minor influence on our results. Third, the evaluation of diastolic LV 
function with conventional Doppler, ratio of mitral peak velocity of early filling (E) to mitral 
peak velocity of late filling (A) and pulmonary vein filling patterns was limited due to preload 
dependency and not including Valsalva maneuver, ratio of mitral peak velocity of early filling 
(E) to early diastolic mitral annular velocity (E'), isovolumetric relaxation time or Tissue 
Doppler Imaging. 
 
In conclusion, this study demonstrated that asymptomatic LV dysfunction is a 
predictor of CV outcome in open vascular surgery patients. These data suggest that 
preoperative risk stratification should not solely include symptomatic heart failure, already 
acknowledged in ACC/AHA and ESC perioperative guidelines, however asymptomatic LV 
dysfunction should be imbedded as well. Standard preoperative evaluation of LV function 
could be argued based on our results, suggesting a move towards more routine use of cardiac 
echo in open vascular surgery patients. 
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ABSTRACT 
 
Background The co-existence between chronic obstructive pulmonary disease (COPD) and 
heart failure has been previously described. However, the co-existence between COPD and 
subclinical left ventricular (LV) dysfunction, without the presence of heart failure symptoms, is 
less well understood. This study determined the relationship and clinical relevance of COPD 
and subclinical LV dysfunction in vascular surgery patients.  
 
Methods 1,005 consecutive vascular surgery patients were included in which COPD was 
determined using spirometry and LV function using echocardiography. Mild COPD was 
defined as FEV1 ≥80% of predicted + FEV1/FVC-ratio <0.70. Moderate/severe COPD was 
defined as FEV1 <80% of predicted + FEV1/FVC-ratio <0.70. Systolic LV dysfunction was 
defined as LV ejection fraction <50% and diastolic LV dysfunction was diagnosed based on 
E/A-ratio, pulmonary vein flow and deceleration time. Multivariate regression analyses were 
used to evaluate the impact of COPD and LV dysfunction on all-cause mortality. The mean 
follow-up time was 2.2 ± 1.8 years. 
 
Results Both, mild and moderate/severe COPD were associated with increased risk for 
subclinical LV dysfunction with odds ratios of 1.6 (95%-CI: 1.1 to 2.3) and 1.7 (95%-CI: 1.2 to 
2.4), respectively. Mild or moderate/severe COPD in combination with LV dysfunction was 
associated with an increased risk for all-cause mortality (mild: HR 1.7, 95%-CI: 1.1 to 3.6, 
moderate/severe: HR 2.5, 95%-CI: 1.5 to 4.7). 
 
Conclusions COPD was associated with an increased risk for subclinical LV dysfunction. 
COPD + subclinical LV dysfunction was associated with an increased risk for all-cause 
mortality compared with patients with COPD + normal LV function. Echocardiography may 
be useful to detect subclinical cardiovascular disease and risk stratify COPD patients 
undergoing vascular surgery. 
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INTRODUCTION 
 
Every year, there are 100 million adults who undergo a noncardiac surgical procedure across 
the world.1 This number is expected to increase by 25% by the year 2020.2 The risk of 
perioperative complications increases in patients with co-morbidities. There is increasing 
evidence that chronic lung disease, such as chronic obstructive pulmonary disease (COPD), 
and cardiovascular disease are common co-morbidities in these surgical patients. Interestingly, 
it appears that these co-morbidities are interrelated and often co-exist in the same patients, 
independent of age and smoking history.3, 4 These patients have extremely poor prognosis 
following surgery. With the increasing preoperative use of echocardiography and spirometry, it 
may now be possible to identify patients with mild COPD and subclinical left ventricular (LV) 
dysfunction before surgery, providing an opportunity to determine the clinical significance of 
mild COPD and subclinical LV dysfunction in patients undergoing noncardiac surgical 
procedures. In the current study, we determined the relationship of LV dysfunction to COPD 
and the impact that these co-morbidities have, independently and collectively, on the risk of 
mortality in these patients. We hypothesized that COPD would be independently associated 
with LV dysfunction and that the presence of even subclinical LV dysfunction in patients with 
COPD would significantly increase the risk of mortality.  
 
 
MATERIAL AND METHODS 
 
Study population 
The patient population consisted of 1,005 consecutive patients undergoing lower extremity 
artery, abdominal aortic aneurysm or abdominal aortic stenosis, or carotid artery repair. Both 
open and endovascular procedures were included. The study was performed at the department 
of vascular surgery of the Erasmus Medical Center in Rotterdam, the Netherlands, during the 
time period between 2002 and 2008. The study was approved by the hospital’s ethics 
committee and performed with informed consent of all patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Cardiac history was assessed 
and ischemic heart disease was defined as a history of angina pectoris, coronary 
revascularization or myocardial infarction. Additional clinical data included: age, gender, 
cerebrovascular disease (defined as a history of ischemic or hemorrhagic stroke), abdominal 
aortic disease (defined as abdominal aortic aneurysm or stenosis), renal dysfunction (serum 
creatinine >2.0 mg/dL), diabetes mellitus (fasting blood glucose ≥7.0 mmol/L or requirement 
for insulin or oral anti-diabetic medication), hypertension (blood pressure ≥140/90 mmHg in 
non-diabetic patients and ≥130/80 mmHg in diabetics or the use of antihypertensive 
medication), hypercholesterolemia (defined as low-density lipoprotein cholesterol >3.5 
mmol/L or the requirement of lipid-lowering medication), and smoking status. The use of the 
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prescription medications was captured and included β-blockers, statins, aspirin, oral 
anticoagulants, angiotensin-converting enzyme (ACE) inhibitors, diuretics, nitrates, 
corticosteroids, and bronchodilators.  
 
Chronic obstructive pulmonary disease 
The diagnosis of COPD was based on preoperative post-bronchodilator spirometry, which 
was performed in 95% of the patients according to the guidelines of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD). Mild COPD was defined as forced expiratory 
volume in one second (FEV1) 80% of predicted or greater in the presence of FEV1/forced 
vital capacity (FVC) ratio of <0.70.5 Moderate/severe COPD was defined as FEV1/FVC 
<0.70 and FEV1 <80% of the predicted. In those patients who did not have spirometry, the 
diagnosis of COPD was based on symptoms (dyspnea, sputum production, and/or cough) 
plus the use of a pulmonary medication such as bronchodilators and corticosteroids.  
 
Left ventricular function 
Preoperatively, transthoracic echocardiography was performed in all patients using a handheld 
Acuson Cypress Ultrasound System (7V3c transducer). Standard parasternal and apical two- 
and four-chamber views were obtained at rest with the patient in the left lateral decubitus 
position as recommended.6 Left ventricular end-systolic and end-diastolic volumes were 
determined and LV ejection fraction was calculated using the biplane Simpson’s technique.7 
Systolic (S) and diastolic (D) pulmonary vein flow, deceleration time and mitral inflow E/A 
ratios of peak velocities (at early rapid filling E and late filling due to atrial contraction A) were 
determined in apical 4-chamber view as recommended by the American Society of 
Echocardiography.8  Systolic LV dysfunction was defined as LV ejection fraction <50%.9 
Diastolic LV dysfunction was confirmed in patients with E/A-ratio <0.8 (impaired relaxation) 
or >2 (restrictive relaxation).10 Abnormal pulmonary vein flow (S/D <1) was used to 
distinguish normal and pseudo-normal diastolic LV function in patients with E/A-ratio 
between 0.8 and 2.11 Deceleration time >220 ms (impaired relaxation) or <140 ms (restrictive 
relaxation) defined diastolic LV dysfunction in patients with atrial fibrillation.11 Patients with 
both systolic and diastolic LV dysfunction were classified as systolic LV dysfunction. The 
presence of LV dysfunction in combination with heart failure symptoms (shortness of breath, 
fatigue, exercise intolerance, signs of fluid retention)9 defined symptomatic heart failure, 
confirmed in patients with New York Heart Association functional class ≥I. 
 
Follow-up and outcome 
Survival status was determined using municipal civil registries. The mean follow-up time was 
2.2  ± 1.8 years. 
 
Statistical analysis 
Dichotomous data are described as numbers and percentages. Continuous variables are 
described as means ± standard deviation. Continuous data were compared using one-way 
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ANOVA and categorical data were compared using a χ2 test. Cumulative long-term survival 
was determined using the Kaplan-Meier method. Univariate and multivariate Cox regression 
analyses were performed to evaluate the relationship of COPD and LV dysfunction with all-
cause mortality. Multivariate regression analyses were adjusted for age, gender, ischemic heart 
disease, cerebrovascular disease, renal dysfunction, diabetes mellitus, hypertension, 
hypercholesterolemia, and smoking status. A sub-analysis was performed to evaluate the 
prognostic value of COPD towards postoperative outcome, in addition to the Revised Cardiac 
Risk (RCR) index.12 Multivariate regression analyses were adjusted for RCR risk factors (high-
risk type of surgery, symptomatic heart failure, ischemic heart disease, cerebrovascular disease, 
renal dysfunction, and diabetes) next to age, gender hypertension, hypercholesterolemia, and 
smoking status. We report both the crude and the adjusted hazard ratios (HR) with their 95% 
confidence interval (95%-CI). For all tests, a p-value <0.05 (two-sided) was considered 
significant. All analyses were performed using SPSS version 15.0 statistical software (SPSS, 
Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
The baseline study population consisted of 1,005 patients undergoing lower extremity artery 
(N=356), abdominal aortic aneurysm or abdominal aortic stenosis (N=411) or carotid artery 
repair (N=238). Endovascular procedures comprised 36% of the surgical procedures. A 
majority of the patients were men (77%) and the mean age was 67 ± 10 years.  
 
Prevalence of COPD and left ventricular dysfunction 
In total, 638 (64%) patients had no COPD and of the 367 (37%) patients with COPD: 175 
(17%) patients had mild and 192 (19%) patients had moderate/severe COPD. At baseline, LV 
dysfunction was present in 506 (50%) patients. Of the 103 patients with symptomatic heart 
failure, 69 (67%) patients had an LV ejection fraction ≤40 and 34 (33%) patients had an LV 
ejection fraction >40% + abnormal diastolic parameters. Of the 403 patients with subclinical 
LV dysfunction, 130 (32%) patients had an LV ejection fraction ≤40%, 64 (16%) patients had 
an LV ejection fraction >40-50% and 209 (52%) patients had an LV ejection fraction >50% + 
abnormal diastolic parameters (177 patients with abnormal E/A-ratio and 32 patients with 
S/D <1 or abnormal deceleration time).  
 
 Of the patients with no COPD, 232/638 (36%) had subclinical LV dysfunction 
and 52/638 (8%) had symptomatic heart failure (Figure 1). In addition, subclinical LV 
dysfunction and symptomatic heart failure were present in 85/175 (48%) and 19/175 (11%) of 
the patients with mild COPD, respectively. Finally, of the patients with moderate to severe 
COPD, 86/192 (45%) patients had subclinical LV dysfunction and 32/192 (17%) patients had 
symptomatic heart failure. Of the 171 patients with COPD and subclinical LV dysfunction, an 
LV ejection fraction ≤40 was present in 60 (36%) of the patients. In addition, 32/51 (63%) of 
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the patients with COPD + symptomatic heart failure had an LV ejection fraction ≤40 (p < 
0.01). 
 
 
Figure 1: Prevalence of chronic obstructive pulmonary disease and left ventricular dysfunction in 
vascular surgery patients.  
Chronic obstructive pulmonary disease (COPD), left ventricular (LV). 
 
Baseline characteristics 
Clinical parameters are listed in Table 1. Patients with (i) COPD, (ii) LV dysfunction or, (iii) 
COPD + LV dysfunction were older, were likely to be men, had a higher prevalence of 
ischemic heart disease, abdominal aortic disease and were more likely to be treated with β-
blockers or diuretics, compared with patients with normal pulmonary and normal LV function. 
Patients with COPD or COPD + LV dysfunction were also more often smokers and receiving 
corticosteroids and bronchodilators, compared with patients with LV dysfunction or patients 
with normal pulmonary and LV function. In addition, LV dysfunction with or without COPD 
was associated with an increased risk of renal dysfunction, hypertension and use of oral 
anticoagulants and ACE inhibitors. 
 
Association between COPD and left ventricular dysfunction 
Patients with COPD were less likely to have normal LV function, with an odds ratio (OR) of 
0.7 (95%-CI: 0.5 to 0.9) for mild COPD and 0.6 (95%-CI: 0.4 to 0.8) for moderate/severe 
COPD, compared with patients with normal pulmonary function. Mild and moderate/severe 
COPD were both associated with subclinical LV dysfunction (mild: OR 1.6, 95%-CI: 1.1 to 
2.3, moderate/severe: OR 1.7, 95%-CI: 1.2 to 2.4). Mild COPD was not significantly 
associated with heart failure (OR 1.2; 95%-CI: 0.6 to 2.4). However, moderate/severe COPD 
was associated with heart failure with an OR of 2.0 (95%-CI: 1.2 to 3.6). These results are 
demonstrated in Figure 2. 
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Table 1 Baseline characteristics 
No COPD,  
normal  
LV function 
 
 
COPD 
 
LV 
dysfunction 
COPD,        
LV 
dysfunction 
 
 
p-value  
[N=354] [N=145] [N=284] [N=222]  
Demographics      
  Age (± standard deviation) 64 (11) 68 (8) 69 (10) 71 (9) <0.01 
  Male (%)   245 (69) 118 (81) 214 (75) 192 (87) <0.01 
Medical history (%)      
  Ischemic heart disease 104 (29) 61 (42) 141 (50) 124 (56) <0.01 
  Cerebrovascular disease 134 (38) 35 (24) 122 (43) 62 (28) <0.01 
  Abdominal aortic disease 112 (32) 71 (49) 116 (41) 134 (60) <0.01 
  Renal dysfunction  44 (12) 18 (12) 61 (22) 56 (25) <0.01 
  Diabetes mellitus  109 (31) 32 (22) 89 (31) 67 (30) 0.190 
  Hypertension  207 (59) 87 (60) 209 (74) 155 (70) <0.01 
  Hypercholesterolemia 219 (67) 84 (60) 182 (67) 124 (57) 0.056 
  Smoker, current  145 (41) 80 (55) 99 (35) 96 (43) 0.001 
Medication (%)      
  β-blockers  246 (70) 122 (84) 220 (78) 190 (86) <0.01 
  Statins 253 (72) 99 (68) 209 (74) 157 (71) 0.703 
  Aspirin 222 (63) 81 (56) 160 (56) 125 (56) 0.263 
  Oral anticoagulants  45 (13) 16 (10) 64 (23) 39 (18) 0.002 
  ACE inhibitors 90 (25) 39 (27) 108 (38) 73 (33) 0.004 
  ARB 42 (12) 25 (17) 51 (18) 29 (13) 0.201 
  Diuretics  62 (18) 33 (23) 91 (32) 68 (31) <0.01 
  Corticosteroids 17 (5) 39 (27) 21 (7) 47 (21) <0.01 
Bronchodilators 14 (4) 44 (30) 17 (6) 69 (31) <0.01 
Angiotensine-converting enzyme (ACE), angiotensin-receptor blocker (ARB), chronic obstructive pulmonary disease 
(COPD), left ventricular (LV).  
 
 
Association between COPD, left ventricular dysfunction and long-term follow-up 
During follow-up, 164 (16%) patients died of whom 77 (47%) patients had COPD. Mortality 
rate in patients with normal pulmonary + normal LV function was 8%, in those with COPD 
was 15%, in those with LV dysfunction was 20%, and in patients with COPD + LV 
dysfunction was 25% (p < 0.01). Cumulative 6-year survival rates according to pulmonary and 
LV function (log rank p < 0.01) are shown in Figure 3. Of the COPD patients who died during 
follow-up, 26 (34%) patients had mild COPD and 51 (66%) patients had moderate/severe 
COPD. A cardiovascular cause of death could be attributed in 54/77 (70%), 19/26 (73%), and 
34/51 (67%) patients with no-, mild- or moderate/severe COPD, respectively (p = 0.351). 
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Figure 2:  Association between chronic obstructive pulmonary disease and left ventricular function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic obstructive pulmonary disease (COPD), left ventricular (LV). 
 
 
Figure 3: Cumulative six-year survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic obstructive pulmonary disease (COPD), left ventricular (LV). 
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Mild COPD 
Patients with mild COPD + normal LV function did not have an increased risk for all-cause 
mortality (HR 1.0, 95%-CI: 0.4 to 2.1), compared with patients with normal pulmonary and LV 
function. However, patients with mild COPD + subclinical LV dysfunction had an increased 
risk for all-cause mortality with an HR of 1.7 (95%-CI: 1.1 to 3.6). Patients with mild COPD + 
overt heart failure had the highest risk for all-cause mortality with an HR of 2.7 (95%-CI: 1.2 
to 5.9). These results are shown in Table 2.  
 
Moderate/severe COPD 
Patients with moderate/severe COPD had an increased risk for all-cause mortality, compared 
with patients with normal pulmonary function (HR 2.2, 95%-CI: 1.3 to 4.5). Hazard ratio was 
2.5 (95%-CI: 1.5 to 4.7) for patients with moderate/severe COPD and subclinical LV 
dysfunction, and 3.8 (95%-CI: 1.6 to 9.1) for patients with overt heart failure. These results are 
shown in Table 2.  
 
Table 2 
Association between COPD, LV function and long-term  
all-cause mortality 
 
 
 
 
 
 
 
 
Univariate Multivariate 
COPD LV function N (%) HR 95%-CI HR 95%-CI 
No normal 29/354  (8) reference reference 
Mild  normal 7/71 (10) 1.2 0.5-2.6 1.0 0.4-2.1 
 
subclinical 
dysfunction  
13/85 (15) 
2.1 1.2-4.1 1.7 1.1-3.6 
 heart failure  6/19 (32) 4.5 2.2-9.4 2.7 1.2-5.9 
Moderate/severe normal   15/74 (20) 3.0 1.7-5.4 2.2 1.3-4.5 
 
subclinical 
dysfunction  
23/86 (27) 
3.3 1.8-6.0 2.5 1.5-4.7 
 
heart failure  13/32 (41) 6.1 2.8-13.4 3.8 1.6-9.1 
Multivariate analyses adjusted for: age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes 
mellitus, hypertension, hypercholesterolemia, and smoking status. Chronic obstructive pulmonary disease (COPD), hazard 
ratio (HR), left ventricular (LV). 
 
 
COPD and Revised Cardiac Risk index 
Multivariate analyses demonstrated that mild COPD was not associated with an increased risk 
for long-term all-cause mortality (HR 1.0, 95%-CI: 0.6 to 1.6), in addition to RCR risk factors. 
However, moderate/severe COPD was associated with an increased risk for long-term all-
cause mortality (HR 1.7, 95%-CI: 1.2 to 2.5), in addition to the RCR risk factors.   
 
 
DISCUSSION 
The present study showed that both mild and moderate/severe COPD are associated with an 
increased risk of LV dysfunction in vascular surgery patients. Approximately one out of three 
patients had COPD and in more than half of these patients, LV dysfunction was also present. 
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In COPD patients with LV dysfunction, thre out of four patients had subclinical LV 
dysfunction. Both mild and moderate/severe COPD patients, who had subclinical LV 
dysfunction, were at increased risk for all-cause mortality compared with COPD patients with 
normal LV function.  
 
Several studies have been performed to evaluate the co-existence between 
moderate/severe COPD and heart failure. In 2005, Rutten et al. evaluated the prevalence of 
heart failure in COPD patients aged above 65 years during periods of clinical stability. They 
reported that heart failure was present in 20.5% of these moderate/severe COPD patients,3 and 
concluded that the prevalence of heart failure in stable COPD patients may be four times 
higher than in the general population of individuals over 65 years of age.3, 13 In another 
observational study, Macchia et al. showed that one out of four patients with heart failure, 
among a cohort of 1,020 heart failure patients, were also on treatment for COPD. In addition, 
the presence of COPD reduced the survival of these heart failure patients.4 The prevalence of 
LV dysfunction in COPD patients may be increased because both disorders share similar risk 
factors, such as age, male gender and smoking,14 or because of systemic inflammation and 
oxidative stress associated with chronic lung disease.  
 
While preoperative cardiac risk indices, such as the widely used RCR index, are used 
for more than three decades,12, 15-17 the development and implementation of preoperative 
pulmonary risk indices has been complicated by conflicting results from multiple studies 
addressing this issue.18-20 However, as stated in a systematic review regarding ‘preoperative 
pulmonary risk stratification for non-cardiothoracic surgery’ performed by Smetana et al, 
postoperative pulmonary complications are equally prevalent and contribute similarly to (i) 
morbidity, (ii) mortality, and (iii) length of hospital stay of surgical patients, in comparison with 
cardiac complications.21 Among 15 studies reported in this review article, 13 studies 
demonstrated that COPD was the most frequently identified risk factor for postoperative 
pulmonary complications.21 In preoperative risk stratification of patients undergoing abdominal 
aortic aneurysm repair, both COPD and heart failure have been adapted as strong risk factors 
for adverse postoperative events.22-24 One could therefore ask the question whether it is 
advisable to use separated cardiac and pulmonary risk indices. Especially, since it is known that 
COPD and heart failure often co-exist and, as we have shown in the present study that (i) mild 
COPD and subclinical LV dysfunction often co-exist as well, (ii) the combination of these two 
is associated with an increased risk for long-term all-cause mortality, and (iii) moderate/severe 
COPD is independently associated with an increased risk for long-term all-cause mortality, in 
addition to the RCR index. An important question remains if diagnosing and treatment of 
pulmonary and LV dysfunction will lead to improved long-term outcome. To address this issue, 
a randomized, controlled trial including vascular surgery patients undergoing standard 
preoperative spirometry and echocardiography, could provide us with final answers addressing 
preoperative risk using an ‘integrated cardio-pulmonary risk index’.  
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Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, although two experienced 
investigators performed off-line assessments of the obtained ultrasound images, we cannot rule 
out interobserver variability to have had minor influence on our results. Third, not all patients 
did have a preoperative pulmonary function test. In those patients who did not have a 
pulmonary function test, the diagnosis of COPD was based on symptoms and use of 
pulmonary medication. 
 
The present study demonstrated that both mild and moderate/severe COPD were 
associated with an increased risk for subclinical LV dysfunction in patients undergoing vascular 
surgery. Patients with mild and moderate/severe COPD who had subclinical LV dysfunction 
were at increased risk for all-cause mortality, compared with COPD patients with normal LV 
function. These data suggest that preoperative echocardiography may be useful to detect 
subclinical cardiovascular disease and risk stratify COPD patients undergoing vascular surgery.  
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ABSTRACT 
 
Background Left ventricular (LV) function and high-sensitive C-Reactive Protein (hs-CRP) 
independently predict cardiac events. The prognostic value of LV dysfunction in patients with 
normal or elevated hs-CRP is less well understood. The present study evaluated the combined 
prognostic value of LV function and hs-CRP towards cardiac outcome of vascular surgery 
patients and the impact of optimal pharmacological treatment.  
 
Methods Echocardiography was performed preoperatively in 1,116 consecutive vascular 
surgery patients. Using a 17-segment wall motion score index (WMSI), LV function was 
categorized as normal (WMSI 1 to 1.5), mildly hypokinetic (WMSI >1.52.5) and severely 
hypokinetic (WMSI >2.5). Hs-CRP was measured in all patients and concentrations >6.5 
mg/L were considered elevated, after receiver operating curve analyses. Perioperative troponin 
T measurements and electrocardiograms were performed routinely. Study endpoints were 
perioperative cardiac events and long-term mortality. Multivariate regression analyses evaluated 
the relation between LV function, hs-CRP, standard pharmacological treatment (statins, β-
blockers, angiotensin blocking agents) and postoperative outcome.  
 
Results WMSI >1.5 was associated with an increased risk for perioperative cardiac events and 
long-term mortality, in patients with normal (OR 2.54, 95%-CI: 1.21 to 3.08 and HR 2.10, 
95%-CI: 1.08 to 3.12) or elevated hs-CRP (OR 1.84, 95%-CI: 1.29 to 3.73 and HR 2.18, 95%-
CI: 1.05 to 2.88). WMSI >1.5 + elevated hs-CRP was associated with the highest risk for 
perioperative cardiac events or long-term mortality (OR 1.63, 95%-CI: 1.43 to 4.85 and HR 
2.37, 95%-CI: 2.81 to 6.11). Standard pharmacological treatment of WMSI >1.5 was associated 
with improved long-term survival in patients with normal (HR 0.34, 95%-CI: 0.17 to 0.81) or 
elevated hs-CRP (HR 0.61, 95%-CI: 0.42 to 0.82).  
 
Conclusions The present study demonstrated that LV dysfunction is predictive for 
postoperative outcome of vascular surgery patients with normal or elevated hs-CRP. 
Furthermore, increased hs-CRP has additional value to predict postoperative outcome of 
patients with LV dysfunction. Finally, standard pharmacological treatment of LV dysfunction 
improved long-term outcome.  
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INTRODUCTION 
 
Vascular surgery patients are at increased risk for perioperative cardiac events.1 Over the years, 
several cardiac risk indices have been developed for preoperative risk stratification.2, 3 In 
patients with ≥1 cardiac risk factor, echocardiography should be considered before surgery.4, 5 
In addition, the resting wall motion score index (WMSI), which is widely accepted in evaluating 
left ventricular (LV) function, has a prognostic value in the prediction of cardiovascular 
outcome of patients with ischemic heart disease.6-9  
 
Biochemical markers, such as high sensitive C-reactive protein (hs-CRP), are 
increasingly used in cardiac risk stratification. Elevated hs-CRP concentrations reflect an 
inflammatory state associated with atherosclerosis.10 In addition, elevated hs-CRP 
concentrations are associated with an increased risk for cardiac events in patients with and 
without coronary artery disease.11-14 Therefore, we hypothesized that WMSI and hs-CRP could 
have an independent prognostic value in the prediction of future cardiac events. The aim of 
the present study, performed in vascular surgery patients with normal or elevated hs-CRP, was 
to evaluate the prognostic value of LV function for postoperative outcome using the WMSI 
and to address the impact of standard pharmacological treatment for LV dysfunction on long-
term survival. 
 
 
METHODS 
 
Study population 
The study population consisted of 1,116 consecutive patients undergoing vascular surgery 
during the period between 2002 and 2009. The study was performed at the Erasmus Medical 
Center in Rotterdam, a tertiary hospital in the Netherlands. The study was approved by the 
hospital’s ethics committee and performed with informed consent of all patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Clinical data included: age, 
gender, ischemic heart disease (defined as a history myocardial infarction, coronary 
revascularization or the presence of pathologic Q-waves on preoperative electrocardiogram), 
cerebrovascular disease (defined as a history of ischemic or hemorrhagic stroke), renal 
dysfunction (serum creatinine >2.0 mg/dL), diabetes mellitus (fasting blood glucose ≥6.1 
mmol/L or requirement of anti-diabetic medication), hypertension (blood pressure ≥140/90 
mmHg in non-diabetics and ≥130/80 mmHg in diabetics or requirement of antihypertensive 
medication), hypercholesterolemia (history of hypercholesterolemia or low density lipoprotein 
cholesterol >3.5 mmol/L), chronic obstructive pulmonary disease (history of chronic 
obstructive pulmonary disease or according the Global Initiative on Obstructive Lung Diseases 
classification),15 and smoking status. The use of prescription medications was recorded and 
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included β-blockers, statins, aspirin, oral anticoagulants, angiotensin blocking agents 
(angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), and diuretics.   
 
Biomarkers 
Serial troponin T measurements (Roche Diagnostics, Mannheim, Germany) were obtained 
from all patients before surgery, postoperatively on day 1, 3, 7 and before discharge. Troponin 
T concentrations >0.03 ng/mL were considered to be elevated.16 Patients with elevated 
troponin T concentrations before surgery were not included in the study. Peripheral blood 
samples for hs-CRP were routinely performed one day before surgery. C-Reactive Protein was 
measured by a high-sensitive nephelometric assay on a Beckman-Immage analyzer (Beckman-
Coulter, Fullerton, California, USA). Optimal specificity and sensitivity of hs-CRP to predict 
postoperative outcome was calculated using receiver operating curve analyses and a cut off 
value ≥6.5 mg/L was used in the analyses.  
 
Wall motion score at rest 
Preoperatively, transthoracic echocardiography was performed in all patients using a handheld 
Acuson Cypress Ultrasound System (7V3c transducer). Standard parasternal and apical two- 
and four-chamber views were obtained during rest with the patient in the left lateral decubitus 
position as recommended.17 Wall motion abnormalities were determined using the 17-segment 
model as recommended by the ‘American Society of Echocardiography’.18 Systolic motion of 
each segment was graded as follows: 1 = normal, 2 = mild to moderate hypokinesis (reduced 
wall thickening and excursion), 3 = severe hypokinesis (marked reduced wall thickening and 
excursion), 4 = akinesis (no wall thickening and excursion), 5 = dyskinesis (paradoxical wall 
motion away from the center of the left ventricle during systole).19 If a segment was not 
visualized because of echo dropout or technical reasons, the score was not given for this 
segment. Wall motion score index at rest was calculated as the cumulative sum of the scores 
from each segment divided by the number of segments visualized. Wall motion was categorized 
normal (WMSI 1 to 1.5 ~ LV ejection fraction >54%), mildly hypokinetic (WMSI >1.5 to 2.5 
~ LV ejection fraction 28 to 53%), severely hypokinetic WMSI >2.5 ~ LV ejection fraction 
<28%).20, 21  
 
Study outcomes 
Main study endpoints were perioperative cardiac events (defined as nonfatal myocardial 
ischemia or infarction up to 30 days after surgery) and long-term mortality. Myocardial 
ischemia was diagnosed in patients with normal preoperative and elevated troponin T 
concentrations postoperatively.16 Elevated troponin T concentrations in combination with 
electrocardiographic changes (new onset ST-T changes and pathological Q waves) or 
symptoms of angina pectoris defined myocardial infarction.22 Long-term mortality was 
assessed by reviewing the municipal civil registries. Median follow-up was 2 years (interquartile 
range 1 to 3). Standard pharmacological management of wall motion abnormalities and 
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cardiovascular risk reduction was considered to be treatment with statins in combination with 
β-blockers and angiotensin blocking agents.23, 24 
 
Statistical analysis 
Dichotomous data are described as numbers and percentages. Continuous variables are 
described as means ± standard deviation (SD) or as median ± interquartile range. Continuous 
data were compared using ANOVA and categorical data were compared using a χ2 test. 
Logistic regression analyses were performed to evaluate the relationship between WMSI and 
hs-CRP with perioperative myocardial damage. To study the influence of hsCRP on the WMSI 
groups, interactions terms between hsCRP and WMSI were used. Cox regression analyses were 
performed to evaluate the relationship between WMSI and hs-CRP with long-term mortality. 
Cumulative long-term survival was determined using the Kaplan-Meier method. Multivariate 
regression analyses were adjusted for age, gender, ischemic heart disease, renal dysfunction, 
diabetes mellitus, hypercholesterolemia, hypertension, smoking, chronic obstructive pulmonary 
disease and high-risk surgery (Model 1). In Model 2, multivariate regression analyses were 
adjusted for medication use and the risk factors described in model 1. We report both the 
crude and the adjusted odds and hazard ratios (OR and HR) with their 95% confidence 
interval (95%-CI). To evaluate the effect of standard medical treatment (statins + β-blockers or 
angiotensin blocking agents) on long-term outcome, multivariate Cox regression analyses were 
performed with propensity score adjustment for optimal medical treatment. Variables used in 
Model 1 were included in the propensity score model. For all tests, a p-value <0.05 (two-sided) 
was considered significant. All analyses were performed using SPSS version 15.0 statistical 
software (SPSS, Inc., IL, USA). No extramural funding was used to support this work. The 
authors are solely responsible for the design and conduct of this study, all study analyses, the 
drafting and editing of the article, and its final contents. 
 
 
RESULTS 
 
Study population 
A total of 1,116 patients undergoing lower extremity artery (N=387), carotid artery (N=465) 
and abdominal aorta (N=264) repair were included in the study. Endovascular surgery 
comprised 35% of the procedures. The majority of patients were men (77%) and the mean age 
was 67 ± 10 years. A WMSI >1.5 was detected in 474 (42%) patients, of which 268 (57%) 
patients had a WMSI >1.5 to 2.5 and 206 (43%) patients had a WMSI >2.5. Baseline 
characteristics stratified to WMSI are provided in Table 1. A WMSI >1.5 was associated with 
increased age and male gender. Ischemic heart disease, renal dysfunction, diabetes mellitus, 
hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, and smoking were 
associated with WMSI >1.5 as well. In addition, usage of β-blockers, oral anticoagulants, 
angiotensin blocking agents, and diuretics was higher in patients with a WMSI >1.5. Median 
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level of hs-CRP was 4.9 (± 6.3) and hs-CRP was elevated (≥6.5 mg/L) in 395 (35%) patients. 
The distribution of elevated hs-CRP was not significantly different between the WMSI groups.  
 
Table 1 Baseline characteristics stratified to wall motion score index 
WMSI 1-1.5 WMSI >1.5 p-value  
[N=642] [N=474]  
Demographics 
 
   
  Age (± SD) 66 (11) 70 (9) <0.001 
  Male (%) 454 (71) 474 (84) <0.001 
  Systolic blood pressure (± SD) 142 (24) 139 (24) 0.109 
  Diastolic blood pressure (± SD) 79 (12) 79 (12) 0.314 
  Heart rate (± SD) 71 (13) 72 (13) 0.114 
Medical history (%)    
  Ischemic heart disease  160 (25) 260 (55) <0.001 
  Cerebrovascular disease  226 (35) 171 (36) 0.763 
  Renal dysfunction  89 (14) 104 (22) <0.001 
  Diabetes mellitus   120 (19) 118 (25) 0.012 
  Hypertension  387 (60) 337 (71) <0.001 
  Hypercholesterolemia 280 (44) 247 (52) 0.005 
  Chronic obstructive pulmonary disease   185 (29) 184 (37) <0.001 
  Smoker, current  286 (45) 184 (39) 0.035 
Surgery type (%)    
  Open  401 (63) 316 (67) 0.147 
Medication (%)    
  β-blockers  475 (74) 370 (78) 0.032 
  Statins  459 (72) 368 (78) 0.021 
  Aspirin 374 (58) 293 (62) 0.231 
  Oral anticoagulants  82 (13) 96 (20) 0.001 
  Angiotensin receptor blocking agents  219 (38) 204 (49) 0.001 
  Diuretics  134 (21) 153 (32) <0.001 
High-sensitive C-reactive protein (hs-CRP), standard deviation (SD), wall motion score index (WMSI). 
 
  
Postoperative outcome 
The study endpoint of perioperative cardiac events was reached in 194 (17%) patients and 182 
(16%) patients died during follow-up. Cumulative long-term survival stratified to WMSI and 
hs-CRP is provided in Figure 1. Multivariate regression analyses demonstrated that WMSI >1.5 
was associated with an increased risk of perioperative myocardial damage (OR 1.84, 95%-CI: 
1.10 to 2.89) and long-term mortality (HR 1.72, 95%-CI: 1.09 to 2.77) as depicted in Table 2. In 
addition, elevated hs-CRP was associated with an increased risk of perioperative myocardial 
damage (OR 2.00, 95%-CI: 1.19 to 3.37) and long-term mortality (HR 2.55, 95%-CI: 1.39 to 
3.56). Patient with WMSI >1.5 and elevated hs-CRP had the highest risk for perioperative 
myocardial damage or long-term mortality (OR 4.16, 95%-CI: 2.54 to 6.81 and HR 4.10, 95%-
CI: 2.64 to 6.37, respectively). Interaction terms were used to identify the direct influence of 
hsCRP on the relation between WMSI and survival rates, and no direct interaction was 
observed between the different WMSI groups and hsCRP with respect to long-term survival. 
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Figure 1: Wall motion score index and hs-CRP: cumulative long-term survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High-sensitive C-reactive protein (hs-CRP), wall motion score index (WMSI). 
 
 
Table 2 Wall motion score index and hs-CRP: postoperative outcome 
 Model 1* Model 2** 
30-day myocardial damage N (%) OR [95%-CI] OR [95%-CI] 
WMSI 1-1.5 hs-CRP ≤6.5 mg/L 38/431 (9) reference reference 
WMSI 1-1.5 hs-CRP >6.5 mg/L 37/211 (18) 2.05 1.23-3.43 2.00 1.19-3.37 
WMSI >1.5 hs-CRP ≤6.5 mg/L 51/290 (18) 1.83 1.13-3.00 1.84 1.10-2.89 
WMSI >1.5 hs-CRP >6.5 mg/L 68/184 (37) 4.45 2.74-7.23 4.16 2.54-6.81 
Long-term mortality N (%) HR [95%-CI] HR [95%-CI] 
WMSI 1-1.5 hs-CRP ≤6.5 mg/L 33/431 (8) reference reference 
WMSI 1-1.5 hs-CRP >6.5 mg/L 42/211 (20) 2.76 1.73-4.39 2.55 1.39-3.56 
WMSI >1.5 hs-CRP ≤6.5 mg/L 39/290 (13) 1.80 1.11-2.90 1.72 1.09-2.77 
WMSI >1.5 hs-CRP >6.5 mg/L 68/184 (37) 4.19 2.72-6.47 4.10 2.64-6.37 
* Model 1: adjusted for age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus,  
hypercholesterolemia, hypertension, smoking, chronic obstructive pulmonary disease and high risk surgery. ** Model 2: 
adjusted risk factors described in model 1 and the use of β-blocker, statines, aspirin, angiotensin-converting enzyme inhibitors 
and diuretics. Confidence interval (CI), hazard ratio (HR), high-sensitive C-reactive protein (hs-CRP), odds ratio (OR), 
wall motion score index (WMSI). 
 
 
 In patients with normal hs-CRP, WMSI >1.5 was associated with increased risk for 
perioperative cardiac events and long-term mortality with an OR of 2.54 (95%-CI: 1.21 to 
3.08) and a HR of 2.10 (95%-CI: 1.08 to 3.12). A sub-analysis was performed to assess the 
separate predictive values of a WMSI >1.5 to 2.5 and a WMSI >2.5. This analysis 
demonstrated that both were associated with an increased risk for perioperative myocardial 
damage (OR 1.86, 95%-CI: 1.28 to 3.57 and OR 3.31, 95%-CI: 3.01 to 5.13) and long-term 
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mortality (HR 1.96, 95%-CI: 1.16 to 3.34 and HR 2.38, 95%-CI: 1.31 to 4.03), respectively 
(Table 3). 
 
 In patients with elevated hs-CRP; WMSI >1.5 was associated with increased risk for 
perioperative cardiac events and long-term mortality with an OR of 1.84 (95%-CI: 1.29 to 
3.73) and a HR of 2.18 (95%-CI: 1.05 to 2.88). A sub-analysis was performed to assess the 
predictive value of WMSI >1.5 to 2.5 and WMSI >2.5, which demonstrated that both were 
associated with an increased risk for perioperative myocardial damage (OR 1.63, 95%-CI: 1.43 
to 4.85 and OR 2.37, 95%-CI: 2.81 to 6.11) and long-term mortality (HR 1.61, 95%-CI: 1.19 to 
3.06 and HR 2.65, 95%-CI: 2.24 to 4.02), respectively (Table 3). 
 
 
Table 3 
Wall motion score index and postoperative outcome, categorized 
according to hs-CRP levels ≤6.5 and >6.5 mg/L 
 Model 1* Model 2** 
30-day myocardial damage  N (%) OR [95%-CI] OR [95%-CI] 
hs-CRP ≤6.5 mg/L       
 WMSI 1-1.5 35/433 (8) reference reference 
 WMSI >1.5-2.5 24/166 (15) 1.92 1.18-3.50 1.86 1.28-3.57 
 WMSI >2.5 30/124 (24) 3.24 2.98-4.90 3.31 3.01-5.13 
        
hs-CRP >6.5 mg/L       
 WMSI 1-1.5 39/211 (19) reference reference 
 WMSI >1.5-2.5 32/102 (31) 1.71 1.52-4.97 1.63 1.43-4.85 
 WMSI >2.5 34/82 (42) 2.48 2.66-5.67 2.37 2.81-6.11 
Long-term mortality N (%) HR [95%-CI] HR [95%-CI] 
hs-CRP ≤6.5 mg/L       
 WMSI 1-1.5 28/433 (6) reference reference 
 WMSI >1.5-2.5 21/166 (13) 2.20 1.31-3.67 1.96 1.16-3.34 
 WMSI >2.5 23/124 (19) 3.43 1.48-4.29 3.38 1.31-4.03 
        
hs-CRP >6.5 mg/L       
 WMSI 1-1.5 41/211 (19) reference reference 
 WMSI >1.5-2.5 33/102 (32) 1.67 1.26-3.32 1.61 1.19-3.06 
 WMSI >2.5 36/82 (44) 2.71 2.13-4.89 2.65 2.24-4.02 
* Model 1: adjusted for age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus,  
hypercholesterolemia, hypertension, smoking, chronic obstructive pulmonary disease and high risk surgery. ** Model 2: 
adjusted risk factors described in model 1 and the use of β-blocker, statines, aspirin, angiotensin-converting enzyme inhibitors 
and diuretics. Confidence interval (CI), hazard ratio (HR), high-sensitive C-reactive protein (hs-CRP), odds ratio (OR), 
wall motion score index (WMSI). 
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WMSI >1 and standard pharmacological treatment 
Of the patients with WMSI >1.5 + normal hs-CRP (N=290), 113 (40%) patients received 
standard pharmacological treatment (statins + β-blockers + angiotensin blocking agents). In 
addition, 60/184 (33%) patients with WMSI >1.5 + elevated hs-CRP received standard 
pharmacological treatment. Cumulative long-term survival of patients with WMSI >1.5 
stratified by (i) normal or elevated hs-CRP and (ii) receiving standard or suboptimal 
pharmacological treatment is demonstrated in Figure 2. Standard pharmacological treatment 
was associated with improved long-term survival in patients with normal (HR 0.34, 95%-CI: 
0.17 to 0.81) and elevated hs-CRP (HR 0.61, 95%-CI: 0.42 to 0.82), compared with patients 
receiving suboptimal pharmacological treatment, as demonstrated in Table 4. 
 
 
Figure 2: Medical treatment in patients with WMSI >1.5: cumulative long-term survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High-sensitive C-reactive protein (hs-CRP), wall motion score index (WMSI). 
 
 
DISCUSSION 
 
Our results indicate that LV dysfunction is predictive for perioperative cardiac events and 
long-term mortality of vascular surgery patients with normal or elevated hs-CRP. Furthermore, 
elevated hs-CRP has additional prognostic value of patients with LV dysfunction, to predict 
postoperative cardiac outcome. Finally, optimal pharmacological treatment of LV dysfunction 
improved long-term outcome of patients with normal or elevated hs-CRP. 
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Table 4 
Medical treatment in patients with wall motion score index >1.5: 
influence on long-term mortality 
 Model 1* Model 2** 
hs-CRP ≤6.5 mg/L N (%) OR [95%-CI] OR [95%-CI] 
Suboptimal medication 18/69 (26) reference reference 
Optimal medication 21/221 (10) 0.39 0.18-0.82 0.39 0.18-0.81 
hs-CRP >6.5 mg/L N (%) OR [95%-CI] OR  [95%-CI] 
Suboptimal medication 32/54 (59) reference reference 
Optimal medication 36/130 (28) 0.52 0.31-0.88 0.51 0.30-0.86 
* Model 1: adjusted for age, gender, ischemic heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus,  
hypercholesterolemia, hypertension, smoking, chronic obstructive pulmonary disease and high risk surgery. ** Model 2: 
adjusted risk factors described in model 1 and the use of β-blocker, statines, aspirin, angiotensin-converting enzyme inhibitors 
and diuretics. Confidence interval (CI), hazard ratio (HR), high-sensitive C-reactive protein (hs-CRP), odds ratio (OR), 
wall motion score index (WMSI). 
 
 
Atherosclerosis is a systemic inflammatory disease of the vasculature, known to affect 
multiple sections of the arterial tree, such as the lower extremity-, abdominal aortic-, carotid- 
and coronary arteries, simultaneously.25 Coronary atherosclerosis causes gradual reduction of 
the vascular cross-sectional area resulting in coronary artery stenosis. Coronary artery stenosis 
is an important cause of postoperative morbidity and mortality in the vascular surgery 
population.26 During vascular surgery there is an increased myocardial oxygen-demand due to 
high catecholamine production.1 Intra-operative increases of myocardial oxygen-demand can 
therefore lead to an oxygen-supply and demand imbalance, in patients with coronary artery 
stenosis, and subsequent reduced myocardial blood supply. This imbalance will lead to 
ischemia characterized by metabolic changes, regional systolic wall motion abnormalities and 
global systolic left ventricular dysfunction at a later stage.27 Preoperative risk assessment of 
vascular surgery patients provides information on the likelihood of the occurrence of 
postoperative cardiac events. Potential tools for preoperative risk assessment are cardiac risk 
indices,2, 3 (stress) echocardiography,28, 29 and biomarkers.30  
 
Previous studies have shown that a WMSI at rest has prognostic value to predict 
adverse outcome, in patients with ischemic heart disease or heart failure.6-9 Carluccio et al. 
demonstrated that a WMSI >1.5 at rest was a powerful predictor of adverse cardiac events 
after a first acute myocardial infarction.6 In addition, Madsen et al. demonstrated that resting 
WMSI >1.3 provided independent prognostic information on survival of patients with 
congestive heart failure.8 In line with these studies we found that a WMSI >1.5 at rest was 
associated with an increased risk for perioperative myocardial damage and long-term mortality.  
 
C-Reactive Protein is an inflammatory marker of atherosclerosis and is found within 
atherosclerotic plaques of both coronary and peripheral arterial vessels. The median level of 
hs-CRP has been found to be significantly higher in patients who later develop cardiac events 
 117 
compared with patients with normal hs-CRP.13, 30 A patient’s individual risk for future 
cardiovascular disease can therefore be stratified according to their hs-CRP concentrations 31. 
We found that hs-CRP >6.5 mg/L was associated with an increased risk for perioperative 
cardiac events and long-term mortality. In addition, the current study is the first to evaluate the 
prognostic implications of a WMSI at rest in vascular surgery patients, with a focus on patients 
with normal or elevated hs-CRP, separately. We found that a WMSI >1.5 at rest was associated 
with perioperative myocardial damage and long-term mortality in both hs-CRP groups. 
Importantly, increased hs-CRP has additional value to predict postoperative outcome in 
patients with LV dysfunction. As a marker of inflammatory state, it indicates for ongoing 
processes which can influence the general condition, especially in patients with LV 
dysfunction.   
 
Comprehensive prognostic risk stratification provides an overall framework for 
physicians to identify risk factors and to help make predictions based on these risk factors. 
Prognostic information help the clinician in the decision for targeted treatment interventions. 
Appropriate patient management, therefore, should not only include the assessment of the 
perioperative cardiac risk, it should however include therapeutic strategies to decrease the risk 
even more. Our results provide an indication that postoperative survival of patients with a 
WMSI >1.5 is improved in patients receiving pharmacological treatment with statins in 
combination with (i) β-blockers or  (ii) angiotensin blocking agents, both in patients with 
normal hs-CRP as in patients with increased hs-CRP. Although patients with a WMSI >1.5 in 
combination with increased hs-CRP have worst survival, optimal medical treatment might 
improve the outcome of these patients.  
 
Our results suggest that preoperative risk stratification should not solely include 
cardiac risk indices. The assessment of the WMSI and hs-CRP could provide the clinician with 
a guide regarding the presence or absence of coronary artery disease and severity of the 
atherosclerotic process, both associated with increased risk of perioperative myocardial damage 
and long-term mortality.      
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, although two experienced 
investigators performed an off-line assessment of the ultrasound images, we cannot rule out 
interobserver variability to have had a minor influence on our results. Third, the current study 
was not designed as a randomized, controlled trial to evaluate the impact of pharmacological 
treatment of a WMSI >1.5.  
 
The present study demonstrated that LV dysfunction is predictive for postoperative 
outcome of vascular surgery patients with normal or elevated hs-CRP. Furthermore, elevated 
hs-CRP has additional value to predict postoperative outcome of patients with LV 
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dysfunction. Finally, optimal pharmacological treatment of LV dysfunction improved long-
term outcome of patients with normal or elevated hs-CRP. Our data suggest that routine use 
of cardiac echo and hs-CRP measurements might improve (i) risk stratification and (ii) long-
term survival of vascular surgery patients. 
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ABSTRACT 
 
Background Coronary revascularization of the suspected culprit coronary lesion assessed by 
preoperative stress testing is not associated with improved outcome of vascular surgery 
patients.  
 
Methods Fifty-four major vascular surgical patients underwent preoperative dobutamine 
echocardiography and intraoperative transesophageal echocardiography. The locations of left 
ventricular rest wall motion abnormalities and new wall motion abnormalities (NWMAs) were 
scored using a seven-wall model. During 30-day follow-up, postoperative cardiac troponin 
release, myocardial infarction, and cardiac death were noted. 
 
Results Rest wall motion abnormalities were noted by dobutamine echocardiography in 17 
patients (31%), and by transesophageal echocardiography in 16 patients (30%). NWMAs were 
induced during dobutamine stress echocardiography in 17 patients (31%), whereas NWMAs 
were observed by transesophageal echocardiography in 23 patients (43%), κ-value = 0.65. 
Although preoperative and intraoperative rest wall motion abnormalities showed an excellent 
agreement for the location (κ-value = 0.92), the agreement for preoperative and intraoperative 
NWMAs in different locations was poor (κ-value = 0.26 to 0.44). The composite cardiac 
endpoint occurred in 14 patients (26%).  
 
Conclusions There was a poor correlation between the locations of preoperatively assessed 
stress-induced NWMAs by dobutamine echocardiography and those observed intraoperatively 
using transesophageal echocardiography. However, the composite endpoint of outcome was 
met more frequently in relation with intraoperative NWMAs.  
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INTRODUCTION 
 
Vascular surgical patients represent a population at increased risk for developing postoperative 
adverse cardiac outcome.1, 2 Cardiac stress testing before surgery is widely used to identify 
patients at increased risk for postoperative cardiac events. Recently, prophylactic coronary 
revascularization was studied in vascular surgery patients.3 However, revascularization of the 
suspected intraoperative culprit coronary lesion, assessed by preoperative testing, was not 
associated with improved outcome.  
 
Although the pathophysiology of perioperative myocardial infarction (MI) is not 
entirely clear, it is now well accepted that coronary plaque rupture, leading to thrombus 
formation and subsequent vessel occlusion, is an important cause. This is similar to the 
nonsurgical setting. The surgical stress response includes a catecholamine surge with associated 
hemodynamic stress, vasospasm, reduced fibrinolytic activity, platelet activation, and 
consequent hypercoagulability.4 In patients with significant coronary artery disease (CAD), MI 
may also be caused by a sustained myocardial supply or demand mismatch due to tachycardia 
and increased myocardial contractility. The association of postoperative MI with myocardial 
ischemia and nontransmural or circumferential subendocardial infarction supports this 
mechanism. Although transmural ischemia is considered to be relatively uncommon, half of all 
fatalities have direct evidence of plaque disruption defined as fissure or rupture of plaque and 
hemorrhage into the plaque cavity.5-7  
 
The use of intraoperative transesophageal echocardiography (TEE) recognized a high 
prevalence of transient myocardial ischemic episodes causing regional wall motion 
abnormalities (WMAs) in patients undergoing major noncardiac surgery and requiring vigilant 
monitoring for serious cardiac outcome.8-10 Those transient events reflect the balancing effects 
of coronary reserve and myocardial viability vs. a multifactorial perioperative ischemic load 
(burden). Different detection modalities, such as persantine-thallium scintigraphy and 
electrocardiography were compared with intraoperative TEE in detecting ischemia with 
inconclusive results.11, 12 However, the location of ischemic events has never been a primary 
goal in all previous investigations. 
 
Our hypothesis is that, although dobutamine echocardiography (DE) can identify 
patients at risk, the location of the cardiac event is difficult to foresee because of the 
unpredictable plaque rupture of non-significant, vulnerable, coronary artery lesions. In this 
study, we matched preoperative assessed ischemic left ventricular (LV) territories using DE 
and intraoperatively observed new wall motion abnormalities (NWMAs) using TEE to 
examine the chance of reproducibility of a NWMA at the same location pre- and 
intraoperatively. This matching correlation would be more emphasizing if perioperative 
NWMAs were predictive of postoperative cardiac outcomes.  
 
 124 
MATERIAL AND METHODS 
 
Study participants 
In this prospective cohort study, patients older than 40 years scheduled for noncardiac vascular 
surgery at Erasmus University Medical Center, Rotterdam, the Netherlands, between June 
2005 and September 2008 were candidates for inclusion. Patients had to be scheduled for 
abdominal aortic aneurysm repair, abdominal aortic stenosis surgery, or lower limb arterial 
reconstruction. We used the Lee’s Revised Cardiac Risk index, which included a history of 
ischemic heart disease, heart failure, cerebrovascular accidents, insulin therapy for diabetes 
mellitus, and renal disease with serum creatinine >2.0 mg/dL, to abbreviate the cardiac risk 
factors and to identify patients at risk.13 All patients underwent DE before surgery. Exclusion 
criteria for the study were the inability to retrieve adequate echocardiographic views pre- or 
intraoperatively. After approval from the medical ethics committee board and after obtaining 
informed consent from the patients, we included 54 consecutive adult patients.  
 
Dobutamine echocardiography  
All patients underwent DE to evaluate LV wall motion using dobutamine (± atropine) as a 
stressor. Two-dimensional echocardiography was performed at rest using Hewlett-Packard 
Sonos 1000 echo apparatus (Hewlett-Packard, Andover, MA) with 2.5- and 3.5-MHz 
transducers. The technique yielded standard parasternal and apical echocardiographic views 
under basal conditions and throughout graded dobutamine infusion. A stepwise incremental 
dose of dobutamine was administered, beginning at 10 µg·kg-1·min-1 and increased by 10 µg·kg-
1·min-1 every 3 min until a definite endpoint was attained.14-16 During the dobutamine infusion, 
heart rate, blood pressure, and electrocardiography were monitored. When the target heart rate 
(85% of maximum age- and gender-predicted heart rate) was not obtained at the maximum 
dobutamine dose (40 µg·kg-1·min-1), atropine (0.25 to 1.0 mg) was administered.15, 17 Test 
endpoints were achievement of (i) target heart rate, (ii) maximal dose of dobutamine and 
atropine, (iii) extensive NWMAs, (iv) more than 2 mV downsloping ST-segment depression 
measured 80 ms after the J-point compared with the baseline, (v) hypertension (blood pressure 
>240/120 mmHg), (vi) a decrease in systolic blood pressure of more than 40 mmHg 
compared with at rest, (vii) significant arrhythmias, or (viii) any intolerable adverse effects 
considered to be the result of dobutamine or atropine. An intravenous β-blocker (metoprolol 1 
to 5 mg) was available to reverse the adverse effects of dobutamine/atropine. The test was 
completed only after all ischemic regions had returned to baseline.  
 
Transesophageal echocardiography 
After induction of anesthesia and endotracheal intubation, the TEE probe was inserted. We 
based our TEE examination on the recommendations of the ‘American Society of 
Echocardiography Council for Intraoperative Echocardiography and the Society of 
Cardiovascular Anesthesiologists’ guidelines for performing a comprehensive intraoperative 
multiplane TEE examination.18 The LV wall motion was monitored in six views, namely, three 
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midesophageal views (the four-chamber midesophageal view, the midesophageal two-chamber 
view, and the midesophageal long-axis view) and three transgastric views (basal, midpapillary, 
and apical transgastric views). Baseline images of the LV in short- and long-axis were acquired 
and tape-recorded for offline analysis. The TEE probe depth and imaging planes of the basal 
views were noted to reproduce equivalent views intraoperatively. To improve the detection of 
intraoperative NWMAs, we adopted a semicontinuous method, keeping the TEE probe in the 
transgastric position with the midpapillary LV short-axis view continuously displayed and 
repeating the whole set of the examination views every 10 minutes and whenever there was 
echocardiographic suspicion of (i) NWMAs, (ii) hemodynamic change, or (iii) surgical 
maneuver requiring special attention. For safety reasons, echocardiographic monitoring was 
freezed whenever the probe temperature exceeded 37.5˚C, which allowed the probe to cool 
down shortly. 
 
Transesophageal echocardiography images were obtained using a standard adult 5-
MHz multiplane transesophageal probe (GE LOGIQ 500 Probe, model H4552TB; General 
Electric, Stockton, CA) and the VingMed® System 5 Echocardiographic Imaging System 
(General Electric-VingMed Ultrasound, Horton, Norway). The main investigator was 
responsible for intraoperative image acquisition and passed a comprehensive training in 
transesophageal echocardiography in the study institute and performed 150 comprehensive 
TEE examinations as recommended by the ‘American society of Echocardiography Council 
for Intraoperative Echocardiography and the Society of Cardiovascular Anesthesiologists’.18 
The occurrences of LV NWMAs, as well as the segmental location of each abnormality, were 
recorded for each patient. The training physicians (anesthesiologists and surgeons) were 
blinded to intraoperative echocardiographic findings except if significant NWMAs (involving 
more than four segments) necessitating immediate management were apparent on the screen. 
 
Interpretation of echocardiographic views 
Dobutamine echocardiography test results and intraoperative TEE recordings were scored for 
rest WMAs and NWMAs using a 17-segment model as proposed by the ‘American Society of 
Echocardiography’ and interpreted accordingly into a seven-wall LV model.19-21 Transcription 
of LV segments to their LV wall involvement was performed as shown in Figure 1, redrawn 
based on the illustrations of LV wall in the transthoracic echocardiography reports 
recommended by our institute and in the recommendation of the ‘American Society of 
Echocardiography Council for Intraoperative Echocardiography and the Society of 
Cardiovascular Anesthesiologists’ for the comprehensive TEE examination.18 
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Figure 1: Left ventricular (LV) myocardial segmentation for echocardiographic wall motion analysis with 
corresponding disitribution of coronary arterial blood supply, showing segmental distribution of the 
seven LV walls in dobutamine echocardiography (A) and in transesophageal echocardiography (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Circumflex artery (Cx), left anterior descending coronary artery (LAD), right coronary artery (RCA). 
 
 
A five-point scale was used for wall motion analysis: 1 = normal, 2 = mild-moderate 
hypokinesis, 3 = severely hypokinetic, 4 = akinesis, 5 = dyskinetic, as used earlier.14-17 
Recorded echocardiographic loops were displayed simultaneously with rest images in a cine-
loop format for interpretation. All images were analyzed at one time by two experienced 
readers blinded to clinical, electrocardiography, or other perioperative patient data. A NWMA 
was interpreted whenever a new or worsening regional LV motion was observed. Normal wall 
motion or an unchanged rest WMA was not considered for myocardial ischemia. 
Disagreements in interpretation were resolved by consensus.  
 
Definition of endpoints 
All patients were monitored postoperatively for the development of adverse cardiac events. 
Standard electrocardiography and cardiac troponin T (cTnT) were serially measured after 
surgery on days 1, 3, 7, and 30, or at discharge. Tests were repeated when patients had 
symptoms and/or signs of clinical myocardial ischemia. Troponin T level was measured by an 
electrochemiluminescence immunoassay on the Elecsys 2010 (Roche Diagnostics, Mannheim, 
Germany). The recommended lower limit of 0.03 ng/mL was used to define positive troponin 
T levels because lower levels do not meet the imprecision criteria of less than 10%. 
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The study endpoint was the combination of elevated cTnT, MI, and cardiac death. 
Criteria for MI diagnosis included at least two of the following: cTnT ≥0.1 ng/mL, typical 
electrocardiographic changes (new Q waves >1 mm or >30 ms in electrocardiogram), and 
typical chest pain complaints. Cardiac death was defined as fatal MI (postmortem evidence of 
acute MI or definite criteria for MI within the 24 h before death) and sudden cardiac death. 
Sudden cardiac death was defined as unexpected natural death due to cardiac causes, within 1 h 
of the onset of acute symptoms. 
 
Statistical analysis 
Categoric variables are expressed as percentages and were compared using the Pearson's χ2 
test. Continuous variables are presented as mean (± SD) and were compared using the 
unpaired Student t-test. Correlation between DE and intraoperative TEE results in different 
LV locations was tested by means of kappa statistic (κ), to verify whether a paired rest WMA 
or NWMA locality, estimated by both techniques, might differ from agreement that could 
occur by chance alone. The κ measure of agreement between two observations ranges between 
0 and 1 (0 = chance agreement, less than 0.4 = poor agreement, 0.4 to 0.75 = fair to good 
agreement, and more than 0.75 = excellent agreement). The measured κ value is presented in 
table or text. For all tests, a p-value <0.05 (two-sided) was considered significant. All analyses 
were performed using the syntax commands of SPSS® v15.0 statistical package for Windows® 
(SPSS Inc., Chicago, IL). 
 
 
RESULTS 
 
Fifty-four consecutive patients were enrolled in the study. Preoperative baseline clinical 
characteristics, including baseline echocardiographic variables, are shown in Table 1. None of 
the examined patients had pacing devices. Operative characteristics are shown in Table 2. We 
excluded six eligible patients from our study: two because of inability to insert the TEE probe 
that encountered resistance and four cases because of improper visualization of standard echo 
views mentioned in the methods. 
 
 Dobutamine echocardiography and TEE showed rest WMAs in 17 (31%) and 16 
(30%) patients, respectively: κ value on patient base = 0.92. The agreement for location of rest 
WMAs was excellent: κ range = 0.77 to 1.0. Stress-induced NWMAs during DE occurred in 17 
patients (31%), whereas intraoperative NWMAs were observed by TEE in 23 patients (43%): κ 
value on patient base = 0.65. However, the agreement for location of NWMAs, using a seven-
wall model was poor: κ range = 0.26 to 0.44. Echocardiographic locations of NWMAs are 
presented in Figure 2 and Table 3. κ value for interobserver variability for the different LV walls 
ranged between 0.91 and 0.98. A random sample of 10 patients was selected and rescored for 
LV wall motion by each scoring investigator. Intraobserver κ value for the different LV walls 
ranged between 0.97 and 1.00. 
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Table 1 
Baseline and perioperative patient characteristics in all and sub-
populations, based on the acquisition of a perioperative NWMA 
Preoperative  dobutamine 
echocardiography 
Intraoperative transesophageal  
echocardiogeraphy 
 
NWMA 
absent 
NWMA 
present 
p- 
value 
NWMA 
absent 
NWMA 
present 
p- 
value 
 
[N=17] [N=37]  [N=23] [N=31]  
Demographics (mean ± SD) 
 
     
Age  70 (12 64 (12) NS 71 (12) 61 (11) < 0.05 
Male (%)   15 (88) 33 (89) NS 20 (87) 28 (90) NS 
Medical history (%)       
Angina pectoris 6 (46) 7 (54) NS 10 (44) 3 (10) NS 
Myocardial infarction 10 (59) 14 (38) NS 14 (61) 10 (32) < 0.05 
Coronary revascularization a 6 (43) 7 (57) NS 7 (30) 7 (23) NS 
Stroke 5 (29) 6 (16) NS 7 (30) 4 (13) NS 
Diabetes mellitus b 8 (47) 4 (11) < 0.05 6 (26) 6 (19) NS 
Renal dysfunction c 5 (29) 3 (8) < 0.05 6 (26) 2 (7) < 0.05 
Hypertension d 11 (65) 23 (62) NS 15 (65) 19 (61) NS 
Hypercholesterolemia 13 (77) 16 (43) < 0.05 15 (65) 14 (45) NS 
COPD 8 (47) 14 (38) NS 13 (57) 9 (29) < 0.05 
Congestive heart failure 0 (0) 3 (8) NS 3 (13) 0 (0) < 0.05 
Echocardiography (mean ± SD)      
LV hypertrophy (%) 9 (53) 14 (38) NS 14 (61) 9 (29) NS 
Ejection fraction  45 (10) 48 (7) NS 45 (6) 45 (5) NS 
Fractional area change  44 (8) 43 (8) NS 45 (9) 43 (8) NS 
Fraction shortening  25 (5) 28 (5) NS 26 (4) 27 (6) NS 
ASA physical status classification (%)     
ASA class I 0 (0) 3 (8) NS 0 (0) 3 (10) NS 
ASA class II 4 (24) 9 (24) NS 5 (22) 8 (26) NS 
ASA class III 8 (47) 21 (57) NS 12 (52) 17 (55) NS 
ASA class IV 5 (29) 4 (11) NS 6 (26) 3 (10) NS 
Revised Cardiac Risk factors (%)      
I 0 (0) 17 (46) 0.001 2 (9) 15 (48) < 0.05 
II 3 (18) 11 (30) NS 6 (26) 8 (26) NS 
≥ III  14 (61) 9 (39) < 0.001 15 (65) 8 (26) < 0.01 
Medication (%)      
β-blockers  17 (100) 37 (100) NS 23 (100) 31 (100) NS 
Statins  14 (82) 15 (41) < 0.05 16 (70) 13 (42) < 0.05 
ACE inhibitors   7 (41) 6 (16) < 0.05 9 (39) 4 (13) < 0.05 
Calcium-channel blockers   6 (35) 3 (8) < 0.05 6 (26) 3 (10) NS 
Aspirin   11 (65) 24 (65) NS 14 (61) 21 (68) NS 
Nitrates  1 (6) 1 (3) NS 2 (9) 0 (0) NS 
Diuretics 5 (29) 7 (19) NS 8 (35) 4 (13) NS 
a Coronary artery bypass graft surgery and/or percutaneous coronary intervention procedures. b Fasting blood sugar ≥7 
mmol/L or use of hypoglycemic agents. c Serum creatinine level ≥2.0 mg/dL [177 mmol/L] or requirement of dialysis. d 
Arterial blood pressure ≥140/90 mmHg or use of antihypertensive drugs. Continuous variables are shown as mean 
(±SD), while dichotomous variables are shown as number (% of column totals). American Society of Anesthesiologists 
(ASA), chronic obstructive pulmonary disease (COPD), left ventricular (LV), new wall motion abnormality (NWMA), 
non significant (NS), standard deviation (SD). 
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Table 2 
Population operative characteristics with respect to the distribution of 
hemodynamic covariates on the acquisition of a perioperative NWMA 
All 
patients 
Intraoperative  
transesophageal echocardiogeraphy 
 
 
NWMA 
absent 
NWMA 
present 
p- 
value 
 
[N=54] [N=23] [N=31]  
Anesthetic technique 
 
   
General anesthesia (%) 31 (57) 10 (44) 21 (68) NS 
Combined anesthesia (%) 23 (43) 13 (57) 10 (32) NS 
Surgical procedure     
Open aortic prosthetic repair (%) 34 (63) 17 (74) 17 (55) NS 
 Clamping duration (minute)  (mean ± SD) 49.4 (54.6) 52.4 (45.1) 47.9 (55.7) NS 
Lower extremity revascularization (%) 20 (38) 6 (26) 14 (45) NS 
Procedure duration (minute)  (mean ± SD) 267 (72) 275 (45) 265 (64) NS 
Operative blood loss (liter)  (median ± IQR) 0.5 (.6-1.9) 0.6 (.2-1.9) 0.5 (.4-1.8) NS 
Intraoperative fluid administration    
Crystalloids (liter)  (mean ± SD) 4.0 (.2) 4.6 (2.9) 3.8 (1.9) NS 
Colloids (liter)  (mean ± SD) 1.5 (.8) 1.6 (.8) 1.4 (.7) NS 
Packed cells (units)  (mean ± SD) 4.3 (1.5) 3.8 (1.8) 4.5 (1.2) NS 
Plasma in (units)  (mean ± SD) 3.0 (1.0) 2.5 (1.1) 3.1 (.8) NS 
Cell-saver blood (units) (median ± IQR) 0.4 (.3-1.2) 0.4 (.2-1.0) 0.6 (.3-1.4) NS 
Hemodynamic variables    
Heart rate (bpm) (mean ± SD) 67.1 (11.9) 69.6 (11.5) 66.5 (7.7) NS 
Mean arterial pressure (mmHG)  (mean ± SD) 77.7 (13.4) 80.5 (11.5) 73.2 (15.4) NS 
Intraoperative urine output (liter)  (median ± IQR) 0.5 (.4-.7) 0.7 (.5-.8) 0.6 (.4-.7) NS 
Interquartile range (IQR), new wall motion abnormality (NWMA), non significant (NS), standard deviation (SD). 
 
  
 During 30-day follow-up, the composite endpoint occurred in 15 patients (28%); 
cTnT release in 14 (26%), MI in 6 (11%), and cardiac death in 3 (6%) (Table 4). Of these 15 
patients, 10 (67%) experienced both pre- and intraoperative NWMAs, whereas in 4 (27%), 
only intraoperative NWMAs were observed. Troponin release was observed in only one 
patient (7%) without pre- and intraoperative NWMAs. This patient did not experience 
ischemic symptoms or electrocardiographic abnormalities. The relation of pre- and 
intraoperative NWMAs and postoperative outcome is presented in Table 4. In all six patients 
who experienced a postoperative MI, the location of electrocardiographic changes matched 
with the intraoperatively observed NWMAs by TEE, whereas in 2 patients (33%), there was an 
agreement with the preoperatively induced ischemia during DE. 
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Figure 2: Agreement for location in ischemic left ventricular (LV) walls between pre- and 
intraoperative echocardiography.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During 30-day follow-up the composite endpoint occurred in 15 (28%) patients; cTnT release 
in 14 (26%), MI in 6 (11%), and cardiac death in 3 (6%), (Table 4). In these 15 patients, 10 
(67%) experienced both pre and intraoperative NWMAs, while in 4 patients (27%) only 
intraoperative NWMAs were observed. In only one patient (7%) without pre- and 
intraoperative NWMAs, troponin release was observed. This patient did not experience 
ischemic symptoms or electrocardiographic abnormalities. The relation of preoperative and 
intraoperative NWMAs and postoperative outcome is presented in Table 4. In all 6 patients 
who experienced a postoperative MI, the location of electrocardiographic changes matched 
with the intraoperatively observed NWMAs by TEE, while in 2 (33%) there was an agreement 
with the preoperative induced ischemia during DE. 
 
 Figure 3 represents the subdivision of the total population according to pre- and 
intraoperative development of NWMAs and postoperative cardiac outcome. The presence of 
multivessel CAD as detected by DE and intraoperatively by TEE was in favor of a composite 
outcome (p < 0.05 for DE and p = 0.001 for intraoperative TEE) but not a single-vessel 
disease (p = NS). In Table 5, we present the calculated diagnostic indices of both preoperative 
DE and intraoperative TEE for the study outcomes. 
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Table 3 
Agreement for the association and locality distribution of 
(i) rest and (ii) ischemic LV walls presenting with WMAs 
during preoperative DE and intraoperative TEE 
Preoperative dobutamine  
echocardiography 
Intraoperative transesophageal 
echocardiography 
K 
 
N (%) N (%)  
Patiens with rest WMA 
 
17 (31) 16 (30) 0.917 
Location    
 Anterior wall 7 (41) 9 (56) 0.821 
 Antero-septal wall 10 (59) 12 (75) 0.843 
 Septal wall 11 (65) 11 (69) 1.0 
 Lateral wall 7 (41) 9 (56) 0.821 
 Posterior wall 7 (41) 7 (44) 1.0 
 Inferior wall 9 (53) 9 (56) 1.0 
 Apical wall 13 (76) 10 (63) 0.769 
Patients with NWMA 
 
17 (31) 23 (89) 0.653 
Location    
 Anterior wall 5 (29) 6 (26) 0.292 
 Antero-septal wall 8 (47) 14 (61) 0.440 
 Septal wall 9 (53) 13 (57) 0.321 
 Lateral wall 5 (29) 9 (39) 0.351 
 Posterior wall 4 (24) 5 (22) 0.260 
 Inferior wall 4 (24) 8 (35) 0.395 
 Apical wall 9 (53) 4 (17) 0.351 
Single vessel reversible ischemia 7 (41) 8 (35) 0.233 
Multivessel reversible ischemia 10 (69) 15 (65) 0.336 
Dobutamine echocardiography (DE), Kappa measurement value (K), left ventricular (LV), new wall motion abnormalities 
(NWMA), transesophageal echocardiography (TEE), wall motion abnormalities (WMA). 
 
 
Table 4 
Postoperative patient outcomes according to ischemia wall agreement 
between pre- and intraoperative NWMAs 
All  
patients 
Preoperative dobutamine 
echocardiography 
Intraoperative transesophageal 
echocardiogeraphy 
 
 
NWMA 
absent 
NWMA 
present 
p-value NWMA 
absent 
NWMA 
present 
p- 
value 
 
[N=54] [N=17] [N=37]  [N=23] [N=31]  
Postoperative outcomes 
 
      
p.o. cTnT release 14 (26) 9 (53) 5 (14) < 0.05 13 (57) 1 (3) < 0.001 
p.o. MI 6 (11) 6 (35) 0 (0) < 0.001 6 (26) 0 (0) < 0.05 
Cardiac death 3 (6) 2 (12) 1 (3) NS 3 (13) 0 (0) < 0.05 
Composite outcome 15 (28) 10 (59) 5 (14) 0.001 14 (61) 1 (3) < 0.001 
New wall motion abnormalities (NWMAs), postoperative cardiac troponin T (p.o. cTnT), postoperative myocardial 
infarction (p.o. MI). 
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Figure 3: Composite cardiac outcome according to perioperative new wall motion abormalities 
(NMWAs). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 
Sensitivity, specificity, positive, and negative predictive value of 
preoperative DE and intraoperative TEE for the study outcomes 
Echocardiographic 
technique 
Intraoperative 
NWMA 
p.o. 
cTnT 
p.o. 
MI 
Cardiac 
death 
Composite 
endpoint 
Sensitivity 
DE 61% 64% 100% 67% 67% 
TEE - 93% 100% 100% 93% 
Specificity 
DE 90% 80% 77% 71% 82% 
TEE - 75% 65% 61% 77% 
Positive predictive value 
DE 82% 53% 35% 12% 59% 
TEE - 57% 26% 13% 61% 
Negative predictive value 
DE 76% 87% 100% 97% 87% 
TEE - 97% 100% 100% 97% 
Dobutamine echocardiography (DE), postoperative cardiac troponin T (p.o. cTnT), postoperative myocardial infarction (p.o. 
MI), transesophageal echocardiography (TEE). 
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DISCUSSION  
 
In this study, we used echocardiography to observe the location of NWMAs induced 
preoperatively during DE and those developed intraoperatively by TEE monitoring in 54 high-
risk vascular surgery patients. By using the κ coefficient, we observed an excellent correlation 
between pre- and intraoperative rest WMAs (κ range 0.8 to 1.0), indicating concordance 
between pre- and intraoperative echocardiographic recordings. However, poor agreement 
correlations were found between pre- and intraoperative locations of NWMAs (κ range ≤0.4). 
 
  Although patients with severe and unstable CAD are warranted to undergo 
preoperative stress testing to direct towards the optimal prophylactic strategy, those who have 
stable CAD do not show much benefit from stress testing over clinical stratification. 
Dobutamine echocardiography, among other stress tests, accurately determines reversible 
ischemic regions. However, those tests have stronger negative than positive predictive power, 
particularly in the stable CAD population. Perioperative β-blockade has proven to be a 
sufficient prophylactic regime in such patients. In the current investigation, approximately 45% 
of our population presented with established CAD, 14% presented with two risk factors, and 
43% presented with three or more risk factors among the Lee’s Revised Cardiac Risk index, 
with fair LV function in average estimated by mean ejection fraction. This stratification puts 
this population in the gray zone of where optimized medical therapy is weighed against 
coronary revascularization. The purpose of this study was to determine which of the two 
prophylactic measures is optimal in order to provide better postoperative cardiac outcome.22, 23 
 
Autopsy studies have shown the pathologic similarity of perioperative MI to that 
occurring in the nonoperative setting, however, they were unsuccessful in predicting the site of 
vulnerable plaque rupture in most instances of perioperative MI based on the severity of 
coronary stenosis.6, 7 This means that selective targeting of isolated culprit plaques by means of 
a focused revascularization technique as a prophylactic measure cannot be used with adequate 
results. 
  
Because of the high propensity of CAD in the peripheral arterial disease population 
requiring elective surgical intervention, preoperative cardiac evaluation might suggest an 
indication for coronary revascularization in those presenting with severe coronary artery 
stenosis.5, 24, 25 Pooled data from previous studies were not favor of preoperative coronary 
revascularization before major noncardiac surgery. In the Coronay Artery Revascularization 
Prophylaxis (CARP)-trial, coronary arterial revascularization in 258 symptomatically stable 
patients with severe CAD, did not confer beneficial perioperative or long-term outcome 
compared with the control group (252 patients) before major vascular operations.3 Similar 
findings were shown in the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography (DECREASE-V) randomized pilot study, in which 101 high-risk vascular 
surgery patients were randomized either to no intervention (N=52) or coronary 
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revascularization before vascular surgery (N=49).26 The Coronary Artery Surgery Study 
(CASS)-trial investigators suggested similar conclusions when equivocal long-term outcomes 
were observed between coronary artery bypass graft surgery and intensive medical treatment 
patient groups.27 These findings remained unchanged after 10 year of follow-up. Comparable 
results were shown by medical treatment, surgical treatment, or percutaneous coronary 
intervention.28 Finally, reports of unwanted outcomes have been addressed for percutaneous 
coronary intervention before noncardiac surgery in the population at risk for CAD.29, 30 
Indeed, the reason that coronary artery bypass grafting was found superior to percutaneous 
coronary intervention before vascular surgery in one study, was the more extensive 
revascularization in the coronary artery bypass graft group.31 
 
 We reported postoperative cardiac outcomes as 26, 11 and 6% for postoperative 
cTnT release, MI, and cardiac death, respectively. These events were predictable by the 
induction of NWMAs by a DE stress test and even better predicted by the occurrence of 
intraoperative NWMAs. In our population, NWMAs induced during DE or detected 
intraoperatively by TEE presented more with multivessel CAD form, which was also 
correlated with the combined cardiac outcome (p = 0.003 for multivessel reversible ischemia 
by preoperative DE and p = 0.001 for multivessel reversible ischemia by intraoperative TEE) 
but not a single coronary vessel-related NWMAs (p = NS). This indicated the more extensive 
nature of CAD they had.  
 
 We found perfect matching of intraoperative NWMA location with postoperative 
electrocardiographic locality of MI, indicating the accumulation of most perioperative stressors 
on the vulnerable myocardium of the vascular surgery patient in the intraoperative phase 
exhausting the moribund coronary reserve around the end of surgery, which would hence yield 
most fatal MIs in the immediate postoperative phase up to 12 hours. This coincides with the 
well-established knowledge that more than 50% of perioperative MIs do occur in the 
immediate postoperative period and lead to recommending twice daily electrocardiography in 
the first postoperative day. In addition, we reported postoperative cTnT release in 14 patients 
(26%). In 8 (57%) of them, troponin release was not associated with MI. LeManach et al. found 
earlier postoperative abnormal troponin in a larger cohort of vascular surgical patients (14% of 
1,136 patient population). Increased cardiac troponins were related to postoperative MI (in 
35% of the patients with increased troponin levels) in two distinct fashions (early and late), 
indicating two different sets of myocardial stressors nearer and later from the end of surgery.32 
The prevalence of increased postoperative troponin in our study is similar to or even reduced 
to that reported in other research in similar populations.25, 33, 34 Silent myocardial ischemic 
events would result from the effects of perioperative stressors in a myocardial demand or 
supply mismatch insufficient to progress to evident myocardial damage. This is supported by 
the finding that perioperative cTnT is related to poor long-term cardiac outcomes. This would 
explain the higher rates of subclinical ischemic events (increased cTnT or transient NWMAs) 
over harder cardiac events in our and other populations.23, 25, 35 
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 Intraoperative TEE showed an additional incremental value on the prediction of 
postoperative cardiac events. Both preoperative NWMAs during DE and intraoperative 
NWMAs detected by TEE had a significant association with the composite cardiac outcome (p 
< 0.001). No events of cardiac death or postoperative MI occurred in patients without 
intraoperative NWMAs.  
 
We had several limitations in this study. Some patients were excluded for either 
technical difficulty in image acquisition at any stage or inappropriate views to judge LV wall 
motion. We could not continue to enroll more patients because of time factors, limiting the 
level of power of our significant results, especially those related to the regression analysis. 
Some NWMAs were probably missed, particularly before probe insertion after the start of 
anesthesia induction. Coronary angiography was not clinically indicated preoperatively in the 
studied patients, and hence, we could not relate our findings to the more pathognomonic 
angiographic data. Some reversible segmental LV WMAs could have been missed in some 
views while obtaining others for offline analysis. Nevertheless, concomitant mechanical effects 
such as tethering by a coexisting myocardial scarring or ballooning effect during aortic cross-
clamping would have influenced our judgment for a NWMA. Finally, κ measurement is a 
useful statistic to look for the chance of agreement between two sets of readings. However, it 
has few flaws, particularly its vulnerability towards difference in prevalence regardless a fixed 
specificity and sensitivity between the two readings, particularly when sophisticated variables 
and heterogenous examination groups are used.36, 37 
 
In patients undergoing major vascular surgery, preoperative DE and intraoperative 
TEE monitoring of wall motion changes had good correlation with postoperative cardiac 
cTnT release and MI. However, TEE had a stronger association with all postoperative cardiac 
events. Reproducibility of WMAs in the same myocardial wall locations at different 
perioperative times was not achievable. This suggests the superiority of optimized medical 
therapies over the invasive interventions focused on particular culprit lesions for the 
prophylaxis against perioperative myocardial ischemia. In our population, receiving β-blocking 
medication, the higher predictive power of intraoperative TEE over preoperative DE for 
postoperative outcomes further emphasizes the importance of optimized medical treatment 
over preoperative cardiac testing in fairly stable populations with CAD. 
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LEFT VENTRICULAR VOLUME AND FUNCTION 
 
Over the last decades, echocardiography has developed to be an established noninvasive 
imaging technique, widely available for cardiovascular investigation. Determination of 
myocardial function is vital for the clinical evaluation of cardiovascular diseases. Altered 
cardiac function can be detected with echocardiography as regional myocardial wall motion 
abnormalities, changes in left ventricular volumes, and global left ventricular dysfunction.1 
 
Regional wall motion abnormalities can identify and quantify areas of previous 
myocardial infarction. Visual assessment categorises wall motion on the basis of the (i) degree 
of endocardial excursion, (ii) degree of endocardial thickening during systole, (iii) timing of 
motion, and (iv) shape of the left ventricle. Timing is particularly important and accurate wall 
motion assessment requires a frame-by-frame review to overcome the limited temporal 
resolution of the human eye.2  
 
Although there is tremendous variability in the coronary artery blood supply to the 
myocardium, a model with 16-segments assigned to one of the three major coronary arteries is 
recommended for visual interpretation of regional wall motion.3 Therefore, individual 
myocardial segments can be assigned to one major coronary artery with recognition of 
anatomic variability. Normally, the endocardium thickens during systole; however, ischemic 
myocardium shows different patterns of wall thickening or even thinning during systole. Wall 
motion abnormalities at rest represent scar tissue (irreversible myocardial damage) or viable 
myocardium (reversible myocardial damage). 
 
Echocardiographic assessment of left ventricular volumes plays an important role in 
the evaluation of pathologic remodelling, a process leading to left ventricular dilatation 
(eccentric remodelling) which is associated with systolic left ventricular dysfunction.4 
Progressive ventricular dilatation can result in (i) distortion of the cavity shape and (ii) 
disruption of the mitral annulus and sub-valvular apparatus, which is an important cause of 
mitral regurgitation.5 Evaluating left ventricular volumes is, therefore, essential for optimal 
timing of surgical mitral valve replacement. Left ventricular dilatation is associated with global 
systolic left ventricular dysfunction, characterized by a reduced left ventricular ejection 
fraction.4 The left ventricular ejection fraction is widely used to diagnose systolic heart failure 
and in decision making of pacemaker or internal automatic defibrillator implantation.   
 
The biplane Simpson’s method is considered to be the preferred method to calculate 
left ventricular volumes and ejection fraction and requires imaging in apical, four- or two-
chamber views. First, the endocardial border has to be outlined in end-diastole and end-systole, 
and the left ventricular cavity is divided into a series of disks of equal height, along its long-
axis. When the central-axis of the left ventricular cavity is defined and the endocardial border is 
identified, the volume of each disk can be automatically calculated. In addition, the ventricular 
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volume is calculated by summing the disk volumes, which are equally spaced along the left 
ventricular long-axis. Once the left ventricular volumes have been measured, left ventricular 
ejection fraction can be calculated.6 However, in more than 15% of patients examined with 
ultrasound, poor ultrasonic windows preclude optimal visualisation of the endocardial border.7  
 
Analysing left ventricular volumes and function relies on the identification of the 
endocardial border of the left ventricular cavity and is often performed subjectively with the 
use of visual interpretation (‘eye-balling’). This approach is dependent on the eye of an 
experienced observer and can be misleading in situations of (i) irregular heart rhythm, (ii) very 
large or small left ventricle size, and (iii) extreme heart rates.8, 9 The biplane Simpson’s method 
is considered to be semi-objective because it requires manual tracing of the endocardial 
border.8  
 
Two-dimensional echocardiography, currently the most frequently used technique for 
the structural analysis of the heart, has limitations regarding the observation of the cardiac 
anatomy. Two-dimensional estimation of left ventricular volumes and ejection fraction are 
flawed due to foreshortening errors and reliance upon geometric models. The development of 
three-dimensional echocardiography has improved the reproducibility and accuracy to 
determine left ventricular volumes and ejection fraction, compared with two-dimensional 
echocardiography.10 In addition, measurements of changes in left ventricular volumes and 
ejection fraction with three-dimensional echocardiography have shown to be similar to those 
obtained with cardiac magnetic resonance.9 
 
 
STRAIN RATE IMAGING IN ECHOCARDIOGRAPHY 
 
The main application of new technologies is to improve the quantification of 
echocardiography. The interpretation of regional myocardial function is the most challenging 
aspect of echocardiography, as well as the most difficult to quantify. Recent developments in 
tissue-Doppler, strain rate imaging, and speckle tracking echocardiography may prove useful 
for this purpose.  
 
Tissue-Doppler imaging is a technique which measures high amplitude signals of 
myocardial tissue motion. Echocardiographic techniques utilizing tissue-Doppler imaging are 
more sensitive than conventional echocardiography in the detection of subtle (regional) 
changes in left ventricular contractile function.11 However, because tissue-Doppler imaging is a 
Doppler-based technique, its angle dependency remains a serious limitation.12 The assessment 
of apical myocardial segments, for instance, is known to be suboptimal with tissue-Doppler 
imaging.13 Furthermore, due to its Doppler-based properties, tissue-Doppler imaging velocity 
is unable to discriminate active deformation of the left ventricle (as a result of myocardial fibre 
shortening and lengthening) from passive deformation.  
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Strain and strain rate imaging have demonstrated to be a more reliable method to 
quantify myocardial function. Essentially, myocardial strain represents the rate of myocardial 
deformation or stretch reflected by (i) longitudinal and circumferential strain (shortening of the 
myocardium) and (ii) radial strain (lengthening of the myocardium).12 Myocardial strain 
measured with tissue-Doppler imaging is dependent on the angle of incidence between the 
ultrasound beam and myocardial motion. At angles greater than 20º, Doppler-derived strain 
and strain rate are significantly underestimated.14 Recently, myocardial stain and strain rate can 
be measured using speckle tracking derived parameters.  
 
 
SPECKLE TRACKING ECHOCARDIOGRAPHY 
 
In 1991, speckle tracking echocardiography was introduced, an imaging modality for the 
quantification of left ventricular volumes and function, which is angle-independent.15 Speckle 
tracking is a technique that tracks the movement of natural acoustic markers, or ‘speckles’, 
which are present on standard grey scale ultrasound tissue images.16 These speckles appear as a 
result of scattering, reflection, and interference of the ultrasound beam in myocardial tissue. 
With the use of wall motion tracking software, speckle movement (and therefore myocardial 
tissue movement) can be visualized from frame-to-frame during the cardiac cycle.17 Speckle 
tracking echocardiography has the advantage to assess myocardial strain or active thickening, 
independent of Doppler angle of incidence used in tissue-Doppler strain methods. Therefore, 
it has been introduced for clinical applications, such as dyssynchrony analysis.18  
 
However, speckle tracking applied to two-dimensional images is limited because 
regions of the myocardium represented by speckle patterns in reality move through three-
dimensional space, rather than being limited by the two-dimensional sector, resulting in 
reliance on geometric modelling.10, 19 Regardless of its limitations, a study conducted by 
Nishikage et al.20 demonstrated a significant correlation between two-dimensional speckle 
tracking echocardiography and cardiac magnetic resonance for measuring left ventricular 
volumes. A good correlation for left ventricular ejection fraction was found, although a 
significant underestimation was observed in two-dimensional speckle tracking 
echocardiography compared with cardiac magnetic resonance. The results demonstrated by 
Nishikage et al. are promising, however, one could ask the question whether three-dimensional 
speckle tracking echocardiography provides better results.  
 
This question has recently been answered in a manuscript conducted by Nesser et al.21 
In this manuscript, the accuracy of three- vs. two-dimensional speckle tracking 
echocardiography for measuring end-systolic and end-diastolic left ventricular volumes was 
compared. Cardiac magnetic resonance was used as the reference technique for both two- and 
three-dimensional echocardiography. The main finding of this study was that the inter- and 
intraobserver variability was lower and less spread in measurements obtained from three-
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dimensional speckle tracking echocardiography compared with two dimensional speckle 
tracking echocardiography. This might imply that three-dimensional speckle tracking 
echocardiography could be an attractive new method, not only for the assessment of left 
ventricular volumes, however for the assessment of left ventricular function as well (Figure 1). 
 
 
Figure 1: An example of a three-dimensional speckle tracking echocardiogram from a heart failure 
patient with ischemic cardiomyopathy demonstrating the representative long-axis and short-axis 
tomographic planes, the three-dimensional wire-mesh display, and the time-volume curve.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
End-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF). 
 
 
SPECKLE TRACKING ECHOCARDIOGRAPHY AND CARDIAC MAGNETIC 
RESONANCE  
 
In comparison with other noninvasive cardiac imaging procedures, such as nuclear cardiology, 
cardiac computed tomography, and cardiac magnetic resonance, echocardiography has both 
limitations and advantages. In patients with obstructive lung disease, obesity, chest wall 
deformities, increases in heart rate, and hyperventilation image quality impairment may cause 
difficulties in analysis of echocardiographic images. However, echocardiography has the 
advantage of being (i) safe (i.e. no radiation or ionizing substances required), (ii) widely 
available, (iii) noninvasive, (iv) feasible in almost all circumstances including interventional 
settings such as catheterization laboratories or operating rooms, (v) at relatively low cost.22 
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Cardiac magnetic resonance has the ability to provide information about cardiac anatomy, 
function, and perfusion simultaneously and has a superior spatial resolution compared with 
echocardiography. However, cardiac magnetic resonance has a lower temporal resolution, 
usually requires breath-holding sequences during data acquisition, is relatively expensive and 
less available compared with echocardiography, and may be limited in patients with implanted 
metallic prosthetics. Nesser et al. have compared three-dimensional speckle tracking 
echocardiography with cardiac magnetic resonance and found that three-dimensional speckle 
tracking echocardiography measurements were in close agreement with the cardiac magnetic 
resonance reference values, in the presence of an adequate trans-thoracic two-dimensional 
acoustic window. However, both inter- and intraobserver variability were lower and less spread 
in measurements obtained with cardiac magnetic resonance, compared with measurements 
obtained with three-dimensional speckle tracking echocardiography.21 These finding are 
probably related to superior spatial and contrast resolution of cardiac magnetic resonance.  
 
 
FUTURE PERSPECTIVE 
 
The echo community has put lot of efforts in guidelines and standardization in left ventricular 
function assessment, being aware of the limitations of non-quantitative measurements as such 
eye-balling evaluation of ejection fraction and regional myocardial function. Objective 
quantification of left ventricular volumes and function with three-dimensional speckle tracking 
echocardiography could be an attractive new method to complete standardization of left 
ventricular function assessment. In addition, three-dimensional speckle tracking 
echocardiography might prove its value over cardiac magnetic resonance in interventional 
settings such as catheterization laboratories and operating rooms. During catheterization or 
surgery, the use of cardiac magnetic resonance is limited, due to practical reasons. However, an 
immediate visual and quantitative feedback of left ventricular function, without the need for 
off-line analysis, is of utmost important in these clinical settings.23  
 
To achieve automated assessment of left ventricular volumes and function with three-
dimensional speckle tracking ultrasound, shortcomings have to be overcome such as (i) low 
temporal resolution and (ii) random noise affecting the ability to track speckles during the 
cardiac cycle.21 The positive results of Nesser et al, however, have provided an insight on how 
global and regional left ventricular function could be evaluated in the decades lying ahead.    
 
 
REFERENCES 
 
1. Hauser AM, Gangadharan V, Ramos RG, et al. Sequence of mechanical, electrocardiographic and clinical 
effects of repeated coronary artery occlusion in human beings: echocardiographic observations during 
coronary angioplasty. J Am Coll Cardiol. 1985;5(2 Pt 1):193-197. 
 145 
2. Kvitting JP, Wigstrom L, Strotmann JM, et al. How accurate is visual assessment of synchronicity in 
myocardial motion? An In vitro study with computer-simulated regional delay in myocardial motion: 
clinical implications for rest and stress echocardiography studies. J Am Soc Echocardiogr. 1999;12(9):698-705. 
3. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature 
for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging 
Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 
2002;105(4):539-542. 
4. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper 
from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac 
Remodeling. J Am Coll Cardiol. 2000;35(3):569-582. 
5. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation. 1999;100(9):999-
1008. 
6. Stamm RB, Carabello BA, Mayers DL, et al. Two-dimensional echocardiographic measurement of left 
ventricular ejection fraction: prospective analysis of what constitutes an adequate determination. Am Heart 
J. 1982;104(1):136-144. 
7. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-
dimensional echocardiography. American Society of Echocardiography Committee on Standards, 
Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 
1989;2(5):358-367. 
8. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the 
American Society of Echocardiography's Guidelines and Standards Committee and the Chamber 
Quantification Writing Group, developed in conjunction with the European Association of 
Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 
2005;18(12):1440-1463. 
9. Jenkins C, Bricknell K, Hanekom L, et al. Reproducibility and accuracy of echocardiographic 
measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll 
Cardiol. 2004;44(4):878-886. 
10. Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from 
real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27(4):460-468. 
11. Gorcsan J, 3rd, Deswal A, Mankad S, et al. Quantification of the myocardial response to low-dose 
dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. Am J 
Cardiol. 1998;81(5):615-623. 
12. Urheim S, Edvardsen T, Torp H, et al. Myocardial strain by Doppler echocardiography. Validation of a 
new method to quantify regional myocardial function. Circulation. 2000;102(10):1158-1164. 
13. Edvardsen T, Skulstad H, Aakhus S, et al. Regional myocardial systolic function during acute myocardial 
ischemia assessed by strain Doppler echocardiography. J Am Coll Cardiol. 2001;37(3):726-730. 
14. Nesbitt GC, Mankad S, Oh JK. Strain imaging in echocardiography: methods and clinical applications. Int J 
Cardiovasc Imaging. 2009;25 Suppl 1:9-22. 
15. Bohs LN, Trahey GE. A novel method for angle independent ultrasonic imaging of blood flow and tissue 
motion. IEEE Trans Biomed Eng. 1991;38(3):280-286. 
16. Leitman M, Lysyansky P, Sidenko S, et al. Two-dimensional strain-a novel software for real-time 
quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr. 2004;17(10):1021-
1029. 
17. Yeung F, Levinson SF, Parker KJ. Multilevel and motion model-based ultrasonic speckle tracking 
algorithms. Ultrasound Med Biol. 1998;24(3):427-441. 
18. Suffoletto MS, Dohi K, Cannesson M, et al. Novel speckle-tracking radial strain from routine black-and-
white echocardiographic images to quantify dyssynchrony and predict response to cardiac 
resynchronization therapy. Circulation. 2006;113(7):960-968. 
19. Meunier J. Tissue motion assessment from 3D echographic speckle tracking. Phys Med Biol. 
1998;43(5):1241-1254. 
20. Nishikage T, Nakai H, Mor-Avi V, et al. Quantitative assessment of left ventricular volume and ejection 
fraction using two-dimensional speckle tracking echocardiography. Eur J Echocardiogr. 2009;10(1):82-88. 
21. Nesser HJ, Mor-Avi V, Gorissen W, et al. Quantification of Left Ventricular Volumes using Three-
Dimensional Echocardiographic Speckle Tracking; Comparison with MRI. Eur Heart J. 2009. 
22. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance 
(CMR): Consensus Panel report. Eur Heart J. 2004;25(21):1940-1965. 
23. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 
2006;7(2):79-108. 
 
 
 
 146 
 
 
 
 147 
 
 
 
 
 
 
PART II 
 
Asymptomatic atherosclerosis in 
patients with symptomatic peripheral 
arterial disease 
 
 
 
 
 
 
 
 
 
 
 148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
Chapter  10 
 
Perioperative cardiac damage in vascular 
surgery patients 
 
European Journal of Vascular and Endovascular Surgery 2010; 
in press 
 
 
Willem-Jan Flu 
Olaf Schouten 
Jan-Peter van Kuijk 
Don Poldermans  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
ABSTRACT 
 
Background Patients undergoing vascular surgery are at increased risk for developing cardiac 
complications. Majority of patients with perioperative myocardial damage are asymptomatic. 
Our objective is to review the available literature addressing the prevalence and prognostic 
implications of perioperative myocardial damage in vascular surgery patients.  
 
Methods An Internet-based literature search was performed using MEDLINE to identify all 
published reports on perioperative myocardial damage in vascular surgery patients. Only those 
studies published from 2000 to 2010 evaluating myocardial damage using troponin I or T, with 
or without symptoms of angina pectoris were included. 
 
Results Thirteen studies evaluating the prevalence of perioperative myocardial ischemia or 
infarction were included in the study. The incidence of perioperative myocardial ischemia 
ranged from 14 to 47% and the incidence of perioperative myocardial infarction ranged from 1 
to 26%. In addition, 10 studies evaluating the prognostic value of perioperative myocardial 
ischemia towards postoperative mortality or the occurrence of major adverse cardiac events 
were included. In the retrieved studies, hazard ratios varied from 1.9 to 9.0.  
 
Conclusion The high prevalence and asymptomatic nature of perioperative myocardial 
damage, combined with a substantial influence on postoperative mortality of vascular surgery 
patients, underline the importance of early detection and adequate management of 
perioperative myocardial damage. 
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INTRODUCTION 
 
This article provides an extended overview regarding the prevalence and prognostic value of 
perioperative myocardial ischemia and infarction in vascular surgery patients. In addition, 
treatment options in order to reduce the risk of perioperative myocardial damage are provided 
based on the current available literature. 
 
Perioperative myocardial ischemia and infarction 
The heart is an organ with a high metabolic demand and requires a continuous high level of 
myocardial oxygen-supply. The amount of oxygen supplied to the myocardium is determined 
by the blood flow in the coronary arteries and the oxygen carrying capacity of the blood. 
Therefore, an increase of myocardial oxygen-demand must be met by an increase in coronary 
blood flow. In addition, an imbalance between oxygen-supply and oxygen-demand results in 
myocardial damage, characterized by myocardial ischemia and myocardial infarction (MI).1  
 
In general, myocardial damage can be subdivided according to two pathological 
processes.2 Type 1 MI is defined as an acute coronary syndrome that occurs when a vulnerable 
coronary plaque ruptures, leading to acute coronary thrombosis, ischemia, and infarction. 
Myocardial damage may also be caused by a prolonged imbalance between myocardial oxygen-
supply and demand in the presence of stable coronary artery disease, called type 2 MI. In this 
case, myocardial damage is caused by an increased myocardial oxygen-demand in response to 
stress, which is not met by a sufficient increase of coronary blood flow.3   
 
During surgery, high catecholamine production is responsible for vasoconstriction 
and hemodynamic stress,4 associated with an increased oxygen-demand of the myocardium. 
Perioperative myocardial damage may occur when the increased oxygen-demand is not met by 
an adequate increase of oxygen-supply.5 This is similar to MIs occurring in the nonsurgical 
setting, however, surgery itself is a significant stress factor leading to an increased risk of 
plaque rupture. Two retrospective studies investigated the coronary pathology of fatal 
perioperative MI. As demonstrated in the autopsy study by Dawood et al, 55% of the fatal 
perioperative MIs have direct evidence of plaque disruption defined as fissure or rupture of 
plaque and haemorrhages into the plaque cavity.6 Similar autopsy results were found in the 
study of Cohen and Aretz, who observed that plaque rupture was present in 46% of patients 
with postoperative MI.7 
 
Next to surgical stress, hemodynamic fluctuations during surgery are an important 
cause of perioperative myocardial damage as well. Perioperative fluid administration increases 
the pre- and afterload in the left ventricle, making patients susceptible for perioperative 
myocardial damage.8 On the other hand, perioperative preload reductions in the left ventricle 
can result in tachycardia with a concomitant reduction of coronary perfusion, leading to 
perioperative myocardial damage.9 
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It is estimated that of the 230 million patients undergoing major surgery annually, 
approximately 1% (2,300,000 patients) suffer perioperative MI with a cardiovascular mortality 
rate around 0.3% (690,000 patients).10 However, cardiac risk imbedded in surgical 
interventions can differ depending on the magnitude, duration, location, blood loss, and fluid 
shifts related to the specific procedure. In 2005, Boersma et al. developed a model to risk 
stratify surgical procedures, based on the occurrence of 30-day cardiac death and MI.11 Surgical 
procedures were classified low cardiac risk (<1%), intermediate cardiac risk (1-5%), or high 
cardiac risk (>5%) for the development of 30-day adverse cardiac outcome. High cardiac risk 
surgery is considered to be open lower extremity revascularization and open abdominal aortic 
surgery. In addition, percutaneous transluminal angioplasty, endovascular aortic aneurysm 
repair, and carotid surgery are considered to have intermediate cardiac risk because they are 
associated with reduced myocardial stress and the need for lower fluid administration 
compared with open lower extremity revascularization and open abdominal aortic surgery.12  
 
 
METHODS 
 
A systematic Medline search was undertaken to identify studies addressing perioperative 
cardiac damage, assessed with troponin I or T, in patients undergoing elective peripheral 
vascular surgery published during the period between 2000 and 2010. The keywords used were 
‘cardiac troponin, vascular surgery’, ‘perioperative ischemia, vascular surgery’, ‘cardiac ischemia, 
vascular surgery’ in combination with ‘prevalence’, ‘incidence’, ‘prognostic value’, ‘long-term 
outcome’, ‘long-term mortality’, and ‘major adverse cardiac events’. The retrieved articles were 
also searched for any relevant references. The current manuscript included solely studies 
addressing the prognostic value of increased troponin T or I levels when using regression 
analyses or contingency table analyses. 
 
 
RESULTS 
 
Prevalence of perioperative myocardial damage 
Vascular surgery patients are at increased risk for developing perioperative cardiac 
complications, especially patients undergoing open lower extremity revascularization and open 
abdominal aortic surgery. In 1981, Brown et al. described that around 40% of the patients 
undergoing elective abdominal aortic aneurysm resection had a history of either MI of angina 
pectoris.13 In addition, Hertzer et al. performed routine coronary angiography in more than 
1000 patients in order to detect uncorrected coronary artery disease in patients with advanced 
peripheral vascular disease.14 They found coronary artery disease to be highly present in these 
patients with a prevalence of severe three-vessel disease in 18% of the patients and left main 
disease in 4% of patients.14 In 1989, Oeyang et al. observed that episodes of perioperative 
myocardial damage in patients having peripheral vascular surgery are most often silent.15 Utoh 
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et al. performed routine coronary angiography in patients undergoing abdominal aneurysm 
repair and demonstrated that the incidence of silent ischemia was 20%. In addition, the authors 
concluded that the number of coronary risk factors and resting electrocardiograms were not 
worthwhile for predicting silent coronary artery disease.16  
 
Perioperative myocardial damage is difficult to diagnose due to its silent nature. In 
1994, Adams 3rd et al. demonstrated that the measurement of cardiac troponin I is a sensitive 
and specific method for the diagnosis of perioperative MI in vascular surgery patients.17 
Hereafter, several studies have correlated serial cardiac troponin measurements with 
continuous 12-lead ST-segment analyses after major vascular surgery.18 Troponin elevations 
occurred after prolonged, transient, postoperative ST-segment depression and peak troponin 
elevations correlated with the duration of ST depression.19 Landesberg et al. demonstrated that 
85% of postoperative cardiac complications were preceded by prolonged ST-segment 
depression 20. In addition,  Fleisher et al. found that 78% of patients with cardiac complications 
had at least one episode of prolonged myocardial ischemia (i.e., >30 minutes) either before or 
during the cardiac event.21 The hypothesis that ST-depression can lead to perioperative MI is 
further supported by increased troponin T levels during or shortly after prolonged ST-
depression ischemia.22 Episodes of perioperative ST-depression, indicating endocardial (non-
transmural) myocardial ischemia, has been described in up to 41% of vascular surgery patients 
and mostly occurs within the first two days after surgery.23 ST-elevation-type ischemia is 
considered relative uncommon, confirmed by the incidence of intraoperative ST-elevation 
(12%) in a study performed by London et al.24 Recent studies using highly sensitive troponin 
essays demonstrated that low-level (>0.03 ng/mL) troponin elevations postoperatively are 
common in high cardiac risk patients, even with little or no evidence of ischemia during 
electrocardiogram monitoring.25   
 
In the current study we performed a systematic Medline search to evaluate the 
prevalence of myocardial ischemia or infarction in vascular surgery patients detected with 
troponin I or T measurement, whether or not in combination with electrocardiogram changes 
or symptoms of angina pectoris. As demonstrated in Table 1, the incidence of perioperative 
myocardial ischemia ranged from 14 to 47% and the incidence of perioperative MI ranged 
from 1 to 26%. The wide range of incidence might be related to (i) different cut off values of 
troponin I or T used in the study, (ii) a variety of vascular procedures included in the studies, 
and (iii) that patients specific cardiac risk factors differed between the studies. For example, in 
the study performed by Ali et al. the highest incidence of perioperative myocardial damage 
(both ischemia and infarction) was found, probable related to the fact that this study only 
included patients undergoing open abdominal aortic repair. In addition, Schouten et al. 
included only included patients with ≥3 cardiac risk factors (age >70 years, angina pectoris, 
MI, congestive heart failure, stroke, renal dysfunction, and diabetes mellitus). In the study 
performed by Abraham et al, around 75% of the patients underwent endovascular abdominal  
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Table 1 
Prevalence of perioperative myocardial ischemia or MI in 
vascular surgery patients 
 
Study 
Surgical 
procedure 
 
N 
Myocardial 
ischemia 
 
MI 
Bollinger et al.26 
(2009) 
 
 
AAA 
lower extremity 
 
133 cTnI >2.0 
 
14% -  
Flu et al.27 
(2009) 
 
 
AAA 
carotid  
 
627 cTnT >0.03 
 
17% cTnT >0.2  
+ AP or   
ECG changes 
5% 
Ali et al. 28 * 
(2008) 
 
 
AAA 43 cTnI >0.54 47%  cTnI >0.54  
+ AP or   
ECG changes 
26% 
 
McFalls et al.29 
(2008) 
 
 
AAA 
lower extremity 
377 cTnI >0.1 27% cTnI >0.1  
+ AP or   
ECG changes 
10% 
Schouten et al.30 ** 
(2007) 
 
 
AAA 
 
 
77 cTnT >0.03 
 
30%  cTnT >0.2  
+ AP or   
ECG changes 
7% 
Barbagallo et al.31 
(2006) 
 
 
AAA 
lower extremity 
 
75 cTnI >0.5 33% cTnT >0.05  
+ AP or   
ECG changes 
12% 
Abraham et al.32 *** 
(2005) 
 
 
AAA 
 
 
149 cTnT >0.02 
 
11% ↑ cTnT +  
ECG changes 
1% 
 
Manach et al.33 
(2005) 
 
 
AAA  
 
 
1136 cTnI >0.2 14% cTnI >1.5 5% 
Landesberg et al.19 
(2003) 
 
 
AAA  
lower extremity  
carotid 
503 cTnI >0.6  
or  
cTnT >0.03 
23% 
 
↑ cTnI or  
↑ cTnT   
+ symptoms 
11% 
Kim et al.34 * 
(2002) 
 
 
AAA 
lower extremity 
 
229 cTnI >0.4 
 
43% 
 
↑ cTnI + 
ECG changes 
3% 
Haggart et al.36 
(2001) 
 
 
AAA 
lower extremity 
 
35 cTnI >0.5 
 
29% cTnI >0.5  
+ AP or   
ECG changes 
14% 
Andrews et al.36 
(2001) 
 
 
AAA 
lower extremity 
carotid 
100 cTnI >0.8 
 
18% ↑ CKMB  
+ AP or   
ECG changes 
12% 
Godet et al.38 
(2000) 
AAA 
 
 
316 cTnI >0.5 
 
16% cTnI >1.5 
 
8% 
Abdominal aortic aneurysm (AAA), agina pectoris (AP), cardiac troponin I (cTnI), cardiac troponin T (cTnT), 
electrocardiogram (ECG), myocardial infarction (MI). 
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aortic aneurysm repair and patients with  increased cardiac troponin T in combination with a 
significant postoperative increase in serum creatinine (>50%) were excluded from the study. 
Importantly, Abraham et al. report the highest incidence of perioperative myocardial damage 
within the first three days after surgery.32 
 
Prognosis after perioperative myocardial damage 
In order to put the significance of perioperative myocardial damage into perspective, it is 
pivotal to address the influence of perioperative myocardial damage on long-term 
postoperative outcome. Multiple studies have been performed over the years to evaluate this 
issue. In 1982, Jamieson et al. were one of the first to describe the influence of ischemic heart 
disease on early and late mortality after surgery for peripheral occlusive vascular disease. The 
authors concluded that coronary artery disease is a major determinant of both early and late 
mortality after arterial reconstruction and that selective myocardial revascularization may 
improve survival of these patients.38 Because perioperative myocardial damage is most often 
silent, the great majority of patients with perioperative myocardial damage (95%) remain 
untreated. This might contribute to an increased risk of long-term cardiovascular mortality as 
well.15,39,40  
 
In multiple studies performed between the period between 2000 and 2010, 
perioperative myocardial damage defined as postoperative troponin elevations whether or not 
in combination with ST-segment alterations has been related to adverse short-, mid- and long-
term cardiac morbidity and mortality, as outlined in Table 2.19,26,28,29,31,33,34,36,41,42 In the current 
study, hazard ratios describing the prognostic value of troponin T or I towards postoperative 
mortality or the occurrence of major adverse cardiac events varied from 1.9 to 9.0.  
 
In patients undergoing vascular surgery, asymptomatic elevated troponin T levels 
were associated with an increased risk, of more than four- to six-fold, for cardiac events during 
a six month follow-up period, as demonstrated by Kim et al.34 Landesberg et al. and Kertai et al. 
studied the prognostic value of low- and intermediate-to-high cut off levels of troponin T 
elevations on long-term mortality after vascular surgery. These studies demonstrated that 
postoperative troponin T elevations even at low cut off levels were independent and 
complementary predictors of long-term mortality.19,41 In addition, early mortality after 
perioperative MI ranges between 3.5 to 25% and is higher in patients with an intermediate-to-
high level troponin elevation, compared with patients with a low level troponin elevation.19,29,33.  
 
Endovascular surgery is associated with a reduced incidence of perioperative 
myocardial damage, compared with open vascular surgery, possibly explained by reduced 
myocardial stress during endovascular procedures.12 However, Winkel et al. recently 
demonstrated that asymptomatic perioperative myocardial damage, defined as cardiac troponin 
T elevations in the absence of ischemic symptoms or electrocardiogram abnormalities, was 
associated with an increased mortality risk of patients undergoing endovascular abdominal 
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aortic aneurysm repair.42 During a 2.9 year follow-up of 220 patients, they found that patients 
with asymptomatic myocardial damage had a mortality rate of 49%, compared with 15% for 
patients without perioperative myocardial damage (p < 0.001).  
 
 
Table 2 
Prognostic value of increased perioperative troponin T or I levels 
for cardiac outcome of  vascular surgery patients 
Study Surgical 
procedure 
 
N 
Troponin  
I or T  
Cardiac  
outome 
Bollinger et al.26 
(2009) 
AAA 
lower extremity 
133 cTnI >2.0 
 
MACE, 
mortality, 
1-year       
HR 9.0 (3.6-23.2) 
HR 8.5 (2.9-24.9) 
 
Winkel et al42 
(2009) 
AAA 220 cTnT >0.01 
 
mortality, 
long-term 
HR 2.3 (1.1-5.1) 
Ali et al. 28 * 
(2008) 
AAA 43 cTnI >0.54 MACE,  
long-term 
OR 5.4 (1.2-24) 
McFalls et al.29 
(2008) 
AAA 
lower extremity 
377 cTnI >0.1 mortality , 
1-year 
 
p < 0.01* 
Barbagallo et al.31 
(2006) 
AAA 
lower extremity 
75 cTnI >0.5 MACE, 
1-month 
p < 0..003* 
 
 
Manach et al.33 
(2005) 
AAA  1136 cTnI >0.2 
 
mortality,  
in hospital 
p < 0.05* 
 
 
Kertai et al.41 
(2004) 
AAA  
lower extremity 
393 cTnT >0.1 
 
mortality, 
long-term  
HR 1.9 (1.1-3.1) 
 
 
Landesberg et al.19  
(2003) 
AAA  
lower extremity 
carotid 
447 cTnI >0.6  
or  
cTnT >0.03 
 
mortality,  
long-term 
OR 2.2 (1.48-3.42) 
 
 
Kim et al.34 * 
(2002) 
AAA 
lower extremity 
229 cTnI >0.4 
 
mortality,  
6-month 
OR 4.9 (1.3-19) 
 
 
Andrews et al.36 
(2001) 
AAA 
lower extremity 
carotid 
100 cTnI >0.8 
 
MACE,  
in hostpital 
p < 0.001* 
* Contingency table analyses evaluating increased risk for adverse cardiac outcome associated with perioperative increases of 
troponin T. Abdominal aortic aneurysm (AAA), cardiac troponin I (cTnI), cardiac troponin T (cTnT), major adverre 
cardiac event (MACE). 
 
 
 
DISCUSSION 
 
Prevention of perioperative myocardial damage 
In general, the management of perioperative myocardial damage is focussed on (i) coronary 
plaque stabilization to reduce acute coronary syndromes, with subsequent supply-ischemia 
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(type I MI), that occurs when a coronary plaque ruptures and (ii) limiting surgical stress which 
is the cause of sustained myocardial oxygen-supply-demand imbalance (type 2 MI). The high 
incidence of perioperative myocardial damage reflects the high prevalence of underlying 
ischemic heart disease in the vascular surgery population.43 Therefore, adequate preoperative 
evaluation is inevitable to: identify patients at increased cardiac risk, initiate risk reduction 
therapy, and select optimal surgical and anaesthesia techniques. In conventional preoperative 
cardiac risk indices, such as the Adapted Lee index; age, heart failure, ischemic heart disease, 
cerebrovascular disease, renal dysfunction, diabetes mellitus, and high-risk surgery such as 
vascular surgery, have been identified as independent predictors of perioperative cardiovascular 
events.11  
 
Pharmacological treatment 
The unpredictable progression of an instable coronary plaque during surgical stress is the most 
important target for systemic pharmacological therapy to reduce the incidence of perioperative 
myocardial damage.  
 
β-blockers 
In the nonsurgical setting β-blockers are widely used for the prevention and treatment of 
ischemic heart disease and heart failure, all major determinants of adverse postoperative 
outcome. Proposed mechanisms by which β-blockers exert intraoperative cardioprotective 
effects include heart rate control, reduction of systolic pressure and ventricular contractile 
force, and its anti-arrhythmic properties. Long-term; β-blockers reduce mechanical stress 
imposed to coronary plaques and thereby prevent plaque rupture.44 In addition, the anti-
inflammatory properties of β-blockers exert a beneficial effect towards coronary plaque 
stabilization as well.45 In addition, β-blockers are known to reduce the process of adverse 
cardiac remodelling in patients with impaired left ventricular function, which is highly 
prevalent in the vascular surgery population, by inhibiting the sympathetic nervous system and 
hormone activation (A-type and B-type natriuretic peptides and norepinephrine).46  
 
In the most recent ‘European Society of Cardiology’ (ESC) guidelines, β-blockers are 
recommended (class I, level of evidence B) in patients scheduled for high-risk surgery. In 
addition, β-blockers should be considered (class IIa, level of evidence B) in patients 
undergoing intermediate-risk surgery, such as percutaneous transluminal angioplasty, 
endovascular aortic aneurysm repair, and carotid surgery.47 Factors which influence the 
effectiveness of perioperative β-blockers treatment are the patients underlying cardiac risk 
factors and variations in treatment protocols, such as β-blocker type, β-blocker dose, and 
timing of β-blocker initiation before surgery. As recommended in ESC guidelines, β-blocker 
treatment should be initiated optimally between 30 days and at least 1 week before surgery with 
a target heart rate between 60 to 70 beats per minute and systolic blood pressure >100 
mmHG.    
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Statins  
Statins are widely used to decrease low-density lipoprotein cholesterol in patients with 
hypercholesterolemia. Additionally, statins seem to stabilize atherosclerotic plaques during 
surgery through pleiotropic effects and therefore have a beneficial influence on cardiovascular 
outcome.48 Multiple studies have not only shown beneficial effects of statins in patients with 
coronary artery disease, but in patients undergoing vascular surgery as well.49 In the most 
recent ESC guidelines, initiation of statins is recommended in patients undergoing high-risk 
surgery, optimally between 30 days and at least 1 week before surgery (class I, level of evidence 
B).47\ 
 
Antiplatelet agents 
The perioperative surgical stress results in a hypercoagulable state which, in combination with 
atherosclerotic plaques, serves as the perfect substrate for the development of perioperative 
cardiac damage. Antiplatelet drugs are established agents in the prevention of cardiovascular 
and cerebrovascular ischemic events. Treatment with aspirin or clopidogrel is recommended in 
patients with stable coronary artery disease to prevent cardiovascular events.50 Aspirin 
irreversibly blocks platelet cyclo-oxygenase-1 known to decrease the tromboxane-A2 synthesis. 
Thereby aspirin reduces platelet activation and vasoconstriction.51 Aspirin reduces the risk of 
nonfatal MI by 34% and in the setting of secondary prevention reduces cardiovascular events 
by 27% and cardiovascular deaths by 18%.52 Most recent ESC guidelines addressing 
perioperative care state that continuation of aspirin should be considered in  the perioperative 
period of patients previously treated with aspirin (class IIa, level of evidence B).47 The 
thienopyridine derivate clopidogrel is an antiplatelet agent that inhibits the adenosine 
diphosphate mediated platelet aggregation.53 Randomized, controlled studies are needed to 
investigate the role of clopidogrel as a preventive treatment in patients with asymptomatic 
cardiac damage. 
 
Prophylactic revascularization  
Preoperative cardiac risk evaluation by means of risk factor assessment and noninvasive testing 
may identify vascular surgery patients with asymptomatic coronary artery disease. Two 
randomized, controlled trials have evaluated the potential benefit which may be expected from 
preoperative revascularization in these patients. The Coronary Artery Revascularization 
Prophylaxis (CARP) trial randomized 510 patients with significant coronary artery stenosis to 
either receive revascularization or no revascularization before vascular surgery.54 The main 
finding of the CARP trial was that there was no difference in the primary outcome of long-term 
mortality (median follow-up 2.7 years) of patients who underwent preoperative coronary 
revascularization compared with patients who received optimized medical therapy (22 vs. 23%, 
relative risk: 0.98, 95%-CI: 0.70 to 1.37). In the prospectively randomized Dutch 
Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE)-
V trial,55 mainly including patients with three-vessel coronary artery disease, comparable results 
to the CARP trial were obtained. Although the study population in the DECREASE-V trial 
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reflected vascular surgery patients at highest cardiac risk, revascularization did not improve 
cardiovascular outcomes. The incidence of the composite endpoint of 30-day cardiovascular 
mortality and MI was 43 vs. 33% (OR 1.4, 95%-CI: 0.7 to 2.8). In addition, no benefit was 
observed during one-year follow-up after coronary revascularization, 49 vs. 44% (OR 1.2, 95%-
CI: 0.7 to 2.3; p = 0.48).  The results from these trials indicate that prophylactic coronary 
revascularization of cardiac stable patients provides no benefit for postoperative outcome, with 
an exception for patients with left main coronary artery stenosis. The reasoning behind this 
apparent lack of benefit could be related to the fact that perioperative myocardial damage is not 
only caused by a significant blood flow limiting coronary artery stenosis (Type 1 MI). The 
perioperative stress response (evoking type 2 MI) may cause non-flow limiting coronary 
plaques to rupture during surgery and to become flow limiting after al. This may explain why 
surgical or percutaneous treatment of flow-limiting coronary plaques apparently provides 
insufficient extra protection on top of pharmacological treatment. In the most recent ESC 
guidelines’ addressing perioperative care, it is only recommended to consider prophylactic 
revascularization in patients undergoing high-risk surgery, such as lower extremity 
revascularization or open abdominal aortic surgery, with proven ischemic heart disease (class 
IIb, level of evidence B).47 
 
Future perspective: is there a role for remote ischemic preconditioning? 
Because prophylactic coronary revascularization had not proven to be successful, there remains 
a need for alternative strategies to protect the myocardium during vascular surgery. Research 
performed by Przyklenk et al. in a canine heart model demonstrated that brief occlusions of a 
coronary artery may protect the myocardial bed supplied by that coronary artery from 
prolonged ischemia.56 In addition, Gho et al. demonstrated that brief ischemia in "remote" 
organs (i.e. after occlusion of the anterior mesenteric artery or left renal artery) protects the 
myocardium against infarction as effectively as myocardial preconditioning, described by 
Przyklenk et al.57 Therefore, brief ischemia followed by reperfusion in one organ may provide 
systemic protection from prolonged ischemia in another organ. In patients undergoing 
abdominal aneurysm repair, remote ischemic preconditioning has been evaluated as well. Ali et 
al. included 82 patients which were randomized to conventional abdominal aortic aneurysm 
repair (control) and abdominal aortic aneurysm repair with remote ischemic preconditioning.58 
Two cycles of intermittent cross clamping of the common iliac artery with 10 minutes ischemia 
followed by 10 minutes reperfusion served as the remote ischemic preconditioning stimulus. 
The authors found that remote ischemic preconditioning reduced the incidence of 
postoperative myocardial injury, MI, and renal impairment. In addition, in a small pilot study, 
Walsh et al. demonstrated that remote ischemic preconditioning reduced urinary biomarkers of 
renal injury in patients undergoing elective endovascular abdominal aneurysm repair.59 
However, the authors point out that future large scale trials are needed to determine the effect 
of remote ischemic preconditioning on the occurrence of major adverse cardiac events.  
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CONCLUSION 
 
The high prevalence and asymptomatic nature of perioperative myocardial damage, combined 
with a substantial influence on postoperative mortality of vascular surgery patients, underlines 
the importance of early detection and adequate management of perioperative myocardial 
damage. With the use of preoperative cardiac risk indices, high cardiac risk patients at risk for 
developing perioperative myocardial damage during vascular surgery can be unveiled. Routine 
assessment of perioperative cardiac troponin levels and/or continuous electrocardiogram 
monitoring can detect perioperative myocardial damage in patients at risk. In order to reduce 
the risk of developing perioperative myocardial damage, pharmacological treatment with β-
blockers, statins, and aspirin has demonstrated to exert beneficial effects. In addition, 
prophylactic coronary revascularization does not seem to provide sufficient extra protection on 
top of pharmacological treatment. Future randomized, controlled trials are needed to evaluate 
if remote ischemic preconditioning or treatment with clopidogrel may serve as novel  
preventive treatment strategies to reduce asymptomatic myocardial damage during vascular 
surgery. 
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ABSTRACT 
 
Aims Patients with peripheral atherosclerotic disease often have multiple affected vascular 
beds (AVB), however, data on long-term follow-up and medical therapy are scarce. We 
assessed the prevalence and prognostic implications of polyvascular disease on long-term 
outcome in symptomatic peripheral arterial disease (PAD) patients. 
 
Methods Two thousand nine hundred and thirty-three consecutive patients were screened 
before surgery for concomitant documented cerebrovascular disease and coronary artery 
disease. The number of AVB was determined. Cardiovascular medication as recommended by 
guidelines was noted at discharge.  
 
Results Single, two and three AVB were detected in 1,369 (46%), 1,249 (43%) and 315 (11%) 
patients, respectively. During a median follow-up of 6 years, 1.398 (48%) patients died, of 
which 54% secondary to cardiovascular cause. After adjustment for baseline cardiac risk 
factors and discharge-medication, the presence of 2-AVB or 3-AVB was associated with all-
cause mortality (HR 1.3, 95%-CI: 1.2 to 1.5; HR 1.8, 95%-CI: 1.5 to 2.2) and cardiovascular 
mortality (HR 1.5, 95%-CI: 1.2 to 1.7; HR 2.0, 95%-CI: 1.6 to 2.5) during long-term follow-up, 
respectively. Patients with 2- and 3-AVB received extended medical treatment compared with 
1-AVB at time of discharge. 
 
Conclusions Polyvascular atherosclerotic disease in PAD patients is independently associated 
with an increased risk for all-cause and cardiovascular mortality during long-term follow-up.  
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INTRODUCTION 
 
Peripheral arterial disease (PAD) is a multifactorial syndrome that most commonly affects 
people over 60 years of age.1 As population age increases, the prevalence of atherosclerotic 
disease and its associated adverse outcomes will increase. Cardiovascular risk profiles have 
been established in several large studies, showing an equal risk factor distribution among all 
populations and across age groups and gender.2, 3 It has to be noted that the process of 
established atherothrombosis is not limited to a single arterial location. The Reduction of 
Atherothrombosis for Continued Health (REACH) registry showed that one out of 6 patients 
with PAD, cerebrovascular disease (CVD) or coronary artery disease (CAD) had involvement 
of 1 or 2 other arterial beds.1, 4 The REACH registry also demonstrated a substantial gap 
between recommended clinical guidelines and actual clinical practices in the care of patients 
with or at risk for atherothrombosis. A pattern of underutilization of established medical 
therapies and lifestyle interventions was shown throughout all geographic regions studies and 
vascular disease subtypes.1 Consequently, patients with PAD have a three to six-fold increased 
risk for the occurrence of cardiovascular mortality compared with patients without PAD.5, 6 
Therefore, the importance of risk factor reduction in patients with PAD has resulted in 
universally recommended atherothrombotic risk factor reduction, with the objective of 
decreasing the high incidence of heart disease and cerebrovascular disease associated with 
PAD.7, 8   
  
 However, although these large studies have identified the risk factor profiles and 
treatment protocols of atherosclerotic patients, most data are based on the screening of 
polyvascular disease, especially in the primary care setting. Therefore, the aim of the current 
study was to assess (i) the prevalence and number of affected vascular beds, and (ii) the 
prognostic implications of polyvascular disease on short- and long-term mortality in high-risk 
vascular surgery patients with symptomatic PAD.   
 
 
METHODS 
 
Study design and population 
This retrospective single-centre study comprised a population of 2,933 consecutive patients 
with PAD, referred for elective major vascular surgery. All patients underwent a major vascular 
surgery procedure during the time period 1990 to 2008, and included lower extremity 
revascularization, abdominal aortic surgery (dilatating or stenotic) or carotid surgery. From 
1990 until 2001, standard preoperative screening included a detailed cardiac history, physical 
examination, electrocardiogram (ECG), standard laboratory measurements and additional 
(stress)-testing if indicated. After 2002, standard preoperative echocardiography was added to 
the screening program. The study complies the Declaration of Helsinki. Patient enrolment was 
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performed after approval of the hospital’s ethics committee and after informed consent of all 
patients (or their guardians) at time of inclusion. 
 
Patient data 
At baseline all medical records were reviewed to determine the presence of documented CAD 
and CVD. Patients undergoing lower extremity revascularization or abdominal aortic surgery 
were screened for the concomitant presence of documented CAD and CVD. Patients 
undergoing carotid surgery were screened for CAD and PAD. Coronary artery disease was 
defined as a documented history of ischemic heart disease [composite of angina pectoris, 
myocardial infarction (MI), percutaneous coronary intervention or coronary artery bypass 
grafting], using myocardial stress-testing (ergometry, stress-echocardiography, or CT-scan) or 
coronary angiogram. Patients with stable or unstable angina pectoris were classified as having 
documented CAD according the ESC guidelines.9 The presence of coronary ischemia was 
established by one of the following techniques: exercise ECG [horizontal or down-sloping ST-
segment depression or elevation (≥1 mm (0.1 mV) for ≥60-80 ms after the end of the QRS 
complex)], or exercise testing with echocardiography, CT-scan (≥50% stenosis in one or more 
of the coronary arteries).10 The presence of documented CVD was defined as a history of 
cerebrovascular accident or transient ischemic attack (TIA). Cerebrovascular accidents had to 
be confirmed by a CT-scanning report. The diagnosis of TIA had to be confirmed by a 
neurologist report. Lower extremity arterial disease was defined as current intermittent 
claudication with ankle-brachial-index <0.9, or a history of intermittent claudication with a 
previous intervention, such as angioplasty, stenting, atherectomy, peripheral arterial bypass 
graft, or other vascular intervention including amputation. Polyvascular disease was defined as 
the presence of 2 or 3-AVB. One-AVB included: PAD, 2-AVB: PAD and CAD or CVD, 3-
AVB: PAD and CAD and CVD.  
 
 Finally, the use of the following medication was recorded at discharge: aspirin, statins, 
ß-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor 
blockers, oral anticoagulants, and ticlopidines. Treatment goals were defined according the 
current guidelines and included low-dose aspirin (75-325 mg daily) and statins (low-
intermediate risk patients: target LDL level <100 mg/dL, high-risk patients <70 mg/dL) for 
patients with PAD, and if necessary combined with antihypertensive drugs to receive a target 
blood pressure below 140/90 mmHg.7 Additionally, PAD patients with diabetes should receive 
ACE-inhibitors to a target blood pressure less than 130/80 mmHg.7 Patients with CAD should 
be treated with aspirin, statins (target LDL <100 mg/dL) and ß-blockers, and additionally with 
ACE-inhibitors or Angiontensin receptor blockers in case of diabetes mellitus and/or heart 
failure.11    
 
Risk factors 
All cardiac risk factors were determined at baseline, including age, gender, body mass index, 
smoking status, hypertension (defined as systolic blood pressure ≥140 mmHg, diastolic blood 
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pressure ≥90 mmHg in non-diabetics, systolic blood pressure ≥130 mmHg, diastolic blood 
pressure ≥80 mmHg in diabetics or the use of antihypertensive medication), diabetes mellitus 
(fasting blood glucose ≥7.0 mmol/L or requirement for insulin and/or oral anti-diabetic 
medication), hypercholesterolemia (low density lipoprotein cholesterol >135 mg/dL and/or 
the requirement of lipid-lowering medication), chronic obstructive pulmonary disease 
(according to the Global Initiative on Obstructive Lung Disease-classification)12 and chronic 
renal insufficiency (serum creatinine >2.0 mg/dL). The cardiac risk score was calculated 
according the adapted Lee cardiac index which assigns 1 point for each of the following 
characteristics: high-risk surgery, ischemic heart disease, heart failure, cerebrovascular disease, 
chronic renal insufficiency, and diabetes mellitus.13 
 
Follow-up and endpoints 
The median follow-up of all patients was 6 years (interquartile range 2 to 9). Primary study 
endpoint was the occurrence of all-cause mortality. Survival status was assessed by reviewing 
the municipal civil registries. Cause of death was ascertained by examining death certificates, 
and otherwise by reviewing medical records. Cause of death was further classified as either 
cardiovascular or noncardiovascular death. Cardiovascular death was defined as any death with 
a cerebro-cardiovascular complication as the primary or secondary cause and includes death 
following MI, serious cardiac arrhythmias (defined as the presence of a sustained cardiac 
rhythm disturbance that required urgent medical intervention), congestive heart failure, stroke 
(cerebrovascular event or transient ischemic attack), and surgery related bleeding complications 
(only a postoperative cause of death). Sudden unexpected death was classified as a 
cardiovascular death. 
 
Statistics  
Continuous data were compared using analysis of variance, and are expressed as mean ± SD. 
Categorical data are presented as percentage frequencies and compared using χ2 tests. Analyses 
for trends in all baseline characteristics (including age) between the number AVB were 
performed with linear-by-linear association. Logistic regression analysis was used to determine 
the association between polyvascular disease (2 and 3-AVB compared with 1-AVB) and short-
term mortality (30 days). Cumulative survival of patients with 1, 2, or 3-AVB was determined 
by the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate 
Cox regression models were used to investigate the association between AVB (patients with 1-
AVB as reference group) and mortality during long-term follow-up. All multivariate analyses 
were primarily adjusted for demographics (age and gender) and cardiovascular risk factors 
(smoking, hypertension, diabetes mellitus, hypercholesterolemia, renal dysfunction, heart 
failure and COPD). Secondary adjustments were made for medications usage recommended by 
the ESC/ACC guidelines in patients with PAD, including aspirin, statins, ß-blockers in case of 
prior myocardial infarction and angiotensin-converting enzyme (ACE) inhibitors in case of 
heart failure.7 Finally, adjustment was made for preoperative hemoglobin levels. To evaluate 
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the effect of medication use (aspirin, statins, ß-blockers and ACE-inhibitors) on long-term 
outcome, multivariate Cox regression analyses were performed with propensity score 
adjustment for each medication. Separate propensity scores were developed with logistic 
regression analyses for each type of medication. Variables included in the propensity score 
model were demographics (age and gender), cardiovascular risk factors (smoking, 
hypertension, diabetes mellitus, hypercholesterolemia, renal dysfunction, heart failure and 
COPD), medication use and hemoglobin. Statistical analyses were performed using SPSS 
software (SPSS version 15.0; SPSS, Inc., Chicago, Illinois). Hazard ratios (HR) were calculated 
from these models along with their 95% confidence intervals (95%-CI). A p-value <0.05 (two-
sided) was considered statistically significant.   
 
 
RESULTS 
 
Description of the study population 
The study population consisted of 2,933 consecutive patients with PAD referred for elective 
major vascular surgery. Lower extremity revascularization was performed in 1,031 (35%) 
patients, abdominal aortic surgery in 1,170 (40%) patients, and carotid surgery in 732 (25%) 
patients, respectively. Coronary artery and cerebrovascular disease were detected in 1,248 
(43%) and 1,037 (35%) patients, respectively. In patients referred for lower extremity 
revascularization, 454 (44%) and 144 (14%) patients had concomitant documented CAD and 
CVD, respectively. Coronary artery disease and CVD were present in 575 (49%) and 166 
(14%) of the patients referred for abdominal aortic surgery. Patients referred for carotid 
surgery, 219 (30%) and 79 (11%) patients had concomitant CAD and PAD. The number of 
affected vascular beds was determined at baseline, and one-vessel disease (1-AVB), two-vessel 
disease (2-AVB) and three-vessel disease (3-AVB) was detected in 1,369 (46%), 1,249 (43%) 
and 315 (11%) patients, respectively (Figure 1). 
 
Lee cardiac index and number of affected vessels 
Baseline characteristics of the study population were compared between the groups with 
different number of affected vascular beds and included demographic parameters and 
cardiovascular risk factors. A significant trend for an increased number of cardiovascular risk 
factors was present in patients with 2- or 3-AVB, compared with 1-AVB. Additionally, risk 
factor patterns were calculated following the Lee cardiac index and showed a relationship with 
the number of affected vessels. A Lee risk score of ≥3 was only present in 5% of patients with 
1-AVB while 252 (80%) patients had a Lee risk score of ≥3 in patients with 3-AVB (p < 0.001, 
Figure 2). 
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Figure 1:  Number of affected vascular beds in the total study population and subdivided for type of 
surgery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral arterial disease (PAD), abdominal aortic aneurysm (AAA), lower extremity arterial disease (LEAD), 
cerebrovascular disease (CVD), affected vascular beds (AVB). 
 
 
Figure 2:  Distribution of the Lee cardiac index according to the number of affected vascular beds. 
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Medication use and number of affected vessels 
Medication use at time of hospital discharge was registered and compared between the 
different patient groups (Table 1). Aspirin, statins, ß-blockers and ACE-inhibitors were used by 
1,502 (51%), 1,131 (39%), 1,293 (44%) and 740 (25%) patients, respectively. There was a clear 
relationship between the year of surgery and medical treatment intensity after surgery (Figure 3). 
Importantly, aspirin was used in ≥50% of the patients from 1996, whereas statins and ß-
blockers were prescribed in ≥50% of the patients from 2002. The number of AVB (1- vs. 2- 
vs. 3-AVB) showed a relationship with the use of statins (34 vs. 41 vs. 51%, p < 0.001), ß-
blockers (37 vs. 48 vs. 60%, p < 0.001) and ACE-inhibitors (19 vs. 28 vs. 40%, p < 0.001). In 
contrast, there was no significant relationship between the number of AVB and aspirin use (53 
vs. 49 vs. 53%, p = 0.25).  
 
Table 1 Baseline characteristics of the study population 
 
Total 
[N=2,933] 
1-AVB 
[N=1,369] 
2-AVB 
[N=1,249] 
3-AVB 
[N=315] 
p- 
value 
Demographics   
Age (year), mean ± SD 66 (11) 66 (12) 67 (11) 68 (10) <0.001 
Male (%) 2.189 (75) 958 (70) 984 (78) 257 (82) <0.001 
Year of surgery (%)  0.001 
 < 1992 429 (15) 187 (14) 205 (16) 37 (12)  
 1993-1995 653 (22) 323 (24) 270 (22) 60 (19)  
 1996-1998 586 (20) 303 (22) 228 (18) 55 (18)  
 1999-2001 353 (12) 177 (13) 150 (12) 26 (8)  
 2002-2004 249 (9) 96 (7) 112 (9) 41 (13)  
 2005-2008 663 (23) 283 (21) 285 (23) 314 (11)  
Cardiovascular risk factors (%)   
Smoking     <0.001 
 no 1.139 (39) 585 (43) 456 (37) 98 (31)  
 current 1.092 (37) 490 (36) 471 (38) 131 (42)  
 history 702 (24) 294 (22) 322 (26) 86 (27)  
Hypertension 1.514 (52) 594 (43) 706 (57) 214 (68) <0.001 
Hypercholesterolaemia 798 (27) 289 (21) 392 (31) 117 (37) <0.001 
Renal dysfunction 297 (10) 95 (7) 146 (10) 56 (18) <0.001 
Chronic heart failure 206 (7) 24 (2) 126 (10) 56 (18) <0.001 
COPD 557 (19) 201 (15) 271 (22) 85 (27) <0.001 
Medication at discharge (%)   
Aspirin 1.502 (51) 726 (53) 610 (49) 166 (53) 0.25 
Statin 1.131 (39) 463 (34) 506 (41) 162 (51) <0.001 
β-blocking agents 1.293 (44) 506 (37) 599 (48) 188 (60) <0.001 
Diuretics 696 (24) 244 (18) 340 (27) 112 (36) <0.001 
ACE inhibitors 740 (25) 260 (19) 335 (28) 125 (40) <0.001 
Calcium antagonists 711 (24) 265 (19) 360 (29) 86 (27) <0.001 
AT-II antagonists 157 (5) 61 (5) 71 (6) 25 (8) 0.01 
Oral anticoagulants 1.108 (38) 463 (34) 505 (40) 140 (44) <0.001 
Ticlopidines 132 (5) 45 (3) 60 (5) 27 (9) <0.001 
Affected vascular beds (AVB), angiotensin converting enzyme (ACE), angiotensin-II (AT-II), chronic obstructive 
pulmonary disease (COPD).  
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Figure 3: Postoperative prescription of aspirin, statins, ß-blockers, and ACE-inhibitors stratified 
according to the year of surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Angiotensin converting enzyme (ACE). 
 
 
Table 2 30-day survival 
Events Univariate Multivariate (1) Multivariate (2) 
 
N (%) OR [95%-CI] OR [95%-CI] OR [95%-CI] 
All-cause mortality 
  1-AVB (N=1,369) 36 (3) reference reference reference 
 2-AVB (N=1,249) 57 (5) 1.87 1.22-2.88 1.59 1.01-2.50 1.65 1.03-2.63 
 3-AVB (N=315) 19 (6) 2.53 1.42-4.50 1.76 0.95-3.27 2.46 1.29-4.71 
Cardiovascular mortality 
 1-AVB (N=1,369) 29 (3) reference reference reference 
 2-AVB (N=1,249) 47 (5) 1.87 1.16-3.00 1.52 0.93-2.50 1.56 0.94-2.60 
 3-AVB (N=315) 14 (7) 2.23 1.16-4.30 1.44 0.72-2.89 1.94 0.94-4.02 
Multivariate (1): adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal 
dysfunction, heart failure, chronic obstructive pulmonary disease, and haemoglobin. Multivariate (2): adjustment for age, 
gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal dysfunction, heart failure, chronic obstructive 
pulmonary disease, haemoglobin + medication use, including: aspirin, statins, ß-blockers, and ACE-inhibitors. Affected 
vascular beds (AVB), angiotensin converting enzyme (ACE), confidence incidence (CI), odds ratio (OR).  
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Short-term outcome 
During the first 30 postoperative days, 112 (3.8%) patients died, of which 90 (80%) patients 
died secondary to a cardiovascular cause. Using univariate analysis, patients with 2- or 3-AVB 
had a significant increased mortality risk compared with patients with 1-AVB (2-AVB: OR 1.9, 
95%-CI: 1.22 to 2.88, 3-AVB: OR 2.5, 95%-CI: 1.42 to 4.50), respectively (Table 2). This 
increased risk was present for the occurrence of cardiovascular death as well (2-AVB: OR 1.9, 
95%-CI: 1.16 to 3.00, 3-AVB: OR 2.2, 95%-CI: 1.16 to 4.30). In multivariate analysis 2- and 3-
AVB were independently associated with all-cause mortality (2-AVB: OR 1.7, 95%-CI: 1.03 to 
2.63, 3-AVB: OR 2.5, 95%-CI: 1.29 to 4.71). However, cardiovascular mortality was not longer 
significantly associated with polyvascular disease during short-term follow-up. 
 
Long-term outcome 
After one-year follow-up, 308 (11%) patients died, of which 227 (74%) and 71 (26%) 
secondary to a cardiovascular or non-cardiovascular cause, respectively. Patients with 2- or 3-
AVB had an increased risk for the occurrence of 1-year all-cause mortality (2-AVB: HR 1.3, 
95%-CI: 1.03 to 1.7; 3-AVB: HR 1.6, 95%-CI: 1.1 to 2.3) and cardiovascular mortality (2-AVB: 
HR 1.7, 95%-CI: 1.2 to 2.2; 3-AVB: HR 1.7, 95%-CI: 1.1 to 2.6), compared with patients with 
1-AVB, respectively. During long-term follow-up, 1,389 (47%) patients reached the primary 
endpoint of all-cause mortality. A cardiovascular or non-cardiovascular cause of death was 
detected in 849 (61%) and 434 (31%) patients, respectively.  
 
In the remaining 106 (3.6%) patients, no specific cause of death could be determined. 
The occurrence of all-cause mortality showed a significant relationship with the number of 
affected vascular beds (1-AVB 43%, 2-AVB 50%, 3-AVB 54%, p < 0.001). Kaplan-Meier 
estimates for long-term mortality stratified according the number of AVB showed that patients 
with 2- or 3-AVB had lower survival compared with patients with 1-AVB (Figure 4).  
 
 At 1-year follow-up, survival rates in patients with 1-, 2-, and 3-AVB were 91.4, 87.9 
and 83.6%, respectively. Furthermore, at 10-year follow-up, survival rates in 1-, 2- and 3-AVB 
were 48.0, 40.6, 29.2,% respectively. Log rank rest compared cumulative survival between 1- 
and 2-AVB and 2- and 3-AVB and showed a significant difference in survival between both 
comparisons (p < 0.001). After multivariate regression analysis, adjusted for baseline 
demographic and risk factors, a strong relationship between the number of AVB and the risk 
of all-cause and cardiovascular mortality was detected at both 1 and 10 years of follow-up 
(Table 3). During long-term follow-up, patients with 2 or 3-AVB had an increased risk for the 
occurrence of all-cause mortality (2-AVB: HR 1.3, 95%-CI: 1.15 to 1.45; 3-AVB: HR 1.8, 95%-
CI: 1.50 to 2.15), and also for the occurrence of cardiovascular mortality (2-AVB: HR 1.5, 
95%-CI: 1.24 to 1.68; 3-AVB: HR 2.0, 95%-CI: 1.60 to 2.51), compared with patients with 1-
AVB, respectively.   
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Figure 4: Kaplan-Meier estimates for long-term all-cause mortality, stratified according to the number of 
affected vascular beds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Affected vascular beds (AVB). 
 
 
Table 3 Long-term survival 
Events Univariate Multivariate (1) Multivariate (2) 
 
N (%) HR [95%-CI] HR [95%-CI] HR [95%-CI] 
All-cause mortality 
  1-AVB (N=1,369) 558 (43) reference  reference reference 
 2-AVB (N=1,249) 630 (50) 1.32 1.18-1.48 1.27 1.13-1.43 1.29 1.15-1.45 
 3-AVB (N=315) 171 (54) 1.87 1.57-2.22 1.62 1.36-1.94 1.79 1.50-2.15 
Cardiovascular mortality 
 1-AVB (N=1,369) 334 (24) reference reference reference 
 2-AVB (N=1,249) 401 (32) 1.50 1.29-1.73 1.42 1.22-1.65 1.45 1.24-1.68 
 3-AVB (N=315) 114 (36) 2.14 1.73-2.65 1.81 1.45-2.27 2.00 1.60-2.51 
Multivariate (1): adjustment for age, gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal 
dysfunction, heart failure, chronic obstructive pulmonary disease, and haemoglobin. Multivariate (2): adjustment for age, 
gender, smoking, hypertension, diabetes mellitus, hypercholesterolaemia, renal dysfunction, heart failure, chronic obstructive 
pulmonary disease, haemoglobin + medication use, including: aspirin, statins, ß-blockers, and ACE-inhibitors. Affected 
vascular beds (AVB), confidence interval (CI), hazard ratio (HR). 
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Optimal medical therapy according the ESC/ACC guidelines was 57% in the patient group 
that underwent surgery between 2002 and 2008. During this period, aspirin (HR 0.52, 95%-CI: 
0.37 to 0.72), statins (HR 0.38, 95%-CI: 0.27 to 0.53) and ACE-inhibitors (HR 0.32, 95%-CI: 
0.11 to 0.94) were significantly associated with lower mortality rates in propensity adjusted 
analysis. Of note, over 90% of the patients who underwent surgery after 2002 were on 
perioperative ß-blocker therapy.   
 
  
DISCUSSION 
 
To our knowledge, the current study is the first to show a strong relationship between the 
number of affected vessel beds and long-term prognosis in patients with known symptomatic 
PAD. Compared with 1-AVB, patients with 2- or 3-AVB had significantly higher rates of all-
cause and cardiovascular mortality during long-term follow-up after major vascular surgery. 
The process of atherosclerotic vascular disease is a diffuse progressive condition that usually 
affects multiple vascular territories concomitantly. All manifestations of arterial diseases are 
preceded by atherosclerotic plaques formation in the arterial wall. The presence of risk factors 
like hypertension, diabetes mellitus, smoking and hypercholesterolemia make patients prone 
for the development of atherosclerotic plaques. Therefore, lifestyle modification and medical 
treatment are strongly recommended for patients with atherosclerotic disease.7, 8 
  
 Until now, most data regarding the prevalence and long-term prognosis of patients 
with polyvascular disease included determination of polyvascular disease in the primary care 
setting, while follow-up was generally limited to 1-year.4, 14 In most studies and registries, data 
on the prevalence of polyvascular disease were mainly on the presence of risk factors, 
symptoms and medical treatment. Hirsch et al. found a prevalence of polyvascular disease 
(PAD and CVD) of 16% in the primary care setting, which was observed by the REACH 
registry as well.1, 15 Recent data from the CRUSCADE investigators in patients presenting with 
non-ST-segment elevation acute coronary syndrome, reported a prevalence of 12% established 
PAD, 10% documented CVD, and 43% prior CAD.16 Objective determination of polyvascular 
disease by screening and/or additional testing was performed primary by Hertzer et al. who 
observed a prevalence of CAD in 44, 30 and 33% of the PAD patients, respectively.17 Analysis 
of the REACH registry showed that 2- or 3-AVB is present in 48 or 14% of PAD patients, 
respectively.4 We demonstrated in the current study of patients with known PAD, a 
documented prevalence of 2- and 3-AVB of 43 and 11%, respectively. The slightly higher 
prevalence of polyvascular disease in the PAD subset of REACH patients is likely due to the 
inclusion of patients with ≥3 atherothrombotic risk factors without symptomatic vascular 
disease, in the REACH registry. 
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 The current study showed a significant association between the presence of multiple 
risk factors and the presence of polyvascular disease, which was in line with previous studies 
that focused on the prevalence of risk factors in several atherosclerotic populations.14, 15, 18 
Atherothrombotic risk factor reduction is universally recommended for patients with PAD to 
reduce their high incidence of heart disease and stroke.7, 8, 19-21 Although we found that patients 
with 2- or 3-AVB received better medical treatment compared with patients with lone PAD, 
there was still a underutilization of medication. In this study, aspirin use was observed in more 
than 50% of the patients included after 1996 and was associated with increased survival rates, 
which is in line with a recent meta-analyses.22 The underutilization of optimal medical therapy 
is strongly related to the implementation of the guidelines on PAD after 2003, as before the 
implementation of guidelines only a minority of patients received a combination of aspirin, 
statins, ACE-inhibitors and in cases of ischemic heart disease additional ß-blockers was used.7 
Thereafter, the use of statins and ß-blockers has strongly increased, and 57% of the patients 
included in this cohort received optimal medical therapy. As reported by others, aspirin, statins 
and ACE-inhibitor use were all significantly associated with increased survival rates.22 The gap 
between guideline recommendations and clinical practice in PAD patients remains a 
concerning and significant problem. Potential reasons for this undertreatment could be related 
to (i) low perception of the risk associated with PAD compared with CAD and CVD, and (ii) 
the absence of healthcare campaigns directed at providing information to individuals with 
PAD, especially during the previous decade. 
 
 Data regarding the perioperative outcome in the polyvascular patient population are 
scarce, as most studies are directed at one-year mortality rates. Our study showed that patients 
with 2- or 3-AVB had higher perioperative mortality rates compared with patients with 1-AVB 
(5% and 6% vs. 3% p < 0.001, respectively). Cardiovascular mortality was present in 75% of 
the patients that died within the first 30 days after major vascular surgery. In multivariate 
analyses polyvascular disease was significantly associated with increased all-cause mortality 
rates. Our data are in keeping with others reporting 30-day mortality rates up to 6%, of which 
76% are due to cardiovascular cause in major vascular surgery patients.18 Bhatt et al. reported a 
30-day all-cause mortality rate of 7.3% in patients presenting with non-ST-elevation acute 
coronary syndrome and concomitant 3-AVB. In this study, only 3-AVB was significantly 
associated with increased all-cause mortality (OR 1.25, 95%-CI: 1.02 to 1.54) in multivariate 
analysis.16 
 
 After one-year follow-up, 11% of the patients died of which 74% secondary to a 
cardiovascular cause. A significant association between the number of AVB and the 
occurrence of all-cause and cardiovascular mortality was observed. Mortality rates increased 
from 8% in 1-AVB to 16% in 3-AVB. These findings are in keeping with others, as in the 
REACH registry one-year all-cause and cardiovascular mortality rates were approximately 
doubled in patients with polyvascular disease, compared with single arterial disease.14 
Furthermore, the Polyvascular Atherothrombosis Observational Survey (PATHOS) found that 
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patients with acute myocardial infarction or stroke and concomitant PAD had an increased 
mortality risk (OR 2.05, 95%-CI: 1.31 to 3.22) compared with patients without PAD.23 These 
findings support the need for increased awareness of the cross-risk that is related to the 
overlap between the various arterial locations of atherothrombosis. 
 
 No prior large studies investigated the long-term prognosis of patients with 
polyvascular atherosclerotic disease up to 10 years. The current study found that after a follow-
up period of 5 years, 50% of the patients with 3-AVB had already died, pointing at the grave 
prognosis of polyvascular disease. Criqui et al. performed the first long-term outcome study in 
565 patients with large-vessel PAD and detected an increased relative risk for cardiovascular 
mortality (RR 5.9, 95%-CI: 3.0 to 11.4) after 10-years follow-up, compared with patients 
without PAD.5 Eagle et al. and Sutton et al. observed that during 10-year follow-up, CAD 
patients with concomitant PAD had a 25% greater likelihood of mortality compared with 
CAD patients without PAD at any point in time.24, 25 Recently, Welten et al. performed a 
propensity-matched study in PAD and CAD patients, showing that during a mean follow-up 
of 6 ± 4 years, patients with PAD had a significantly worse long-term prognosis compared 
with patients with CAD (unadjusted HR 2.4, 95%-CI: 2.18 to 2.65).18 Hence, patients with 
combined PAD, CAD and/or CVD have the worst prognosis. Therefore, early objective 
detection and treatment of asymptomatic concomitant cardiovascular risk factors in patients 
with PAD is recommended and strongly emphasized by the current guidelines.7, 8 
 
Limitations  
Potential limitations of the current study merit consideration. First, this study has the 
disadvantage of a retrospective design. Second, the standardized protocol for preoperative 
screening did not include echocardiography before 2002; therefore there could be an 
underestimation of subclinical atherosclerosis in patients undergoing surgery before this date. 
In addition, diagnostic methods and accuracy have changed over time, which could have 
influenced the criteria for the presence of documented CAD or CVD. Third, a specific cause 
of death could not be established in 3.6% of the patients that died during the follow-up period. 
One year after the last patient had been included, mortality rates were verified according the 
civil registries, however, reviewing the death certificates or contacting the treating general 
practioner could not establish cause of death. Therefore, we performed two additional analyses 
in which patients for whom cause of death was unknown were regarded either as 
cardiovascular or noncardiovascular deaths. These analyses found similar results with no 
influence on the significance of the outcome parameters. Finally, although this study detected 
significant associations between medical treatment and increased survival rates, these results 
need to be interpreted with some caution as this study only included medical treatment at 
discharge and no evaluation of treatment adherence during follow-up was available. 
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Conclusion 
Polyvascular atherosclerotic disease in PAD patients scheduled for elective major vascular 
surgery is independently associated with an increased risk for all-cause and cardiovascular 
mortality during long-term follow-up. Peripheral arterial disease patients with polyvascular 
disease have more atherosclerotic risk factors and receive extended medical treatment, mainly 
as a result of the implementation of guidelines. However, as PAD patients with polyvascular 
disease still receive sub-optimal cardioprotective medication, more attention should be given to 
optimization of life style modification and treatment. 
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ABSTRACT 
 
Background Cardiovascular (CV) complications are the leading cause of morbidity and 
mortality in vascular surgery patients. The Revised Cardiac Risk (RCR) index, identifying 
cardiac risk factors, is commonly used for preoperative risk stratification. However, a more 
direct marker of the underlying atherosclerotic disease, such as the common carotid artery 
intimamedia thickness (CCA-IMT) may be of predictive value as well. The current study 
evaluated the prognostic value of the CCA-IMT for postoperative CV outcome.  
 
Methods In 508 vascular surgery patients, the CCA-IMT was measured using high-resolution 
B-mode ultrasonography. We recorded the RCR factors: ischemic heart disease, heart failure, 
cerebrovascular disease, diabetes mellitus and renal dysfunction. Repeated troponin T 
measurements and electrocardiograms were performed postoperatively. The study endpoint 
was the composite of 30-day CV events and long-term CV mortality. Multivariate regression 
analyses were used to assess the additional value of CCA-IMT for the prediction of cardiac 
events.  
 
Results In total, 30-day events and long-term CV mortality were noted in 122 (24%) and 81 
(16%) patients, respectively. The optimal predictive value of CCA-IMT, using receiver-
operating characteristic curve analysis, for the prediction of CV events was calculated to be 
1.25 mm (sensitivity 70%, specificity 80%). An increased CCA-IMT was independently 
associated with 30-day CV events (OR 2.20, 95%-CI: 1.38 to 3.52) and long-term CV mortality 
(HR 6.88, 95%-CI: 4.11 to 11.50), respectively.  
 
Conclusions This study shows that an increased CCA-IMT has prognostic value in vascular 
surgery patients to predict 30-day CV events and long-term CV mortality, incremental to the 
RCR index. 
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INTRODUCTION 
 
Cardiovascular (CV) complications are the leading cause of morbidity and mortality in vascular 
surgery patients.1 Adequate preoperative evaluation is inevitable to (i) identify patients at 
increased risk, (ii) initiate risk reduction therapy, and (iii) select optimal surgical and anaesthesia 
techniques. Heart failure, ischemic heart disease, cerebrovascular disease, renal dysfunction, 
diabetes mellitus, and high-risk surgery, as summarised in the Revised Cardiac Risk (RCR) 
index, have been identified as independent predictors of perioperative CV events.2, 3 However, 
a more direct marker of the underlying atherosclerotic disease, such as the common carotid 
artery intimamedia thickness (CCA-IMT),4 may be of predictive value as well. Although an 
increased CCA-IMT is associated with an increased risk for myocardial infarction and stroke,5, 6 
limited information is available concerning the predictive value of an increased CCA-IMT for 
postoperative CV events in vascular surgery patients. This study evaluated the predictive value 
of the CCA-IMT for CV events in vascular surgery patients, incremental to the predictive value 
of the RCR index. 
 
 
METHODS 
 
Study population 
The study population was derived from a cohort of 1,005 consecutive vascular surgery patients 
undergoing lower extremity artery, abdominal aortic aneurysm, abdominal aortic stenosis, or 
carotid artery repair during the period between 2002 and 2008. During the period between 2004 
and 2008, standard CCA-IMT measurements were performed and 508 consecutive patients 
with CCA-IMT measurements were included during this time period, with exclusion of patients 
undergoing carotid artery repair. Both open and endovascular procedures were included. The 
study was approved by the hospital’s ethics committee and performed with informed consent 
of all patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Risk factors according to the 
RCR index were recorded such as: heart failure (defined as the presence of heart failure 
symptoms according the New York Heart Association classification or previous hospital 
admission for decompensated heart failure), ischemic heart disease (defined as history of angina 
pectoris, coronary revascularization, or myocardial infarction), cerebrovascular disease (defined 
as a history of ischemic or hemorrhagic stroke), renal dysfunction (defined as serum creatinin 
>2 mg/dL), and diabetes mellitus (defined as fasting blood glucose ≥7.0 mmol/L or 
requirement for insulin and/or anti-diabetic medication). Cardiac risk score was determined for 
each patient according the RCR index with one point assigned to each characteristic. 
Furthermore; age, sex, body mass index, hypertension (blood pressure was measured during 
preoperative evaluation at the outpatient clinic and hypertension was defined as systolic blood 
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pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg in nondiabetic patients, systolic 
blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg in diabetics, or the use of 
antihypertensive medication), hypercholesterolemia (low-density lipoprotein cholesterol >3.50 
mmol/L), chronic obstructive pulmonary disease (according to the Global Initiative on 
Obstructive Lung Diseases classification), and smoking status were recorded. Finally, use of the 
following medication was recorded: β-blockers, statins, aspirin, oral anticoagulants, angiotensin-
converting enzyme inhibitors, calcium antagonists, and diuretics. Medication use was 
ascertained if medication was documented at least one month before surgery. 
 
Measurement of the intimamedia thickness 
The CCA-IMT was measured according to the ‘Mannheim Carotid Intima-Media Thickness 
Consensus’ scanning and reading protocol recommendations.7-9 Measurements were taken at 
10 mm proximal to the carotid bifurcation in the near and far wall of the left and right 
common carotid artery. Repeated measurements were performed along a minimum of 10 mm 
length. Four measurements were taken from both the left and right common carotid artery, 
two of which in the near and two in the far wall. The maximal measurement, of these eight 
measurements, was used. Plaques (defined as a focal structure encroaching into the arterial 
lumen of at least 0.5 mm)7 when present, were not used in the CCA-IMT measurements. 
Measurements were electrocardiogram-gated at the peak of the QRS complex to control for 
changes in CCA-IMT during the cardiac cycle. Two sonographers, unaware of the clinical 
information for each patient, performed the measurements with an interobserver correlation of 
the 96.2%. 
 
Clinical cardiac outcome and follow-up 
Serial electrocardiograms and troponin T measurements were obtained from all patients before 
surgery, postoperatively on day 1, 3, 7, and before discharge. Main study endpoints were (i) 30-
day CV events defined as myocardial infarction, myocardial ischemia, and CV mortality, and 
(ii) long-term CV mortality. Myocardial ischemia was present when cardiac enzyme levels were 
elevated >0.03 ng/mL.10 Myocardial infarction was present when cardiac enzyme levels were 
elevated >0.03 ng/mL in combination with electrocardiographic changes such as new-onset 
ST-T changes, new-onset left bundle branch block or development of pathological Q waves.11 
Thirty-day follow-up was completed during regular follow-up visits at the outpatient clinic and, 
if needed, by reviewing hospital records or the electronic patient file. Long-term mortality was 
assessed by approaching the municipal civil registries. All surviving patients received a mailed 
questionnaire and, if needed, survival status was completed by approaching the referring 
physician. Mortality was considered CV unless explicit proof of a noncardiac cause could be 
delivered. Mean follow-up was 1.8 ± 1.1 years.  
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Statistical analysis 
Dichotomous data are described as numbers and percentages. The continuous variables age and 
body mass index are described as means ± SD. Differences in baseline characteristics between 
CCA-IMT groups were evaluated using χ2 tests for categorical data. Continuous data were 
compared using one-way ANOVA. Receiver operating characteristic curve analysis was used to 
assess the optimal cut off value of CCA-IMT for predicting 30-day CV events and long-term 
CV mortality. The optimal value of CCA-IMT for predicting 30-day CV events and long-term 
CV mortality was defined as the concentration with the largest sum of sensitivity plus 
specificity. Uni- and multivariate logistic regression analysis were performed to evaluate the 
prognostic value of an increased CCA-IMT towards 30-day CV events and Cox regression 
analysis towards long-term CV mortality. Multivariate regression analyses were adjusted for age, 
sex, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, current 
smoking, β-blocker use, statin use, and aspirin use. We report crude and adjusted odds and 
hazard ratios (OR and HR) with their 95%-CI. For all tests, a p < 0.05 (two-sided) was 
considered significant. Cumulative long-term survival was determined by the Kaplan-Meier 
method. All analyses were performed using SPSS version 15.0 statistical software (SPSS, 
Chicago, IL). No extramural funding was used to support this work. The authors are solely 
responsible for the design and conduct of this study, all study analyses, the drafting and editing 
of the article, and its final contents. 
 
 
Figure 1: Receiver operating characteristics curve analysis of the common carotid artery intimamedia 
thickness to predict postoperative cardiovascular events. Sensitivity and specificity are plotted for various 
levels.  
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RESULTS 
 
A total of 508 patients undergoing lower extremity artery repair (N=245) and abdominal aortic 
aneurysm or abdominal aortic stenosis repair (N=263) were included in the study. 
Endovascular procedures comprised 38% of the studied surgical procedures. Mean age was 68 
± 11 years and 78% were men. Mean CCA-IMT (i.e. mean of the maximum CCA-IMT 
measurements) was 1.07 ± 0.35. In total, 30-day CV events were observed in 122 patients 
(24%) and long-term CV mortality in 81 patients (16%). The optimal predictive value of CCA-
IMT for the prediction of 30-day CV events and long-term CV mortality was calculated to be 
1.25 mm (sensitivity 70%, specificity 80%) (Figure 1).  
 
 
Table 1 Baseline characteristics according to CCA-IMT groups 
All CCA-IMT <1.25 CCA-IMT ≥1.25 p-value 
 
[N=508] [N=363] [N=145]  
Demographics 
 
    
  Age (± SD) 68 (11) 67 (11) 71 (10)  0.01 
  Male (%) 394 (78) 271 (75) 123 (85) 0.01 
  Body mass index (± SD) 26 (4) 26 (4) 26 (3) 0.70 
Medical history (%)     
  Heart failure  56 (11) 32 (9) 24 (17) 0.01 
  Ischemic heart disease  221 (44) 157 (43) 64 (44) 0.86 
  Cerebrovascular disease  83 (16) 45 (12) 38 (26) <0.01 
  Renal dysfunction  103 (20) 63 (17) 40 (28) 0.01 
  Diabetes mellitus  124 (24) 83 (23) 41 ()28 0.20 
  Hypertension  340 (67) 235 (65) 105 (72) 0.10 
  Hypercholesterolemia  249 (49) 174 (48) 75 (52) 0.44 
  Chronic obstructive pulmonary disease 126 (25) 81 (22) 45 (31) 0.04 
  Smoker, current  221 (44) 156 (43) 65 (45) 0.70 
RCR index (%)     
 0-1 risk factors  250 (49) 196 (54) 54 (37) <0.01 
 2 risk factors  145 (29) 101 (28) 44 (30) <0.01 
 >3 risk factors 111 (22) 64 (18) 47 (32) <0.01 
Surgery type (%)     
  Open  314 (62) 220 (61) 94 (65) 0.376 
Medication (%)     
  β-blocker   397 (78) 274 (76) 123 (85) 0.02 
  Statin  343 (68) 241 (66) 102 (70) 0.39 
  Aspirin  287 (57) 211 (58) 76 (52) 0.24 
  Oral anticoagulant  87 (17) 57 (16) 30 (21) 0.18 
  Angiotensin-converting enzyme inhibitor   153 (30) 111 (31) 42 (29) 0.72 
Calcium-antagonist  
 
92 (18) 56 (15) 36 (25) 0.01 
Diuretic 
 
121 (24) 77 (21) 44 (30) 0.03 
 Common carotid artery intimamedia thickness (CCA-IMT), revised cardiac risk (RCR), standard deviation (SD). 
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In total, 145 patients (29%) had an increased CCA-IMT defined as a CCA-IMT ≥1.25 
mm. Patients with an increased CCA-IMT were older (71 vs. 67 years, p = 0.01) and more 
likely to be male (85% vs. 75%, p = 0.013) compared with patients with a CCA-IMT <1.25 
mm. Other factors associated with an increased CCA-IMT were a history of heart failure, 
cerebrovascular disease, chronic obstructive pulmonary disease, β-blocker use, calcium-
antagonist use and diuretic use. Baseline characteristics according the CCA-IMT groups are 
listed in Table 1. 
 
30-day outcome 
The study endpoint 30-day CV events was reached in 122 (24%) patients, of which 66 (18%) 
occurred in patients with a CCA-IMT <1.25 and 56 (39%) in patients with an increased CCA-
IMT (p < 0.01) as shown in Table 2. During 30-day follow-up, 117 (23%) had a nonfatal 
myocardial event, of which 30 patients (26%) had a myocardial infarction and 87 patients 
(74%) had myocardial ischemia. In total, 61 (17%) patients with a CCA-IMT <1.25 and 56 
(39%) patients with an increased CCA-IMT had a nonfatal myocardial event (p < 0.01).  
 
 
Table 2 CCA-IMT and postoperative outcome 
CCA-IMT <1.25 CCA-IMT ≥1.25 Univariate 
 
[N=363]  [N=145]  
30-day (%) 
 
  OR [95%-CI] 
   Cardiovascular events  [N=122] 66 (18) 56 (39) 2.93 1.85-4.34 
   All-cause mortality  [N=25] 10 (3) 15 (10) 4.07 1.79-9.30 
Long-term (%)   HR [95%-CI] 
   Cardiovascular mortality  [N=81] 24 (7) 57 (39) 6.90 4.23-11.13 
   All-cause mortality  [N=113] 53 (15) 60 (41) 3.28 2.26-4.77 
Confidence interval (CI), common carotid artery intimamedia thickness (CCA-IMT), hazard ratio (HR), odds ratio 
(OR). 
 
 
The study endpoint CV mortality was reached in 21 (4%) patients, of which 6 (2%) 
occurred in patients with a CCA-IMT <1.25 and 15 (10%) in patients with an increased CCA-
IMT (p < 0.01). Multivariate analysis showed that the RCR index was predictive for 30-day CV 
events (2 risk factors: OR 1.96, 95%-CI: 1.12 to 3.43; ≥3 risk factors: OR 6.43, 95%-CI: 3.66 
to 11.28), as shown in Table 3 (Model 1). When adding CCA-IMT to this model, an increased 
CCA-IMT was independently associated with 30-day CV events (OR 2.20, 95%-CI: 1.38 to 
3.52), as shown in Table 3 (Model 2).  
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Table 3 Multivariate association between CCA-IMT and 30-day follow-up 
 Model 1 * Model 2 ** 
 
[N=508] OR [95%-CI] OR [95%-CI] 
Cardiovascular events  
 
     
RCR index ***      
 1 risk factor 34/250 1.00  1.00  
 2 risk factors 35/146 1.96 1.12-3.43 1.86 1.06-3.28 
 ≥3 risk factors 53/112 6.43 3.66-11.28 5.70 3.21-10.11 
CCA-IMT      
 <1.25 66/363 - - 1.00  
 ≥1.25  56/145 - - 2.20 1.38-3.52 
All-cause mortality      
RCR index ***      
 1 risk factor 6/250 1.00 0.90-8.22 1.00  
 2 risk factors 9/146 2.73 1.32-12.21 2.42 0.80-7.37 
 ≥3 risk factors 10/112 4.02 0.90-8.22 2.92 0.93-9.15 
CCA-IMT      
 <1.25 10/363 - - 1.00  
 ≥1.25  15/145 - - 3.76 1.44-8.93 
* Model 1: predictive value of RCR index for adverse outcome. Multivariate analyses were adjusted for age, gender, 
hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, current smoking, β-blocker use, statin 
use, and aspirin use.  
** Model 2: additional value of CCA-IMT for prediction of adverse outcome additionally to clinical risk factors. 
Multivariate analysis adjusted for RCR risk factors and risk factors described in model 1. *** RCR risk 
factors: heart failure, ischemic heart disease, cerebrovascular disease, diabetes mellitus, renal dysfunction, and 
high-risk surgery.  
Confidence interval (CI), common carotid artery intimamedia thickness (CCA-IMT), odds ratio (OR), revised cardiac risk 
(RCR). 
 
 
Long-term outcome 
During long-term follow-up, 81 (16%) patients died due to a CV cause. Of these patients, 24 
(7%) had a CCA-IMT <1.25 mm and 57 (39%) had an increased CCA-IMT (Table 2). 
Cumulative 5-year survival (log rank p < 0.01) is shown in Figure 2. Multivariate analyses 
showed that the RCR index was predictive for CV mortality for patients with 2 and ≥3 risk 
factors with HRs of 2.02 (95%-CI: 1.05 to 3.88) and 3.81 (95%-CI: 1.95 to 7.45), respectively 
(Table 4, Model 1). When including CCA-IMT in the model (Table 4, Model 2), an increased 
CCA-IMT was independently associated with CV mortality with an HR of 6.57 (95%-CI: 3.93 
to 10.96). The incremental value of CCA-IMT in the prediction of CV events is further 
illustrated in Figure 3.  
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Table 4 Multivariate association between CCA-IMT and long-term mortality  
 Model 1 * Model 2 ** 
 
[N=508] HR [95%-CI] HR [95%-CI] 
Cardiovascular events  
 
     
RCR index ***      
 1 risk factor 27/250 1.00  1.00  
 2 risk factors 24/146 1.84 1.02-3.35 1.74 0.95-3.19 
 ≥ 3 risk factors 35/112 3.66 2.08-6.43 2.97 1.67-5.29 
CCA-IMT      
 <1.25 24/363 - - 1.00  
 ≥1.25  57/145 - - 6.88 4.11-11.50 
All-cause mortality      
RCR index ***      
 1 risk factor 48/250 1.00  1.00  
 2 risk factors 37/146 1,53 0.94-2.50 1.50 0.92-2.44 
 ≥3 risk factors 40/112 2.49 1.53-4.04 2.14 1.31-3.49 
CCA-IMT      
 <1.25 53/363 - - 1.00  
 ≥1.25  69/145 - - 2.88 1.94-4.27 
* Model 1: predictive value of RCR index for adverse outcome. Multivariate analyses were adjusted for age, gender, 
hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, current smoking, β-blocker use, statin 
use, and aspirin use.  
** Model 2: additional value of CCA-IMT for prediction of adverse outcome additionally to clinical risk factors. 
Multivariate analysis adjusted for RCR risk factors and risk factors described in model 1. *** RCR risk 
factors: heart failure, ischemic heart disease, cerebrovascular disease, diabetes mellitus, renal dysfunction, and 
high-risk surgery.  
Confidence interval (CI), common carotid artery intimamedia thickness (CCA-IMT), hazard ratio (HR), revised cardiac 
risk (RCR). 
 
 
Figure 2: Cumulative long-term survival. 
 
 
 
 
 
 
 
 
 
 
 
Common carotid artery intimamedia thickness (CCA-IMT). 
 188 
Figure 3: Incremental value of CCA-IMT in the prediction of postoperative cardiovascular mortality. 
 
 
 
 
 
 
 
 
 
  
 
       . 
 
 
 
 
 
 
Risk factors: age, gender, current smoking, hypercholesterolemia, chronic obstructive pulmonary disease. Common carotid 
artery intimamedia thickness (CCA-IMT), revised cardiac risk (RCR). 
 
 
DISCUSSION 
 
To our knowledge, our study is the first to describe the prognostic value of an increased CCA-
IMT in patients undergoing vascular surgery. We have found a cut off value (maximum CCA-
IMT) of 1.25 mm, using receiver operating characteristic curve analysis, to be most indicative 
for the prediction of 30-day CV events and long-term CV mortality. In patients with an 
increased CCA-IMT, the occurrence of 30-day CV events was more than twice as high 
compared with patients with a CCA-IMT <1.25 mm. The occurrence of long-term CV 
mortality was more than five times higher in patients with an increased CCA-IMT compared 
with patients with a CCA-IMT <1.25 mm. 
 
Atherosclerosis, a systemic inflammatory disease, is known to affect multiple sections 
of the arterial tree simultaneously. Previous studies have demonstrated a correlation between 
an increased CCA-IMT with cardiac risk factors and coronary atherosclerosis.12-14 However, 
the extent of the atherosclerotic process is thought to differ between the vascular beds. In the 
general population, the median carotid IMT ranges from 0.5 to 1.0 mm,15 and the CCA-IMT is 
considered increased being >1.0 mm.16  In the prediction of myocardial infarction and stroke, 
The Rotterdam Study found the average maximum CCA-IMT to be 1.03 ± 0.22 and divided 
the carotid IMT into quartiles based on the population distribution. Using maximal CCA-IMT 
cut off values of 0.88, 0.99, and 1.12 mm, they have defined mild, moderate, and severe 
thickening of the carotid wall, respectively.12, 17 The Multi-Ethnic Study of Atherosclerosis 
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study also divided the maximal common carotid IMT in quartiles and found cut off values of 
0.74, 0.84, 0.97, and 2.45 mm, respectively.18 Our study population consisted of major vascular 
surgery patients, which are prone to have atherosclerosis. In comparison, the Rotterdam study 
and Multi-Ethnic Study of Atherosclerosis study were population-based studies. As patients 
with operable vascular disease may have more diffuse and more severe vascular disease, this 
might explain our relatively high cut off value for CCA-IMT to predict future CV events.  
 
The carotid IMT is increasingly used as a surrogate marker of early atherosclerosis, 
which is associated with CV diseases such as myocardial infarction, stroke and peripheral 
arterial disease. Several studies have demonstrated that carotid IMT is associated with risk of 
CV events.5, 19 This study was performed to evaluate the predictive value of the CCA-IMT for 
preclinical stages of atherosclerosis. Therefore, focal thickened regions in the carotid arteries 
were excluded, as they reflect later stages of atherosclerosis. A meta-analysis performed by 
Lorenz et al,12 in which 37,197 patients were included, provided data on the use of carotid IMT 
to predict myocardial infarction and stroke in the general population. In this study an absolute 
carotid IMT difference of 0.1 mm was associated with an increased risk for myocardial 
infarction of 10 to 15% and an increased risk for stroke of 13 to 18%. However, as reported in 
the Mannheim Carotid IMT Consensus statement, the Food and Drug Administration does 
not yet approve carotid IMT as a surrogate marker of vascular events. Although, it is stated 
that carotid IMT is the most important candidate to be studied, as an independent marker for 
CV events.7 To our knowledge, the prognostic value of an increased CCA-IMT has not been 
previously described in patients undergoing vascular surgery. Only limited information is 
available regarding the prognostic value of CCA-IMT in patients undergoing cardiac 
interventions. Lacroix et al.20 evaluated whether CCA-IMT thickening was related to an 
increased risk of CV events after percutaneous transluminal coronary angioplasty. Univariate 
analysis demonstrated that a CCA-IMT >0.7 mm was associated with increased CV events 
after percutaneous transluminal coronary angioplasty (p = 0.03). They concluded CCA-IMT 
could be useful to identify high-risk patients. Aboyans et al.21 enrolled 609 patients undergoing 
coronary artery bypass grafting and hypothesized CCA-IMT could be used for perioperative 
and long-term risk stratification. However, in multivariate analysis, CCA-IMT failed to be an 
independent predictor for secondary CV events after coronary artery bypass grafting. Both 
studies mentioned above included patients with known coronary artery disease and long-term 
follow-up included nonfatal CV events as well. This might explain our relatively high cut off 
value for CCA-IMT to predict future CV events.  
 
The ‘American Society of Echocardiography Carotid IMT task force’ have stated that 
carotid IMT imaging should not be performed in patients with established atherosclerotic 
vascular disease or if the results would not be expected to alter therapy. They recommend 
prospective studies to investigate the effectiveness of carotid ultrasound imaging in support to 
improve CV outcome.5 It is suspected that 95% of the episodes of perioperative myocardial 
infarction and ischemia are asymptomatic,1, 22-25 and subsequently, these patients do not receive 
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adequate treatment. We have shown that an increased CCA-IMT is an independent predictor 
of perioperative myocardial infarction and ischemia and could therefore contribute to optimize 
medical treatment as well. With current ultrasound scanners, CCA-IMT can be easily used in 
clinical routine for objective and reproducible cardiac risk assessment. Importantly, CCA-IMT 
has an additional value, incremental to subjective cardiac risk assessment using the RCR index. 
Validation of our results in future studies is needed to justify the recommendation of standard 
CCA-IMT measurements in preoperative risk stratification of vascular surgery patients. 
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective major vascular surgery. Second, although two experienced 
investigators performed offline assessments of the obtained ultrasound images, we cannot rule 
out interobserver variability to have had minor influence on our results.26 Third, we did not 
validate the CCA-IMT cut off point in a prospective group of patients undergoing vascular 
surgery.  
 
In conclusion, the present study shows that an increased CCA-IMT of ≥1.25 mm has 
a prognostic value in vascular surgery patients to predict 30-day CV events and long-term, 
incremental to the widely used RCR index. 
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ABSTRACT 
 
Objectives This study evaluated the prognostic value of asymptomatic low ankle-brachial 
index (ABI) to predict perioperative myocardial damage, incremental to conventional cardiac 
risk factors imbedded in preoperative cardiac risk indices (Revised Cardiac Risk index and 
Adapted Lee index). 
 
Methods Preoperative ABI measurements were performed in 627 consecutive vascular 
surgery patients (carotid artery or abdominal aortic aneurysm repair). An ABI <0.90 was 
considered abnormal. Patients with ABI >1.40 or (a history of) intermittent claudication were 
excluded. Serial troponin T measurements were performed routinely before and after surgery. 
The main study endpoint was perioperative myocardial damage, the composite of myocardial 
ischemia and infarction. Multivariate regression analyses, adjusted for conventional risk factors, 
evaluated the relation between asymptomatic low ABI and perioperative myocardial damage.   
 
Results In total, 148 (23%) patients had asymptomatic low ABI (mean 0.73, standard 
deviation ± 0.13). Perioperative myocardial damage was recorded in 107 (18%) patients. 
Multivariate regression analyses demonstrated that asymptomatic low ABI was associated with 
an increased risk of perioperative myocardial damage (OR 2.4, 95%-CI: 1.4 to 4.2). 
 
Conclusions This study demonstrated that asymptomatic low ABI has a prognostic value to 
predict perioperative myocardial damage in vascular surgery patients, incremental to risk 
factors imbedded in conventional cardiac risk indices. 
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INTRODUCTION 
 
Cardiac complications form the leading cause of postoperative morbidity or mortality, with a 
prevalence reported to range between 2.2 an 19.0% in vascular surgery patients.1 The high 
incidence of perioperative cardiac complications reflects the high prevalence of underlying 
ischemic heart disease.2, 3 Adequate preoperative evaluation is inevitable in vascular surgery 
patients to (i) identify patients at increased cardiac risk (ii) initiate risk-reduction therapy and 
(iii) select optimal surgical and anaesthesia techniques. In conventional preoperative cardiac 
risk indices (Revised Cardiac Risk index and Adapted Lee index), age, heart failure, ischemic 
heart disease, cerebrovascular disease, renal dysfunction, diabetes mellitus, and high-risk 
surgery have been identified as independent predictors of perioperative cardiovascular events.4, 
5 
 
 Peripheral arterial disease (PAD) is associated with an increased risk of cardiovascular 
mortality and morbidity. The ankle-brachial index (ABI) is a simple noninvasive test to screen 
patients with suspected PAD.6, 7 In the nonsurgical setting, a resting low ABI (<0.90) has been 
associated with a two- to fourfold increased risk of cardiovascular mortality or severe 
cardiovascular events compared with normal ABI.7-10 Low ABI has demonstrated to improve 
risk prediction for cardiovascular mortality and major nonfatal myocardial infarction 
(nonsurgical setting), even beyond risk prediction properties using cardiac risk scores.9, 11 
However, the predictive value of asymptomatic low ABI for perioperative myocardial damage 
has not been studied yet. The current study evaluated if asymptomatic low ABI has a predictive 
value for perioperative myocardial damage, independent from conventional risk factors 
imbedded in cardiac risk indices.   
 
 
MATERIAL AND METHODS 
 
Study population 
The original study population consisted of 1,113 consecutive patients undergoing vascular 
surgery during the period between 2002 and 2009. The study was performed at the Erasmus 
Medical Center in Rotterdam, a tertiary hospital in the Netherlands. After exclusion of (i) lower 
extremity arterial or abdominal aortic stenosis repair patients, (ii) patients with (a history of or 
current) intermittent claudication assessed with the Edinburgh questionnaire,12 and (iii) patients 
with asymptomatic ABI >1.40,13 a total 627 patients were included (Figure 1). The study was 
approved by the hospital’s ethics committee and performed with the informed consent of all 
patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Clinical data included: age, 
sex, ischemic heart disease (defined as a history myocardial infarction, coronary 
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revascularization or the presence of pathologic Q-waves on preoperative electrocardiogram), 
cerebrovascular disease (defined as a history of ischemic or haemorrhagic stroke), renal 
dysfunction (serum creatinine >2.0 mg/dL), diabetes mellitus (fasting blood glucose ≥6.1 
mmol/L or requirement of anti-diabetic medication), hypertension (blood pressure ≥140/90 
mmHg in non-diabetic patients and ≥130/80 mmHg in diabetics or requirement of 
antihypertensive medication), hypercholesterolemia (history of hypercholesterolemia or low-
density lipoprotein cholesterol >3.5 mmol/L), chronic obstructive pulmonary disease (history 
of chronic obstructive pulmonary disease or according the Global Initiative on Obstructive 
Lung Diseases classification), and smoking status. The use of the prescription medication was 
recorded and included β-blockers, statins, angiotensin-converting enzyme inhibitors, aspirin 
and, oral anticoagulants. Preoperatively, transthoracic echocardiography was performed in all 
patients using a hand-held Acuson Cypress Ultrasound System (7V3c transducer) 
manufacturers address 1220 Charleston Road, Mountain View, CA 94043. Standard parasternal 
and apical two- and four-chamber views were obtained during rest with the patient in the left 
lateral decubitus position, as recommended.14 Left ventricular end-systolic and end-diastolic 
volumes were determined and left ventricular ejection fraction was calculated using the biplane 
Simpson’s technique.15 Systolic left ventricular dysfunction was defined as left ventricular 
ejection fraction <50%.  
  
Ankle-brachial index 
The ABI at rest was measured in each patient by trained technicians, using a Doppler 
ultrasonic instrument with an 8-MHz vascular probe (Imexdop CT+ Vascular Doppler; 
Nicolet Vascular, Madison, WI, USA). The ABI in the right and left leg was calculated by 
dividing the right and the left ankle pressures by the brachial pressure. The higher of the two 
brachial blood pressures was used if a discrepancy in systolic blood pressure was present. 
Further, the higher of the dorsalis pedis and posterior tibial artery pressures was used if a 
discrepancy in systolic blood pressure between the two arteries was measured.16 Asymptomatic 
low ABI was defined as an ABI <0.90 with an inter- and intraobserver agreement of 97 and 
98%, as shown previously.17  
 
Study outcomes 
The main study endpoints were perioperative myocardial damage (defined as nonfatal 
myocardial ischemia or infarction up to 30 days after surgery) and long-term mortality. Serial 
electrocardiograms and troponin T measurements were obtained from all patients before 
surgery, postoperatively on days 1, 3, 7 and before discharge. Myocardial ischemia was present 
in patients with normal preoperative and elevated (>0.03 ng/mL) troponin T levels 
postoperatively.18 Elevated troponin T levels in combination with electrocardiographic changes 
(new-onset ST-T changes and pathological Q-waves) or symptoms of angina pectoris defined 
myocardial infarction.19 Patients with elevated troponin T levels before surgery were not 
included in the study. Long-term mortality was assessed by approaching the municipal civil 
registries. Median follow-up was 2 years (interquartile range [IQR] 1 to 3). 
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Statistical analysis 
Dichotomous data are described as numbers and percentages. Continuous variables are 
described as mean ± standard deviation (SD). Continuous data were compared using one-way 
ANOVA and categorical data were compared using a χ2 test. Logistic regression analyses were 
performed to evaluate the relationship between asymptomatic low ABI and perioperative 
myocardial damage. Cox regression analyses were performed to evaluate the relationship 
between asymptomatic low ABI and long-term mortality. Cumulative long-term survival was 
determined using the Kaplan-Meier method. Multivariate regression analyses were adjusted for 
sex, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease, current 
smoking and risk factors imbedded in conventional cardiac risk indices (age, ischemic heart 
disease, symptomatic heart failure, cerebrovascular disease, renal dysfunction, diabetes mellitus, 
and high-risk surgery). We report both the crude and the adjusted odds ratio (OR) and hazard 
ratio (HR) with their 95% confidence intervals (95%-CI). For all tests, a p-value <0.05 (two-
sided) was considered significant. All analyses were performed using SPSS version 15.0 
statistical software (SPSS, Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
Prevalence of PAD and baseline characteristics 
The initial study population consisted of 690 patients. In total, 54 patients with (a history of) 
intermittent claudication and nine patients with an asymptomatic ABI >1.40 were excluded 
from the analyses. Therefore, 627 patients, without (a history of) intermittent claudication, 
undergoing carotid artery stenosis (N=241), or abdominal aortic aneurysm (N=386) repair 
were included in the study. In total, 148 (23%) patients had asymptomatic low ABI (mean 0.73, 
SD ± 0.13). The distribution of asymptomatic low ABI values is demonstrated in Figure 2. In 
addition, baseline characteristics stratified to ABI are shown in Table 1. The majority of 
patients were males (82%) and the mean age was 70 (SD ± 8.6) years. Asymptomatic low ABI 
was associated with ischemic heart disease, renal dysfunction, smoking and a left ventricular 
ejection fraction <50%.  
 
Perioperative myocardial damage 
The study endpoint perioperative myocardial damage, was reached in 107 (17%) patients, as 
shown in Table 2. Of these patients, 76 (71%) had myocardial ischemia and 31 (29%) had 
myocardial infarction. Symptoms of angina pectoris were reported in only six (6%) patients. As 
demonstrated in Table 2, the prevalence of perioperative myocardial damage was the highest in 
patients undergoing abdominal aortic aneurysm repair or open surgery. In addition, 32% 
(47/148) of patients with asymptomatic low ABI had perioperative myocardial damage, 
compared with 13% (60/479) of patients with normal ABI. 
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Figure 1: Overview of the selected patient population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ankle-brachial index (ABI). 
 
 
Multivariate analyses showed that risk factors imbedded in the Revised Cardiac Risk 
index and Adapted Lee index (combined risk factors) were predictive for perioperative 
myocardial damage, as shown in Table 3A, Model 1. When including ABI in the model (Table 
3A Model 2 + 3), asymptomatic low ABI was independently associated with an increased risk 
of perioperative myocardial damage with an OR of 2.4 (95%-CI: 1.4 to 4.2). The risk for 
developing myocardial damage was higher in patients with asymptomatic ABI <0.70 (OR 2.6, 
95%-CI: 1.4 to 5.1) compared with patients with asymptomatic ABI 0.70-0.89 (OR 2.3, 95%-
CI: 1.3 to 4.4). In addition, patients with low ABI and (a history of) intermittent claudication 
had the highest risk for developing perioperative myocardial damage (OR 2.8, 95%-CI: 1.2 to 
6.4). Multivariate sub-analyses performed in patients undergoing abdominal aortic aneurysm 
repair, and patients undergoing carotid repair separately, demonstrated that asymptomatic low 
ABI was associated with an increased risk for myocardial damage in both groups with ORs of 
1.9 (95-CI: 1.1 to 3.6) and 5.3 (95%-CI: 2.4 to 19.8), respectively.    
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Table 1 Baseline characteristics of the study population 
ABI ≥0.9 ABI <0.9 p-value 
 
[N=479] [N=148]  
Demographics 
 
   
  Age (± SD) 70 (9) 69 (8) 0.91 
  Body mass index (± SD ) 26 (3) 26 (4) 0.94 
  Male (%)   378 (79) 130 (88) 0.02 
Medical history (%)    
  Ischemic heart disease  183 (37) 71 (48) 0.01 
  Clinical  heart failure  48 (10) 19 (13) 0.30 
  Cerebrovascular disease 231 (48) 69 (47) 0.73 
  Renal dysfunction  67 (14) 33 (23) 0.03 
  Diabetes mellitus  117 (24) 38 (29) 0.57 
  Hypertension  278 (63) 82 (65) 0.61 
  Hypercholesterolemia  287 (61) 67 (62) 0.78 
  Chronic obstructive pulmonary disease  155 (32) 56 (38) 0.22 
  Smoking, current  162 (34) 69 (46) 0.01 
Echocardiography (%)    
Left ventricular ejection fraction  <50%  79 (17) 50 (34) <0.01 
Medication (%)    
  β-blockers  368 (77) 121 (82) 0.21 
  Statins  357 (75) 99 (67) 0.08 
  Angiotensin-converting  enzyme inhibitors  120 (27) 40 (32) 0.37 
  Aspirin 287 (60) 81 (55) 0.26 
Oral anticoagulants  
 
57 (12) 26 (18) 0.08 
Ankle-brachial index (ABI), standard deviation (SD). 
 
Abdominal aortic aneurysm (AAA), ankle-brachial index (ABI). 
 
Long-term mortality 
In total, 111 (18%) patients died during follow-up (Table 2) and the prevalence of long-term 
mortality was the highest in patients undergoing abdominal aortic aneurysm repair. Of the 
Table 2 Ankle-brachial index and postoperative outcome 
ALL ABI >0.9 ABI <0.9 p-value  
[N=627] [N=479] [N=148]  
Perioperative myocardial damage 
 
     
All procedures 107/6
27 
(17) 60/479 (13) 47/148 (21) <0.01 
AAA open procedures 67/20
8 
(32) 42/148 (28) 25/60 (42) <0.01 
 endovascular procedures 20/17
8 
(11) 9/138 (6) 11/40 (28) <0.01 
Carotid open procedures 16/15
6 
(10) 8/125 (7) 8/31 (26) <0.01 
 endovascular procedures 4/85 (5) 1/68 (2) 3/17 (18) <0.01 
Long-term mortality       
All procedures 111/6
27 
(18) 74/479 (15) 43/148 (27) <0.01 
AAA open procedures 60/20
8 
(29) 36/148 (24) 24/60 (40) <0.01 
 endovascular procedures 33/17
8 
(19) 23/138 (17) 10/40 (25) <0.01 
Carotid open procedures 13/15
6 
(8) 10/125 (8) 6/31 (19) <0.01 
 endovascular procedures 5/85 (6) 2/68 (3) 3/17 (18) <0.01 
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patients who died, 36% (40/111) had perioperative myocardial damage and 39% (43/111) 
patients had asymptomatic low ABI. Cumulative 6-year survival (log rank p < 0.01) is shown in 
Figure 3. Survival rates in patients with normal ABI and asymptomatic low ABI were (i) 87 ± 
2% and 72 ± 5% during a two-year follow-up, (ii) 76 ± 3% and 59 ± 6% during a four-year 
follow-up, and (iii) 60 ± 6% and 48 ± 9% during six-year follow-up, respectively. 
 
Multivariate analyses showed that the combined risk factors were predictive for long-
term mortality, as shown in Table 3B, Model 1. When including ABI in the model (Table 3B 
Model 2 + 3), asymptomatic low ABI was independently associated with an increased risk of 
long-term mortality with an HR of 1.9 (95%-CI: 1.2 to 2.8). The risk of long-term mortality 
was higher in patients with asymptomatic ABI <0.70 (HR 2.4, 95%-CI: 1.5 to 3.8) compared 
with patients with asymptomatic ABI 0.70 to 0.89 (HR 1.6, 95%-CI: 1.1 to 2.6). In addition, 
patients with low ABI and (a history of) intermittent claudication had the highest risk of long-
term mortality (HR 3.0, 95%-CI: 1.2 to 3.4).  
 
Multivariate sub-analyses performed in patients undergoing abdominal aortic 
aneurysm repair and patients undergoing carotid repair separately, demonstrated that 
asymptomatic low ABI was associated with an increased risk for long-term mortality in both 
groups with HRs of 1.8 (95%-CI: 1.2 to 3.0) and 2.3 (95%-CI: 1.7 to 7.9), respectively.    
 
a Model 1: Predictive value of combined risk factors derived from the Revised Cardiac Risk and Adapted Lee Risk 
indices: multivariate analyses adjusted for: sex, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease and 
current smoking. b Model 2: Predictive value of low ABI: multivariate analyses adjusted for combined risk factors, sex, 
left ventricular ejection fraction <40%, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease and 
current smoking. c Model 3: Predictive value of low ABI: multivariate analyses adjusted as in model 2 and for medication 
use (β-blockers, statins, aspirin, oral anticoagulants, and angiotensin-converting enzyme inhibitors). d insulin dependent. 
Ankle-brachial index (ABI), confidence interval (CI), odds ratio (OR).  
 
Table 3A Multivariate association between ABI and myocardial damage 
Model 1a Model 2b Model 3c  
OR [95%-CI] OR [95%-CI] OR [95%-CI] 
Combined risk factors 
 
 
 
    
 Age (>70 years) 1.6 2.1-5.2 1.4 1.9-5.0 1.4 1.9-4.8 
 Symptomatic heart failure 3.2 1.7-5.5 3.1 1.6-5.8 3.1 1.6-6.0 
 Ischemic heart disease 2.4 1.3-4.6 2.6 1.5-5.2 2.7 1.7-5.3 
 Cerebrovascular disease 1.4 1.9-6.1 1.6 1.9-6.7 1.7 2.0-6.9 
 Renal dysfunction 1.7 1.8-7.7 1.5 1.6-7.3 1.5 1.6-7.2 
 Diabetes mellitusd 1.2 1.1-3.0 1.3 1.2-3.3 1.3 1.2-3.4 
 High-risk surgery 7.3 3.6-14.6 8.4 3.8-18.4 9.2 4.0-21.0 
ABI      
 ≥0.90 - - reference 
- 
reference 
  <0.90 asymptomatic - - 2.4 1.4-4.1 2.4 1.4-4.2 
 <0.90 intermittent claudication - - 2.7 1.2-6.0 2.8 1.2-6.4 
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a Model 1: Predictive value of combined risk factors derived from the Revised Cardiac Risk and Adapted Lee Risk 
indices: multivariate analyses adjusted for: sex, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease and 
current smoking. b Model 2: Predictive value of low ABI: multivariate analyses adjusted for combined risk factors, sex, 
left ventricular ejection fraction <40%, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease and 
current smoking. c Model 3: Predictive value of low ABI: multivariate analyses adjusted as in model 2 and for medication 
use (β-blockers, statins, aspirin, oral anticoagulants, and angiotensin-converting enzyme inhibitors). d insulin dependent. 
ankle-brachial index (ABI), confidence interval (CI), hazard ratio (HR). 
 
 
Figure 2:  Distribution of ankle-brachial index (ABI) <0.90 in asymptomatic patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3B Multivariate association between ABI and long-term mortality 
Model 1a Model 2b Model 3c  
HR [95%-CI] HR [95%-CI] HR [95%-CI] 
Combined risk factors 
 
 
 
    
 Age (>70 years) 3.2 1.3-4.2 3.0 1.2-4.3 3.0 1.2-4.2 
 Symptomatic heart failure 2.6 1.6-3.4 2.5 1.6-4.0 2.3 1.4-3.7 
 Ischemic heart disease 2.0 1.2-4.9 1.8 1.1-5.2 1.7 1.1-5.4 
 Cerebrovascular disease 1.2 1.1-3.2 1.3 1.2-3.8 1.3 1.1-3.9 
 Renal dysfunction 2.3 1.6-4.0 1.9 1.1-3.7 1.9 1.1-3.6 
 Diabetes mellitus d 1.2 1.2-3.5 1.7 1.4-3.7 1.7 1.4-3.8 
 High-risk surgery 2.9 1.6-3.4 2.0 1.2-3.8 1.9 1.1-3.7 
ABI      
 ≥0.90 - - reference 
- 
reference 
  <0.90 asymptomatic - - 2.0 1.3-3.0 1.9   1.2-2.8 
 <0.90 intermittent claudication - - 3.1 1.2-3.6 3.0   1.2-3.4 
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Figure 3:  Cumulative long-term survival.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ankle-brachial index (ABI). 
 
  
DISCUSSION 
 
The current study demonstrated that asymptomatic low ABI was present in around one out of 
four patients undergoing carotid artery stenosis or abdominal aortic aneurysm repair. To our 
knowledge, this study is the first to demonstrate that asymptomatic low ABI has prognostic 
value to predict perioperative myocardial damage in vascular surgery patients, incremental to 
risk factors imbedded in conventional cardiac risk indices. 
 
Ischemic heart disease, cerebrovascular disease, and PAD result from atherosclerotic 
arterial disease. Atherosclerosis is a systemic inflammatory disease of the vasculature and a 
response to injury, lipid peroxidation, and inflammation. The process of atherosclerosis is 
known to affect multiple sections of the arterial tree simultaneously.20 Large international 
registries, such as the REACH registry, have shown a high prevalence of multiple-affected 
vascular beds in patients with PAD (around 20%) indicating that these patients often have 
concomitant ischemic heart or cerebrovascular disease.21 The ABI is a noninvasive and reliable 
indicator for the atherosclerotic status of the lower leg vasculature.6, 7 Multiple studies have 
demonstrated that the majority of patients with PAD, defined as ABI <0.90, are 
asymptomatic.10, 22, 23 Patients with asymptomatic PAD have an increased risk for 
cardiovascular disease, equal to patients with intermittent claudication.8 The high prevalence of 
asymptomatic PAD suggests that ABI should be systematically measured in high-risk 
hospitalized patients to ensure that appropriate secondary prevention programs are initiated.24 
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In our patients population, three out of four patients with low ABI did not have (a history of) 
intermittent claudication.  
 
The current study is the first to demonstrate that, after adjusting for risk factors 
imbedded in conventional cardiac risk indices, asymptomatic low ABI was associated with an 
increased risk of perioperative myocardial damage in vascular surgery patients. The prevalence 
of myocardial ischemia has been evaluated in the nonsurgical setting that focused on patients 
with symptomatic PAD and without clinical ischemic heart disease. In a study conducted by 
Raby et al, the prevalence of myocardial ischemia detected with Holter monitoring was around 
18% and was demonstrated to be an independent predictor of two-year prognosis.25 The ABI 
collaboration group demonstrated that low ABI has the potential to improve risk prediction 
for major nonfatal myocardial infarction, beyond the Framingham Risk Score.11 Recently, 
Mostaza et al. evaluated silent myocardial ischemia, detected with exercise stress tests, in 85 
patients with asymptomatic low ABI. Although the sample size in this study was limited, the 
authors found that a positive exercise test was present in 16% of patients with asymptomatic 
low ABI, compared with 3.5% in control patients.26 As the authors themselves state, the real 
prevalence of ischemic heart disease in these patients remains unknown, because no additional 
tests were performed in patients with a positive exercise test. To our knowledge, the impact of 
asymptomatic low ABI on perioperative myocardial damage in vascular surgery patients has 
not been studied yet. The current study demonstrated that the risk of patients with 
asymptomatic low ABI to develop perioperative myocardial damage was more than twice as 
high compared with patients with normal ABI. In line with previous studies, endovascular 
surgery was associated with a reduced incidence of perioperative myocardial damage, possibly 
explained by reduced myocardial stress during endovascular procedures.27, 28  
 
Perioperative myocardial damage is most often silent and the great majority of these 
patients (95%) remain untreated, which might contribute to an increased risk of long-term 
cardiovascular mortality.25, 27, 29-31 Multiple studies have demonstrated that low ABI has the 
potential to improve prediction of long-term mortality over and above conventional risk 
factors.9,11 In line with these studies, we found that after adjusting for conventional risk factors, 
imbedded in conventional cardiac risk indices, asymptomatic low ABI was associated with 
increased risk of long-term mortality after vascular surgery.  
 
Our results indicate that preoperative counselling of vascular surgery patients 
undergoing carotid stenosis or aortic aneurysm repair should include systematic screening for 
asymptomatic lower extremity PAD by measuring the ABI. A recent study conducted by 
Hoeks et al. has observed a care gap between guideline recommendations and clinical practice 
in PAD patients.32 Standard screening for asymptomatic PAD could reduce this observed care 
gap by initiating recommended medical treatment with (i) statins, (ii) antiplatelet therapy to 
reduce the risk of adverse cardiovascular ischemic events, and (iii) angiotensin-converting 
enzyme inhibition, which may be considered for cardiovascular risk reduction.33 The presence 
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of asymptomatic lower-extremity PAD creates the need for optimal lifestyle modification and 
screening for additional risk factors. Our results indicate that asymptomatic lower-extremity 
PAD is associated with an increased risk for systolic left ventricular dysfunction and ischemic 
heart disease. Standard cardiac evaluation during preoperative counselling should therefore be 
considered in asymptomatic lower-extremity PAD patients. Asymptomatic systolic left 
ventricular dysfunction with an ejection fraction <40% should be treated with an angiotensin-
coverting enzyme inhibitor or, in case of intolerance, an angiotensin receptor blocker. In 
patients with a history of ischemic heart disease, β-blocker treatment should be initiated as 
well.34 Patients with asymptomatic lower-extremity PAD are at increased risk for perioperative 
myocardial damage. Perioperative montoring with cardiac biomarkers, such as troponin T, 
could be justified since the majority of perioperative myocardial damage is silent and patients 
therefore remain untreated. Available evidence suggests that β-blockers reduce perioperative 
ischemia and the latest American College of Cardiology / American Heart Accociation 
(ACC/AHA) guidelines on perioperative care provide a (class IIa, level of evidence B) 
recommendation to initiate β-blocker treatment in patients with one or more cardiovascular 
risk factors.35  
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, we did not address nonfatal 
cardiovascular events during long-term follow-up. Third, we included both open and 
endovascular surgical procedures. The number of endovascular procedures has increased in the 
past three years, which has influenced the median follow-up period.  
 
In conclusion, the current study demonstrated that asymptomatic low ABI has 
prognostic value to predict perioperative myocardial damage in vascular surgery patients, 
incremental to conventional risk factors imbedded in the RCR and Adapted Lee Risk indices. 
These data suggest that ABI measurements should be systematically performed in patients 
scheduled for carotid artery stenosis or abdominal aortic aneurysm repair to ensure that 
appropriate perioperative treatment is initiated. 
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ABSTRACT 
 
Background Asymptomatic low ankle-brachial index (ABI) and subclinical increased common 
carotid artery intimamedia thickness (CCA-IMT) are predictors of cardiac events. This study is 
the first to evaluate the separate and combined prognostic values of these markers in one 
cohort of vascular surgery patients.  
 
Methods 400 patients undergoing abdominal aortic aneurysm repair, without intermittent 
claudication, a history of lower extremity revascularization or cerebrovascular disease, were 
included. In all patients, preoperative CCA-IMT measurements (using high-resolution B-mode 
ultrasonography) and ABI measurements were performed. CCA-IMT >1.25 mm was 
considered increased and an ABI <0.9 was considered low. Study endpoints were 30-day 
myocardial damage (defined as troponin T release >0.03 ng/mL) and long-term mortality. 
Multivariate regression analyses, adjusted for conventional cardiac risk factors, evaluated the 
prognostic value of ABI and CCA-IMT towards the study endpoints. Mean follow-up was 2.5 
± 2.2 years. 
 
Results Of the included patients, 75 (19%) patients had an ABI <0.9, 59 (15%) patients had a 
CCA-IMT>1.25 and 34 (9%) patients had both. In total, 82 (21%) patients had 30-day 
myocardial damage and 77 (19%) patients died during follow-up. An ABI <0.9 and CCA-IMT 
>1.25 were separately associated with 30-day myocardial damage (OR 2.6, 95%-CI: 1.4 to 6.2 
and OR 2.1, 95%-CI: 1.3 to 7.4) and long-term mortality (HR 3.2, 95%-CI: 1.6 to 6.7 and HR 
3.9, 95%-CI: 1.8 to 8.8). However, the combination of an ABI <0.9 + CCA-IMT >1.25 was 
associated with the highest risk (30-day myocardial damage: OR 5.2, 95%-CI: 2.0 to 11.1 and 
long-term mortality: HR 5.6, 95%-CI: 2.5 to 12.5), compared with patients with an ABI >0.9 + 
CCA-IMT <1.25. 
 
Conclusions Although asymptomatic ABI <0.9 and subclinical CCA-IMT >1.25 
independently predict 30-day myocardial damage and long-term mortality in patients 
undergoing abdominal aortic aneurysm repair, a combination of these markers is associated 
with the highest risk.   
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INTRODUCTION 
 
Atherosclerosis is a systemic, chronic inflammatory disease affecting the intima layer of the 
vessel wall. During the earlier phases of atherosclerosis, symptoms do not occur and remain 
absent for several decades. Atherosclerosis is known to affect multiple sections of the arterial 
tree simultaneously, such as the coronary-, lower extremity-, and carotid arteries. Therefore, 
individuals with one manifestation of atherosclerosis are more likely to have concomitant 
disease in other vascular territories as well.  
 
Patients undergoing abdominal aortic aneurysm repair are at significant risk for both 
perioperative and long-term cardiovascular events, related to a high prevalence of underliying 
coronary artery disease. However, preoperative risk stratification for adverse cardiac outcome 
using traditional cardiac risk factors is suboptimal indicating the necessity to improve cardiac 
evaluation before surgery.1-2 Preoperative evaluation of subclinical manifestations of the 
atherosclerotic process could be considered to improve the prediction of cardiac outcome. 
 
Surrogate markers reflecting the severity and extent of the atherosclerotic process, 
such as the ankle-brachial index (ABI) and the common carotid artery intimamedia thickness 
(CCA-IMT), have demonstrated to predict adverse cardiac events. However, the predictive 
value of these two markers combined has not been evaluated in one cohort of patients 
undergoing abdominal aortic aneurysm repair. The present study was performed to evaluate 
the separate and combined prognostic values of low ABI and increased CCA-IMT towards 
postoperative outcome of patients undergoing abdominal aortic aneurysm repair. 
 
 
MATERIAL AND METHODS 
 
Study population 
The original study population consisted of 499 patients undergoing abdominal aortic aneurysm 
repair during the period between 2002 and 2009. After exclusion of patients with a history of or 
current (i) intermittent claudication assessed with the Edinburgh questionnaire,3 (ii) 
asymptomatic ABI >1.40,4 (iii) lower extremity revascularization, or (iv) cerebrovascular 
disease, 400 patients were included in the study. The study was performed at the Erasmus 
Medical Center in Rotterdam, a tertiary hospital in the Netherlands. The study was approved by 
the hospital’s ethics committee and performed with the informed consent of all patients.  
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Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Clinical data included age, 
sex, ischemic heart disease (defined as a history of myocardial infarction, coronary 
revascularization, or the presence of pathologic Q-waves on preoperative electrocardiogram), 
renal dysfunction (serum creatinine >2.0 mg/dL), diabetes mellitus (fasting blood glucose ≥6.1 
mmol/L or requirement of anti-diabetic medication), hypertension (blood pressure ≥140/90 
mmHg in non-diabetic patients and ≥130/80 mmHg in diabetics or requirement of 
antihypertensive medication), hypercholesterolemia (history of hypercholesterolemia or low-
density lipoprotein cholesterol >3.5 mmol/L), chronic obstructive pulmonary disease (history 
of chronic obstructive pulmonary disease or according the Global Initiative on Obstructive 
Lung Diseases classification), and smoking status. The use of the prescription medications was 
recorded and included β-blockers, statins, inhibitors of the renin-angiotensin-aldosterone 
system (RAAS inhibitors: ACE inhibitors, angiotensin-II receptor blockers, renin inhibitors, 
aldosterone antagonists), aspirin, and oral anticoagulants.  
  
Ankle-brachial index 
The ABI at rest was measured in each patient by trained technicians, using a Doppler 
ultrasonic instrument with an 8-MHz vascular probe (Imexdop CT+ Vascular Doppler; 
Nicolet Vascular, Madison, WI, USA). The ABI in the right and the left leg was calculated by 
dividing the right and the left ankle pressures by the brachial pressure. The higher of the two 
brachial blood pressures was used if a discrepancy in systolic blood pressure was present. 
Further, the higher of the dorsalis pedis and posterior tibial artery pressures was used if a 
discrepancy in systolic blood pressure between the two arteries was measured.16 Asymptomatic 
low ABI was defined as an ABI <0.90 with an inter- and intraobserver agreement of 97 and 
98%, as described previously.5-6  
 
Common carotid artery intimamedia thickness 
The CCA-IMT was measured according to the ‘Mannheim Carotid Intima-Media Thickness 
Consensus’ scanning and reading protocol recommendations.7-8 Measurements were taken at 
10 mm proximal to the carotid bifurcation in the near and far wall of the left and right 
common carotid artery. Repeated measurements were performed along a minimum of 10 mm 
length. Four measurements were taken from both the left and right common carotid artery, 
two of which in the near and of which two in the far wall. The maximal measurement, of these 
eight measurements, was used. Plaques (defined as a focal structure encroaching into the 
arterial lumen of at least 0.5 mm)7 when present, were not used in the CCA-IMT 
measurements. Measurements were electrocardiogram-gated at the peak of the QRS complex 
to control for changes in CCA-IMT during the cardiac cycle. Two sonographers, unaware of 
the clinical information for each patient, performed the measurements with an interobserver 
correlation of the 96.2%, as shown previously.9 In addition, a cut off value of CCA-IMT of 
1.25 mm was used to predict the occurrence of the study endpoints.9 
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Left ventricular ejection fraction 
Preoperatively, transthoracic echocardiography was performed in all patients using a hand-held 
Acuson Cypress Ultrasound System (7V3c transducer), manufacturers address 1220 Charleston 
Road, Mountain View, CA 94043. Standard parasternal and apical two- and four-chamber views 
were obtained at rest with the patient in the left lateral decubitus position, as recommended.10 
Left ventricular end-systolic and end-diastolic volumes were determined and left ventricular 
ejection fraction was calculated using the biplane Simpson’s technique.11 Systolic left ventricular 
dysfunction was defined as left ventricular ejection fraction <50%.  
 
Study outcomes 
The main study endpoints were perioperative myocardial damage (defined as nonfatal 
myocardial ischemia or infarction up to 30 days after surgery) and long-term mortality. Serial 
electrocardiograms and troponin T measurements were obtained from all patients before 
surgery, postoperatively on days 1, 3, 7, and before discharge. Myocardial ischemia was present 
in patients with normal preoperative and  elevated (>0.03 ng/mL) troponin T levels 
postoperatively.12 Elevated troponin T levels in combination with electrocardiographic changes 
(new-onset ST-T changes and pathological Q-waves) or symptoms of angina pectoris defined 
myocardial infarction.13 Patients with elevated troponin T levels before surgery were not 
included in the study. Long-term mortality was assessed by approaching the municipal civil 
registries. Mean follow-up was 2.5 ± 2.2 years. 
 
Statistical analysis 
Dichotomous data are described as numbers and percentages. Continuous variables are 
described as mean ± standard deviation (SD). Continuous data were compared using one-way 
ANOVA and categorical data were compared using a χ2 test. Logistic regression analyses were 
performed to evaluate the relationship between asymptomatic low ABI, subclinical increased 
CCA-IMT and perioperative myocardial damage. Cumulative long-term survival was 
determined using the Kaplan-Meier method. Cox regression analyses were performed to 
evaluate the relationship between asymptomatic low ABI, subclinical increased CCA-IMT and 
long-term mortality. Multivariate regression analyses were adjusted for sex, 
hypercholesterolemia, hypertension, chronic obstructive pulmonary disease, current smoking, 
and risk factors imbedded in conventional cardiac risk indices (age, ischemic heart disease, 
symptomatic heart failure, renal dysfunction, diabetes mellitus, and high-risk surgery),14-15 and 
medication use. We report both the crude and the adjusted odds ratio (OR) and hazard ratio 
(HR) with their 95% confidence intervals (95%-CIs). For all tests, a p-value <0.05 (two-sided) 
was considered significant. All analyses were performed using SPSS version 15.0 statistical 
software (SPSS, Inc., Chicago, IL, USA).  
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RESULTS 
 
Baseline characteristics 
The initial study population consisted of 499 patients. Patients with (a history of) or current 
intermittent claudication (N=21), ABI >1.40 (N=6), lower extremity revascularization (N=14), 
or cerebrovascular disease (N=58) were excluded from the analyses. Therefore, 400 patients 
undergoing abdominal aortic aneurysm repair were included in the study. In total, 197 patients 
(49%) underwent open and 203 patients (51%) underwent endovascular surgery. Of the 400 
patients, 75 (19%) patients had asymptomatic low ABI, 59 (15%) patients had subclinical 
CCA-IMT >1.25 mm, and 34 (9%) patients had asymptomatic low ABI + subclinical CCA-
IMT >1.25 mm.  
 
Table 1 Baseline characteristics according to ABI and CCA-IMT 
 
ABI 
>0.9 
 
CCA-IMT 
<1.25 
 
[N=232] 
Low 
ABI 
 
CCA-IMT 
<1.25 
 
[N=75] 
ABI 
>0.9 
 
INCREASED 
CCA-IMT 
 
[N=59] 
Low 
ABI 
 
INCREASED 
CCA-IMT 
 
[N=34] 
 
 
P 
for 
trend 
 
 
Demographics (mean ± SD) 
 
     
Age  69 (12) 72 (7) 74 (7) 73 (8) 0.008 
Male (%)   199 (86) 65 (87) 53 (87) 30 (88) 0.564 
Heart rate  71 (14) 72 (17) 70 (13) 75 (14) 0.550 
Medical history (%)      
Ischemic heart disease  79 (34) 42 (56) 34 (58) 20 (59) 0.034 
Heart failure  12 (5) 7 (10) 8 (13) 4 (12) 0.002 
Renal dysfunction  35 (15) 16 (21) 13 (22) 8 (24) 0.042 
Diabetes mellitus   30 (13) 19 (25) 14 (24) 4 (12) 0.262 
Hypertension   131 (57) 51 (68) 42 (71) 22 (65) 0.120 
Hypercholesterolemia   89 (38) 30 (40) 26 (44) 13 (38) 0.897 
COPD  115 (50) 41 (55) 32 (54) 19 (56) 0.465 
Smoker, current  78 (34) 34 (45) 17 (29) 16 (47) 0.508 
Surgery type (%)      
Open 115 (50) 38 (51) 25 (42) 20 (58) 0.695 
Echocardiography (%)      
LVEF < 50% * 25 (11) 21 (28) 16 (27) 15 (44) <0.001 
Medication (%)      
β-blockers  195 (84) 70 (93) 48 (81) 31 (91) 0.454 
Statins  165 (71) 51 (68) 35 (59) 21 (62) 0.150 
Aspirin  118 (51) 47 (63) 33 (56) 16 (47) 0.845 
Oral anticoagulants   23 (10) 9 (12) 11 (19) 6 (18) 0.166 
RAAS inhibitors 88 (38) 35 (47) 25 (42) 16 (47) 0.312 
Diuretics 49 (21) 13 (17) 14 (24) 6 (18) 0.892 
* No heart failure symptoms. Ankle-brachial index (ABI), common carotid artery intimamedia thickness 
(CCA-IMT), left ventricular ejection fraction (LVEF). 
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Baseline characteristics stratified to ABI and CCA-IMT are demonstrated in Table 1. 
The majority of patients were males (82%) and the mean age was 70 (SD ± 8.6) years. 
Asymptomatic low ABI, subclinical CCA-IMT >1.25 mm, or a combination these two markers 
were associated with a history of ischemic heart disease, heart failure, and renal dysfunction. In 
addition, asymptomatic low ABI, subclinical CCA-IMT >1.25 mm, or a combination these two 
markers were associated with a left ventricular ejection fraction <50%.   
 
 A contingency table sub-analysis was performed to compare patients with (i) 
asymptomatic low ABI or subclinical CCA-IMT >1.25 mm to patients with (ii) a combination 
these two markers. Although a history of ischemic heart disease, symptomatic heart failure, and 
renal dysfunction were equally present in the two groups (with p-values of 0.541, 0.975 and 
0.618, respectively), the presence of left ventricular ejection fraction <50% was significantly 
increased in patients with asymptomatic low ABI + subclinical CCA-IMT >1.25 mm (p < 
0.001). 
 
Perioperative myocardial damage 
The study endpoint perioperative myocardial damage was reached in 82 (21%) patients, of 
whom 61 (74%) had myocardial ischemia and 21 (26%) had myocardial infarction. In total, 
25/203 (12%) of the patients undergoing endovascular, and 57/197 (29%) of the patients 
undergoing open procedures had perioperative myocardial damage. These results are 
demonstrated in Table 2. The prevalence of perioperative myocardial damage was the lowest 
(11%) in patients with an ABI >0.9 + CCA-IMT <1.25 mm and the highest (44%) in patients 
with asymptomatic low ABI + subclinical CCA-IMT >1.25 mm.  
 
Table 2 ABI, CCA-IMT and postoperative outcome after 
abdominal aortic aneurysm repair 
 Open  
procedures 
 
[N=197] 
Endovascular  
procedures 
 
[N=203] 
Perioperative myocardial damage (N=82) 
ABI >0.9 CCA-IMT <1.25 33/232 (11%) 23/115 20% 10/117 9% 
Low ABI CCA-IMT <1.25 20/75 (27%) 14/38 37% 6/37 16% 
ABI >0.9 increased CCA-IMT 14/59 (24%) 9/25 36% 5/34 15% 
Low ABI increased CCA-IMT 15/34 (44%) 11/20 55% 4/14 36% 
Long-term mortality (N=77)     
ABI >0.9 CCA-IMT <1.25 24/232 (12%) 12/115 10% 12/117 10% 
Low ABI CCA-IMT <1.25 22/75 (27%) 13/38 34% 9/37 24% 
ABI >0.9 increased CCA-IMT 16/59 (29%) 8/25 32% 8/34 24% 
Low ABI increased CCA-IMT 15/34 (44%) 9/20 45% 6/14 43% 
Ankle-brachial index (ABI), common carotid artery intimamedia thickness (CCA-IMT). 
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Multivariate analyses demonstrated that risk factors imbedded in conventional cardiac 
risk indices were predictive for perioperative myocardial damage, as presented in Table 3, Model 
1. When including ABI and CCA-IMT in the model (Table 3 Model 2 + 3 and Figure 1), the 
presence of asymptomatic low ABI + CCA-IMT <1.25 or ABI >0.9 + subclinical CCA-IMT 
>1.25 mm were both independently associated with an increased risk of perioperative 
myocardial damage with ORs of 2.6 (95%-CI: 1.4 to 6.2) and 2.1 (95%-CI: 1.3 to 7.4). 
However, the risk for developing myocardial damage was the highest in patients with 
asymptomatic low ABI + subclinical CCA-IMT >1.25 mm (HR 5.2, 95%-CI: 2.0 to 11.1).  
 
Table 3 
Multivariate association between ABI, CCA-IMT and perioperative 
events 
Model 1a Model 2b Model 3c 
 
HR [95%-CI] HR [95%-CI] HR [95%-CI] 
Cardiac risk factors 
 
 
 
    
Age (>70 years) 1.6 1.2-3.6 1.5 1.2-3.6 1.6 1.3-4.0 
Symptomatic heart failure 3.0 1.5-5.6 3.0 1.6-5.7 3.2 1.6-5.8 
Ischemic heart disease 2.4 1.2-4.4 2.5 1.1-4.4 2.6 1.2-4.6 
Renal dysfunction 1.5 1.1-6.5 1.5 1.3-7.2 1.6 1.3-7.5 
Diabetes mellitus d 1.2 1.3-4.9 1.2 1.4-4.1 1.3 1.4-4.2 
High-risk surgery 3.3 1.1-3.9 3.4 1.2-4.3 3.5 1.2-4.6 
      
ABI >0.9 CCA-IMT <1.25       
Low ABI CCA-IMT <1.25   2.6 1.3-5.5 2.6 1.4-6.2 
ABI >0.9 increased CCA-IMT   1.9 1.2-6.4 2.1 1.3-7.4 
Low ABI increased CCA-IMT   4.1 1.6-9.8 5.2 2.0-11.1 
a Model 1: Predictive value of risk factors imbedded in preoperative cardiac risk indices: multivariate 
analysis adjusted for: gender, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease, and 
current smoking  
b  Model 2: Predictive value of ABI <0.9 and/or CCA-IMT > 1.25: multivariate analyses adjusted 
for risk factors imbedded in preoperative cardiac risk indices + gender, hypercholesterolemia, hypertension, 
chronic obstructive pulmonary disease and current smoking 
c Model 3: Predictive value of ABI <0.9 and/or CCA-IMT > 1.25: multivariate analyses adjusted 
as in model 2 and for medication use (β-blockers, statins, aspirin, oral anticoagulants and RAAS inhibitors). 
 
Ankle-brachial index (ABI), common carotid artery intimamedia thickness (CCA-IMT), rennin-angiotensin-
aldosteron system (RAAS).  
 
 
Long-term mortality 
In total 77 patients (19%) died during follow-up (Table 2). In total, 42 (21%) of the 197 patients 
who had open surgery died, compared with 35 (17%) of the 203 patients who had 
endovascular surgery. As demonstrated in Table 2, the lowest incidence of long-term mortality 
(11%) was noted in patients with ABI >0.9 + CCA-IMT <1.25 mm. In addition, the highest 
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incidence of long-term mortality (44%) was noted in patients with asymptomatic low ABI + 
subclinical CCA-IMT >1.25 mm. 
 
Multivariate analyses demonstrated that risk factors imbedded in conventional cardiac 
risk indices were predictive for long-term mortality, as presented in Table 4, Model 1. When 
including ABI and CCA-IMT in the model (Table 4 Model 2 + 3 and Figure 1), the presence of 
asymptomatic low ABI + CCA-IMT <1.25 mm or ABI >0.9 + subclinical CCA-IMT >1.25 
mm were both independently associated with long-term mortality with HRs of 3.2 (95%-CI:  
1.6 to 6.7) and 3.9 (95%-CI: 1.8 to 8.8). However, the risk for long-term mortality was the 
highest in patients with asymptomatic low ABI + subclinical CCA-IMT >1.25 mm (HR 5.6, 
95%-CI: 2.5 to 12.5). 
 
 
Figure 1: Ankle-brachial index (ABI), common carotid artery intimamedia thickness 
(CCA-IMT) and postoperative outcome 
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DISCUSSION 
 
This study demonstrated that asymptomatic low ABI, subclinical CCA-IMT >1.25 mm, or a 
combination of asymptomatic low ABI + subclinical CCA-IMT >1.25 mm were all associated 
with an increased risk for perioperative myocardial damage and long-term mortality. However, 
a combination of asymptomatic low ABI + subclinical CCA-IMT >1.25 mm was associated 
with the highest risk for the study endpoints.  
 
Table 4 
Multivariate association between ABI, CCA-IMT and long-term 
mortality 
Model 1a Model 2b Model 3c 
 
HR [95%-CI] HR [95%-CI] HR [95%-CI] 
Cardiac risk factors 
 
 
 
    
Age (>70 years) 3.0 1.2-4.5 3.2 1.2-4.6 3.2 1.2-4.6 
Symptomatic heart failure 2.5 1.3-5.1 2.6 1.4-5.2 2.6 1.4-5.4 
Ischemic heart disease 1.9 1.1-5.3 2.1 1.2-5.4 2.0 1.2-5.4 
Renal dysfunction 2.1 1.2-6.9 2.0 1.4-7.4 2.1 1.4-7.9 
Diabetes mellitus d 1.3 1.3-4.1 1.4 1.3-4.5 1.4 1.4-4.9 
High-risk surgery 1.4 0.8-4.0 1.5 0.8-4.2 1.5 0.9-4.6 
      
ABI >0.9 CCA-IMT <1.25       
Low ABI CCA-IMT <1.25   2.9 1.4-5.9 3.2 1.6-6.7 
ABI >0.9 increased CCA-IMT   3.2 1.5-6.9 3.9 1.8-8.8 
Low ABI increased CCA-IMT   4.6 2.1-10.1 5.6 2.5-12.5 
a Model 1: Predictive value of risk factors imbedded in preoperative cardiac risk indices: multivariate 
analysis adjusted for: gender, hypercholesterolemia, hypertension, chronic obstructive pulmonary disease, and 
current smoking  
b  Model 2: Predictive value of ABI <0.9 and/or CCA-IMT > 1.25: multivariate analyses adjusted 
for risk factors imbedded in preoperative cardiac risk indices + gender, hypercholesterolemia, hypertension, 
chronic obstructive pulmonary disease and current smoking 
c Model 3: Predictive value of ABI <0.9 and/or CCA-IMT > 1.25: multivariate analyses adjusted 
as in model 2 and for medication use (β-blockers, statins, aspirin, oral anticoagulants and RAAS inhibitors). 
 
Ankle-brachial index (ABI), common carotid artery intimamedia thickness (CCA-IMT), rennin-angiotensin-
aldosteron system (RAAS).  
 
 
Adequate risk stratification of patients undergoing noncardiac surgery is of utmost 
importance to identify patients at risk for perioperative cardiac events. Over the years, several 
cardiac risk indices have been developed to identify those patients at risk, however, the Revised 
Cardiac Risk (RCR) index is nowadays widely used and considered to be the best available 
cardiac risk index for patients undergoing noncardiac surgery.15 Cardiac risk factors imbedded 
in the RCR index are (i) ischemic heart disease, (ii) symptomatic heart failure, (iii) 
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cerebrovascular disease, (iv) insulin dependent diabetes mellitus, (v) renal dysfunction, and (vi) 
high-risk surgery. Several noninvasive assessment techniques, such as measuring the ABI or 
CCA-IMT, have been evaluated to determine whether they increase the accuracy of 
preoperative risk assessment.  
 
The ABI is a noninvasive test to screen for patients with possible peripheral arterial 
disease. Low ABI (ABI <0.90) at rest has been associated with an increased risk of 
cardiovascular events and mortality, compared with a normal ABI.16-19 In addition, low ABI 
demonstrated to improve risk prediction for cardiovascular events and mortality in nonsurgical 
17, 20 and surgical 5 settings, even beyond the risk prediction properties of conventional cardiac 
risk scores such as the RCR index.15  
 
The CCA-IMT is a direct marker to quantify the atherosclerotic process in the carotid 
artery. Several studies in the nonsurgical population demonstrated that carotid IMT is 
associated with an increased risk of cardiovascular events and that measuring the CCA-IMT 
increases the power of traditional risk factors to predict cardiovascular events.21-24 Of note, an 
increased CCA-IMT demonstrated to predict adverse cardiac events in patients undergoing 
cardiac interventions 25-26 or vascular surgery 9 as well.  
 
In 1994, Bots et al. were the first to evaluate the association between an increased 
CCA-IMT and asymptomatic low ABI within the general population. The authors concluded 
that increased CCA-IMT reflects generalized atherosclerosis, as indicated by its association with 
asymptomatic low ABI.27 This finding has been confirmed in several studies 28-30 and in 2008 
Hayashi et al. stated that measurements of the ABI and CCA-IMT might provide good 
prognostic indicators for the prevalence of coronary heart disease. However, the prognostic 
value of low ABI, increased CCA-IMT or the combination of low ABI + increased CCA-IMT 
has not been evaluated in one cohort of patients undergoing vascular surgery.  
 
In the present study we found that low ABI and increased CCA-IMT >1.25 mm were 
both associated with 30-day cardiovascular events and long-term mortality. However, patients 
with a combination of low ABI + increased CCA-IMT >1.25 mm constituted the highest risk 
for the study endpoints. Interestingly, a history of ischemic heart disease, symptomatic heart 
failure, or renal dysfunction, documented during preoperative visits at the outpatients clinic, 
were equally present in patients with asymptomatic ABI <0.9 and/or subclinical CCA-IMT 
>1.25 mm. However, transthoratic echocardiography was performed in all patients before 
surgery and the prevalence of systolic left ventricular dysfunction was evaluated. Interestingly, 
the prevalence of asymptomatic systolic left ventricular dysfunction with a left ventricular 
ejection fraction <50% was increased in patients with a combination of asymptomatic low ABI 
+ subclinical CCA-IMT >1.25 mm compared with patients with solely a low ABI or an 
increased CCA-IMT >1.25 mm (p < 0.001). This notion could explain why patients with a 
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combination of low ABI + increased CCA-IMT >1.25 mm constituted the highest risk for the 
study endpoints.  
 
In the latest ‘European Society of Cardiology’perioperative guidelines, symptomatic 
heart failure symptoms are considered a well acknowledged risk factor for adverse cardiac 
outcome 31. In most recent ‘European Society of Cardiology guidelines for the diagnosing and 
treatment of acute and chronic heart failure’, it is stated that asymptomatic left ventricular 
dysfunction is associated with high mortality as well.32 In vascular surgery patients, this notion 
is supported by a study conducted by Flu et al, demonstrating that asymptomatic left 
ventricular dysfunction is associated with increased 30-day cardiovascular events and long-term 
cardiovascular mortality.33 Based on a cost-effectiveness consideration, however, routine 
preoperative echocardiography might not be applicable. The association of low ABI, increased 
CCA-IMT, and especially the combination these markers with asymptomatic systolic left 
ventricular dysfunction, could indicate that routine ABI and CCA-IMT measurements may 
play an important role to detect asymptomatic left ventricular dysfunction in patients 
undergoing abdominal aneurysm repair. Especially, in patients with a combination of low ABI 
+ increased CCA-IMT, the presence of left ventricular dysfunction should be excluded with 
cardiac echo. In addition, in patients with asymptomatic systolic left ventricular dysfunction 
with a left ventricular ejection fraction <50%, treatment with β-blockers and angiotensin 
blocking agents should be initiated as recommended.32 
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, although two experienced 
investigators performed off-line assessments of the obtained ultrasound images, we cannot rule 
out interobserver variability to have had minor influence on our results 34. Third, we did not 
validate the CCA-IMT cut off point in a prospective group of patients undergoing vascular 
surgery. Third, we included both open and endovascular surgical procedures. The number of 
endovascular procedures has increased the last three years, which has influenced the median 
follow-up period.  
 
In conclusion, asymptomatic low ABI and subclinical CCA-IMT >1.25 mm 
independently predict 30-day myocardial damage and long-term mortality in patients 
undergoing abdominal aortic aneurysm repair. Interestingly, a history of ischemic heart disease, 
symptomatic heart failure, or renal dysfunction was equally present in patients with 
asymptomatic low ABI and/or subclinical CCA-IMT >1.25 mm. However, a combination of 
asymptomatic low ABI + subclinical CCA-IMT >1.25 mm was associated with the highest risk 
for the study endpoints, possibly related to an increased incidence of asymptomatic systolic left 
ventricular dysfunction.   
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ABSTRACT 
 
Objective Metabolic syndrome (MetSyn) is a well-known risk factor for cardiovascular (CV) 
disease in the general population; however, the additional predictive value for CV events in 
high-risk patients with peripheral arterial disease (PAD) is unknown. The aims of the current 
study were to assess and compare: (i) prevalence of MetSyn, and (ii) predictive value of MetSyn 
for CV events, in patients with either occlusive or aneurysmatic PAD.  
 
Methods We screened 2069 patients scheduled for lower occlusive arterial revascularization 
(N=1,031) or abdominal aortic aneurysm repair (N=1,038) for the presence of MetSyn. Adult 
Treatment Panel III report (ATP III) was used for defining MetSyn. Central obesity was 
defined as body-mass-index >30 kg/m2. Main outcomes were the occurrence of CV events 
and CV mortality during a median follow-up of 6 years (IQR 2 to 9 yrs). 
 
Results Metabolic syndrome was diagnosed in 421 (41%) and 432 (42%) patients with 
occlusive and aneurysmatic PAD, respectively (p = 0.72). Patients with occlusive or 
aneurysmatic PAD and MetSyn had an increased risk for the development of CV events, when 
compared with patients without MetSyn (27 vs 18% and 27 vs 19%, p < 0.001, respectively). In 
occlusive and aneurysmatic PAD, MetSyn was independently associated with an increased risk 
of CV events (HR 1.6, 95%-CI: 1.2 to 2.1 and HR 1.4, 95%-CI: 1.1 to 1.8). No significant 
association between the presence of MetSyn and CV mortality was observed. 
 
Conclusions Metabolic syndrome is highly prevalent in high-risk PAD patients. In occlusive 
and aneurysmatic PAD patients, MetSyn is an independent predictor of long-term CV events. 
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INTRODUCTION 
 
The metabolic syndrome (MetSyn), also known as the insulin resistance syndrome or 
Syndrome X, is the concurrence of multiple metabolic abnormalities associated with 
cardiovascular (CV) disease. The prevalence of MetSyn in the general healthy population is 9-
22%, and increases up to 50% in patients with known cerebrocardiovascular disease.1-3 
Importantly, the prevalence depends on the definition of MetSyn.4  
 
In 1988, Raeven was the first who defined MetSyn, based on the fundamental 
pathogenic process of insulin resistance.5 In 1999, the World Health Organization (WHO) 
defined specific metabolic components and laboratory thresholds for the definition of MetSyn, 
primarily based on the presence of insulin resistance.6 The U.S. National Cholesterol 
Education Program (NCEP) redefined the MetSyn in 2003, in an attempt to simplify the 
clinical application of its criteria.7 Of note, the fundamental pathogenic mechanism was not 
longer insulin resistance, but the presence of abdominal obesity.8  
 
Metabolic syndrome was primarily developed as a predictor of CV disease in healthy 
populations, however, only recently studies have indeed demonstrated the association between 
MetSyn and increased risk of CV events.1, 9-11 Important to notice is that these studies had 
different definitions of MetSyn and varying study populations. In patients with known 
cerebrocardiovascular disease it has been demonstrated that MetSyn was associated with 
increased risk for CV events and CV mortality.9 However, the prevalence and predictive value 
of MetSyn in patients with occlusive peripheral arterial disease (PAD) or abdominal aortic 
aneurysms (AAA) has been examined only in low to intermediate risk patients or small groups 
of AAA patients.1, 12-15  
 
Therefore, the primary aim of the current study was to assess the prevalence of 
MetSyn in these two high-risk populations. In addition, as data about the predictive value of 
MetSyn in these high-risk patients is scarce,3, 11 the secondary aim of the current study was to 
assess the long-term predictive value of MetSyn in patients with either established occlusive or 
aneurysmatic PAD which has not been previously examined.  
 
 
METHODS 
 
Study design and population 
This retrospective study included a total of 2933 patients with PAD, scheduled for elective 
lower extremity revascularization (N=1,031), abdominal aortic aneurysm surgery (N=1,038) 
and carotid endarterectomy (N=864) during the time period 1990 to 2008. The focus of the 
current study was to examine the prevalence and predictive value of MetSyn in patients with 
occlusive lower extremity arterial disease (symptomatic PAD requiring surgical intervention) or 
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aneurysmatic PAD (N=2,069). Patients undergoing surgery for occlusive disease with a history 
of aneurysmatic PAD were regarded as occlusive disease (3%), while patients undergoing 
surgery for aneurysmatic PAD and a history of occlusive disease were regarded as aneurysmatic 
PAD (10%). Patient enrolment was performed after approval of the hospital’s ethics 
committee. 
 
Patient data 
At baseline all medical records were reviewed to determine the presence of documented 
ischemic heart disease and cerebrovascular disease. Ischemic heart disease was defined as a 
composite of previous angina pectoris, myocardial infarction, percutaneous coronary 
intervention or coronary artery bypass grafting. In addition, all (cardiac) risk factors were 
determined at baseline, including age, gender, body-mass-index (BMI), smoking status, chronic 
obstructive pulmonary disease (according to the Global Initiative on Obstructive Lung 
Diseaseas-classification)16 and chronic renal insufficiency (serum creatinine >2.0 mg/dL). 
During preoperative evaluation fasting glucose and lipid-profiles (total cholesterol, HDL, LDL, 
triglycerides) were measured. Finally, the use of the following medication was recorded: aspirin, 
statins, β-blockers, diuretics, angiotensin-converting enzyme (ACE) inhibitor, oral 
anticoagulants and ticlopidines. 
 
Metabolic syndrome 
The presence of MetSyn was defined according the National Cholesterol Education Program’s 
(NCEP) Adult Treatment Panel III report (ATP III), which identified the MetSyn as a 
multiplex risk factor for CV disease.17 According the ATP III report, diagnosis of MetSyn can 
be made when 3 out of 5 of the following characteristics are present: (i) abdominal obesity 
(waist circumference men >102 cm, women >88 cm), (ii) triglycerides ≥150 mg/dL (>1.695 
mmol/L), (iii) HDL cholesterol in men <40 mg/dL (<0.9 mmol/L) or in women <50 mg/dL 
(<1.0 mmol/L), (iv) systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 
mmHg, and (v) fasting glucose ≥110 mg/dL (>6.1 mmol/L). For the current study we defined 
abdominal obesity as BMI >30 kg/m2.18  
 
Follow-up and endpoints 
The median follow-up of all patients was 6 years (interquartile (IQR) range 2 to 9). Primary 
study endpoint was the occurrence of CV events, defined as a composite of myocardial 
infarction, percutaneous coronary intervention / coronary artery bypass grafting or 
cerebrovascular accident / transient ischemic attack. Follow-up data were recorded by 
reviewing the medical records. Secondary endpoint included CV mortality. Survival status was 
completed by reviewing the municipal civil registries. Cause of death was ascertained by 
examining the death certificates, and otherwise by reviewing the medical records. 
Cardiovascular death was defined as any death with a cerebro-cardiovascular complication as 
the primary or secondary cause and included death following myocardial infarction, serious 
cardiac arrhythmias (defined as the presence of a sustained cardiac rhythm disturbance that 
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required urgent medical intervention), congestive heart failure, stroke (cerebrovascular event or 
transient ischemic attack), surgery related bleeding complications (only a postoperative cause of 
death), and others. Sudden unexpected death was classified as a CV death as well. 
 
Statistics  
Continuous data were compared using analyses of variance, and are expressed as mean ± 
Standard Deviation (SD). Categorical data are presented as percentage frequencies and 
compared using a χ2 test. Cumulative estimated event rates of patients with or without MetSyn 
were determined by the Kaplan-Meier method and compared using the log-rank test. 
Univariate and multivariate Cox regression models were used to investigate the association 
between MetSyn (patients without MetSyn as reference group) and pre-specified endpoints. 
Multivariate analyses were adjusted for potential confounders (age, gender, smoking, heart 
failure, chronic renal insufficiency, and history of cerebrocardiovascular disease). We used 
interaction terms to study a possible interaction between these potential confounders and the 
primary endpoint for both groups of patients. Statistical analyses were performed using SPSS 
software (SPSS version 15.0; SPSS, Inc., Chicago, Illinois). Hazard ratios (HR) were calculated 
from these models along with their 95% confidence intervals (95%-CI.). A two-sided p-value 
<0.05 was considered statistically significant. 
 
 
Figure 1:  Distribution of the metabolic syndrome components among patients with occlusive or 
aneurysmatic peripheral arterial disease. 
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Table 1 Baseline characteristics of the study population 
 Metabolic Syndrome 
 
Group 1  
occlusive disease 
Group 2  
aneurysmatic disease 
MetSyn in group 1  
vs 
MetSyn in group 2  
yes  no yes no  
 
[N=421] [N=610] [N=432] [N=606] p-value 
Demographics (%) 
Age >70 years  142 (34) 254 (42) 207 (48) 355 (39) <0.001 
Male (%) 372 (65) 442 (73) 365 (85) 505 (83) <0.001 
Medical history (%) 
Ischemic heart disease 215 (51) 239 (39) 239 (55) 277 (46) 0.19 
CVA/TIA 80 (19) 64 (11) 81 (19) 71 (12) 0.90 
Metabolic syndrome components  
Abdominal obesity (%) 89 (21) 32 (5) 388 (68) 141 (30) 0.21 
Triglycerides ≥150mg/dL 394 (94) 123 (20) 433 (76) 50 (11) 0.05 
HDL Cholesterol      
 men <40 mg/dL 255 (94) 81 (18) 369 (75) 39 (10) 0.09 
 women <50 mg/dL 140 (94) 27 (16) 67 (81) 10 (12) 0.25 
Blood pressure ≥130/85  409 (94) 433 (71) 537 (94) 334 (72) 0.22 
Fasting glucose 6.1 mmol/L 112 (27) 55 (9) 324 (57) 131 (28) <0.001 
Additional risk factors (%) 
Smoking     0.08 
 no 120 (29) 260 (43) 148 (34) 249 (41)  
 current 185 (44) 233 (38) 158 (37) 220 (36)  
 history 116 (27) 117 (19) 126 (29) 137 (23)  
Renal insufficiency 69 (16) 51 (8) 60 (14) 67 (11) 0.29 
Chronic heart failure 54 (11) 37 (7) 36 (8) 45 (7) 0.10 
COPD 69 (16) 101 (17) 124 (29) 171 (28) <0.001 
Medication at discharge (%) 
Aspirin 223 (53) 192 (32) 215 (50) 219 (36) 0.31 
Statin 255 (61) 121 (20) 223 (52) 159 (26) 0.01 
β-blocking agents 237 (56) 167 (27) 260 (60) 261 (43) 0.25 
ACE-inhibitors 142 (34) 136 (22) 143 (33) 132 (22) 0.87 
Diuretics 138 (33) 124 (20) 131 (30) 129 (21) 0.46 
Oral anticoagulants 201 (48) 382 (63) 115 (27) 191 (32) <0.001 
Ticlopidines 30 (7) 15 (3) 14 (3) 19 (3) 0.01 
Angiotensin coverting enzyme (ACE), cerebrovascular accident/transient ischemic attack (CVA/TIA), chronic obstructive 
pulmonary disease (COPD), high density lipoprotein (HDL), metabolic syndrome (MetSyn), peripheral arterial disease 
(PAD). 
 
 
RESULTS 
 
Baseline characteristics of the total study population 
A total of 2,069 eligible patients, referred for lower extremity revascularization (N=1,031) or 
abdominal aortic aneurysm repair (N=1,038) comprised the study population (Table 1). 
Diagnosis of MetSyn was established in 421 (41%) and 432 (42%) patients with occlusive and 
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aneurysmatic PAD, respectively (p = 0.72). The distribution of the number of MetSyn 
components among occlusive and aneurysmatic PAD patients with or without MetSyn is 
shown in Figure 1. In addition, baseline characteristics of patients with occlusive and 
aneurysmatic PAD and MetSyn are shown in Table 1. 
 
 
Figure 2a: Kaplan-Meier estimated of cardiovascular event rates during long-term follow-up in patients 
with occlusive arterial disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolic syndrome (MetSyn), cardiovascular (CV). 
 
Occlusive peripheral arterial disease 
Patients with occlusive PAD and MetSyn were more likely to have a history of 
cerebrocardiovascular disease (ischemic heart disease/cerebrovascular disease), smoking habits 
(current or history), chronic renal insufficiency and chronic heart failure (p < 0.001), compared 
with patients without MetSyn. Lipid spectrum disorders and hypertension were the most often 
present components in patients with MetSyn. Medical treatment with aspirin, statins and β-
blockade was higher in patients with MetSyn (p < 0.001). In addition, patients with MetSyn 
were more often treated with antihypertensive drugs (p < 0.001). During a median follow-up of 
6 years (IQR 2 to 9), 228 (22%) occlusive disease patients developed CV events. Patients with 
MetSyn had an increased risk for the occurrence of CV events, compared with patients without 
MetSyn (27 vs 19%, p = 0.001). Kaplan-Meier estimates for long-term CV event rates showed 
that patients with MetSyn had higher event rates compared with patients without MetSyn 
(Figure 2a). Moreover, the presence of MetSyn proved to be an independent prognostic factor 
for long-term cardiovascular events (HR 1.61, 95%-CI: 1.2 to 2.1). For the occurrence of late 
cardiovascular events, diabetes mellitus, and BMI >30 kg/m2 were the independent prognostic 
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factors contributing to the MetSyn (Table 2). Furthermore, age (HR 1.02, 95%-CI: 1.0 to 1.1), 
ischemic heart disease (HR 2.16, 95%-CI: 1.6 to 2.9) and chronic renal insufficiency (HR 2.93, 
95%-CI: 2.1 to 4.2) were independent predictors for long-term cardiovascular events. No 
interaction between age, gender, smoking, heart failure, chronic renal insufficiency, and history 
of cerebrocardiovascular disease and the occurrence of cardiovascular events in patients with 
MetSyn was observed. The secondary endpoint CV mortality occurred in 337 (33%) patients. 
Regression analyses demonstrated no association between the presence of MetSyn and the 
occurrence of all-cause or CV mortality. 
 
Table 2 
Long-term cardiovascular events in occlusive of aneurysmatic 
peripheral arterial disease 
 HR [95%-CI] 
Occlusive peripheral arterial disease 
 Metabolic syndrome 1.61 1.23-2.11 
 Abdominal obesity 1.79 1.25-2.58 
 Triglycerides ≥150 mg/dL 1.10 0.80-1.52 
 HDL cholesterol 1.31 0.88-1.96 
 Blood pressure ≥130/85   1.15 0.77-1.71 
 Fasting glucose ≥6.1 mmol/L 2.07 1.49-2.86 
Aneurysmatic peripheral arterial disease 
 Metabolic syndrome 1.36 1.05-1.76 
 Abdominal obesity 0.95 0.57-1.60 
 Triglycerides ≥150 mg/dL 1.50 1.09-2.07 
 HDL cholesterol 0.98 0.71-1.35 
 Blood pressure ≥130/85   0.88 0.61-1.25 
 Fasting glucose ≥6.1 mmol/L 1.10 0.84-1.44 
 Long-term cardiovascular events in occlusive or aneurysmatic peripheral arterial disease. Confidence interval (CI), hazard 
ratio (HR), high density lipoprotein (HDL). 
 
Aneurysmatic peripheral arterial disease 
Aneurysmatic PAD patients with MetSyn were significantly younger and had more often a 
history of cerebrocardiovascular disease (p < 0.05). At discharge, patients with MetSyn were 
more often treated with aspirin, statins and β-blocking agents, compared with aneursymatic 
patients without MetSyn (p < 0.001). Hypertension was the most frequent component of 
MetSyn and medical treatment was in line with this finding as the majority of the MetSyn 
patients were treated with diuretics or ACE-inhibitors (p < 0.001). Cardiovascular events 
occurred in 153 (27%) aneurysmatic PAD patients with MetSyn, compared with 88 (19%) of 
the patients without MetSyn (p = 0.001). Estimates for long-term CV event rates according the 
Kaplan-Meier curves, demonstrated that patients with MetSyn had significantly higher event 
rates compared with patients without MetSyn (Log rank test, p = 0.006) (Figure 2b). Using 
multivariate analyses, the presence of MetSyn in patients with aneurysmatic PAD was an 
independent predictor for long-term CV events (HR 1.36, 95%-CI: 1.1 to 1.8). Of the 
components contributing to the MetSyn, only elevated triglycerides were significantly 
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associated with an increased risk of long-term CV events. In line with occlusive disease 
patients, age (HR 1.03, 95%-CI: 1.0 to 1.1), Ischemic heart disease (HR 1.45, 95%-CI: 1.1 to 
1.9) and chronic renal insufficiency (HR 3.60, 95%-CI: 2.6 to 4.9) were independent predictors 
for long-term cardiovascular events. Using interaction terms, no significant interaction for age, 
gender, smoking, heart failure, chronic renal insufficiency, and history of cerebrocardiovascular 
disease were demonstrated.  
 
 
Figure 2b: Kaplan-Meier estimated of cardiovascular event rates during long-term follow-up in patients 
with aneurysmatic peripheral arterial disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolic Syndrome (MetSyn), cardiovascular (CV). 
 
Of note, during long-term follow-up 324 (31%) patients died due to a CV cause. However, no 
association between the presence of MetSyn and CV mortality was observed in patients with 
aneurysmatic PAD. Additional analyses were performed to study the predictive usefulness of 
MetSyn in patients without diabetes. After excluding the patients with known DM (N=362, 
17%), and those with a fasting glucose >7.0 mmol/L (N=142), there was a remaining 
population of 1,564 patients (76%). Using multivariate Cox regression analysis, MetSyn 
remained to be an independent predictor of adverse cardiovascular events with a HR of 1.4 
(95%-CI: 1.09 to 1.81). Furthermore, we evaluated the predictive value of MetSyn using three 
(N=563, 27%), four (N=256, 12%) or five (N=34, 1,6%) criteria for the diagnosis of MetSyn. 
In multivariate analyses, MetSyn defined with the three, four and five criteria were all 
independently associated with a 1.3 (95%-CI: 1.1 to 1.6), 1.8 (95%-CI: 1.3 to 2.3) and 2.2-fold 
(95%-CI: 1.2 to 4.1) increased risk of CV events.  
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DISCUSSION 
 
To our knowledge, this is the first study demonstrating the predictive value of MetSyn on the 
occurrence of CV events in patients with symptomatic occlusive and aneurysmatic PAD. We 
found a high prevalence of MetSyn in both groups of patients. In addition, in both occlusive 
and aneurysmatic PAD patients, MetSyn was an independent predictor for the occurrence of 
CV events during long-term follow-up, compared with PAD patients without MetSyn. No 
association between the presence of MetSyn and the occurrence of CV mortality was observed. 
 
Metabolic syndrome has 2 potential pathophysiological processes, including (i) insulin 
resistance, and (ii) obesity and disorders of adipose tissue. In line with Raeven et al.5 who 
proposed the first definition of MetSyn, the WHO identified insulin resistance as the 
fundamental mechanism. Insulin resistance and hyperinsulinemia directly causes other 
metabolic risk factors, including an increased body fat content.6 The emphasis of insulin 
resistance as the basic pathophysiological mechanism is based on the presence of reduced 
insulin sensitivities throughout several degrees of obesity.10 In contrast, by the NCEP expert 
panel 7, 17 the rising prevalence of MetSyn was considered to be a direct consequence of the 
“obesity epidemic”, as obesity directly or indirectly contributes to hypertension, high serum 
cholesterol, low HDL cholesterol and hyperglycemia. Although there is no definite consensus 
about the leading pathophysiological mechanism of MetSyn, a combined process of increased 
obesity and insulin resistance with a strong interaction seems most appropriate mechanism.  
 
A direct consequence of the lack of consensus about the pathogenic mechanisms of 
MetSyn, are the differences in clinical criteria for the diagnosis recommended by at least 3 
organizations, including the ATP III 17, the WHO 6 and the American Association of Clinical 
Endocrinologists (AACE).19 Although their criteria are similar in several aspects, they reveal 
fundamental differences in positioning of the predominant causes of the syndrome. In the 
ATP III criteria, priority is given to abdominal obesity as a contributor of MetSyn, recognized 
by increased waist circumference.17 In contrast, the WHO regarded insulin resistance as a 
required component for diagnosis, while this was not explicitly required in the ATP III 
definition.6 Furthermore, abdominal obesity was defined as a BMI >30 kg/m2. The AACE 
criteria appear to be a hybrid of the ATP III and WHO criteria. In this set of criteria, 
abdominal obesity is a major criteria and is defined as BMI >30 kg/m2.19 These different 
abdominal obesity parameters could influence the prevalence of MetSyn and its predictive 
value for CV events. However, a meta-analysis by Gami et al. demonstrated that the 
heterogeneity between the predictive values of the WHO and ATP III criteria was not 
explained by the use of different obesity metrics. Currently, ATP III criteria are most 
commonly used as they provide a practical tool to identify patients at increased risk for CV 
disease.20 Furthermore, WHO and AACE criteria require additional oral glucose tolerance 
testing if impaired fasting glucose and diabetes are absent.  
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The prevalence of MetSyn is strongly related to the definition of MetSyn, but to the 
target population as well. The impact of MetSyn as a growing and pressing problem for the 
general population is reflected by the high prevalence of the condition in healthy subjects (9-
22%).1, 2 The current study showed a prevalence of 41 and 42% of MetSyn in patients with 
symptomatic occlusive and aneurysmatic PAD, respectively. Previous studies reported that the 
prevalence of MetSyn in PAD patients can be up to 58%, which is even higher than in patients 
with coronary heart disease (41%) or cerebrovascular disease (43%).3, 11 These findings have 
important clinical implications, considering that PAD is highly prevalent in the adult 
population and is associated with an increased risk of CV events.21, 22 The current study 
observed no difference in prevalence of MetSyn in patients with aneurysmatic compared with 
patients with occlusive PAD. These findings have not been examined by previous studies, 
however, the difference in prevalence might be a result of the small sample size of previous 
studies compared with the present study.3, 23 In addition, the use of different criteria for 
defining MetSyn could have influenced the observed prevalence. In the present study we used 
ATP III criteria as these provide a practical tool to identify patients at increased risk for CV 
events and have been acknowledge as a reliable prognostic indicator of adverse cardiac 
outcome.20 
 
In this study the presence of MetSyn in patients with established occlusive or 
aneurysmatic PAD was independently associated with an increased risk for the occurrence of 
CV events during long-term follow-up. Although patients undergoing vascular surgery are 
classified as being a high-risk population for perioperative and long-term adverse cardiac 
outcome, the present study demonstrated that diagnosing MetSyn has an additional value for 
long-term prognosis. Therefore, based on our results we support the clinical use of MetSyn as 
a prognostic factor for long-term cardiac outcome in both patients with occlusive and 
aneurysmatic PAD. Despite the high prevalence of MetSyn in patients with aneurysmatic PAD, 
the correlation between MetSyn and CV events seemed to be less strong compared with 
patients with occlusive disease. The most reasonable explanation for this low correlation could 
be the difference in risk factors and the pathophysiological processes. Occlusive arterial disease 
is a direct consequence of atherosclerotic wall damage, while aneurysmatic PAD is an 
inflammatory process of the arterial wall with subsequent weakening of the aortic wall as a 
result of connective tissue degradation.24 In the present study these differences were 
underlined by different risk factor patterns, especially lower age at presentation in patients with 
occlusive disease and high prevalence of COPD (a connective tissue disease as well) in patients 
with aneurysmatic PAD.  
 
Some studies have demonstrated no additional effect of MetSyn above its individual 
components for the prediction of cardiovascular events.20 In the present study of patients with 
occlusive PAD, obesity and elevated fasting glucose levels were independent predictors. In 
aneurysmatic PAD patients, only hypertriglyceridemia was an independent predictor of adverse 
outcome. MetSyn is a unique and uniform entity, requiring at least three out of five diagnostic 
 232 
components; therefore, it is reasonable that the combination of components (MetSyn) has an 
additional value in the current study. In addition, using only the significant individual 
components for predicting future cardiovascular events, the importance of the non-significant 
components would be under-estimated. To study the specific influence of diabetes as an 
individual component on the predictive value of MetSyn, we performed additional analyses in 
which we excluded patients with known DM and/or fasting glucose levels >7.0 mmol/L. 
Importantly, MetSyn remained to be an independent predictor of cardiovascular events during 
long-term follow-up. The kind, magnitude and number of the diagnostic components are likely 
to influence the prognostic information of MetSyn; therefore, future studies should be 
performed using MetSyn as a weighted-risk model in which each component has its own 
predictive value. Previous studies in patients with PAD have been performed and observed a 
predictive value of MetSyn for future vascular events.12-15 However, most of these studies 
included patients out of the general population 12, 13 (low-risk) or patients with symptomatic 
PAD (intermediate-risk).14, 15 Of note, one study included a small number of patients with 
AAA, but no association between the presence of MetSyn and future vascular events or all-
cause mortality was detected.15 In contrast, the current study included high-risk patients and a 
large cohort of AAA patients.  
 
No relation between the presence of MetSyn and CV mortality was observed in 
patients with either occlusive or aneurysmatic PAD. According to the WHO and ATP III 
definition, the primary clinical outcome of MetSyn as a multiplex risk factor is the 
development of CV disease in patients free of cardiac history.6, 17 A meta-analysis addressing 
MetSyn and CV risk showed an increased risk for the development of CV events (RR 2.18, 
95%-CI: 1.6 to 2.9) and CV death (RR 1.91, 95%-CI: 1.5 to 2.5).25 However, this meta-analysis 
included a diversity of study populations evaluating studies with and without previous histories 
of CV disease. In addition, definitions of MetSyn were different between the included studies. 
We performed additional analyses using a diagnosis of MetSyn based on three, four or even 
five diagnostic criteria for MetSyn to explore whether the risk estimates changed with the 
number of criteria. These analyses demonstrated that with an increased number of diagnostic 
criteria the risk of cardiovascular events increased as well, however; the accuracy of the risk 
estimates diminished. Importantly, the current study included high-risk PAD patients of which 
almost 50% had a history of CV disease. This could be a possible explanation for the absence 
of a relation between the presence of MetSyn and the risk of CV mortality as well. Patients 
with PAD are known to be at increased risk of CV mortality, and based on the present study 
the presence of MetSyn had no incremental risk for CV mortality in these patients. Therefore, 
the presence of MetSyn only has an additional value as a predictor for CV events in high-risk 
PAD patients. Finally, patients with MetSyn received more optimal medical treatment. 
Although this did not influence the risk of developing CV events, medical treatment could 
possibly be related to a stabilization of the risk for CV mortality.   
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Potential limitations of the current study merit consideration. First, we used the ATP 
III criteria for the definition of MetSyn; however, abdominal obesity was defined as BMI >30 
kg/m2 instead of increased waist circumference. Although this abdominal obesity parameter 
could have influenced the outcome parameters, the meta-analysis discussed above 
demonstrated that obesity metrics did not influence the predictive value of MetSyn.25 Second, 
for the current study we used ATP III criteria for defining MetSyn. As there are other 
definitions using different combinations of diagnostic criteria, this could have influenced the 
prognostic information in this study. Third, this study has the inherent limitations of a 
retrospective study design. Although the present study found no association between MetSyn 
and increased CV mortality risk, other studies did show this relation. This might be related to 
the associations between target population, cardiovascular disease history, and the prevalence 
of MetSyn. Finally, although medication at discharge was recorded, no data on medication 
during the follow-up period were available.  
 
 
CONCLUSION 
 
Patients with occlusive or aneurysmatic PAD have a high prevalence of metabolic syndrome. 
In both patients with occlusive or aneurysmatic PAD, the presence of metabolic syndrome was 
independently associated with an increased risk for the occurrence of CV events during long-
term follow-up. Concomitant presence of metabolic syndrome in patients with occlusive or 
aneurysmatic PAD was not associated with an increased long-term risk of CV mortality. 
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ABSTRACT 
 
Introduction N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts adverse 
cardiac outcome in patients undergoing vascular surgery. However, several conditions might 
influence this prognostic value, including anemia. In this study, we evaluated whether anemia 
confounds the prognostic value of NT-proBNP for predicting cardiac events in patients 
undergoing vascular surgery. 
 
Methods A detailed cardiac history, resting echocardiography, hemoglobin and NT-proBNP 
levels were obtained in 666 patients before vascular surgery. Anemia was defined as serum 
hemoglobin <13 g/dL for men and <12 g/dL for women. Troponin T measurements and 12-
lead electrocardiograms were performed on postoperative days 1, 3, 7 and 30 and whenever 
clinically indicated. The primary endpoint of the study was the composite of 30-day 
postoperative cardiovascular death, nonfatal myocardial infarction, and troponin T release. 
Receiver operating characteristic curve analysis was used to assess the optimal cut off value of 
NT-proBNP for the prediction of the composite endpoint. Multivariate regression analysis was 
used to assess the additional value of NT-proBNP for the prediction of postoperative cardiac 
events in nonanemic and anemic patients. 
 
Results Anemia was present in 206 patients (31%) before surgery. Hemoglobin level was 
inversely related with the NT-proBNP levels (β coefficient = -2.242, p = 0.025).  The optimal 
predictive cut off value of NT-proBNP for predicting the composite cardiovascular outcome 
was 350 pg/mL. After adjustment for clinical cardiac risk factors, both anemia (OR 1.53, 95%-
CI: 1.07 to 2.99) and elevated levels of NT-proBNP (OR 4.09, 95%-CI: 2.19 to 7.64) remained 
independent predictors for postoperative cardiac events. However, elevated levels of NT-
proBNP were not predictive for the risk of adverse cardiac events in the subgroup of anemic 
patients (OR 2.16, 95%-CI: 0.90 to 5.21). 
 
Conclusions Both anemia and NT-proBNP are independently associated with an increased 
risk for postoperative cardiac events in patients undergoing vascular surgery. NT-proBNP has 
less predictive value in anemic patients. 
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INTRODUCTION 
 
In patients with extensive comorbidities, scheduled for major vascular surgery, a simple 
screening biomarker associated with adverse cardiac events would be useful for identifying 
those patients who might benefit from additional cardiac diagnostic testing or therapeutic 
interventions. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is synthesized in the 
ventricular myocardium in response to ventricular wall stress, such as in heart failure and 
coronary artery disease.1, 2 It has been suggested that measurement of NT-proBNP levels 
might improve preoperative cardiac risk stratification for surgical patients.3-5 Anemia is 
independently related to both elevated NT-proBNP levels,6-8 and adverse cardiac outcome 
after vascular surgery.9 It is unknown whether the association between anemia and elevated 
NT-proBNP levels is attributable to subclinical ventricular dysfunction, coronary artery 
disease, or both. Nonetheless, anemia may be an important confounding variable that may 
affect the prognostic value of NT-proBNP levels for predicting cardiac risk for surgical 
patients. To further increase the diagnostic accuracy of NT-proBNP for preoperative 
screening, it is important to identify factors that influence NT-proBNP levels and their 
interaction with identifying risk for adverse events. The purpose of this study was to evaluate 
whether anemia influences the prognostic value of preoperative NT-proBNP levels for 
identifying patients undergoing vascular surgery at risk for adverse cardiac events.  
 
 
METHODS 
 
The study population consisted of 666 consecutive patients undergoing elective vascular 
surgery at the Erasmus Medical Center, Rotterdam, the Netherlands, during the period 
between June 2004 and April 2008. These patients were identified in a prospectively 
maintained database of all patients undergoing vascular surgery at this institution. The Medical 
Ethics Committee of the hospital was informed about the study, and all procedures of this 
retrospective study met with the approval of the Medical Ethics Committee of the Erasmus 
Medical Center.  
 
Study procedures 
Before surgery, a detailed cardiac history was obtained including the use of cardiovascular 
medication and the presence of cardiac risk factors. The latter included age, angina pectoris, 
prior myocardial infarction, history of heart failure or current congestive heart failure, prior 
stroke or transient ischemic attack, diabetes mellitus (fasting glucose level ≥7.0 mmol/L or 
medication to control diabetes), renal dysfunction (defined as an estimated glomerular filtration 
rate <60 mLmin-11.73 m-2 using the Modification of Diet in Renal Disease formula),10 
hypertension (arterial blood pressure ≥140/90 mmHg or medical therapy to control 
hypertension), and hypercholesterolemia (plasma cholesterol level ≥5.5 mmol/L or treatment 
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with lipid-lowering drugs). Other data collected included history of chronic obstructive 
pulmonary disease (defined as a forced expiratory volume in 1 second <70% of age and gender 
predictive value), site of surgery (abdominal aortic, peripheral, or carotid), and type of 
procedure (endovascular or open). Peripheral venous blood samples were obtained for 
measurement of hemoglobin and NT-proBNP levels in all patients during the preoperative 
outpatient clinic visit or at hospital admission. The NT-proBNP concentration was determined 
using an electrochemoluminescence assay on an Elecsys 2010 (Hoffman-La Roche, Basel, 
Switzerland). The method is a “sandwich”-type quantitative immunoassay based on polyclonal 
antibodies against epitopes in the N-terminal part of proBNP. The lower detection limit was 5 
pg/mL. Intraassay coefficients of variance at 271 and 6,436 pg/mL were 1.9 and 0.9%, 
respectively. Assays were performed by a laboratory technician blinded to the patients' clinical 
data. The preoperative hemoglobin value was defined as the last measurement obtained before 
surgery. Preoperative anemia was defined based on World Health Organization criteria as a 
serum hemoglobin level <12 g/dL for men and <12 g/dL for women.11 
 
Preoperatively, patients underwent a two-dimensional transthoracic 
echocardiographic examination at rest. Left ventricular (LV) ejection fraction (LVEF) was 
assessed in the apical, 4- or 2-chamber views. Quantification of the LV volumes was 
performed using the modified Simpson’s rule. The LVEF was calculated as (LV end systolic 
volume – LV end diastolic volume) x 100/ LV end diastolic volume. Impaired LV systolic 
function was considered when the LVEF was <40%. Congestive heart failure was defined as 
suggestive clinical signs and symptoms with pulmonary congestion on chest radiograph in the 
presence of impaired LV function.  
 
Twelve-lead electrocardiography (ECG) and serum cardiac troponin T measurements 
were performed immediately before surgery and on postoperative days 1, 3, 7, and 30 or at 
hospital discharge and whenever clinically indicated. ECG data were initially processed by a 
technician and analyzed by 2 experienced investigators who were blinded to patients’ clinical 
data. Troponin T level was measured using a whole blood rapid test (TropT version 2, Roche 
Diagnostics, Mannheim, Germany). The upper limit of normal for this assay is 0.03 ng/mL. 
 
Study endpoints 
The primary endpoint of this study was the composite outcome of death within 30 days of 
surgery because of cardiac events, nonfatal myocardial infarction, and increased serum cardiac 
troponin T levels, which was considered to be a non-Q wave myocardial infarction. 
Cardiovascular death was defined as any death with a cardiovascular cause, including those 
deaths after a cardiac procedure, cardiac arrest, myocardial infarction, pulmonary embolus, 
stroke, or sudden deaths not ascribed to other causes. A myocardial infarction was defined as 
the presence of two of the following three criteria: (i) characteristic ischemic symptoms lasting 
>20 min, (ii) ECG changes including acute ST elevation, followed by appearance of Q waves 
or loss of R waves, new left bundle-branch block, new persistent T wave inversion for at least 
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24 h, or new ST segment depression that persisted >24 h, or (iii) a positive value for troponin 
T, defined as >0.10 ng/mL.12 
 
Data analysis 
Continuous data with a normal distribution are expressed as means and were compared using 
Student’s t-test. Continuous data with a significant skewed distribution are expressed as 
medians and were compared using the Mann-Whitney U-statistic test. Data are presented as 
percentages unless otherwise indicated. The association between hemoglobin and NT-proBNP 
plasma levels and the composite cardiovascular outcome was assessed using multivariate linear 
regression analysis adjusted for age (per decade), angina pectoris, myocardial infarction, heart 
failure, stroke, diabetes mellitus, renal dysfunction, and site and type of surgery. Receiver 
operating characteristic curve analysis was used to assess the optimal cut off value of NT-
proBNP for the prediction of the composite endpoint. The optimal value of NT-proBNP for 
predicting the postoperative composite cardiac outcome was defined as the concentration with 
the largest sum of sensitivity plus specificity. Univariate and multivariate logistic regression 
analyses were used to evaluate the relationship among anemia, increased levels of NT-proBNP, 
and the study endpoint. Interaction between anemia and NT-proBNP was evaluated by forcing 
this interaction term in the multivariate regression model. Subgroup analyses for the prognostic 
value of elevated levels of NT-proBNP were conducted when there was a statistically 
significant interaction term. We report crude and adjusted odds ratios (ORs) and their 95% 
confidence interval (95%-CI). For all tests, a p-value < 0.05 (two-sided) was considered 
significant. All analyses were performed using SPSS version 15.0 statistical software (SPSS, 
Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
Of the 666 patients, 250 underwent abdominal aortic aneurysm repair, 218 underwent lower 
limb arterial reconstructions, and 198 underwent carotid artery surgery. Baseline characteristics 
of the patients are presented in Table 1. Endovascular procedures comprised 30% of the 
studied surgical procedures (40% abdominal aortic, 8% lower limb, and 43% carotid artery). 
The majority of patients were men (76.6%), and the mean age was 68.2 ± 10.5 yr. Anemia was 
present in 206 patients (31%). Univariate factors associated with anemia were diabetes mellitus 
(p = 0.001), a history of a myocardial infarction (p = 0.010), previous coronary intervention (p 
< 0.001), renal dysfunction (p < 0.001), and heart failure (p = 0.002). Notably, patients with a 
history of stroke were less likely to have anemia (p = 0.002). Except for diuretics (p = 0.018), 
no association was seen between medication use and the incidence of anemia. Importantly, 
median levels of NT-proBNP were significantly higher in anemic compared with nonanemic 
patients (624.8 pg/mL and 141.4 pg/mL, respectively; p < 0.001). Hemoglobin levels were 
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inversely related to NT-proBNP levels (β coefficient for log-NT-proBNP for each 0.1-point 
increase in hemoglobin level was –0.063; p < 0.001).  
 
a defined as a serum hemglobin level <13 g/dL for men and a level <12 g/dL for women  b mean (SD)  c median 
(interquartile range) 
 
Ninety-one patients (14.3%) experienced the composite endpoint of cardiovascular 
death, nonfatal myocardial infarction, or non-Q wave myocardial infarction. Of these patients, 
41 (6.2%) experienced ECG changes compatible with myocardial infarction. Thirteen patients 
(1.9%) had a cardiovascular death.  
Table 1 Baseline characteristics according to the presence or absence of anemia 
All patients No anemia a Anemia p-value 
 
 
 [N=666] [N=460] [N=206]  
Demographics     
Age b 68.2 (±10.5) 67.1 (±10.4) 70.6 (±10.4) <0.001 
Men (%) 76.6 75.7 78.6 0.429 
Body mass index (kg/m2) b 25.8 (±4.0) 26.0 (±3.9) 25.3 (±4.3) 0.037 
Medical history (%)     
Hypertension 50.6 52.6 46.1 0.131 
Diabetes mellitus 24.7 19.6 35.9 0.001 
Angina pectoris 23.5 22.7 25.2 0.489 
Myocardial infarction 29.5 26.4 36.4 0.010 
Coronary intervention 19.8 15.7 29.1 <0.001 
Renal dysfunction 11.0 5.2 23.8 <0.001 
Heart failure  6.4 4.2 11.2 0.002 
Cerebrovascular accident 38.9 42.9 30.1 0.002 
COPD   23.6 25.3 20.0 0.166 
Hypercholesterolemia 37.9 40.0 33.7 0.317 
Surgery (%)     
Site    0.221 
 carotid 29.7 34.8 18.0  
 abdominal aortic 37.6 38.3 36.1  
 lower extremity 32.7 25.7 45.4  
Type    0.122 
 endovascular  69.3 32.6 26.3  
 open  30.7 67.4 73.7  
Medication (%)     
  ACE inhibitors 32.4 31.7 34.0 0.589 
  Diuretics 27.2 24.4 33.5 0.018 
  Calcium-antagonists 22.4 21.6 24.1 0.480 
  Aspirin 67.4 68.2 65.5 0.529 
  β-blockers 84.7 83.9 86.7 0.412 
  Statins 76.4 78.0 72.9 0.165 
Laboratory     
  Hemoglobin (g/dL) c 13.7 (12.5-14.7) 14.4 (13.6-15.2) 11.5 (10.6-12.6) <0.001 
  NT-proBNP (pg/mL) c 209.8 (91.4-560.1) 141.3 (68.5-313.9) 624.8 (230.3-1487.5) <0.001 
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Anemia was more frequent in patients with the composite cardiovascular endpoint 
compared with those without postoperative cardiac events (51.6 and 27.8%, respectively; p < 
0.001). Moreover, baseline NT-proBNP levels in the patients with a postoperative cardiac 
event were significantly higher than in those without an event (763.1 pg/mL and 169.2 pg/mL, 
respectively; p < 0.001).  Using receiver operating characteristic curve analysis, the optimal 
value of NT-proBNP for predicting an adverse cardiac event was 350 pg/mL. The sensitivity 
and specificity of predicting this event for patients with a serum NT-proBNP level ≥350 
pg/mL were 71 and 72%, respectively (area under the curve: 0.78, 95%-CI: 0.72 to 0.83) (Figure 
1). In separate adjusted multivariate logistic regression models, the presence of preoperative 
anemia and elevated levels of NT-proBNP were both predictive of postoperative cardiac 
events with ORs of 1.53 (95%-CI: 1.07 to 2.99) and 4.09 (95%-CI: 2.19 to 7.64), respectively 
(Table 2). The sensitivity of anemia for detecting the postoperative outcome is 56.0% and 
specificity is 91.4%. Importantly, because the interaction term between anemia and NT-
proBNP was significant (p = 0.004) for the prediction of the study endpoint, we conducted a 
subgroup analysis for nonanemic and anemic patients. Figure 2 shows that, after adjustment for 
clinical cardiac risk factors, and site and type of surgery, an increased level of NT-proBNP has 
no predictive value of the composite outcome in anemic (OR 2.16, 95%-CI: 0.90 to 5.21) 
compared with nonanemic patients (OR 5.59, 95%-CI: 2.23 to 13.97).  
 
 
Table 2 Odds ratios for postoperative cardiac events 
 OR [95%-CI] p-value 
Anemia   
  Unadjusted model 2.78 (1.77 - 4.37) <0.001 
  Multivariate model a 1.53 (1.07 - 2.99)  0.038 
NT-proBNP ≥350 pg/mL   
  Unadjusted model 7.07 (4.28 - 11.68) <0.001 
  Multivariate model a 4.09 (2.19 - 7.64) <0.001 
a adjusted for age, angina pectoris, myocardial infarction, heart failure, stroke, diabetes mellitus, renal dysfunction, site of 
surgery, and  type of surgery. 
 
 
DISCUSSION 
 
In this study, an association was observed between increased preoperative NT-proBNP levels 
and the risk for postoperative cardiac events in patients undergoing vascular surgery. However, 
our results demonstrate that anemia is a confounding factor in this relationship. Although 
preoperative NT-proBNP levels were additive to clinical risk factors for identifying risk for 
postoperative cardiovascular events in patients without anemia, NT-proBNP had less 
predictive value in those with anemia.   
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Figure 1: Receiver operating characteristic curve of N-terminal pro-B-type natriuretic peptide levels to 
predict postoperative cardiac events. Sensitivity and 1-specificity are plotted for various levels. The ideal 
cut off value is indicated by the arrow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Screening value of N-terminal pro-B-type natriuretic peptide (≥350 pg/mL) for the prediction   
of postoperative cardiac events in nonanemic, and anemic patients. * Adjusted for age, angina pectoris, 
myocardial infarction, heart failure, stroke, diabetes mellitus, renal dysfunction, site of surgery, and type 
of surgery. 
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Postoperative cardiac events in patients undergoing vascular surgery are more 
common in patients with preoperative myocardial ischemia, LV dysfunction, and valve 
abnormalities compared with patients without these conditions.13, 14 Several studies have 
shown that serum NT-proBNP is an independent predictor of postoperative cardiac events.3-5 
Because NT–proBNP is synthesized in the ventricular myocardium in response to ventricular 
wall stress,1, 2 the most obvious explanation for this association is increased ventricular 
pressure in response to myocardial ischemia and/or systolic dysfunction in patients prone to 
adverse postoperative cardiac events. In addition, noncardiac factors, such as renal 
dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, and body mass 
index, might influence NT-proBNP levels.15, 16 In these patients with extensive comorbidities, 
an inexpensive, simple, and objective screening test can identify patients at increased risk. 
  
Previous studies have shown that the presence of preoperative anemia increases the 
risk of death or serious morbidity,17, 18 especially in patients with a history of cardiovascular 
disease.19 Recently, Dunkelgrun et al.9 studied the contribution of anemia to the risk of 
perioperative and long-term cardiac outcome in 1,211 patients undergoing elective noncardiac 
open vascular surgery. They found that the presence and severity of anemia are significant 
predictors of 30-day and 5-yr cardiac events, regardless of underlying heart failure or renal 
dysfunction. Our findings that also included patients undergoing endovascular procedures 
seem to confirm these findings.  
 
Anemia is common in patients with chronic heart failure and chronic renal 
insufficiency and is related to adverse outcomes in these populations.20, 21 The cause of anemia 
is largely uncertain and is likely to be multifactorial. Lower hemoglobin levels can be associated 
with hemodilution (pseudoanemia) in heart failure 20 or can be caused and/or worsened by 
various different mechanisms, such as malnutrition,22 iron or vitamin deficiencies,22 and bone 
marrow depression due to increased levels of proinflammatory cytokines.23 However, anemia 
may also enhance subclinical cardiac risk factors, such as mild coronary artery disease and LV 
dysfunction, because cardiac oxygen extraction ratio may be limited.24, 25 In addition, heart 
failure can cause renal dysfunction as a consequence of forward failure leading to a reduction 
of renal perfusion and subsequently anemia by a reduction of erythropoietin production.26, 27 
  
In our study population using World Health Organization criteria for anemia,11 more 
than 30% of patients were anemic before surgery. Because NT-proBNP is released in response 
to ventricular plasma overload,28 NT-proBNP levels are higher in anemic compared with 
nonanemic patients. The effect of anemia on the plasma concentration of NT-proBNP has 
been reported in patients with heart failure and established coronary artery disease.29, 30 
Nonetheless, hemoglobin seems to be inversely associated with NT-proBNP even after 
adjustment for these factors.31  In this study, we found that anemia in vascular surgery patients 
was an independent predictor of NT-proBNP when adjusted for known confounders. Using 
multivariate analyses, we adjusted for heart failure and renal dysfunction, both factors 
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frequently associated with fluid retention. Thus, one explanation for our findings of an 
independent association between anemia with NT-proBNP levels is that anemia may result in 
tissue  hypoxemia 32 or subclinical fluid retention resulting in hemodilution.33, 34 These results 
raise the possibility that anemia may be associated with increased ventricular pressure and 
myocardial strain even before evidence of clinical ventricular dysfunction can be detected. This 
might confound the screening value of NT-proBNP to predict postoperative cardiac events, as 
is shown in our results.  
 
The clinical implications of our findings are that patients scheduled for major vascular 
surgery could potentially be screened for adverse cardiac outcome with a relatively simple and 
objective test, NT-proBNP. However, especially in those patients that might benefit most, i.e., 
those with heart failure and renal disease in whom American College of Cardiology/American 
Heart Association guidelines recommend additional noninvasive testing,35 the prognostic value 
is reduced in the presence of anemia, whereas in nonanemic patients, the prognostic value is 
excellent.  
 
The potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, our analyses are based on single 
baseline determinations of NT-proBNP and hemoglobin levels. As such, we could not address 
the potential importance of hemoglobin change over time, especially in patients with heart 
failure and renal dysfunction. Furthermore, the effects of unmeasured confounding variables 
or complex interactions between covariates, such as perioperative in-stent thrombosis, on the 
observed association and endpoints cannot be excluded. Third, we did not have enough 
information on preoperative blood transfusion to justly incorporate this in our analysis. 
Previous studies have shown divergent views regarding pre- and postoperative blood 
transfusion in vascular surgery, cardiac surgery and patients with acute coronary syndromes.36-
39 Further research is needed to assess the effect of preoperative correction of anemia in 
vascular surgery patients for the reduction of postoperative cardiac events. Regardless of these 
limitations, our study suggests that anemia should be considered during the interpretation of 
preoperative NT-proBNP levels. Moreover, it confirms the previous reports regarding the 
influence of anemia on NT-proBNP levels. 
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ABSTRACT 
 
Aims Abdominal aortic aneurysms (AAA) are often diagnosed at time of (impending) rupture 
leading to a dramatic increase of morbidity and mortality. A simple screening device might be 
the key solution for widespread AAA screening. This study evaluated the diagnostic accuracy 
of a new portable ultrasound scanner (Aortascan BVI 9600) developed for automatic AAA 
detection. 
 
Methods A total of 150 patients with presumed aneurysmatic peripheral atherosclerotic 
disease were included in the study. Patients were first scanned with conventional ultrasound 
(US), serving as reference technique. An infra-renal abdominal aorta diameter of ≥30 mm was 
defined as an AAA. Hereafter, the aorta was scanned using the Aortascan BVI 9600. Statistical 
analyses were performed using SPSS version 15.0 statistical software. 
 
Results Abdominal aortic aneurysms were detected with conventional US in 78 (52%) 
patients, compared with 74 (49%) AAA’s detected with Aortascan BVI 9600. The Aortascan 
BVI 9600 demonstrated a sensitivity, specificity, positive and negative predictive value of 90, 
94, 95 and 89%, respectively, in the detection of AAA’s. 
 
Conclusions The Aortascan BVI 9600 automatically detects the aortic diameter with a 90% 
sensitivity without the need for a trained operator. Because of these unique capabilities, it can 
be used for AAA screening outside the hospital. 
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INTRODUCTION 
 
The prevalence of abdominal aortic aneurysm (AAA), in patients aged above 55 years, ranges 
from 4.1 to 14.2% in men and 0.35 to 6.2% in women.1 The incidence of AAA is known to 
increase, due to an increased life expectancy.2 Effective screening programs for detecting AAA 
are currently not available. Therefore AAA’s are often diagnosed at time of (impending) 
rupture3 which leads to a dramatic increase of morbidity and mortality. Abdominal ultrasound 
(US) and computerized tomography (CT) are the most frequently used noninvasive imaging 
tests to detect or exclude the presence of an AAA. These imaging techniques are expensive and 
require trained staff.  In case of CT, the patient is exposed to a fair amount of radiation. Hence 
these techniques are not ideal for screening purposes. A simple screening device, which is less 
expensive and offers the possibility for use outside the hospital, might be the key solution for 
widespread AAA screening. In 2006, a pilot study conducted by Vidakovic et al.4 demonstrated 
the diagnostic potential of an automatic bladder volume scanner (BVI 6400, Verathon Medical, 
Bothell, USA) to detect AAA. The current study evaluated the diagnostic accuracy of a new 
portable ultrasound scanner [Aortascan BVI 9600 (BVI 9600), Verathon Medical] developed 
for automatic AAA detection.  
 
 
MATERIAL AND METHODS 
 
Study population 
The study population consisted of 150 consecutive patients referred to the outpatient clinic of 
the Department of Vascular Surgery of the Erasmus Medical Center (Rotterdam, The 
Netherlands) for presumed aneurysmatic peripheral atherosclerotic disease. Patient enrolment 
was performed from January until December 2008, after approval of the hospital’s Ethics 
Committee. All patients gave informed consent at time of inclusion. Patients with abdominal 
aortic stents or a previous open aortic reconstruction were excluded from the study. 
 
Baseline characteristics 
A detailed history was obtained from every patient and the following characteristics were 
recorded; age, gender, body mass index, heart failure (defined as the presence of heart failure 
symptoms according the New York Heart Association classification or previous hospital 
admission for decompensated heart failure), ischemic heart disease (defined as history of angina 
pectoris, coronary revascularization or myocardial infarction), cerebrovascular disease (defined 
as a history of ischemic or hemorrhagic stroke), lower extremity arterial disease (defined as 
ankle brachial index <0.9), renal dysfunction (defined as creatinin clearance >2.0 mg/dL), 
diabetes mellitus (fasting blood glucose ≥7.0 mmol/L or requirement for insulin and/or anti-
diabetic medication), hypertension (blood pressure was measured during preoperative 
evaluation at the outpatient clinic and hypertension was defined as systolic blood pressure ≥140 
mmHg, diastolic blood pressure ≥90 mmHg in non-diabetics, systolic blood pressure ≥130 
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mmHg, diastolic blood pressure ≥80 mmHg in diabetics or the use of antihypertensive 
medication), hypercholesterolemia (low-density lipoprotein cholesterol >3.5 mmol/L and the 
requirement of lipid-lowering medication), chronic obstructive pulmonary disease (according to 
the Global Initiative on Obstructive Lung Diseases classification) and smoking status. 
 
Measurement of the abdominal aortic diameter 
All patients were first scanned with conventional US and measurements obtained with 
conventional US served as the reference value. An infra-renal abdominal aorta diameter (either 
anterior-posterior or transverse) of ≥30 mm was defined as an AAA.5 Hereafter, the aorta was 
scanned using the Aortascan BVI 9600. The examinations were performed and reviewed by 2 
physicians, both skilled and experienced in abdominal US. The interobserver variability 
between the two echocardiographists was up to 95% for the measured aortic diameter. 
 
Conventional abdominal ultrasound  
A handheld US device (SonoSite Titan, SonoSite Inc., Bothell, Washington) with a C11/8-
5MHz broadband slightly curved array transducer was used for US evaluation of the 
abdominal aorta. Both anterior-posterior and transverse diameters at the largest portion of the 
abdominal aorta were measured. The aortic diameters were obtained using on-screen callipers 
from the outer edge to edge of the aortic wall, including intraluminal thrombus if present. The 
maximal obtained diameter, measured in the xiphoid to umbilical traject, was used for analysis.  
 
 
 Figure 1: The Aortascan BVI 9600.  
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Figure 2: Screenplay Aortascan BVI 9600. 
 
 
 
 
 
 
 
 
 
 
 
 
The 3D dimensional scan is obtained as a set of 12 mechanically rotated two dimensional scans, 
15 degrees apart. Each planar scan is obtained by mechanically sweeping a single element 
transducer through a 120º arc. The transducer is used for transmission and reception of 
ultrasonic waves at 3.7 MHz. Echoes originating from a depth up to 20 cm were included for 
analysis. Dedicated detection software uses the data obtained from the 3D scan to create a 3D 
geometry of the abdominal aorta. From this 3D geometry, the maximum diameter is deduced 
and displayed as result for the user. The user is also provided with a B-mode image 
representing the cross-sectional scan plane. Electronic callipers are provided to manually 
redefine the maximum diameter when necessary. Each Aortascan BVI 9600 assessment 
consisted of four consecutive scans, located at the midline of the abdomen, starting ~2.5 cm 
below the xiphoid. Scanning locations are shown in Figure 3. Abdominal aortic diameter 
measurements <30 mm were displayed solely as being <3.0 cm. An estimated diameter in mm 
was provided by the Aortascan, when the abdominal aorta diameter was assumed to be >30 
mm. The maximal abdominal aorta diameter was used for the hypothesis on the presence of 
AAA. 
 
Statistics 
Dichotomous data are described as numbers and percentages. The continuous variables age and 
BMI are described as mean ± standard deviation (SD). Differences in baseline characteristics 
between patients with abdominal aorta diameter <30 or >30 mm, detected with conventional 
US, were evaluated using χ2 tests for categorical data. Continuous data were compared using 
one-way ANOVA. For all tests, a p-value less than 0.05 (two sided) was considered significant. 
All analyses were performed using SPSS version 15.0 statistical software (SPSS, Inc., Chicago, 
IL, USA). 
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Figure 3: Scanning locations of the Aortascan BVI 9600. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Correlation between conventional ultrasound and Aortascan BVI 9600 (abdominal aorta size 
<30 mm are not included because not measured with Aortascan BVI 9600). 
 
 
 
 
 
 
 
 
 
 
 
 
Ultrasound (US). 
 
 
 
RESULTS 
 
A total of 150 patients with presumed aneurysmatic peripheral atherosclerotic disease were 
included in the study. Abdominal aortic aneurysms were detected with conventional US in 78 
(52%) patients, compared with 74 (49%) presumed AAA’s detected with Aortascan BVI 9600. 
Mean abdominal aortic size was 39 mm, measured with conventional US. Patients with 
aneurysmatic disease were older (70 vs. 65 years), more likely to be male (89 vs 59%, p < 0.01) 
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and more often a BMI >25 compared with patients with normal abdominal aortic size. Other 
factors associated with an AAA were heart failure, renal dysfunction, and smoking. Baseline 
characteristics are shown in Table 1.  
 
 
Table 1 Baseline characteristics of the study population 
Conventional ultrasound 
No AAA AAA p-value  
[N=72] [N=78]  
Demographics 
 
   
  Age (± SD) 65 (10) 70 (10) 0.022 
  Male (%)    43 (59) 72 (89) <0.01 
  Body mass index (± SD) 25 (3) 27 (4) 0.008 
Medical history (%)    
  Clinical heart failure  4 (6) 16 (20) 0.009 
  Ischemic heart disease   20 (27) 33 (41) 0.082 
  Cerebrovascular disease 27 (37) 19 (24) <0.01 
  Lower extremity arterial disease 42 (58) 27 (33) 0.003 
  Renal dysfunction 4 (6) 18 (23) 0.003 
  Diabetes mellitus 20 (25) 13 (18) 0.300 
  Hypertension 44 (61) 53 (66) 0.510 
  Hypercholesterolemia  37 (51) 45 (56) 0.548 
  Chronic obstructive pulmonary disease 11 (15) 13 (16) 0.870 
  Smoking, current 28 (39) 20 (25) 0.066 
Abdominal aortic aneurysm (AAA), standard deviation (SD), ultrasound (US). 
 
 
In total, 70 (90%) AAA patients measured with conventional US were detected with 
the Aortascan BVI 9600 as well. Furthermore, 68 (95%) patients with normal abdominal aorta 
observed with conventional US had a normal abdominal aorta, measured with the Aortascan 
BVI 9600 as well. False-positive measurements, i.e. a presumed AAA detected with the 
Aortascan BVI 9600, which was not present with conventional US was observed in four 
patients (5%). False-negative measurements, i.e. an AAA detected with conventional US and 
missed with the Aortascan BVI 9600 was present in eight (10%) patients. We have found 
sensitivity, specificity, positive-predictive value and negative-predictive values of 90, 94, 95 and 
89%, respectively (Table 2). Furthermore, the correlation, in measured AAA diameter, between 
conventional US and the Aortascan BVI 9600 is demonstrated in Figure 4. 
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a
Aortascan BVI 9600. Abdominal aortic aneurysm (AAA). 
 
 
DISCUSSION 
 
The current study provides early results on the detection of AAA with the Aortascan BVI 
9600, compared with conventional US. The main finding of this study was that the Aortascan 
BVI 9600 detects abdominal aortic aneurysms with a sensitivity and specificity of 90 and 94%, 
respectively. In addition to this, the positive- and negative- predictive values were 95 and 89%, 
respectively.  
 
The development of aortic aneurysmatic disease is associated with alterations of 
connective tissue in the aortic wall, in which the process of atherosclerosis is regarded an 
important factor.6 The formation of an AAA is initiated when vascular endothelium is injured 
and AAA progression is influenced by factors such as (i) infection and complement activation, 
(ii) shear stress forces, and (iii) increased oxidative stress and cytokine release leading to 
endothelial activation and dysfunction.7, 8 The prevalence and incidence of AAA has been 
widely investigated and a population-based study including 6,386 patients showed a prevalence 
of AAA in 263 (8.9%) men and 74 (2.2%) women.9 Approximately 6% of men have an aortic 
diameter of more than 2.9 cm by the age of 65 years.10  A meta-analysis performed by Cornuz 
et al. in 2004 included around 110,000 patients screened for AAA and concomitant risk factors.  
 
The prevalence of AAA in Europe and America ranged from 4.1 to 14.2% in men 
and from 0.35 to 6.2% in women with all patients aged above 55 years.1 In patients with 
symptomatic atherosclerotic disease, the prevalence of aneurysmatic disease is much higher, as 
data of our own population showed prevalence up to 25%. Therefore, the use of a quick and 
efficient AAA screening tool in this high-risk population, could add significantly to complete 
the patients risk profile. Patients with ruptured AAA have a worse prognosis, as up to 55% of 
the patients that reach the hospital alive will still die in the first 30 postoperative days.11, 12 
Therefore, screening of patients at increased risk for developing AAA and subsequent elective 
surgical interventions may improve outcome. As noted by Hailey et al,13 the non-availability of 
an echo-system and/or operator at the point-of-care may lead to a delay in diagnosis and 
patient management. Although the first portable echo devices were developed in the 1970s,14, 
15 portable echo has become commercially available since 1996.16 In 2003, for instance, 
Table 2 Conventional ultrasound vs. aortascan BVI 9600 
 Aortascan BVI 9600 
Conventional ultrasound AAA yes AAA no p-value 
     
AAA yes 70  (95) 8  (10) <0.01 sensitivitya: 90 
AAA no 4  (5) 68  (90) <0.01 specificitya: 94 
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portable cardiac US (or echo-stethoscope) broadened the application of echocardiography to 
the patient’s bedside.17 The use of portable US for AAA detection was first described by 
Vidakovic et al,4 using the automatic BVI 6400 system. 
 
Ultrasonography provides the possibility to diagnose or rule-out AAA rapidly and 
accurately.18, 19 However, finding the correct cross-sectional scan plane with the maximum 
aortic diameter remains the most difficult part in AAA screening. Small errors in the angle of 
cross-section causes direct errors in the found diameter and may lead to wrong diagnosis. 
Therefore, only well-trained echocardiographists should perform conventional US for the 
detection of AAA. Hence Vidakovic et al.4 proposed to use the automatic BVI 6400 system for 
AAA screening because of (i) potential widespread availability, (ii) low costs (~10.000 €) 
compared with expensive conventional US equipment, and (iii) steep learning curve compared 
with more intensive training required for conventional US. They concluded that the BVI 6400 
is simpler for use, requires a less intensive training period and therefore can be used by a nurse 
or a technician. Furthermore, the BVI 6400 is roughly four times less expensive compared with 
conventional US. In the pilot study conducted by Vidakovic et al, volume measurements of the 
infrarenal abdominal aorta were performed with the BVI 6400 and compared with 
conventional US. On the basis of the technical characteristics of the BVI 6400, they estimated 
that a volume of 14 mL measured with the BVI 6400 corresponded with an abdominal aortic 
diameter of 30 mm, which is considered an AAA. Using the cut off value of >14 mL for the 
presence of AAA, they demonstrated a sensitivity of 94% and specificity of 82% of the BVI 
6400 in the detection of AAA. Furthermore, positive- and negative-predictive values for the 
BVI 6400 to detect AAAs were 88 and 92%, respectively. However, although these data look 
promising, the use of volume measurements, which have to be recalculated, remains 
questionable.  
 
In our study, the Aortascan BVI 9600 directly measured the maximum abdominal 
aortic diameter and therefore, we did not have to estimate a volume cut off value 
corresponding with the abdominal aortic diameter in mm. Consequently, results obtained from 
the Aortascan BVI 9600 can be directly compared with conventional US. With the use of these 
new types of measurements, we found a sensitivity of 90% and an increased specificity of 94% 
compared with the BVI 6400. Furthermore we found a negative-predictive value of 89% and 
an increased positive-predictive value of 95% compared with the BVI 6400. The Aortascan 
BVI 9600 provides a scan depth of 20 cm, which was sufficient for the patient population. 
Hence, no false negatives occurred due to a limited field of view. However, although the 
Aortascan BVI 9600 seems to detect AAA with a sufficient accuracy, the use of the system 
should not be extended as a replacement for conventional US. Patients with AAA detected by 
the Aortascan BVI 9600 should be referred to a radiologist to perform a conventional 
abdominal US. 
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Although we have used conventional US as the reference technique, we are aware that 
the sensitivity and specificity of conventional US is not 100%. This is mainly due to the 
difficulty of finding the right cross-sectional plane and location of the aorta, even for 
experienced operators. The 3D acquisition of the Aortascan BVI 9600 is likely to overcome 
the problems associated with two dimensional US. This was demonstrated in a patient with a 
curved aortic shape (including an AAA) not located at the midline of the abdomen. The 
measurement with conventional US initially produced a false-negative result, where the 
Aortascan BVI 9600 did detect an AAA. The presence of a true AAA was confirmed with a 
second conventional US measurement. This case underlines the need for future studies, 
evaluating the accuracy of the Aortascan BVI 9600, using angio-CT as the reference technique.  
 
 
In conclusion, the Aortascan BVI 9600 automatically detects and calculates the aortic 
diameter with a 90% sensitivity without the need for a trained operator. Because of these 
unique capabilities, it can be used for AAA screening outside the hospital and allows for AAA 
detection in patients who would not have been examined otherwise. However, final diagnosis 
and subsequent treatment requires additional medical examination. 
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ABSTRACT 
 
During major vascular surgery, patients are at high risk for developing myocardial infarction 
and myocardial ischemia, and two risk-reduction strategies can be considered before surgery: 
pharmacological treatment and prophylactic coronary revascularization. β-blockers are 
established therapeutic agents for patients with hypertension, heart failure and coronary artery 
disease. There is still considerable debate concerning the protective effect of β-blocker therapy 
towards perioperative coronary events, which will be outlined it this article. Two randomized 
controlled trials suggest that coronary revascularization of cardiac-stable patients provides no 
benefits in the postoperative outcome. In the current American College of 
Cardiology/American Heart Association guidelines for ‘Perioperative Cardiovascular 
Evaluation and Care for Noncardiac Surgery’, routine prophylactic coronary revascularization is 
not recommended in patients with stable coronary artery disease. However, a recent 
retrospective, observational study suggests that intermediate-risk patients may benefit from 
preoperative coronary revascularization. The present article provides an extended overview of 
leading observational studies, randomized, controlled trials, meta-analyses and guidelines 
assessing perioperative β-blocker therapy and prophylactic coronary revascularization.  
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INTRODUCTION 
 
Among the 30 million patients undergoing noncardiac surgery in the USA annually, cardiac 
complications are the leading cause of perioperative morbidity and mortality.1 A pooled 
analysis of several large studies found an incidence of 2.5% for perioperative cardiac events in 
patients over the age of 40 years (Range: 2.0 to 3.7%).2 These cardiac events were more 
common among vascular surgery patients, with an incidence of 6.2% (Range: 2.2 to 19.0%).3 
Symptoms of perioperative cardiac events are uncommon and it is suspected that 95% of the 
episodes are asymptomatic.1, 4-8 The high frequency of perioperative cardiac complications 
reflects the high prevalence of underlying coronary artery disease (CAD).9 According to the 
American College of Cardiology (ACC)/American Heart Association (AHA) guidelines on 
Perioperative Care, patients with active cardiac conditions need to be evaluated and treated 
before surgery.10 Two risk-reduction strategies can be performed to reduce the incidence of 
cardiac complications: pharmacological treatment and prophylactic coronary revascularization. 
The present article provides an extended and detailed overview of leading observational 
studies, randomized, controlled trials and guidelines assessing perioperative β-blocker therapy 
and prophylactic revascularization. The randomized trials are summarized, allowing the readers 
to place their strengths and weaknesses into perspective. Based on the current available 
literature and our own experience, treatment recommendations in patients scheduled for 
noncardiac surgery are also provided  
 
 
CURRENT CONCEPTS IN PERIOPERATIVE β-BLOCKER THERAPY 
 
β-blockers are established therapeutic agents for patients with hypertension,11 heart failure,12 
and CAD.13 In the nonsurgical setting, β-blockers are widely used for the prevention and 
treatment of ischemic heart disease and heart failure, which are major determinants of the 
occurrence of perioperative cardiovascular complications. Pharmacological risk reduction plays 
an important role in the reduction of perioperative cardiovascular complications, and multiple 
studies have been performed to assess the risk-reduction value of β-blockers. β-blockers are 
known to exert anti-arrhythmic, anti-inflammatory and anti-renin-angiotensin effects, as well as 
shifting energy metabolism.14-16 During surgery, high catecholamine production is responsible 
for vasoconstriction and hemodynamic stress, leading to an increased oxygen-demand1, which 
(in combination with perioperative tachycardia and increased myocardial contractility) can 
result in an oxygen supply–demand mismatch, causing myocardial infarction (MI) or 
ischemia.17, 18 β-blockers have been demonstrated to reduce heart rate and contractile force 
and, therefore, tend to reduce the myocardial oxygen-demand.  
 
Several observational studies have demonstrated the beneficial effects of 
perioperative β-blocker treatment in reducing perioperative cardiovascular complication. 
Wallace et al. showed that treatment with the long-acting β-blocker atenolol resulted in a 
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reduced incidence of postoperative ischemia by 30 to 50%.19 A retrospective study performed 
by Redelmeier et al. evaluated 37,151 elderly surgery patients treated with atenolol, using the 
database of the Canadian Institutes for Health Information. They demonstrated that atenolol 
treatment was associated with greater cardioprotective benefits perioperatively, compared with 
treatment with short-acting β-blockers, such as metoprolol tartrate.20 Lindenauer et al. 
conducted a retrospective cohort study of 782,969 patients, using the Premier’s Perspective 
database for ‘small-to-midsize nonteaching hospitals’ in the USA and concluded that 
preoperative β-blocker therapy was associated with a reduced risk of inhospital death in high-
risk (but not in low-risk) patients undergoing vascular surgery. However, patients with 
moderate risk for CAD did not derive any benefits from β-blocker treatment and may 
experience worse outcomes compared with controls.21 An observational study conducted by 
Feringa et al. showed that bisoprolol treatment was associated with a reduced incidence of 
perioperative myocardial ischemia, detected with Holter monitoring (hazard ratio [HR], 2.49, 
95% confidence interval [95%-CI]: 1.79 to 3.48), and troponin T release (HR 1.53, 95%-CI: 
1.16 to 2.03). They conclude that high-dose bisoprolol and concomitant tight heart-rate control 
may lead to reduced perioperative myocardial ischemia and troponin T release, thereby 
improving long-term outcome.22 Several randomized, controlled trials have demonstrated 
beneficial effects of perioperative β-blocker treatment on the postoperative outcomes of 
surgery patients, of which the most important trials will be discussed in the following sections.  
 
Mangano et al. 
In 1996, Mangano et al. randomized 200 patients with either known or suspected CAD who 
were undergoing high-risk noncardiac surgery to receive atenolol 50 or 100 mg, or placebo.23 
They hypothesized that intensive perioperative β-blockade and strict heart rate control may 
limit the development of ischemia. Treatment was initiated before the induction of anesthesia, 
administered immediately following surgery and continued once-daily throughout the patients’ 
hospital stay for up to 7 days after surgery (Table 1).23  In most patients, atenolol treatment was 
continued for up to 2 years following surgery. Although the study only demonstrated a 
perioperative effect towards ischemia (detected using Holter monitoring), atenolol use was 
associated with significantly lower mortality rates at 6 months after discharge (0 vs. 8%; p = 
0.005), and after 2 years (10 vs. 21%; p = 0.019).  
 
Raby et al. 
In 1999, Raby et al. were the first to demonstrate the beneficial effect of strict heart rate control 
immediately after surgery.24 They included 26 major vascular surgery (MVS) patients with 
preoperative ischemia detected by Holter monitoring. These patients were randomized to 
receive β-blockade with esmolol or placebo immediately following MVS (Table 1).24 This study 
demonstrated that a reduction of postoperative heart rate to 20% below the ischemic threshold 
markedly reduced postoperative ischemia.  
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DECREASE-I trial 
Poldermans et al. performed a randomized, controlled Dutch Echocardiographic Cardiac Risk 
Evaluation Applying Stress Echocardiography (DECREASE)-I trial to assess the effect of 
perioperative bisoprolol treatment on the incidence of death from cardiac causes and nonfatal 
MI within 30 days following MVS (Table 1).25 With the use of preoperative dobutamine stress-
echocardiography, 112 patients with evidence of myocardial ischemia were included in the 
study and defined as high-risk for cardiac events. A total of 59 patients were randomly assigned 
to receive bisoprolol, and 53 to receive standard care. Bisoprolol treatment was started an 
average of 37 days before MVS (Table 2), and careful titration was performed to prevent 
adverse side effects, such as hypotension and bradycardia. Compared with placebo, a reduction 
in the incidence of perioperative cardiovascular death and MI, from 34 to 3.4% (p < 0.001) was 
demonstrated in patients treated with bisoprolol.25  
 
POISE trial 
In 2008, the randomized, controlled Perioperative ischemic evaluation (POISE) trial was 
published and prompted discussion regarding β-blocker use in perioperative care. A total of 
8,351 patients were randomized to receive either metoprolol succinate or placebo (Table 1). 
Metoprolol succinate was administered at high dosages using the following treatment protocol: 
100 mg was given 2-4 h before surgery, another 100 mg within 6 h, and followed by another 
200 mg 12-18 h post-surgery if permitted by heart rate and blood pressure. Therefore, the 
maximum recommended daily dose of 400 mg was administered on the day of surgery and 
treatment was continued with 200 mg daily doses for 30 days post-surgery. The primary 
endpoint of cardiac death, MI or cardiac arrest was reduced in the metoprolol group, compared 
with placebo (5.8 vs. 6.9%, respectively; HR 0.83, 95%-CI: 0.70 to 0.99; p = 0.04). However, 
the 30% decrease in nonfatal MI (3.6 vs. 5.1%, p < 0.01) was accompanied by a 33% increase in 
total mortality (3.1 vs. 2.3%, p = 0.03) and a twofold increased risk in stroke (1.0 vs. 0.5%, p < 
0.01).26 Metoprolol succinate did lower the incidence of MI by more than a quarter (5.7% to 
4.2%); however, this benefit was outweighed by the previously mentioned increased incidence 
of stroke and death.26 Stroke was associated with perioperative bradycardia, hypotension, and 
bleeding complications. Post hoc analysis also showed that hypotension had the largest 
population-attributable risk for death and stroke. Importantly, hypotension can be related to 
the use of a high dose of metroprolol without dose titration.  
 
There is still considerable debate concerning the protective effect of β-blocker therapy 
towards perioperative coronary events, and several randomized, controlled trials have 
demonstrated negative results. We will discuss the most important trials to have questioned the 
use of perioperative β-blockade in the following sections.  
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a Previous MI, typical angina pectoris or atypical angina pectoris with a positive stress-test. b Age >65 years, hypertension, 
current smoking, hypercholesterolemia or DM. c Age >70 years, angina pectoris, previous MI (on basis of history, pathologic 
Q-waves on ECG), CHF (history or compensated), current treatment for ventricular arrhythmias, current treatment for 
DM, limited exercise capacity. d Undergoing intrathoracic or intraperitoneal surgery, history of CHF, transient ischemic 
attack, DM, serum creatinine >175 µmol/L, age >70 years or undergoing emergency or urgent surgery. Atrioventricular 
(AV), coronary artery disease (CAD), chronic heart failure (CHF), Dutch Echocardiographic Cardiac Risk Evaluation 
Applying Stress Echocardiography (DECREASE), diabetes mellitus (DM), left bundle branch block (LBBB), 
myocardial infarction (MI), major vascular surgery (MVS), peripheral arterial disease (PAD), Perioperative Ischemic 
Evaluation (POISE), wall motion index (WMI).  
Table 1 
Randomized, controlled trials demonstrating a beneficial effect of 
perioperative β-blockade towards cardiovascular complications 
TRIAL TRIAL PROTOCOL MAIN FINDINGS 
Mangano et al. 
 
1996 
 
[N=200] 
 
Inclusion criteria: 
• Noncardiac surgery  
• Presence of CAD a or ≥ 1 CAD risk factors b 
Treatment: Atenolol: treatment continued up to 7 days after 
surgery 
• 5-10 mg intravenously 30 min before and after surgery 
• 50-100 mg orally once a day, from day 1-7 following surgery 
Atenolol treatment can 
reduce mortality and the 
incidence of cardiovascular 
complications for as long as 
2 years after surgery 
Raby et al. 
 
1999 
 
[N=26] 
Inclusion criteria: 
• Vascular surgery 
Main exclusion criteria: 
• LBBB or left ventricular hypertrophy   
• ST-T changes precluding accurate Holter interpretation  
Treatment: Esmolol: initiation immediately after surgery 
• 100-300 µg/kg/min intravenously for 48 h 
Esmolol can reduce 
perioperative myocardial 
ischemia 
 
DECREASE-I 
 
1999 
 
[N=112] 
 
Inclusion criteria: 
• Vascular surgery  
• Patients with ≥1 cardiac risk factor c and ischemia during 
cardiac stress testing 
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• Extensive wall motion abnormalities (WMI > 1.7 at rest) 
• Strong evidence during stress testing of left main or severe 
three-vessel disease 
Treatment: Bisoprolol: initiation at least 1 week before surgery, 
treatment continued 30 days after surgery 
• 5-10 mg orally once-daily for 30 days 
Bisoprolol reduces the 
perioperative incidence of 
cardiovascular mortality and 
nonfatal MI 
 
POISE 
 
2008 
 
[N=8351] 
 
Inclusion criteria: 
• Noncardiac surgery 
• Expected hospital stay >24 h 
• Age >45 years 
• At least 1 of the following criteria: history CAD, PAD,   
stroke or hospitalization for CHF in previous 3 years, 
undergoing MVS or any 3 of 7 risk criteria d 
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• Bradycardia, 2nd or 3rd-degree AV block 
• Low-risk surgical procedure 
Treatment: Metoprolol: initiation 2-4 h before surgery, 
treatment continued for 30 days after surgery 
• 100 mg 2-4 hours before surgery,  
• 100 mg up to 6 h after surgery and 200 mg 12 hours later 
• 200 mg orally once-daily for 30 days 
Metoprolol prevents 
nonfatal MI but increases 
the risk of nonfatal stroke 
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POBBLE trial 
The randomized, placebo-controlled Perioperative β-Blockade (POBBLE) trial included low-
risk patients (history of ischemic heart disease was an exclusion criteria) scheduled for MVS.27 
In total, 103 patients were randomized to receive either metoprolol 25 or 50 mg, or placebo 
(Table 2). Treatment began 1 day before surgery and continued until 7 days postoperatively. 
Although the POBBLE trial was designed to evaluate the effect of perioperative β-blockade in 
low-risk patients, they found a remarkable number of perioperative events (i.e., MI, unstable 
angina pectoris, ventricular tachycardia or stroke) in more than 30% of all patients who were 
supposed to have a low prevalence of pre-existing heart disease. Furthermore, this trial did not 
show a difference in the incidence of perioperative cardiovascular events between the two 
small, randomized groups (placebo: 34%, metoprolol 32%; relative risk 0.87, 95%-CI: 0.48 to 
1.55). However, the duration of hospitalization was shorter for those patients receiving 
metoprolol vs. placebo (10 vs. 12 days). It should be mentioned that the POBBLE trial only 
included 103 patients over a period of nearly 3 years and was discontinued because of poor 
recruitment and lack of funding.  
 
MAVS trial 
The Metoprolol After Vascular Surgery (MAVS) trial randomized 496 patients to receive 
metoprolol or placebo. Medical treatment started 2 h before surgery and continued until 
hospital discharge or 5 days after surgery (Table 2).28 In the MAVS trial, there was no difference 
between the metoprolol- and placebo-treated groups for the occurrence of cardiovascular 
death, MI, heart failure, arrhythmias or stroke 30 days postoperatively (10 and 12% respectively; 
p = 0.057).  
 
DIPOM trial 
The randomized, controlled Diabetic Postoperative Mortality and Morbidity (DIPOM) trial 
also did not show a difference in 30-day morbidity and mortality between metoprolol- and 
placebo-treated groups (21 vs. 20%; p = 0.66). This trial included 921 diabetic patients, 
randomized to receive metoprolol 100 mg or placebo. Treatment was started the evening 
before major noncardiac surgery (Table 2). The DIPOM trial concluded that perioperative 
metoprolol did not significantly affect mortality and cardiac morbidity in patients with 
diabetes.29  
 
BBSA trial 
The double-blinded, placebo-controlled Swiss Beta Blocker in Spinal Anesthesia (BBSA) trial 
noted that bisoprolol therapy did not affect cardiovascular outcomes in elderly patients 
undergoing surgery with neuraxial blockade (Table 2).30 The lack of benefit of β-blocker 
treatment could be explained by the varying cardiac risk profiles of the patients included and 
the fact that it was an underpowered study. Interestingly, the authors suggest that 
pholymorphisms in β1-adrenergic receptor genotypes could be associated with different 
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responses to β-blocker therapy and may be of use to optimize therapy by maximizing efficacy 
and limiting toxicity.30   
 
a Age >65 years, hypertension, current smoking, hypercholesterolemia or diabetes mellitus. Angina pectoris (AP), 
American Society of Anaesthesiologists (ASA), atrioventricular (AV), β-blocker in Spinal Anaesthesia (BBSA), 
coronary artery disease (CAD), chronic heart failure (CHF), Diabetic Postoperative Mortality and Morbidity 
(DIPOM),left bundle branch block (LBBB), Metoprolol After Vascular Surgery (MAVS), myocardial infarction (MI), 
Perioperative β-blockade (POBBLE).  
 
 
Table 2 
Randomized, controlled trials demonstrating no beneficial effect of 
perioperative β-blockade towards cardiovascular complications 
TRIAL TRIAL PROTOCOL MAIN FINDINGS 
POBBLE 
 
2005 
 
[N=103] 
 
Inclusion criteria: 
• Vascular surgery patients  
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• MI, unstable AP or AP with a positive cardiac stress test 
Treatment: Metoprolol: initiation 1 day before surgery, 
treatment continued 7 days after surgery 
• 2-4 mg intravenously 5-10 min before intubation 
• 25-50 mg orally twice a day from day 1 to 7 
Metoprolol did not seem to 
reduce 30-day cardiovascular 
events. In patients receiving 
metoprolol treatment, time 
from surgery to discharge 
was decreased. 
MAVS 
 
2006 
 
[N=496] 
Inclusion criteria: 
• Vascular surgery patients 
• ASA < 3  
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• History of CHF or AV block 
Treatment:  Metoprolol: initiation day of surgery, treatment 
continued 5 days after surgery 
• 25-100 mg orally 2 h before and after surgery 
• 25-100 mg orally twice a day, from day 1 to 5 
Metoprolol was not 
effective in reducing the 30-
day and 6-month 
postoperative cardiac event 
rates 
 
DIPOM 
 
2006 
 
[N=921] 
 
Inclusion criteria: 
• Noncardiac surgery patient with diabetes mellitus  
• Age > 40 years 
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• CHF New York Heart Association Class IV 
Treatment:  Metoprolol: initiation 30 min before surgery, 
treatment continued up to 6 days after surgery 
• 50 mg orally evening before surgery 
• 100 mg orally 2 h before surgery 
• 100 mg orally once a day from day 1 to 6 
Metoprolol did not 
significantly affect mortality 
and cardiac morbidity  
 
BBSA 
 
2007 
 
[N=224] 
 
Inclusion criteria: 
• Surgery with spinal block, in-hospital stay > 24 h 
• Presence of CAD or  ≥2 CAD risk factors a  
Main exclusion criteria: 
• Current β-blocker use or history of intolerance 
• History of CHF,  
• High-degree heart block or LBBB 
Treatment:  Bisoprolol: initiation at least 3 h before surgery, 
treatment continued up to 10 days after surgery 
• 5-10 mg orally 3 h before and 6 h after surgery 
• 2-10 mg orally once a day from day 1 to 10 
Bisoprolol did not affect 
cardiovascular outcome 
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A meta-analysis performed by Bangalore et al. was published in the Lancet in 2008 and 
included 33 randomized trials, with a total of 12,306 patients, evaluating perioperative β-blocker 
therapy. They concluded that β-blocker treatment resulted in 16 fewer nonfatal MIs per 1000 
patients, but at the expense of three nonfatal, disabling strokes and possibly three fatal cardiac 
or noncardiac complications.31 Based on these results, the main conclusion was that evidence 
does not support the use perioperative β-blocker therapy in surgery patients. However, the 
authors acknowledged that results derived from the POISE trial had the greatest influence on 
their results.  
 
A comment from Boersma and Poldermans was published in the same edition of the 
Lancet, in which they concluded that the general mechanism underlying the excess cerebral 
complications is unknown and additional hemodynamic data are needed. They stated that these 
data will be crucial to future updates of treatment guidelines.32 
 
 
DISCUSSION: PERIOPERATIVE β-BLOCKADE 
 
There are different explanations regarding the conflicting evidence for perioperative β-blocker 
use. Important factors that may relate to the effectiveness of β-blocker therapy are the patients’ 
underlying cardiac risk and variations of treatment protocols in initiation time, β-blocker type, 
starting dose, dose adjustments for heart-rate control and duration of treatment.  
 
Patients’ cardiac risk profiles 
Boersma et al. have suggested that the absolute risk reduction associated with β-blocker 
treatment is most pronounced in patients who are at high risk for coronary events.33 The 
MAVS trial and DIPOM trial both included many patients at low risk for cardiovascular 
complications. In the MAVS trial, almost 60% of the patients had a Lee Risk index of only 
one. This is in contrast to the DECREASE-I trial, which randomized vascular surgery patients 
with a positive dobutamine echocardiography, so that only 112 patients from an initial 
population of 1,351 patients met the entrance criteria of inducible myocardial ischemia. The 
high incidence of perioperative cardiovascular events could be explained by the selection of 
high-risk cardiac patients, in which bisoprolol treatment was highly effective in reducing 
perioperative cardiovascular mortality and nonfatal MI. 
 
Treatment protocols 
The initiation time of β-blocker treatment may be related to the effectiveness of β-blocker 
therapy. In the DECREASE-I trial, the mean time between initiation of β-blocker treatment 
and surgery was 37 days and the largest effect of perioperative β-blocker treatment was 
demonstrated.25 By contrast, the POBBLE, MAVS, DIPOM and BBSA trials began treatment 
either 1 day before or on the day of surgery.  
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The type of β-blocker used may influence the effectiveness of β-blocker therapy. 
Negative inotropic and chonotropic effects derived from selective β1-blockade are thought to 
exert the most beneficial perioperative effects towards cardiovascular outcome. This may be 
the reason why treatment with the highly β1-selective β-blocker bisoprolol was associated with 
better results compared with metoprolol or atenolol, which are moderately β1-selective.    
 
Aside from the initiation time, the administrated dosage of β-blocker was also 
different among the randomized studies we assessed. In the POISE trial, metoprolol succinate 
could have been administered on the first day of surgery at a dose of up to 400 mg, which is 
100% of the maximum daily therapeutic dose. In the nonsurgical setting, much lower starting 
doses are recommended; for instance, in patients with New York Heart Association Class II 
heart failure, starting doses of 12.5 to 25 mg daily are administered for 2 weeks, and for 
hypertension, the initial dose is between 25 and 100 mg, and usually increased at weekly 
intervals. In the editorial to the publication of the POISE trial, Fleisher and Poldermans 
compared the POISE trial results with results from the DECREASE-I trial, in which patients 
undergoing MVS were treated with low-dose bisoprolol (between 5 and 10 mg once-daily).34 
The incidence of stroke in the DECREASE-I trials was 0,4%, which is comparable with 
placebo, while maintaining a significant reduction in cardiac death and nonfatal MI from 34% 
in the standard-care group to 3.4% in the bisoprolol-treated group in the first DECREASE-I 
trial.25, 34 The DECREASE-I trial has demonstrated that low-dose bisoprolol treatment is 
associated with overall benefits compared with risk.  
 
To maximize the benefit a patient will receive from β-blocker treatment, tight heart-
rate control is paramount, without over-treating the patient. Analyzing the safety and 
tolerability of β-blockers is as important as assessing the beneficial effects of β-blockers 
regarding efficacy. The most important side effects to be expected with β-blocker treatment 
are bradycardia and hypotension, which usually occur dose-dependently. The use of a fixed vs. 
an individualized dose titrated to the patients’ heart rate may also be of importance. As 
recommended by the guidelines for treatment of congestive heart failure and shown in β-
blocker studies for treatment of heart failure, such as the Cardiac Insufficiency Bisoprolol 
Study (CIBIS), β-blocker treatment should begin with a very low dose and then be uptitrated 
to the maximum tolerated dose.12, 35 Titration according to tolerance is of utmost importance 
to obtain tight heart-rate control and prevent adverse side effects such as hypotension. The 
value of adequate heart-rate control in improving cardiovascular outcome is not only 
confirmed in a recent large meta-analysis,36 the latest 2007 ACC/AHA guidelines on 
perioperative care also strongly recommend achieving a heart rate of 65-70 beats per minute.10  
 
A factor that could also influence the effect of β-blockers in surgical patients is the 
duration of β-blocker treatment. Withdrawal of β-blocker therapy shortly before surgery or in 
the immediate postoperative period may contribute to adverse myocardial effects resulting 
from a ‘rebound’ effect, thereby inducing increased arterial blood pressures, heart rates and 
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plasma noradrenalin concentrations.37 Discontinuation of β-blocker therapy immediately after 
MVS could increase the risk of postoperative cardiovascular mortality,38 and early withdrawal 
of β-blockers after surgery is associated with a higher 1-year mortality compared with 
continuous β-blocker therapy, which highlights the importance of continuing β-blocker 
therapy in the perioperative period.39 Recently, it has been suggested that the long-term 
beneficial effects of β-blocker therapy may be explained by a decrease in the progress of 
coronary atherosclerosis.40 In contrast to the instant effect on heart-rate control, the effect of 
β-blockers on plaque stabilization may, therefore, only be achieved after prolonged treatment. 
As demonstrated by Mangano et al, treatment with atenolol during hospitalization can reduce 
mortality and the incidence of cardiovascular complications for as long as 2 years following 
noncardiac surgery.23 In most patients, atenolol treatment was indeed continued up to 2 years 
after surgery.  
 
Guidelines 
Current recommendations concerning perioperative β-blocker use, as provided in the 
ACC/AHA 2006 Guideline Update on ‘Perioperative Cardiovascular Evaluation for 
Noncardiac Surgery: Focused Update on Perioperative β-blocker Therapy’, are illustrated in 
Table 3.41 Although these guidelines advocate perioperative β-blocker use, data from 
observational studies and registries observe a poor compliance with guidelines in 
pharmacological treatment. Several studies have demonstrated that there is still an underuse of 
β-blockers in patients undergoing MVS, even when patients are considered to be at high risk 
for cardiovascular events and despite a worldwide increase in β-blocker prescription.39, 42   
 
 
CURRENT CONCEPTS IN PROPHYLACTIC REVASCULARIZATION 
 
In patients undergoing MVS surgery, there is a high prevalence of significant CAD. A 
classification of 1000 coronary angiograms in peripheral arterial disease patients, performed by 
Hertzer et al, demonstrated a prevalence of 18% for patients with severe three-vessel disease 
and 4% for patients with left main disease. In patients undergoing MVS, preoperative cardiac-
risk evaluation by means of risk-factor assessment and noninvasive testing may often identify 
patients at increased cardiac risk. These patients may either have documented symptomatic 
involvement or be fully asymptomatic. Therefore, in patients requiring MVS within weeks or a 
few months, the need for diagnostic evaluation and subsequent revascularization will have to be 
questioned. When the presence of CAD is confirmed by angiography or cardiac computed 
tomography, coronary revascularization via percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG) can be considered as prophylactic therapy before 
noncardiac surgery in these patients.9 However, the cumulative risk of prophylactic coronary 
revascularization and MVS needs to be weighed up against the risk of the surgical procedure 
performed without preoperative interventions. Several observational studies have evaluated the 
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a Clinical predictors of increased perioperative risk: major - unstable coronary syndromes, decompensated heart failure, 
significant arrhythmias and severe valvular disease; Intermediate - mild angina pectoris, previous myocardial infarction, 
compensated or prior heart failure, diabetes mellitus and renal dysfunction; minor - advanced age, abnormal ECG, rhythm 
other than sinus, low functional capacity, history of stroke, and uncontrolled systemic hypertension.41 
 
value of prophylactic revascularization to prevent adverse cardiovascular events after 
noncardiac surgery.43-48 In 1997, Eagle et al. evaluated 24,959 participants with suspected CAD 
in the Coronary Artery Surgery Study (CASS) database. They demonstrated that, among the 
1,961 patients undergoing higher-risk surgery, prior CABG was associated with fewer 
postoperative deaths compared with medically managed coronary disease.48 The value of PCI 
before MVS was retrospectively evaluated by Gottlieb et al, who found a low rate of 
perioperative cardiovascular events.45 Fleisher et al. retrospectively included 6,895 patients, a 
random sample of the Medicare population, and demonstrated a reduced long-term mortality 
among patients who had previously undergone revascularization (i.e., PCI or CABG) and 
underlined the need for a randomized trial to determine the value of preoperative 
revascularization.46 Back et al. concluded that previous coronary revascularization, defined as 
CABG fewer than 5 years or PCI fewer than 2 years before surgery, may only have a modest 
beneficial effect in preventing adverse cardiovascular events, and stated that further evaluation 
by randomized trial was needed.47 Two prospective, randomized trials have provided new 
insights concerning preoperative interventions; the Coronary Artery Revascularization 
Prophylaxis (CARP) trial and the DECREASE-V trial.  
Table 3 
American College of Cardiology/American Heart Association 
recommendations, focussed on perioperative β-blocker therapy 
Class I 
• β-blockers should be continued in patients undergoing surgery who are receiving β-blockers to treat angina, 
symptomatic arrhythmias, heart failure, hypertension or other Class I guideline indications (Level of Evidence: C) 
•  β-blockers should be given to patients undergoing vascular surgery at high cardiac risk owing to the finding of 
ischemia on preoperative testing (Level of Evidence: B). 
Class IIa 
•  β-blockers are probable recommended for patients in whom preoperative assessment identifies coronary artery 
disease or high cardiac risk, as defined by the presence of multiple clinical risk factors a (Level of Evidence: B). 
•  β-blockers are probable recommended for patients in whom preoperative assessment for vascular surgery 
identifies high cardiac risk as defined by the presence of multiple clinical risk factors a (Level of Evidence: B). 
•   β-blockers are probable recommended for patients in whom preoperative assessment identifies coronary artery 
disease or high cardiac risk as defined by the presence of multiple clinical risk factors a and who are undergoing 
intermediate- or high-risk procedures (Level of Evidence: B). 
Class IIb 
•  β-blockers may be considered for patients who are undergoing intermediate- of high-risk procedures, including 
vascular surgery, in whom preoperative assessment identifies intermediate cardiac risk as defined by the presence 
of a single clinical risk factor a (Level of Evidence: C). 
•  β-blockers may be considered for patients undergoing vascular surgery with low cardiac risk who are not 
currently taking β-blockers (Level of Evidence: C). 
Class III 
•  β-blockers should not be given to patients undergoing surgery who have absolute contraindications to β-
blockade (Level of Evidence: C). 
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CARP trial 
The CARP trial, conducted by McFalls et al, screened 5,859 patients at 18 Veterans Affairs US 
hospitals and was the first prospectively, randomized study to investigate the benefit of 
coronary revascularization before elective MVS.49 In total, 510 patients with significant 
coronary artery stenosis were randomized to either revascularization or no revascularization 
before MVS (Table 4). The main finding of the CARP trial was that there was no difference in 
the primary outcome of long-term mortality (median follow-up 2.7 years) in patients who 
underwent preoperative coronary revascularization compared with patients who received 
optimized medical therapy (22 vs. 23%, relative risk 0.98, 95%-CI: 0.70 to 1.37). No reduction 
in the number of MIs, deaths or length of hospital stay was observed within 30 days. Although 
the study was not powered to test the short-term benefit of prophylactic revascularization, 
results point to the suggestion that prophylactic revascularization may not provide additional 
benefits in reducing the incidence of perioperative and long-term cardiac morbidity and 
mortality in cardiac-stable MVS patients. As the majority of patients in the CARP trial had only 
one or two-vessel disease with a preserved left ventricular function, the optimal preoperative 
management for patients with left main disease, severe left ventricular dysfunction, unstable 
angina pectoris and aortic stenosis was not determined yet. As already noted, the CARP trial 
included 5,859 patients from which 1,048 patients underwent coronary angiography before 
vascular surgery. These patients were used by the CARP investigators in a sub-analysis to 
determine the impact of prophylactic coronary revascularization on long-term survival in 
patients with multi-vessel CAD.50 They have demonstrated that 382 (36.5%) of the 1,048 
patients presented with multi-vessel CAD without previous CABG. No long-term survival 
benefit was observed in patients with two- and three-vessel disease. However, in a cohort of 48 
patients (4.6%) with left main coronary artery stenosis, preoperative revascularization did seem 
to have an improved 2.5-year survival (84 vs. 52%, p < 0.01). A secondary analysis of the CARP 
trial that solely evaluated patients with significant CAD and either critical limb ischemia or 
intermittent claudication indicated that mortality and morbidity were not improved by coronary 
artery revascularization before vascular surgery.51  Another subgroup analysis of the CARP trial, 
performed by Ward et al, demonstrated that rates of perioperative and long-term MIs were 
lower in patients who had undergone CABG before vascular surgery, compared with patients 
with preoperative PCI. In the CABG group, the length of hospital stay was also decreased, and 
the authors concluded that this observation may be related to more complete revascularization 
in the CABG group.52 
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a Age > 65 years, hypertension, current smoking, hypercholesterolemia, or diabetes mellitus. Coronary artery disease 
(CAD), coronary angiography (CAG), Coronary Artery Revascularization Prophylaxis (CARP), Dutch 
Echocardiographic Cardiac Risk Index (DECREASE), left ventricular ejection fraction (LVEF). 
 
DECREASE-V trial 
In the prospectively randomized DECREASE-V trial, comparable results to the CARP trial 
were obtained; however, this trial mainly included patients with three-vessel disease.53 Cardiac-
stable, elective MVS patients were screened for the following risk factors: age of more than 70 
years, history of MI, presence of angina pectoris, congestive heart failure, diabetes mellitus or 
renal dysfunction, and history of cerebrovascular events (Table 4). In total, 430 patients with 
three or more clinical risk factors underwent cardiac-stress testing, from which 101 (23%) 
patients showed extensive stress-induced ischemia. The patients with extensive stress-induced 
ischemia were randomly assigned to receive either no-revascularization (N=52) or 
revascularization (N=49). Of the 49 patients assigned for revascularization, 12 (24%) had two-
vessel disease, 33 (67%) had three-vessel disease and four (8%) had left main disease. Although 
the study population in the DECREASE-V trial reflects MVS patients at highest cardiac risk, 
revascularization did not improve cardiovascular outcomes. The incidence of the composite 
endpoint of 30-day cardiovascular mortality and MI was 43 vs. 33% (OR 1.4, 95%-CI: 0.7 to 
2.8). Furthermore, no benefit was observed during 1-year follow-up after coronary 
revascularization, 49 vs. 44% (OR 1.2, 95%-CI: 0.7 to 2.3; p = 0.48).  Comparable with the 
DECREASE-I trial, a high incidence of perioperative cardiovascular events was observed.25 
This could be explained by the selection of high-risk cardiac patients with extensive ischemia 
during cardiac stress testing. 
 
In 2007, Landesberg et al. included 502 patients in a retrospective observational study, 
in which thallium scanning was performed before MVS. They demonstrated improved long-
term survival in patients with moderate-to-severe ischemia who were undergoing preoperative 
revascularization.54 Furthermore, Landesberg et al. constructed a long-term survival score 
Table 4 
Randomized, controlled trials evaluating the use of prophylactic 
revascularization before vascular surgery 
TRIAL TRIAL PROTOCOL MAIN FINDINGS 
CARP 
 
2004 
 
[N=510] 
 
Inclusion criteria: 
• Elective vascular surgery patients 
• CAG: stenosis of at least 70% in one or more major coronary 
arteries suitable for revascularization 
Main exclusion criteria: 
• Prior revascularization without evidence of recurrent ischemia 
• CAG: stenosis of left main coronary artery of at least 50% 
• LVEF <20% or severe aortic stenosis  
In patients with stable 
CAD, coronary-artery 
revascularization does not 
improve long-term survival 
 
DECREASE-V 
 
101 
 
[N=101] 
Inclusion criteria: 
• Elective vascular surgery patients 
• > three cardiac risk factors a 
• Extensive stress-induced ischemia during cardiac stress testing 
Main exclusion criteria: 
• Emergency surgery patients 
Preoperative coronary 
revascularization was not 
associated with an 
improved outcome 
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(LTSS) for the prediction of cardiac risk in patients undergoing MVS. On the basis of the 
following risk factors, MVS patients were stratified to be at low, intermediate or high cardiac 
risk: age of more than 65 years, presence of diabetes mellitus or congestive heart failure, history 
of MI, chronic renal dysfunction, cerebrovascular disease and ST-segment depression on ECG. 
Intermediate-risk patients (two or three LTSS risk factors) were most likely to benefit from 
preoperative coronary revascularization (3-year mortality: OR 0.45, 95%-CI: 0.21 to 0.97, and 
long-term mortality: HR 0.48, 95%-CI: 0.31 to 0.75; p = 0.001). Patients with a low-risk LTSS 
score (0 or 1) had good long-term survival that was not affected by revascularization. High-risk 
patients (LTSS >4) had poor long-term survival, which was also unaffected by 
revascularization.55, 56 
 
 
DISCUSSION: PROPHYLACTIC REVASCULARIZATION  
 
The main difference between the CARP trial and the retrospective study conducted by 
Landesberg et al, was the criteria for patients inclusion. In the CARP trial, patients with left 
main disease were excluded and 33% of the enrolled patients had three-vessel disease. By 
comparison, in the study conducted by Landesberg et al, 73% of the enrolled patients had left 
main or three-vessel disease.54 In the DECREASE-V trial, preoperative dobutamine stress 
echocardiography, stress nuclear imaging and cardiac-risk scores were used to identify cardiac 
high-risk patients. Therefore, the DECREASE-V trial mainly included patients with three-
vessel disease, the group most likely to benefit from prophylactic revascularization. The 
majority of patients in the CARP trial had one- or two-vessel disease.53 In an editorial paper by 
Garcia and McFalls, it was reported that patients with major risk factors (i.e., unstable coronary 
syndromes, decompensated congestive heart failure, severe valvular abnormalities and life-
threatening arrhythmias) were not included in the major randomized trials because the unstable 
cardiac status would probably influence postoperative cardiovascular outcome.50 No trials exist 
investigating the role of prophylactic revascularization in patients with unstable angina pectoris 
requiring MVS. However, if MVS can be postponed safely, diagnosis and treatment for these 
patients should be in line with the recent guidelines on unstable angina management.13 
 
Guidelines 
In the current ACC/AHA guidelines for ‘Perioperative Cardiovascular Evaluation and Care for 
Noncardiac Surgery’, it is stated that coronary revascularization before noncardiac surgery is 
useful in patients with acute ST-elevation MI, non-ST-elevation MI, high-risk unstable angina 
or stable angina in combination with significant left main coronary artery stenosis, two- or 
three-vessel disease with significant proximal left anterior descending stenosis and either an 
ejection fraction of less than 50% or ischemia during noninvasive testing.10 Furthermore, it is 
stated that the usefulness of preoperative coronary revascularization is not well established for 
high-risk ischemic patients (with an abnormal dobutamine stress echocardiogram with wall 
motion abnormalities in at least five segments) or low-risk ischemic patients (wall motion 
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abnormalities in up to four segments).10 In patients with stable CAD, routine prophylactic 
coronary revascularization is not recommended before noncardiac surgery.10 In patients who 
undergo coronary angiography without stent placement, noncardiac surgery should be 
postponed for at least two weeks.57 Regarding the management of patients with previous 
coronary stenting undergoing noncardiac surgery, a time window to surgery of at least 6 weeks 
for bare-metal stents and 1 year for drug-eluting stents is recommended.58 For CABG, 
noncardiac surgery should be postponed for at least 1 month.57  
 
 
EXPERT COMMENTARY AND FIVE-YEAR VIEW 
 
The value of perioperative β-blocker therapy and preoperative prophylactic coronary 
revascularization has been widely debated over the years. Garcia and McFalls state in their 
editorial paper that it is time for clinicians to shift the emphasis from extensive preoperative 
testing to evidence-based medical therapies, including β-blocker treatment.59  
 
We agree with this statement and propose that all patients undergoing high-risk 
surgical procedures, such as open vascular surgery, should be treated with low dose β-
blockade, preferable the β1-selective β-blocker bisoprolol. Treatment should be initiated at least 
30 days before surgery, and to maximize the beneficial effects, titration according to tolerance 
and heart-rate control between 65 and 70 beats per minute is of utmost importance. 
Furthermore, we promote the idea of prolonged treatment after surgery. Next to β-blockers, 
patients should also receive statins and aspirin, to optimize medical treatment. In all patients 
with unstable angina and coronary artery stenosis, prophylactic revascularization should be 
performed, preferably before surgery if surgery can be safely postponed. Asymptomatic 
patients or patients with one- or two-vessel coronary disease (not including left main disease) 
should receive optimal medical treatment without the need for coronary revascularization. 
Asymptomatic patients with left main, two or three-vessel disease with significant proximal left 
anterior descending stenosis and either an ejection fraction of less than 50% or ischemia during 
noninvasive testing should receive coronary revascularization, next to optimal medical therapy. 
If noncardiac surgery can be postponed, coronary revascularization should be performed 
before surgery. If noncardiac surgery cannot be postponed, coronary revascularization should 
still be performed after surgery.  
 
Future randomized trials are needed to further evaluate the value of β-blocker therapy 
and prophylactic revascularization. Withdrawal of β-blocker therapy shortly before surgery, or 
in the immediate postoperative period, may contribute to adverse myocardial effects resulting 
from a rebound effect, leading to increases in arterial blood pressure, heart rate and plasma 
noradrenalin concentrations. Intraoperative infusion with esmolol may be effective in 
preventing intraoperative tachycardia and reduce intraoperative left ventricular contractile 
force. The short-acting character of esmolol and continuous hemodynamic monitoring during 
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surgery limit adverse side effects, such as hypotension or bradycardia. The beneficial effect of 
intraoperative esmolol treatment next to pre- and postoperative treatment with low-dose 
bisoprolol may further improve postoperative outcome, which should be evaluated in 
randomized, controlled trials. Prophylactic treatment of high-risk patients with CABG or PCI 
apparently provides insufficient extra protection on top of β-blocker treatment as 
demonstrated in the CARP and DECREASE-V trials. Retrospective data indicate that 
prophylactic revascularization may be the most effective option in intermediate-risk cardiac 
patients. To assess the addition value of prophylactic revascularization next to optimal medical 
therapy, future randomized trials are needed, focussing on coronary revascularization and low-
dose β-blocker treatment in low-, intermediate- and high-risk patients groups.     
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ABSTRACT 
 
Background Prophylactic coronary revascularization in vascular surgery patients with 
extensive coronary artery disease was not associated with an improved immediate postoperative 
outcome. However, the potential long-term benefit was unknown. This study was performed to 
assess the long-term benefit of prophylactic coronary revascularization in these patients.  
 
Methods Of 1,880 patients scheduled for major vascular surgery, 430 had >3 risk factors (>70 
yrs, angina pectoris, myocardial infarction, heart failure, stroke, diabetes mellitus, and renal 
failure). All underwent cardiac testing using dobutamine echocardiography or nuclear stress 
imaging. Patients with extensive stress-induced ischemia (≥5 segments or ≥3 walls) were 
randomly assigned to additional revascularization.  
 
Results In total, 101 patients showed extensive ischemia and were assigned to revascularization 
(N=49) or no-revascularization (N=52). After 2.8 years, the overall survival was 64% for 
patients randomly assigned to no preoperative coronary revascularization vs. 61% for patients 
assigned to preoperative coronary revascularization (hazard ratio [HR] 1.18, 95% confidence 
interval [95%-CI]: 0.63 to 2.19, p = 0.61). Rates for survival free of all-cause death, nonfatal 
myocardial infarction, and coronary revascularization were similar in both groups at 49% and 
42% for patients allocated to medical treatment or coronary revascularization, respectively (HR 
1.51, 95%-CI: 0.89 to 2.57, p = 0.13). Only two patients assigned to medical treatment required 
coronary revascularization during follow-up. Also, in patients who survived the first 30 days 
after surgery there was no apparent benefit of revascularization on cardiac events (HR 1.35, 
95%-CI: 0.72 to 2.52, p = 0.36).  
 
Conclusions Preoperative coronary revascularization in high-risk patients undergoing major 
vascular surgery was not associated with an improved postoperative or long-term outcome 
compared with the best medical treatment. 
 283 
INTRODUCTION 
 
According to the guidelines of the American College of Cardiology /American Heart 
Association, it is recommended to perform coronary angiography in patients with high-risk 
noninvasive test results. Subsequently, myocardial revascularization should be performed in 
patients with prognostic high-risk anatomy in whom long-term outcome is likely to be 
improved.1 However in both the Coronary Artery Revascularization Prophylaxis (CARP) trial 
and Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography 
(DECREASE) V trial, prophylactic preoperative coronary revascularization was not associated 
with improved immediate postoperative outcome.2, 3 As recently shown, early surgery after 
coronary stent placement might lead to an increase in adverse cardiac events caused by in-stent 
thrombosis or bleeding complications.4 This might explain the lack of perioperative benefit. 
However, it was expected that at least long-term outcome, such as after the potentially 
hazardous perioperative period, should be improved in these patients. Therefore, we analyzed 
the long-term outcome of the randomized DECREASE V trial to assess whether there was a 
long-term benefit of prophylactic coronary revascularization in high-risk patients undergoing 
major vascular surgery.  
 
 
METHODS 
 
The study design and the perioperative results of the original DECREASE V trial have been 
published previously.2 In brief, patients were considered eligible for the study if they were 
scheduled for elective open abdominal aortic or infrainguinal arterial reconstruction. Patients 
were screened for the prevalence of cardiac risk factors including age >70 years, angina 
pectoris, previous myocardial infarction, compensated congestive heart failure or history of 
congestive heart failure, drug therapy for diabetes mellitus, renal dysfunction (serum creatinine 
>160 µmol/L), and prior stroke or transient ischemic attack. All patients with ≥3 risk factors 
underwent cardiac stress testing before surgery. Those who experienced extensive stress-
induced ischemia were enrolled in the DECREASE V trial. All patients provided informed 
consent, and the Erasmus MC (Rotterdam, The Netherlands) medical ethics committee and 
local research ethics committees approved the study. Out of 1,880 screened patients, 101 
(5.3%) were considered eligible, had ≥3 risk factors, had extensive stress induced myocardial 
ischemia and were subsequently randomized. A total of 49 patients were allocated to best 
medical treatment and preoperative coronary revascularization and 52 patients to best medical 
treatment only.  
 
Cardiac stress testing was performed using dobutamine echocardiography or 
dobutamine or dipyridamole perfusion scintigraphy, as previously described.5, 6 Test results 
were scored according to the extent of stress-induced ischemia using a 17-segment model for 
dobutamine echocardiography and a 6-wall model for stress perfusion scintigraphy. Limited 
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ischemia was defined by the presence of 1 to 4 ischemic segments or 1 to 2 ischemic walls, 
whereas extensive ischemia was defined as ≥5 ischemic segments or ≥3 ischemic walls. 
 
All patients were monitored for cardiac events after screening. The 12-lead 
electrocardiogram and serum troponin T level were systematically assessed 1, 3, 7, and 30 days 
after surgery. Outpatient follow-up was performed at 30 days if a patient had been discharged 
from the hospital. At the outpatient clinic, all patients were screened at 3-month intervals for 
cardiac events using clinical history and 12-lead electrocardiogram and additional tests were 
performed when indicated by the treating physicians. For this report, outcomes were long-term 
all-cause death and a combined endpoint of all-cause death, nonfatal myocardial infarction, and 
coronary revascularization during follow-up. 
 
Myocardial infarction was defined as the presence of two of the three criteria of (i) 
characteristic ischemic symptoms lasting >20 minutes, (ii) electrocardiographic changes, 
including acute ST elevation followed by the appearance of Q waves or loss of R waves; new 
left bundle branch block or new persistent T-wave inversion for ≥24 hours; or new ST 
segment depression that persisted >24 hours, and (iii) a positive troponin T (i.e. >0.10 ng/mL) 
or peak creatinine kinase-MB >8% of increased total creatinine kinase with characteristic 
increase and decrease.  
 
Continuous data were presented as median and corresponding 25th and 75th 
percentiles, whereas dichotomous data are presented as percentages. Differences in clinical and 
surgical characteristics between patients allocated to revascularization or no revascularization 
were evaluated by Wilcoxon's nonparametric tests, χ2 or Fisher's exact tests, as appropriate. 
The incidence of outcome events over time was examined by the Kaplan-Meier method. 
Multivariate (Cox) regression was used to compare differences in overall survival and cardiac 
event free survival between the allocated treatment strategies, adjusted for baseline clinical risk 
factors. Patients who had an event before surgery but after screening were included in the 
analyses as the day of screening was considered to be baseline. Analyses were performed 
according to the intention-to-treat principle. All statistical tests were two-sided and a p < 0.05 
was considered significant. 
 
 
RESULTS 
 
Baseline variables in patients who underwent preoperative coronary revascularization (N=49) 
or best medical treatment only (N=52) are shown in Table 1. In patients allocated to coronary 
revascularization, 32 underwent a percutaneous coronary intervention (PCI), with a bare-metal 
stent in two and drug-eluting stent in 30. Patients continued with dual-antiplatelet therapy 
during surgery. After surgery, patients with bare-metal stents stopped dual-antiplatelet therapy 
after three months and continued with aspirin afterward. Patients with drug-eluting stent 
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continued dual-antiplatelet therapy during follow-up. A bypass procedure was performed in 17 
patients. The impact of drug-eluting stents vs. bare-metal stents could not be assessed because 
of the number of patients included in the study.  
 
Table 1 Baseline characteristics 
 Revascularization  
Yes  No  p-value 
 
[N=49] [N=52]  
Demographics    
Age (yrs) 71 (64,7) 70 (63,8)  
Men (%) 42 (86) 47 (90) 0.55 
Medical history (%)    
Diabetes mellitus 18 (37) 15 (29) 0.53 
Current angina pectoris 25 (51) 22 (42) 0.43 
Previous myocardial infarction 49 (100) 50 (96) 0.50 
Previous heart failure 23 (47) 24 (46) 1.0 
Previous cerebrovascular accident 20 (41) 13 (25) 0.14 
Previous renal failure 9 (18) 11 (21) 0.81 
Medication (%)    
 aspirin 37 (76) 30 (58) 0.09 
 ß-blocker 34 (70) 36 (69) 1.0 
 ACE - inhibitor 28 (57) 22 (42) 0.17 
 statin 34 (69) 30 (58) 0.30 
Cororary artery narrowed >50% (%)    
 right coronary 39 (80) –  
 left artery descending 46 (94) –  
 left circumflex 37 (76) –  
Number of narrowed arteries (%)    
 1 0 (0) –  
 2 12 (24) –  
 3 33 (67) –  
 left main 4 (8) –  
Angiotensin converting enzyme (ACE). 
 
 
The 30-day outcome of the study population has been described in detail previously.2 
Two patients died before vascular surgery because of a ruptured aneurysm after successful 
bypass surgery and 1 patient experienced myocardial infarction after unsuccessful coronary 
revascularization. Revascularization did not improve 30-day outcome after vascular surgery. 
The incidence of all-cause death or nonfatal myocardial infarction for patients with 
preoperative revascularization or medical treatment only was 43 vs. 33% respectively (hazard 
ratio [HR] 1.4, 95% confidence interval [95%-CI]: 0.7 to 2.8 p = 0.30).  
 
During a median follow-up of 2.8 years (interquartile range 0.9 to 4.2 years) 42 of 101 
patients died. After 2.8 years, the overall survival rate was 64% for patients randomly assigned 
to no preoperative coronary revascularization vs. 61% for patients assigned to preoperative 
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coronary revascularization (HR 1.18, 95%-CI: 0.63 to 2.19, p = 0.61; Figure 1). As shown in 
Figure 2, the incidence of all-cause death, nonfatal myocardial infarction, and coronary 
revascularization was similar in both groups. Event-free survival after 2.8 years were 49% and 
42% for patients allocated to medical treatment or coronary revascularization, respectively (HR 
1.51, 95%-CI: 0.89 to 2.57, p = 0.14). In the no-revascularization group, two patients (4%) 
underwent coronary revascularization during follow-up; one patient underwent coronary artery 
bypass surgery 12 months after vascular surgery because of unstable angina pectoris, and one 
patient underwent PCI using drug-eluting stents 27 months after vascular surgery because of 
progressive angina pectoris symptoms.  
 
 
Figure 1: Overall survival in 101 randomly assigned patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Cardiac event-free survival in 101 randomly assigned patients. 
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It might be argued that preoperative coronary revascularization, in particular, stent 
placement, might lead to an increased 30-day risk for in-stent thrombosis or bleeding after 
discontinuation or continuation of antiplatelet therapy.4 Therefore, we performed a separate 
analysis including only patients who survived ≥30 days after surgery (N=36 and N=46 for 
revascularization and medical treatment only, respectively). As shown in Figures 3 and 4, in 
these survivors, no apparent benefit of revascularization was observed. Of patients who 
underwent revascularization, 47% had an event within a median of 2.8 years of follow-up vs. 
44% in those who did not undergo preoperative coronary revascularization (HR 1.35, 95%-CI: 
0.72 to 2.52, p = 0.36). In addition, all-cause mortality did not differ between groups (HR 0.79, 
95%-CI: 0.35 to 1.78, p = 0.57).  
 
 
Figure 3: Overall survival in patients who survived the first 30 days after surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Cardiac event-free survival of patients who survived the first 30 days after surgery. 
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There was no difference in long-term event free survival between patients who 
underwent preoperative PCI or coronary artery bypass grafting (HR 0.91, 95%-CI: 0.44 to 
1.88, p = 0.80). After a median of 2.8 years, event-free survival was 41 vs. 44% for PCI and 
coronary artery bypass grafting, respectively. In addition, for the endpoint of all-cause death, 
no significant difference was observed (HR 0.81, 95%-CI: 0.33 to 1.96, p = 0.64). However, 
patients with an incomplete revascularization procedure had the worst outcome; six of seven 
(86%) patients died within two years after the attempted revascularization compared with 13 of 
42 (31%) with complete revascularization (HR 4.07, 95%-CI: 1.53 to 10.82, p = 0.005, Figure 5).   
 
 
Figure 5: Cardiac event-free survival after successful or not successful preoperative revascularization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
The DECREASE-V study did not show a long-term benefit of prophylactic preoperative 
coronary revascularization in stable patients with multiple cardiac risk factors and extensive 
stress-induced myocardial ischemia scheduled for major vascular surgery.  
 
The current findings were in line with results of large randomized trials in the 
nonsurgical population. Patients with stable multivessel coronary artery disease did not have 
better survival after coronary stent placement or bypass grafting compared with medical 
treatment only. The recent published Medicine, Angioplasty, or Surgery Study (MASS II) was 
the first randomized controlled clinical trial to report 5-year outcomes of nonsurgical patients 
with stable multivessel coronary artery disease treated with either bare-metal stent placement, 
coronary artery bypass grafting, or best medical treatment only.7 That study showed that 
optimal medical therapy in patients with stable multivessel coronary artery disease resulted in 
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similar long-term outcomes in terms of cardiac-related death or all-cause mortality. The 
investigators concluded that “patients with mild to moderate angina can be safely managed 
medically, whereas PCI or [coronary artery bypass grafting] CABG is appropriate if symptoms 
are not adequately controlled by medication or other high-risk features are apparent.”7 The 
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) 
trial also found no additional benefit of coronary revascularization in addition to optimal 
medical therapy in 2,287 patients with objective evidence of myocardial ischemia and 
significant coronary artery disease.8 During a median follow-up of 4.6 years, cumulative event 
rate of all-cause death and myocardial infarction were 19.0% in the PCI group and 18.5% in 
the medical-therapy group. As discussed by the COURAGE trialists, these findings may be 
explained by differences in atherosclerotic plaque morphologic characteristics and vascular 
remodeling associated with acute coronary syndromes compared with stable coronary artery 
disease. Medical treatment in both MASS II and COURAGE included rigorous statin and 
aspirin therapy. This might have prevented vulnerable plaques, which are usually difficult to 
detect and impossible to treat using coronary angioplasty or bypass, to rupture and cause acute 
coronary syndromes. It is important to realize that vulnerable coronary lesions are not 
necessarily severely stenotic, and severely stenotic lesions are not necessarily unstable. Focal 
management of severely stenotic coronary lesions using PCI in both MASS II and COURAGE 
did not reduce the rate of death and myocardial infarction, presumably because the treated, 
severely stenotic lesions were not likely to trigger an acute coronary event.8  
 
Remarkably, in MASS II and COURAGE, annual mortality rates were approximately 
1 to 2% whereas in CARP and DECREASE V the annual mortality rates in patients who 
survived surgery were 6.8 and 8.2%, respectively. Baseline angiographic cardiac status in MASS 
II and COURAGE was not significantly better or worse than in CARP and DECREASE V: 3-
vessel disease was present in 58 and 31% vs. 33 and 75%, respectively. In line with these 
findings, it was recently shown that patients with so-called “polyvascular” disease, i.e. multiple 
vascular beds affected, have a significant worse outcome compared with patients with coronary 
artery disease only.9 In Reduction of Atherothrombosis for Continued Health (REACH), event 
rates (cardiovascular death, MI, stroke, or hospitalization for a cardiovascular event) increased 
with the number of symptomatic vascular beds: 5.3% of patients with risk factors only to 12.6 
with one, 21.1 with two, and 26.3% with three disease locations.9 Because all patients in 
DECREASE V and CARP had proven coronary artery disease and were planned for 
noncardiac vascular surgery, these patients can be considered to have polyvascular disease. 
This indicated that patients scheduled for vascular surgery with extensive coronary artery 
disease should be considered to be a different population than patients without peripheral 
arterial disease, but with coronary artery disease only. However, also in this patient population 
with stable severe coronary artery disease, optimal medical therapy seems to be equal to 
coronary revascularization in addition to best medical treatment. 
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The findings of both CARP and DECREASE V support the current guidelines of the 
American College of Cardiology/American Heart Association for perioperative management in 
high-risk patients to reserve revascularization for cardiac unstable patients. Considering the 
high long-term mortality and cardiac event rates, these patients should be regularly screened 
for the presence of ischemic symptoms, and aggressive anti-ischemic medical therapy must be 
used.  
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ABSTRACT 
 
Background The current guidelines recommend postponing noncardiac surgery (NCS) for ≥6 
weeks after bare metal stent (BMS) placement and 1 year after drug-eluting stent (DES) 
placement. However, much debate has ensued about these intervals. The aim of the present 
study was to assess the influence of different intervals between stenting and NCS and the use 
of dual antiplatelet therapy on the occurrence of perioperative major adverse cardiac events 
(MACEs).  
 
Methods We identified 550 patients (376 with a DES and 174 with a BMS) by cross-matching 
the Erasmus Medical Center percutaneous coronary intervention (PCI) database with the NCS 
database. The following intervals between PCI-BMS (<30 days, <3 months, >3 months) or 
PCI-DES (<30 days, <3 months, 3-6 months, 6-12 months and >12 months) and NCS were 
studied. MACEs included death, myocardial infarction and repeated revascularization.  
 
Results In the PCI-BMS group, the rates of MACEs during the intervals of <30, 30 days–3 
months, and >3 months was 50, 14, and 4%, respectively (overall p < 0.001). In the PCI-DES 
group, the rate of MACE changed significantly with the interval after PCI (35, 13, 15, 6, and 
9% for patients undergoing NCS <30 days, 30 days to 3months, 3 to 6 months, 6 to 12 
months, and >12 months after PCI-DES respectively, overall p < 0.001). Of the patients who 
experienced a MACE, 45 and 55% were receiving single and dual antiplatelet therapy at NCS, 
respectively (p = 0.92). The risk of severe bleeding in patients with single and dual therapy at 
NCS was 4 and 21%, respectively (p < 0.001). 
 
Conclusions We found an inverse relation between the interval from PCI to NCS and 
perioperative MACEs. Continuation of dual antiplatelet therapy until NCS did not provide 
complete protection against MACEs. 
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INTRODUCTION 
 
Approximately 5% of patients who undergo coronary stenting require some form of 
noncardiac surgery (NCS) within one year.1 Surgery increases the risk of thrombosis owing to a 
perioperative stress response; including sympathetic activation promoting reduced fibrinolytic 
activity, platelet activation, and hypercoagulability. In addition, dual antiplatelet therapy is often 
interrupted because of the fear of excessive perioperative bleeding complications. The 
prevention of cardiac complications vs. the risk of severe bleeding creates a double-edged 
sword on the timing of surgery and the antiplatelet regimen. The current guidelines from the 
American College of Cardiology/American Heart Association (ACC/AHA) have recommend 
delaying NCS for ≥6 weeks after PCI with a bare metal stent (BMS) and ≥1 year after PCI 
with a drug-eluting stent (DES).2, 3 However, in a recent large study including patients with 
DES placement these recommendations could not be confirmed.4 Therefore, the aim of the 
present study was to assess the relation among the interval to NCS after PCI, medical therapy 
and the occurrence of perioperative major adverse cardiovascular events (MACEs).     
 
METHODS 
 
The present study included 1,000 patients who had undergone cardiac surgery or NCS after 
successful PCI because of severe ischemia from January 2000 to December 2007. The final 
study population included 550 patients who had undergone NCS. The patients were identified 
by cross matching the Erasmus Medical Centre PCI database with the NCS database (including 
78,000 procedures). The PCI database is a prospectively maintained registry of 13,000 
procedures performed from January 2000 to December 2007.5  
 
All patients underwent PCI using either a BMS (2000 to March 2002) or DES (April 
2002 to 2007; sirolimus or paclitaxel). The patient characteristics were prospectively collected 
directly after the PCI procedure and included the PCI-indication, number of affected and 
stented coronary arteries, left ventricular ejection fraction, and medication use during and after 
PCI. Patients with a BMS were prescribed lifelong aspirin and clopidogrel (loading dose 300 
mg, followed by 75mg daily) for ≥30 days. Patients with a DES usually were prescribed 
lifelong aspirin and clopidogrel for ≥3 months (sirolimus) to 6 months (paclitaxel), or longer, 
at the discretion of the treating physician. The treating physician determined the type of used 
stent at the PCI procedure.        
 
All data on the surgical procedure were retrospectively collected by screening the 
medical charts. The type of surgery was classified and categorized according to the surgical 
risk, determined using the ACC/AHA classification.6 In addition, cardiac history and cardiac 
risk factors were assessed at stenting and surgery. Medication use was assessed during the 
initial PCI procedures and was updated at the point of surgery. The use of proton pump 
inhibitors concomitantly with clopidogrel was also noted. No standard protocol for 
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perioperative antiplatelet therapy was used in the present study population, becuse this was an 
observational study and the surgical procedures included all types of NCS. Consequently, some 
patients received aspirin and/or clopidogrel throughout the surgical procedure, but for other 
patients, aspirin and/or clopidogrel were discontinued five to ten days before surgery. All 
medical records were reviewed to categorize the maintenance of antiplatelet therapy (i.e. no 
therapy, aspirin, clopidogrel or dual antiplatelet therapy) in the period before NCS as 
discontinued >30 days, discontinued 7 to 30 days, or continued to within <7 days before NCS. 
 
The perioperative complications were defined as the occurrence of MACEs (i.e. 
death, myocardial infarction [either ST-elevation or non-ST-elevation myocardial infarction], 
stent thrombosis, repeated revascularization) within 30 days after NCS. Perioperative 
myocardial infarction was defined according to the European Society of Cardiology/ACC 
criteria.7 Bleeding complications were categorized as life-threatening or moderate bleedings, 
during the first 30 postoperative days. Life-threatening bleeding was defined as fatal bleeding, 
intracranial bleeding, or bleeding requiring surgical intervention or transfusion of ≥4 U of 
blood or blood products. Moderate bleeding was defined as bleeding requiring transfusion of 1 
to 3 U of blood or blood products.8 
 
Statistical analyses were performed using the Statistical Package for Social Sciences, 
version 15.0 (SPSS, Chicago, Illinois). Continuous data were compared using Student’s t test 
and are expressed as mean ± SD. Categorical data are presented as percentages, and differences 
between proportions were compared using the χ2 test. To assess whether the risk of the 
occurrence of MACEs after NCS was associated with the interval from PCI to NCS, the 
interval from PCI to NCS was assessed as a categorical variable. Determined by the current 
guidelines and recommendations, the intervals used for patients with a BMS were <30days, <3 
months, and >3 months and for a DES were <30 days, 30 days to 3 months, 3 to 6 months, 6 
to 12 months, and >12 months.3, 4, 9 Logistic regression analyses were used to calculate the 
association between the intervals from PCI to NCS and MACEs. Logistic regression analyses 
were also used to determine possible associations between the presence of cardiac risk factors 
and the development of MACEs. Adjustments were made for age, gender, and all baseline 
cardiac risk factors (history of myocardial infarction, PCI/coronary artery bypass grafting, 
congestive heart failure, renal dysfunction, smoking, hypertension, diabetes mellitus, 
hypercholesterolemia, positive family history of cardiovascular (CV) disease), vessel/stent-
diameter, lesion length and use of proton pump inhibitors during clopidogrel treatment. In all 
analyses, two-tailed tests were performed, and statistical significance was inferred at p ≤ 0.05.   
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RESULTS 
 
A total of 1,000 PCI procedures with stent placement followed by a surgical procedure were 
identified. NCS was performed in 550 patients either after PCI-BMS (N=174) or PCI-DES 
(N=376). No difference was found in the cardiac history or type of indication for PCI between 
the patients undergoing PCI-BMS and PCI-DES (Table 1). Most patients underwent 
intermediate to high-risk surgery; a trend was found for more emergency surgical procedures in 
patients with a DES (p = 0.054; Table 2).   
 
Table 1 Baseline characteristics 
Total BMS DES p-value 
 
[N=550] [N=174] [N=376]  
Demographics 
Age (yrs), mean ± SD 62.6 61.2 63.3 0.04 
Male  74.9% 75.3% 74.7% 0.89 
Medical histroy (%) 
Myocardial infarction  179 (33) 56 (32) 123 (33) 0.77 
CABG 66 (12) 23 (13) 43 (12) 0.61 
PCI 161 (30) 52 (30) 109 (30) 0.95 
Risk factors (%) 
Smoking     
 current 253 (46) 65 (37) 188 (50) <0.001 
 history 86 (16) 10 (6) 76 (20) <0.001 
Hypertension 118 (22) 39 (22) 79 (21) 0.71 
Diabetes mellitus 119 (22) 26 (15) 93 (25) 0.01 
Dyslipidemia 296 (54) 81 (47) 215 (57) 0.02 
Renal failure 47 (9) 7 (4) 40 (11) 0.01 
LVEF <50% 236 (44) 170 (46) 66 (38) 0.07 
PCI indications (%) 0.31 
 Stable angina pectoris 245 (45) 175 (47) 70 (40)  
 Instable angia pectoris 174 (32) 112 (30) 62 (36)  
 Acute myocardial infarction 131 (24) 89 (24) 42 (24)  
Discharge medication (%) 
Aspirin 503 (92) 160 (92) 343 (91) 0.78 
Statin 318 (58) 90 (52) 228 (61) 0.05 
ß-blocking agents 502 (91) 158 (91) 344 (92) 0.79 
ACE-inhibitors 149 (27) 40 (23) 109 (29) 0.14 
Diuretics 48 (9) 10 (6) 38 (10) 0.09 
Calcium antagonists 182 (33) 84 (48) 98 (26) <0.001 
Nitrates 56 (10) 13 (8) 43 (11) 0.15 
Ticloxpidines 477 (87) 151 (87) 326 (87) 0.98 
Clopidogrel use (monthly)    <0.001 
 median 3 2 6  
 interquartile range 1-6 1-3 1-6  
Angiotensin converting enzyme (ACE), bare metal stent (BMS), coronary artery bypass grafting (CABG), drug eluting 
stent (DES), percutaneous coronary intervention (PCI), left ventricular ejection fraction (LVEF). 
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Table 2 Surgical Group* 
BMS DES 
 
[N=174] [N=376] 
High-risk (%)   
 Vascular system 23 (13) 41 (11) 
 Emergency 4 (2) 40 (11) 
Intermediate-risk (%)   
 Nose, mouth, pharynx 13 (8) 15 (4) 
 Eye 29 (17) 42 (11) 
 Digestive system 16 (9) 48 (13) 
 Musculoskeletal system 20 (12) 39 (10) 
 Respiratory system 4 (2) 11 (3) 
 Nervous system 6 (3) 23 (6) 
 Endocrine system - 2 (1) 
 Oncology 1 (1) 1 (1) 
Low-risk (%)   
 Urinary system 28 (16) 49 (13) 
 Cosmetic surgery 9 (5) 18 (5) 
 Dermatologic 9 (5) 17 (5) 
 Miscellaneous 12 (7) 30 (8) 
* Categorized according to ACC/AHA classification. Bare metal stent (BMS), drug-eluting stent (DES).  
 
The median interval between PCI–BMS and NCS was 3.6 years (interquartile range 
1.8 to 5.4). Of the patients who underwent NCS after PCI-BMS, 8 (5%) patients had NCS 
within 30 days, 7 (4%) between 30 days and 3 months, and 159 (91%) after 3 months. During 
the first 30 days after NCS, 11 patients (6%) with PCI-BMS experienced a MACE (10 
cardiovascular death and 1 myocardial infarction). An inverse relation was found between the 
rate of postoperative MACEs and the interval to NCS after PCI-BMS. The rate of MACEs for 
intervals of <30, 30 days to 3 months, and >3 months was 50, 14, and 4%, respectively (overall 
p < 0.001; Figure 1 and Table 3). When NCS was postponed for ≥3 months after PCI with a 
BMS, the lowest risk of perioperative MACE was observed (Figure 1). 
 
Dual antiplatelet therapy was used in 100 and 75% of the patients who underwent 
NCS within 30 days or 30 days to 3 months after PCI-BMS, respectively. Overall, at NCS, 157 
(91%) and 16 (9%) patients were receiving single and dual antiplatelet therapy, respectively. Of 
the patients who experienced a MACE, 5 (46%) and 6 (55%) had been receiving single or dual 
antiplatelet therapy at NCS (p = 0.92). All patients who underwent NCS within 30 days after 
PCI-BMS and experienced a MACE were receiving dual antiplatelet therapy until NCS. 
Patients with concomitant use of proton pump inhibitors and clopidogrel at NCS seemed to 
have greater rates of MACE than patients without proton pump inhibitor use (46 vs 20%); 
however, this was not statistically significance (p = 0.33). Of the patients undergoing PCI-BMS, 
81% had a large stent/vessel diameter (>3.0 mm) or a short lesion length (<25 mm). No 
association was found between the stent/vessel diameter or lesion length and the risk of 
MACEs in these patients. 
 297 
The median time between PCI–DES and NCS was 1.4 years (interquartile range 0.5 to 2.6). 
NCS after PCI-DES was performed within 30 days, at 30 days to 3 months, 3 to 6 months, 6 
to 12 months, and >12 months in 45 (12%), 25 (6%), 27 (7%), 47 (13%) and 232 (62%) 
patients, respectively. A total of 48 patients (13%) experienced a MACE within the first 30 
postoperative days (36 [82%] cardiovascular death, 4 [9%] noncardiovascular death, 2 [5%] 
myocardial infarction, 6 [14%] stent thrombosis). The MACE rate changed significantly with 
the interval after PCI-DES (35, 13, 15, 6, and 9% for patients undergoing NCS <30 days, 30 
days to 3 months, 3 to 6 months, 6 to 12 months, and >12 months after PCI-DES 
respectively; overall p < 0.001; Figure 1 and Table 3). In line with the ACC/AHA guidelines, 
NCS within one year after PCI-DES was associated with an increased rate of MACEs (18 vs 
10%, p = 0.015). On multivariate analysis, patients undergoing NCS within one year after PCI-
DES, had an increased risk of perioperative MACEs (hazard ratio 2.0, 95% confidence 
interval: 1.1 to 3.5) compared with patients undergoing NCS >1 year after PCI-DES. 
 
 
Table 3 30-day MACEs stratified by interval between PCI and NCS 
PCI to NCS interval N (%) p-value 
BMS [N=174]   
 0 - 30 days [N=8] 4 (50) <0.001 
 31 - 90 days  [N=7] 1 (14)  
 >91 days  [N=159] 6 (4)  
 <30 days [N=8] 4 (50) <0.001 
 ≥30 days [N=166] 7 (4)  
 <3 months [N=15] 5 (33) <0.001 
 ≥3 months [N=159] 6 (4)  
DES [N=376] 
 <30 days [N=46] 16 (35) <0.001 
 30d – 3 months  [N=24] 3 (13)  
 3 – 6 months  [N=27] 4 (15)  
 6 – 12 months [N=47] 3 (6)  
 >12 months [N=232] 22 (9)  
 <1years [N=144] 26 (18) 0.015 
 ≥1 years [N=232] 22 (9)  
Bare metal stent (BMS), drug eluting stent (DES), major adverse cardiovascular events (MACEs), noncardiac surgery 
(NCS), percutaneous coronary intervention (PCI). 
 
 
Dual antiplatelet therapy was used in 100 and 80% of the patients during the first 3 
and 6 months after PCI-DES, respectively. Overall, dual antiplatelet therapy was continued 
until NCS in 112 (30%) patients, and 264 (70%) patients received single antiplatelet therapy. 
Of the patients who experienced a perioperative MACE, 56 and 44% had received dual or 
single antiplatelet therapy, respectively (p = 0.72). Because all patients were receiving dual 
antiplatelet therapy during the first 3 to 6 months after PCI-DES, the risk of perioperative 
MACE was only related to the interval to NCS after PCI. No relation was found between the 
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concomitant use of clopidogrel and proton pump inhibitors and the risk of perioperative 
MACEs (28 vs 21% p = 0.38), compared with patients without proton pump inhibitor use. 
Patients in the PCI-DES group more often had a small stent-vessel diameter, but an increased 
lesion length, compared with those in the PCI-BMS group (84 vs 16% and 78 vs 22%, p < 
0.001), respectively. No association was found between the stent/vessel diameter or lesion 
length and the risk of perioperative MACEs (12 vs 15%, p = 0.4, and 11 vs 15%, p = 0.2), 
respectively. 
 
 
Figure 1: Perioperative major adverse cardiac events and antiplatelet regimen in (A) PCI-BMS and (B) 
PCI-DES. Risk of perioperative major adverse cardiac events during prespecified intervals between PCI 
and NCS. Antiplatelet regimens (single or dual antiplatelet therapy) subdivided according to occurrence 
of perioperative major adverse cardiac events 
Bare metal stent (BMS), drug eluting stent (DES), noncardiac surgery (NCS), percutaneous coronary intervention (PCI). 
 
 
Moderate and severe bleeding after surgery occurred in 56 (10%) and 42 (8%) 
patients, respectively. A strong association was found between the use of single or dual 
antiplatelet therapy at NCS and the risk of moderate, severe or any bleeding (p < 0.001; Figure 
2). The risk of severe bleeding in patients receiving single or dual therapy at NCS was 4 and 
21%, respectively (p < 0.001). Additionally, the risk of bleeding was associated with interval 
from PCI to NCS.      
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Figure 2: Bleeding risk according to antiplatelet regimen (single or dual antiplatelet therapy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
The results of the present study revealed an inverse relation between the interval from PCI to 
NCS and the occurrence of MACEs within 30 days after NCS in patients with PCI-BMS or 
PCI-DES. Irrespective of dual antiplatelet therapy continuation until NCS, early surgery after 
stenting was associated with an increased risk of MACEs. In addition, dual antiplatelet therapy 
at NCS increased the bleeding risk. Therefore, elective NCS should preferably be postponed 
for 90 days after PCI-BMS; however, if more urgent surgery is needed, a minimum interval of 
30 days should be recommended. After PCI-DES, NCS should be delayed for ≥1 year.      
 
In response to several small studies that reported cases of late stent thrombosis,10, 11 
the first European Society of Cardiology guidelines recommended dual antiplatelet therapy for 
a minimum of three to four weeks after PCI-BMS. The most recent scientific advisory of the 
ACC/AHA on the discontinuation of dual antiplatelet therapy for patients with coronary stents 
proposed an interval of 6 weeks after PCI-BMS.2, 3 In the present study, the strongest decrease 
in the risk of perioperative MACEs in patients undergoing NCS after PCI-BMS was reached 
when NCS was postponed for a minimum of 30 days from PCI. In contrast, only a small 
additional effect was realized if NCS was postponed until six weeks after PCI compared with 
30 days. Previous studies of patients undergoing NCS after PCI-BMS reported high rates of 
MACEs when NCS was performed within two weeks after PCI,12, 13 and others have 
recommended a delay of ≥6 weeks.14, 15 Recent studies have shown the greatest risk of 
ischaemic events when NCS was performed within 30 days of PCI, and the lowest after 90 
days.9 In line with these studies, our study found the same high risk of perioperative MACE 
with NCS within 30 days of PCI-BMS. However, the number of events in the present study 
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was greater (10.7 vs 5.4%), possibly because of the intensive and close follow-up of our patient 
population. As mentioned by Nutall et al.9 they used no protocol for the detection of 
perioperative MACE. 
 
The occurrence of stent thrombosis is a multifactorial process that includes device-
related factors (e.g. surface coating, stent diameter, stent length) and patient- or lesion-specific 
factors (e.g. interval from PCI to NCS, stent/vessel diameter, antiplatelet therapy, proton pump 
inhibitor use and left ventricular ejection fraction).16 In the present study, only the interval from 
PCI to NCS was independently associated with an increased risk of perioperative MACEs after 
NCS. The continuation of dual antiplatelet therapy until NCS in PCI-BMS patients was not 
associated with lower rates of MACEs in the perioperative phase but was, however, associated 
with an increased risk of bleeding complications. Nuttall et al.9 found no association between 
the different intervals after PCI-BMS and the frequency of bleeding events. After an interval of 
≥30 days, they found a bleeding event rate of 4.6%, in line with our rate of (4%). 
 
A significant association between the interval from PCI-DES to NCS and the risk of 
perioperative MACEs was detected, confirming the ACC/AHA advisory to postpone elective 
NCS for ≥1 year after PCI.3 Although stabilization for the occurrence of MACEs was detected 
at a 6-month interval between PCI and NCS, other studies have shown catastrophic effects of 
early discontinuation.17 The value of at least a 1-year continuation of dual antiplatelet therapy 
after DES placement was also shown.18 In addition, more recent studies have shown that even 
if clopidogrel is stopped after the previous recommended three to six months, those who 
continue dual antiplatelet therapy have better survival and less late in-stent thrombosis than 
those with single or no antiplatelet therapy.18, 19 Rabbits et al.4 performed the largest trial in 
patients with PCI-DES before NCS, and observed a nonsignificant trend-wise decrease in the 
rate of MACEs with an increasing interval after PCI.4 From these cited studies, prolonged dual 
antiplatelet therapy for ≥1 year is supported for patients with PCI-DES. Although our study 
demonstrated stabilization for the risk of MACEs after an interval of six months after PCI, an 
overall reduction in the incidence of MACEs was seen when NCS was performed ≥1 year after 
PCI-DES.  
 
The continuation of dual antiplatelet therapy until surgery was not associated with a 
reduced risk of perioperative MACEs, compared with the discontinuation of dual antiplatelet 
therapy. In patients who underwent NCS within three months after PCI-DES, continuation of 
dual antiplatelet therapy was not sufficiently protective to prevent perioperative MACEs. 
Although this finding surprised us, Rabbitts et al.4 detected the same association. They even 
found that use of thienopyridine <7 days from NCS was associated with an increased rate of 
MACEs, compared with the use of single antiplatelet therapy. In contrast, other studies showed 
the adverse effects of stopping dual antiplatelet too early.12, 19, 20 In our study, all patients who 
developed a MACE during dual antiplatelet therapy had undergone surgery within three 
months after PCI. A possible explanation for the occurrence of MACEs in this specific subset 
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of patients is minimal early re-endothelization of the coronary arteries at the stent-location. The 
combination of aspirin and thienopyridines during the hypercoagulable state during NCS 
seemed insufficient to reduce the risk of in-stent thrombosis during this vulnerable period. 
 
Although the overall bleeding risk was in line with that reported by previous studies4, 
an increased rate of severe bleeding episodes occurred in the PCI-DES patients that was related 
to (i) the use of dual antiplatelet therapy at NCS, (ii) high-risk NCS, and (iii) NCS within 30 
days after PCI.  Harder et al.21 concluded that monotherapy with aspirin or clopidogrel usually 
does not need to be discontinued during surgery, which was confirmed in a meta-analysis by 
Burger et al.21 However, an increased risk of severe bleeding was shown by the Clopidogrel in 
Unstable angina to prevent Recurrent ischemic Events (CURE) trial for patients receiving dual 
antiplatelet therapy.22 Although the use of dual antiplatelet therapy has the disadvantage of an 
increased bleeding risk, the long-term survival effects of thienopyridines seem to outweigh 
these short-term negative effects.  
 
The potential limitations of the present study merit consideration. First, a referral bias 
was possible, because we did not include patients who underwent NCS elsewhere. Second, 
although the present sample size represented a very small part of both databases, a minor 
susceptibility to chance remained. Third, a selection bias for the occurrence of MACEs during 
dual antiplatelet therapy was possible, because these patients were more prone to undergo 
nonelective NCS early after PCI. Although no independent events’ committee adjudicated 
clinical events, this was performed by 2 of us. Finally, we were unable to determine whether 
PCI was performed specifically for the subsequent surgery; however, almost 80% of PCI 
procedures were performed in a stable cardiac setting.      
 
 In conclusion, after PCI-BMS, NCS should preferably be postponed 90 days; 
however, if more urgent surgery is needed, a minimum interval of 30 days should be 
recommended. In patients with PCI-DES, elective NCS should be postponed for ≥1 year after 
PCI. 
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ABSTRACT 
 
Objectives The present study evaluated timing of β-blocker initiation before surgery and its 
relationship with (i) preoperative heart rate and high-sensitive C-reactive-protein (hs-CRP) 
levels and (ii) postoperative outcome. 
 
Background Perioperative guidelines recommend β-blocker initiation days to weeks before 
surgery, based on expert opinions. 
 
Methods In 940 vascular surgery patients, preoperative heart rate and hs-CRP levels were 
recorded, as well as timing of β-blocker initiation before surgery (0-1,>1-4,>4 weeks). Pre- and 
postoperative troponin T measurements and ECGs were performed routinely. Endpoints 
were 30-day cardiac events (composite of myocardial infarction and cardiac mortality) and 
long-term mortality. Multivariate regression analyses, adjusted for cardiac risk factors, 
evaluated the relation between duration of β-blocker treatment and outcome.  
 
Results Treatment was initiated 0-1, >1 to 4, and >4 weeks before surgery in 158 (17%), 393 
(42%), and 389 (41%) patients, respectively. Median heart rate was 74 (±17), 70 (±16), and 66 
(±15) beats per minute (p < 0.001; comparing heart rate of treatment initiation >1 with <1 
week preoperatively) and hs-CRP was 4.9 (±7.5), 4.1 (±.6.0), and 4.5 (±6.3) mg/L (p = 0.782), 
respectively. Multivariate regression analyses demonstrated that treatment initiated >1 to 4 or 
>4 weeks before surgery was associated with a lower incidence of 30-day cardiac events (OR 
0.46, 95%-CI: 0.27 to 0.76, OR 0.48, 95%-CI: 0.29 to 0.79) and long-term mortality (HR 0.52, 
95%-CI: 0.21 to 0.67, HR 0.50, 95%-CI: 0.25 to 0.71) compared with treatment initiated <1 
week preoperatively.  
 
Conclusions Our results indicate that β-blocker treatment initiated >1 week before surgery is 
associated with lower preoperative heart rate and improved outcome, compared with treatment 
initiated <1 week preoperatively. In addition, no reduction of median hs-CRP levels was 
observed, also not in patients receiving β-blocker treatment >1 week before surgery. 
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INTRODUCTION 
 
β-blockers are established therapeutic agents for patients with hypertension,1 heart failure,2 and 
coronary artery disease.3 In the nonsurgical setting, β-blockers are widely used for the 
prevention and treatment of coronary heart disease and heart failure, both important 
determinants of perioperative cardiovascular complications. Over the years, multiple 
observational studies and randomized, controlled trials have been performed to evaluate the 
effect of perioperative β-blocker treatment in patients undergoing noncardiac surgery.4-15 The 
majority of these studies have demonstrated cardioprotection derived from perioperative β-
blocker treatment. 
 
Proposed mechanisms by which β-blockers exert intraoperative cardioprotective 
effects include (i) heart rate control, (ii) reduction of systolic pressure and ventricular 
contractile force, and (iii) its anti-arrhythmic properties. Long-term; β-blockers reduce 
mechanical stress imposed to coronary plaques preventing plaque rupture.16 Patients receiving 
β-blockers tend to have lower plasma concentrations of C-Reactive Protein (CRP) than those 
not receiving β-blockers, and the anti-inflammatory properties of β-blockers are thought to 
stabilize coronary plaques.17-19 In addition, β-blockers are known to lessen adverse cardiac 
remodelling in patients with impaired left ventricular function, which is highly prevalent in the 
vascular surgery population, by inhibiting the sympathetic nervous system and hormone 
activation (A-type and B-type natriuretic peptides and norepinephrine).20-22 Potential side 
effects associated with β-blocker treatment are bradycardia, hypotension and stroke.  
 
Factors that may relate to the effectiveness of β-blocker therapy and the occurrence 
of side effects are variations in treatment protocols, such as (i) β-blocker type, (ii) β-blocker 
dose, and (iii) timing of β-blocker initiation before surgery. However, the duration of β-blocker 
treatment before surgery and its effect on cardiovascular outcome has not been evaluated yet 
in a cohort of vascular surgery patients. The present study was conducted to evaluate timing of 
β-blocker initiation and its influence on preoperative heart rate, preoperative high-sensitive 
CRP (hs-CRP) levels, and postoperative outcome of vascular surgery patients.  
 
 
MATERIAL AND METHODS 
 
Study population  
The original study population consisted of 940 vascular surgery patients undergoing (open or 
endovascular) lower extremity artery, carotid artery, or abdominal aortic repair, receiving 
preoperative β-blocker treatment. Open abdominal aortic aneurysm repair and lower extremity 
revascularization were considered procedures with high cardiac risk. Carotid surgery and 
endovascular surgery were considered procedures with intermediate-cardiac risk. 23 Patients (i) 
undergoing emergency surgery (ii) randomized for β-blocker treatment in previous 
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randomized, controlled trials, and (iii) with preoperative heart rate <50 beats per minute were 
not included in the present study. The study was performed at the Erasmus Medical Center in 
Rotterdam, the Netherlands, during the period between 2002 and 2008. The study was 
approved by the hospital’s ethics committee and performed with informed consent of all 
patients.  
 
Baseline characteristics 
Before surgery, a detailed history was obtained from every patient. Clinical data included: age, 
gender, ischemic heart disease (defined as a history myocardial infarction, coronary 
revascularization or the presence of pathologic Q-waves on preoperative electrocardiogram), 
heart failure (defined as the presence of heart failure symptoms according the New York Heart 
Association classification or previous hospital admission for decompensated heart failure) and 
cerebrovascular disease (defined as a history of ischemic or hemorrhagic stroke). In addition, 
kidney dysfunction (serum creatinine >2.0 mg/dL), diabetes mellitus (fasting blood glucose 
≥6.1 mmol/L or requirement of anti-diabetic medication), hypertension (blood pressure 
≥140/90 mmHg in non diabetic patients and ≥130/80 mmHg in diabetics, or requirement of 
antihypertensive medication), hypercholesterolemia (low density lipoprotein cholesterol >3.5 
mmol/L or requirement of lipid-lowering medication), chronic obstructive pulmonary disease 
(according to the Global Initiative on Obstructive Lung Diseases classification), and smoking 
status were recorded as well. Peripheral blood samples for hs-CRP in mg/L, measured by a 
nephelometric assay on a Beckman-Immage analyzer (Beckman-Coulter, Fullerton, California, 
USA) were routinely performed one day before surgery.  
 
Medication use 
The use of the prescription medications was recorded at baseline and included β-blockers, 
statins, aspirin, oral anticoagulants, inhibitors of the renin-angiotensin-aldosterone system 
(RAAS inhibitors: ACE inhibitors, angiotensin-II receptor blockers, renin inhibitors, 
aldosterone antagonists), and diuretics. During the first preoperative visit at the outpatient 
clinic preoperative β-blocker use was established in patients already receiving β-blockers and in 
patients not already receiving β-blockers, preoperative β-blocker treatment was initiated. 
Preoperative β-blocker use was subdivided according to initiation time of treatment 0 to 1, >1 
to 4, or >4 weeks before surgery. All patients returned to the outpatients clinic after 1 week and 
β-blocker dosage, if needed, was adjusted and titrated according to tolerance to obtain a 
preoperative heart rate between 60 to 70 beats per minute.24 This protocol could not be 
followed in patients in whom β-blocker treatment was initiated <1 week before surgery. 
 
Study outcomes 
Main study endpoints were 30-cardiovascular events and long-term mortality. 30-day 
cardiovascular events was the composite of myocardial damage (defined as myocardial 
ischemia or infarction), stroke and mortality up to 30 days after surgery. Serial 
electrocardiograms and troponin T measurements were obtained from all patients before 
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surgery, postoperatively on day 1, 3, 7, and before discharge. Perioperative myocardial ischemia 
was defined as patients with normal preoperative and elevated (>0.03 ng/mL) troponin T 
levels postoperatively. Elevated troponin T levels in combination with electrocardiographic 
changes (new onset ST-T changes and pathological Q waves) or symptoms of angina pectoris 
defined myocardial infarction.25 Patients with elevated troponin T levels before surgery were 
not included in the study. Long-term mortality was assessed by approaching the municipal civil 
registries. Mean follow-up was 2.2 ± 1.8 years. Secondary endpoints were preoperative heart 
rate (beats per minute) and hs-CRP levels (mg/L). Peripheral blood samples for hs-CRP were 
routinely performed one day before surgery. Optimal specificity and sensitivity of hs-CRP to 
predict postoperative outcome was calculated using receiver operating curve analyses and a cut 
off value >6.5 mg/L was used in the analyses. 
 
Statistical analysis 
Dichotomous data are described as numbers and percentages and categorical data are 
compared using the χ2 test. The continuous variable age is described as mean ± standard 
deviation (SD) and compared using ANOVA. The continuous variables heart rate and hs-CRP 
are described as medians ± interquartile range (IQR) and compared using the Mann–Whitney 
U test. The relation between β-blocker use and postoperative outcome was evaluated with 
regression analyses with propensity score adjustment for β-blocker use. The relation between 
β-blocker use and perioperative myocardial damage was evaluated with logistic regression 
analyses. In addition, the relation between β-blocker use and long-term follow-up was 
evaluated with Cox regression analysis. Multivariate analyses were adjusted for demographics 
(age and gender), cardiovascular risk factors (ischemic heart disease, cerebrovascular disease, 
heart failure, renal dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, chronic 
obstructive pulmonary disease, and smoking status), type of surgery and medication use 
(statins, aspirin and RAAS inhibitors). We report crude and adjusted odds and hazard ratios 
(OR and HR) with their 95% confidence interval (95%-CI). For all tests, a p-value <0.05 (two-
sided) was considered significant. All analyses were performed using SPSS version 15.0 
statistical software (SPSS, Inc., Chicago, IL, USA).  
 
 
RESULTS 
 
Baseline characteristics 
The baseline study population consisted of 940 patients undergoing carotid artery stenosis 
(N=215), abdominal aortic aneurysm (N=405), and lower extremity artery (N=153) repair and 
receiving preoperative β-blocker treatment. A total of 661 (70%) patients received bisoprolol, 
186 (20%) received metoprolol succinate, 49 (5%) received atenolol, and 44 (5%) patients 
received other β-blockers. Clinical parameters, stratified by timing between β-blocker initiation 
and vascular surgery, are demonstrated in Table 1. The majority of patients were males (77%) 
and the mean age was 67 ±10 years. Patients receiving β-blocker treatment >1 week before 
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surgery more often had a history of ischemic heart disease, kidney dysfunction, hypertension, 
and more often received RAAS inhibitors and diuretics, compared with patients who received 
β-blocker treatment <1 week before surgery. 
 
Table 1 Baseline characteristics  
Timing of β-blocker initiation  
before surgery 
 
 
0-1 week >1-4 weeks  >4 weeks p-value* 
 
[N=158] [N=393] [N=389]  
Demographics  
 
    
  Age (± SD) 68 (11) 67 (10) 67 (10) 0.920 
  Median heart rate at day of surgery (± IQR) 74 (17) 70 (16) 66 (15) <0.001 
  Male (%) 117 (74) 310 (79) 279 (76) 0.437 
Medical history (%)     
  Ischemic heart disease 56 (35) 142 (36) 208 (54) <0.01 
  Heart failure 12 (8) 35 (9) 50 (13) 0.090 
  Cerebrovascular disease 69 (44) 118 (30) 137 (35) 0.009 
  Renal dysfunction  28 (18) 55 (14) 87 (22) 0.010 
  Diabetes mellitus  48 (30) 100 (26) 126 (33) 0.100 
  Hypertension  101 (64) 236 (60) 290 (75) <0.01 
  Hypercholesterolemia 79 (50) 165 (42) 198 (51) 0.032 
  Smoker, current  75 (58) 167 (43) 157 (40) 0.313 
  Chronic obstructive pulmonary disease 42 (27) 136 (35) 134 (34) 0.154 
Surgery type (%)     
Open 91 (58) 260 (66) 247 (63) 0.170 
  lower extremity revascularization  29 (18) 92 (23) 110 (28) 0.153 
  abdominal aorta repair  29 (18) 110 (28) 95 (24) 0.163 
  carotid artery repair 33 (22) 58 (15) 42 (11) 0.973 
Endovascular 67 (42) 133 (34) 142 (37) 0.170 
  lower extremity revascularization  16 (10) 30 (8) 43 (11) 0.244 
  abdominal aorta repair  27 (17) 83 (21) 61 (16) 0.091 
  carotid artery repair 24 (15) 20 (5) 38 (10) 0.107 
Echocardiography (%)     
  Left ventricular ejection fraction <40% 26 (17) 71 (18) 84 (22) 0.312 
Laboratory (IQR)     
  Median hs-CRP (mg/L) 1 day before surgery 4.9 (7.5) 4.1 (6.0) 4.5 (6.3) 0.782 
Medication (%)     
  Statins 118 (75) 289 (74) 296 (76) 0.271 
  Aspirin 95 (60) 228 (58) 239 (61) 0.187 
  Oral anticoagulants  25 (16) 57 (15) 71 (18) 0.360 
  RAAS inhibitors 57 (36) 138 (35) 197 (51) <0.01 
  Diuretics 40 (25) 85 (22) 116 (30) 0.030 
* p-value: comparison of groups >1-4 weeks and >4 weeks with group 0-1 week. High-sensitive C-reactive-protein (hs-
CRP), renin-angiotensin-aldosterone system (RAAS). 
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Preoperative heart rate, preoperative hs-CRP and postoperative outcome 
As demonstrated in Table 1, patients receiving β-blocker treatment >1 week before surgery had 
lower median rest heart rate at day of surgery, compared with patients receiving β-blocker 
treatment <1 week preoperatively (p < 0.001). No significant difference was observed in 
median preoperative hs-CRP levels between these groups (p = 0.782). A sub-analysis 
demonstrated that median hs-CRP concentrations were significantly lower in patients receiving 
statin treatment >1 week before surgery (median hs-CRP = 4.0 mg/L), compared with patients 
receiving no statin treatment before surgery (median hs-CRP = 5.7 mg/L, p-value of 0.043).  
 
The influence of median preoperative heart rate and hs-CRP towards postoperative outcome is 
demonstrated in Figure 1. An increased heart rate >70 bpm (42/243 or 17%) or an hs-CRP 
concentration >6.5 mg/L (24/139 or 17%) were both associated with an increased incidence 
of perioperative events (Figure 1), compared with patients with normal heart rate (60 to 70 
bpm) in combination with a hs-CRP concentration ≤6.5 mg/L (53/438 or 12%). In addition, 
an increased heart rate >70 bpm (38/243 or 16%) or hs-CRP concentration >6.5 mg/L 
(23/139 or 17%) were both associated with an increased incidence of long-term mortality 
(Figure 1), compared with patients with normal heart rate (60 to 70 bpm) in combination with a 
hs-CRP concentration ≤6.5 mg/L (27/120 or 23%). Patients with high heart rate (>70 bpm) in 
combination with an hs-CRP >6.5 mg/L had the highest incidence of perioperative events 
(29/120 or 24%) and long-term mortality (27/120 or 23%).  
 
 
Figure 1: Influence of preoperative heart rate and hs-CRP towards postoperative outcome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High-sensitive C-Reactive Protein (hs-CRP). 
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Initiation of β-blocker treatment and postoperative outcome 
During the first 30 days after surgery 150 (16%) patients had troponin T release, of which 114 
(76%) patients had myocardial ischemia and 36 (24%) patients had myocardial infarction. The 
study endpoint 30-day cardiovascular events (composite of troponin T release, stroke, and 30-
day mortality) was reached by 162 patients, as demonstrated in Table 2. In total, 27% (52/158) 
of patients receiving β-blocker treatment <1 week before surgery had a perioperative 30-day 
cardiovascular event, compared with 15% (120/782) of patients who received preoperative β-
blocker treatment >1 week before surgery (Table 3). Multivariate analyses demonstrated that β-
blocker treatment initiated >4 and >1 to 4 weeks before surgery were both associated with a 
reduced incidence of 30-day cardiovascular events with ORs of 0.46 (95%-CI: 0.27 to 0.48) 
and 0.48 (95%-CI: 0.29 to 0.79), compared with patients in whom β-blocker treatment was 
initiated <1 week preoperatively (Table 3). Sub analyses performed in patients undergoing 
vascular surgery associated with high- and intermediate-cardiac risk are demonstrated in Table 
3. 
 
Table 2 
The influence of timing of β-blocker initiation before vascular 
surgery and postoperative outcome 
Timing of β-blocker initiation  
before surgery 
 
 
0-1 week >1-4 weeks  >4 weeks p-value* 
 
[N=158] [N=393] [N=389]  
30-day outcome  
 
    
  Troponin T release 40 (22) 54 (12) 56 (15) 0.032 
  Mortality 6 (4) 8 (2) 11 (3) 0.495 
  Stroke  3 (1.9) 2 (0.5) 2 (0.5) 0.021 
  Cardiovascular events 42 (27) 58 (15) 62 (16) <0.001 
Long-term outcome     
  Diuretics 30 (19) 55 (14) 57 (15) 0.039 
 
 
During long-term follow-up 142 (15%) patients died. Cumulative postoperative 
survival stratified to β-blocker treatment initiation time is demonstrated in Figure 2 (log rank p 
< 0.01). Of the patients who died, 33% (47/142) had perioperative myocardial damage. In 
total, 19% (30/158) of patients receiving β-blocker treatment <1 week before surgery died, 
compared with 15% (112/782) of patients who received preoperative β-blocker treatment >1 
week before surgery (Table 4). Of the patients who died, 72 patients (51%) had myocardial 
damage during 30-day follow-up. Multivariate analyses demonstrated that β-blocker treatment 
initiated >4 and >1 to 4 weeks before surgery was associated with a reduced incidence of long-
term mortality with HRs of 0.52 (95%-CI: 0.21 to 0.67) and 0.50 (95%-CI: 0.25 to 0.71) 
compared with patients in β-blocker treatment was initiated <1 week preoperatively (Table 4). 
Sub analyses performed in patients undergoing surgery associated with high- and intermediate-
cardiac risk are demonstrated in Table 4. 
 311 
Table 3 
Association of time between β-blocker initiation before vascular surgery 
and the presence of 30-day cardiovascular events 
 Univariate Multivariate 
All procedures N (%) OR [95%-CI] OR [95%-CI] 
Timing of β-blocker initiation 162/940      
 0-1 week preoperatively 42/158 (27) reference reference 
 >1-4 weeks preoperatively 58/393 (15) 0.48 0.30 - 0.78 0.46 0.27 - 0.76 
 >4 weeks preoperatively 62/389 (16) 0.54 0.40 - 0.88 0.48 0.29 - 0.79 
High-risk procedures N (%) HR [95%-CI] HR [95%-CI] 
Timing of β-blocker initiation 125/469      
 0-1 week preoperatively 25/58 (43) reference reference 
 >1-4 weeks preoperatively 44/204 (22) 0.35 0.18 - 0.66 0.38 0.19 - 0.79 
 >4 weeks preoperatively 56/207 (27) 0.66 0.36 - 0.97 0.58 0.29 - 0.91 
Intermediate-risk procedures       
Timing of β-blocker initiation 37/471      
 0-1 week preoperatively 17/100 (17) reference reference 
 >1-4 weeks preoperatively 14/189 (7) 0.49 0.23 - 0.97 0.51 0.13 - 0.79 
 >4 weeks preoperatively 6/182 (3) 0.10 0.03 - 0.34 0.12 0.02 - 0.25 
 
 
Table 4 
Association of time between β-blocker initiation before vascular surgery 
and long-term mortality 
 Univariate Multivariate 
All procedures N (%) OR [95%-CI] OR [95%-CI] 
Timing of β-blocker initiation 142/940      
 0-1 week preoperatively 30/158 (19) reference reference 
 >1-4 weeks preoperatively 55/393 (14) 0.57 0.32 - 0.91 0.52 0.21 - 0.67 
 >4 weeks preoperatively 57/389 (15) 0.62 0.35 - 0.94 0.50 0.25 - 0.71 
High-risk procedures N (%) HR [95%-CI] HR [95%-CI] 
Timing of β-blocker initiation 93/469      
 0-1 week preoperatively 17/58 (29) reference reference 
 >1-4 weeks preoperatively 38/204 (19) 0.31 0.17 - 0.57 0.37 0.20 - 0.69 
 >4 weeks preoperatively 43/207 (20) 0.47 0.27 - 0.83 0.46 0.26 - 0.83 
Intermediate-risk procedures       
Timing of β-blocker initiation 49/471      
 0-1 week preoperatively 13/100 (13) reference reference 
 >1-4 weeks preoperatively 17/189 (9) 0.59 0.27 - 0.91 0.46 0.21 - 0.94 
 >4 weeks preoperatively 13/182 (7) 0.37 0.16 - 0.88 0.37 0.15 - 0.91 
 
 
DISCUSSION 
 
The present study evaluated the influence of time, between β-blocker treatment initiation 
before vascular surgery, and postoperative outcome. Our results indicate that β-blocker 
treatment initiated >1 week before surgery is associated with a reduction of preoperative heart 
rate compared with treatment initiated <1 week before surgery. Of note, no reduction of hs-
CRP levels was observed. Importantly, our results indicate that β-blocker treatment initiated 
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>1 week before surgery is associated with an improved postoperative outcome, compared with 
treatment initiated <1 week before surgery. This could be related to adequate heart rate 
control.  
 
Surgical procedures are associated with tachycardia and increased myocardial 
contractility leading to an increased oxygen-demand.26 Maintaining a balance between the 
myocardial oxygen-demand and supply is key to prevent perioperative cardiac events. 
Proposed mechanisms by which β-blockers exert intraoperative cardioprotective effects are (i) 
heart rate control with subsequent prolongation of coronary diastolic filling time and (ii) anti-
arrhythmic properties reducing the risk for tachycardia.17 In addition, β-blockers are known to 
reduce systolic pressure and ventricular contractile force.17, 19  
 
Long-term; β-blockers reduce mechanical stress imposed to coronary plaques 
preventing plaque rupture.16 In addition, the anti-inflammatory properties of β-blockers are 
thought to stabilize coronary plaques.17, 19 Recently, it is suggested that left ventricular 
dysfunction is highly present in the vascular surgery population.27 Long-term β-blocker therapy 
is known to reduce adverse cardiac remodelling in patients with impaired left ventricular 
function by inhibiting the sympathetic nervous system and hormone activation (A-type and B-
type natriuretic peptides and norepinephrine).20, 22  
 
Over the years, multiple randomized, controlled trials evaluated the effectiveness of 
perioperative β-blocker use and provided conflicting evidence regarding its benefit.4-15 In 1996, 
Mangano et al. hypothesized that strict perioperative heart rate control with atenolol may limit 
the development of perioperative ischemia in high-risk surgery patients.9 In addition, Raby et al. 
demonstrated a beneficial effect of heart rate control, using the short acting β-blocker esmolol 
immediately after vascular surgery.11  In the present study, β-blocker treatment >1 week before 
surgery was associated with lower mean preoperative heart rate and improved postoperative 
outcome. 
 
In 2002, Jenkins et al. evaluated the association between β-blocker treatment and 
plasma CRP levels in patients with symptomatic coronary artery disease.18  The authors found 
that patients who were treated with β-blockers had lower plasma concentrations of CRP than 
those not receiving β-blockers, however no differences among types or dosages of β-blockers 
were evident. In our study, all patients received β-blocker treatment and our results indicate 
that longer duration of β-blocker therapy is not associated with an additional reduction of hs-
CRP levels. However, patients receiving statin treatment >1 week before surgery did have 
lower median hs-CRP levels before surgery than those not receiving statin treatment, in line 
with previous studies.28-30 The Novel Approaches for Preventing or Limiting Events 
(NAPLES)-II trial demonstrated that even a single high loading-dose (80 mg) of atorvastatin 
reduced the incidence of periprocedural myocardial infarction in patients undergoing elective 
percutaneous coronary intervention.29 
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In 2008, the perioperative ischemic evaluation (POISE)-trial randomized patients to 
receive either high dosage metoprolol succinate on the day of surgery or placebo, without 
titration of the dose according to heart rate.5 Although a 30% decrease in nonfatal myocardial 
infarction was found in patients treated with high-dose metoprolol succinate, this beneficial 
effect was accompanied by a 33% increase in total mortality and a twofold increased risk of 
stroke, compared with placebo. Metoprolol is metabolized via the CYP 2D6 pathway and 
might interact with other drugs, administered intraoperatively and metabolized via the CYP 
2D6 pathway as well, underlining the importance for adequate β-blocker dosage.31 Poldermans 
et al. performed the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography (DECREASE)-I trial and evaluated the effect of low-dose bisoprolol on 
postoperative outcome after vascular surgery.10 Bisoprolol treatment was started an average of 
37 days before surgery with careful titration according to heart rate to prevent adverse side 
effects. In contrast to the POISE-trial, the incidence of stroke in the DECREASE-I trial was 
comparable with placebo, while reducing the incidence of cardiac death and nonfatal 
myocardial infarction from 34% in the standard-care group to 3.4% in the bisoprolol-treated 
group. Interestingly, in all clinical trials who did not demonstrate a difference in postoperative 
outcome between β-blocker- and placebo-treated groups, β-blocker treatment was initiated <1 
week before surgery.4, 7, 14-15 This could provide an explanation for the conflicting results 
regarding the effect of perioperative β-blocker treatment in the literature up to now.  
 
The most recent ‘European Society of Cardiology’ guidelines, addressing 
perioperative care, recommend that β-blocker treatment should be initiated between 30 days 
and at least 1 week before surgery.24 This recommendation is based on an expert opinion with 
a level of evidence C. In addition, in the 2009 ‘American College of Cardiology 
Foundation/American Heart Association Focused Update on Perioperative β-blockade for 
noncardiac surgery’ it is suggested that when possible and where indicated, β-blockers should 
be started days to weeks before elective surgery.32 The results from the present study underline 
the importance of β-blocker initiation >1 week before vascular surgery. One of the reasons we 
did not observe better survival of patients in whom β-blocker treatment was initiated >4 
weeks, compared with patients in whom β-blocker treatment was initiated >4 weeks before 
surgery, is an increased prevalence of ischemic heart disease and renal dysfunction present in 
this group of patients. 
 
Regarding perioperative β-blocker treatment, the following questions could be asked. 
First, could one give just a slightly higher β-blocker dose in order to achieve adequate heart 
rate control and routinely start the treatment <1 week before surgery to reach an improved 
postoperative outcome as well? As we have learned from the POISE-trial, treatment with high 
β-blocker dosage and without up-titration according to tolerance, is accompanied with an 
increased incidence of side effects (bradycardia, hypotension, and stroke). In the present study, 
the incidence of stroke was increased in patients receiving β-blocker treatment <1 week before 
surgery compared with patients receiving β-blocker treatment >1 week before surgery. In 
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patients in whom β-blocker therapy is initiated shortly before surgery, there might be an 
increased risk of side effects, because treatment is initiated too aggressively and the response to 
β-blocker therapy cannot be adequately monitored during this short period of time leading to a 
danger of overdosing.33 In addition, as recently described by Beattie et al, β-blocked patients do 
not seem to tolerate surgical anaemia when compared with patients who are naive to β-
blockers.34 Although, one could assume that high β-blocker dosage may prevent compensatory 
mechanisms evoked by perioperative anaemia, such as an increase in heart rate, optimal β-
blocker titration in anaemic patients remains to be elucidated. A second question to be asked 
is: what to do with β-blocker naïve patients in urgent need for vascular surgery, i.e. should 
surgery be postponed to obtain adequate heart rate control first? The results of this study have 
demonstrated that β-blocker initiation >1 week before surgery is not associated with a 
reduction of hs-CRP concentrations, which might indicate that anti-inflammatory effects are 
achieved within days. In addition, β-blocker initiation at day of surgery is known to reduce 
preoperative heart rate as well, as demonstrated by Mangano et al.9 and Raby et al.11 Therefore, 
it seems to be justified to state that β-blockers treatment should be ideally initiated >1 week 
before surgery, to perform heart rate titration before surgery.  
 
Potential limitations of these data merit consideration. First, the study population 
consisted of patients referred to a tertiary referral center and may not fully represent a general 
population scheduled for elective vascular surgery. Second, although more than 900 patients 
were included in the study, the observational and retrospective nature of the study remains a 
limitation. Third, nonfatal cardiovascular events during long-term follow-up were not 
addressed, however the study focused on the hard endpoint of long-term mortality. Fourth, 
data in the current study are not randomized according to initiation time of β-blocker 
treatment. Although multivariate analyses were adjusted for known confounders, the 
possibility of unsuspected or uncaptured confounders persists.  
 
The present study provides an indication that β-blocker therapy initiated >1 week 
before surgery is associated with reduced preoperative heart rate and improved postoperative 
outcome, compared with patients in whom β-blocker was initiated <1 week before vascular 
surgery. In addition, no reduction of median hs-CRP levels was observed, also not in patients 
receiving β-blocker treatment >1 week before surgery. Improved postoperative outcome of 
patients receiving β-blocker treatment >1 week before vascular surgery could therefore be 
related to adequate heart rate control. 
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Dr A Margonato and Dr D Gerosa have provided us with a thorough and well-written review 
article ‘β-blockers in noncardiac surgery; do they really work?’ addressing a central question in 
perioperative medicine: do β-blockers sufficiently protect patients for the development of 
perioperative cardiovascular complications? The value of β-blockers has been debated for 
many years and the relevance of this topic will only expand. Cardiac complications are the 
leading cause of perioperative morbidity and mortality 1 in 2020 the number of patients eligible 
for surgery will increase by 25%.2 This Review article provides the reader a clear insight of (i) 
mechanisms of action and characteristic of β-blockers, (ii) pathophysiology of perioperative 
cardiovascular complications, and (iii) provides an extended literature overview of β-blocker 
use in noncardiac and vascular surgery.  
 
Two randomized controlled trials evaluating the protective value of β-blockers, which 
are discussed thoroughly, are the Dutch Echocardiographic Cardiac Risk Evaluation Applying 
Stress Echocardiography (DECREASE)-1 trial performed in Rotterdam 3 and the multi-centre 
Perioperative Ischemic Evaluation (POISE)-trial.4 In DECREASE-I trial, vascular surgery 
patients were treated with the highly selective β 1-adrenoreceptor-antagonist bisoprolol titrated 
to achieve a heart rate between 60-65 beats per minute. Bisoprolol treatment reduced the 
occurrence peri- and postoperative cardiovascular complications.3, 5 The DECREASE-I trial 
included high-risk vascular surgery patients, however promising results in the DECREASE-IV 
trial show beneficial effects of bisoprolol treatment in intermediate risk patients as well.6 The 
incidence of stroke was comparable between patients receiving bisoprolol or placebo. In the 
POISE trial, patients were treated with a relative high dosage of the long-acting β-blocker 
metoprolol succinate. Metoprolol succinate did lower the incidence of myocardial infarction, 
however this benefit was outweighed by an increased incidence of stroke and death.  
 
Different treatment protocols of the DECREASE-I trial, POISE trial and other 
studies are elegantly summarized by the authors and differ in (i) initiation time of therapy, (ii) 
β-blocker type, (iii) mode of administration, and (iv) risk profile of the patients. Dr A 
Margonato and Dr D Gerosa note that the question whether β-blocker use is effective in 
reducing preoperative cardiovascular complication without excessive side effect has not been 
answered yet. They propose that a future randomized, double-blind, placebo-controlled trial is 
needed, which should include a sufficient number of patients with a revised cardiac risk index 
of at least >2, scheduled for vascular and major noncardiac surgery. We propose low dose 
treatment with a highly selective long-acting β-blocker, initiated al least a month before 
surgery. Up-titration according to tolerance to obtain heart rates between 65 and 70 beats per 
minute could demonstrate maximal protection of β-blockers without over treating the patients. 
Intraoperatively, the ultra short β-blocker esmolol, administered via a continuous infusion, 
could be considered as well to maximally prevent the occurrence of adverse myocardial events. 
A randomized double-blind placebo-controlled trial of this kind could provide the final answer 
to the question: β-blockers in noncardiac surgery; do they really work? 
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SUMMARY AND CONCLUSIONS 
 
In this thesis, the influence of asymptomatic manifestations of atherosclerosis towards 
perioperative and long-term outcome (myocardial damage and survivial) is described in patients 
undergoing vascular surgery. In general, the influence of asymptomatic left ventricular 
dysfunction, low ankle-brachial index, and increased intimamedia thickness of the common 
carotid artery were evaluated. In addition, the predictive value of the metabolic syndrome and 
biomarkers, such as N-terminal pro-B-type natriuretic peptide, will be discussed. Furthermore, 
the possibility to screen for asymptomatic abdominal aortic aneurysms with a handheld 
ultrasound devise has been explored. The last part of the thesis has focussed on the value of 
perioperative β-blocker use and prophylactic revascularization in order to reduce the incidence 
of perioperative cardiac events en improve long-term outcome.  
 
 
Part I: Left ventricular function 
 
In Chapter 2, the most frequently used tests for preoperative cardiac risk stratification are 
discussed. Stress echocardiography is recommended (class 1 recommendation, level of evidence 
C) in patients with ≥3 Revised Cardiac Risk factors undergoing high-risk surgery. In addition, 
for patients with 0-2 Revised Cardiac Risk factors undergoing high-risk vascular surgery (class 
IIb recommendation, level of evidence B) or patients undergoing intermediate-risk vascular 
surgery (class IIb recommendation, level of evidence C), stress echocardiography may be 
considered. In addition, rest echocardiography should be considered in all patients undergoing 
high-risk vascular surgery (class IIa recommendation, level of evidence C).1 
 
 Coronary artery disease is the most common cause of myocardial disease, being the 
initial cause in 70% of patients with predominantly systolic heart failure. In order to identify 
patients with coronary artery disease, regional and global wall motion assessment with 
echocardiography plays a pivotal role. As described in Chapter 3, two-dimensional 
echocardiography has the advantage of being (i) safe, (ii) widely available, (iii) noninvasive and 
(iv) feasible in almost all circumstances at low costs, compared with cardiac computed 
tomography, magnetic resonance imaging, or nuclear imaging techniques.  
 
Druing the period between 2002 and 2008, 1,005 patients undergoing vascular surgery at the 
Erasmus Medical Center underwent standard preoperative evaluation using echocardiography, 
regardless the presence of heart failure symptoms. As described in Chapter 4, left ventricular 
(LV) dysfunction was diagnosed in 506, or 50% of the patients included. Interestingly, 403 
patients (80%) had asymptomatic LV dysfunction and 103 patients (20%) had symptomatic 
heart failure. Half of the patients with asymptomatic LV dysfunction had an LV ejection 
fraction <50%. Importantly, pharmacological treatment with angiotensin blocking agents, β-
blockers or diuretics, as recommended in European Society of Cardiology guidelines 2 could be 
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initiated or improved in one third of patients with LV dysfunction (symptomatic or 
asymptomatic). The prognostic implications of asymptomatic LV dysfunction on postoperative 
outcome of patients undergoing vascular surgery are discussed in Chapter 5. In patients 
undergoing open vascular surgery, asymptomatic LV dysfunction was associated with increased 
risk for 30-day cardiovascular events (composite of 30-day myocardial ischemia, myocardial 
infarction and mortality) and long-term cardiovascular mortality. In patients undergoing 
endovascular surgery, the presence of symptomatic heart failure was associated with an 
increased risk for these study endpoints.  
 
Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), and 
cardiovascular disease are common co-morbidities in surgery patients, associated with poor 
outcome. In Chapter 6, we hypothesized that (i) COPD would be independently associated 
with LV dysfunction and that (ii) the presence of asymptomatic LV dysfunction would 
significantly increase the risk of pospoperative mortality of COPD patients. Of the 1005 
included patients, approximately 1 out of 3 patients had COPD detected with spirometry and 
more than half of these patients had LV dysfunction detected with echocardiography. Both 
mild and moderate to severe COPD patients who had asymptomatic LV dysfunction were at 
increased risk for all-cause mortality, compared with COPD patients with normal LV function.    
 
Elevated C-reactive protein (CRP) plasma levels reflect an inflammatory state associated with 
atherosclerosis. Since elevated high-sensitive CRP levels are associated with an increased risk 
for cardiac events in patients with or without coronary artery disease, we evaluated the 
prognostic value of LV dysfunction assessed using the wall motion score index (WMSI) in 
patients with normal or increased high-sensitive CRP in Chapter 7. Results described in this 
chapter indicate that WMSI >1.5 is associated with an increased risk for 30-day myocardial 
damage and long-term mortality in patients with high-sensitive CRP >6.5 or ≤6.5 mg/L. In 
addition, patients with WMSI >1.5 + high-sensitive CRP >6.5 mg/L had the highest risk for 
the study endpoints.  
 
In Chapter 8, dobutamine stress echocardiography was performed before vascular surgery and 
transesophageal echocardiography was performed intraoperatively in 54 patients. The study was 
conducted to compare the location of (i) wall motion abnormalities induced during 
preoperative dobutamine stress echocardiography with (ii) intraoperative wall motion 
abnormalities detected with transesophageal echocardiography. In these patients, an excellent 
correlation between pre- and intraoperative rest wall motion abnormalities was observed, 
however, poor agreement correlations were found between pre- and intraoperative locations of 
new wall motion abnormalities during stress.  
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Chapter 9 provides a brief discussion regarding the accuracy of three- vs. two-dimensional 
speckle tracking echocardiography for measuring end-systolic and end-diastolic LV volumes. 
Recently it has been demonstrated that inter- and intraobserver variability of measurements 
performed with three-dimensional speckle tracking was lower and less spread, compared with 
two-dimensional speckle tracking echocardiography.3 This might imply that three-dimensional 
speckle tracking echocardiography could be an attractive new method for the assessment of LV 
volumes and perhaps function.      
 
 
Part II: Asymptomatic atherosclerosis in patients with symptomatic peripheral arterial 
disease  
 
A systematic Medline search was undertaken in Chapter 10, to identify studies addressing 
perioperative myocardial damage, assessed with troponin I or T, in patients undergoing elective 
peripheral vascular surgery published during the period between 2000 and 2010. The incidence 
of perioperative myocardial ischemia ranged from 14 to 47% and the incidence of perioperative 
myocardial infarction (troponin release + angina pectoris or electrocardiographic changes) 
ranged from 1 to 26%. In addition, hazard ratios describing the prognostic value of troponin T 
or I towards postoperative mortality or the occurrence of major adverse cardiac events varied 
from 1.9 to 9.0.  
 
 The prevalence and prognostic implications of polyvascular disease in patients 
undergoing vascular surgery at the Erasmus Medical Center during the period between 1990 
and 2008 is described in Chapter 11. Single, two and three affected vascular beds were detected 
in 1.369 (46%), 1.249 (43%) and 315 (11%) patients, respectively. Compared with patients with 
one affected vascular beds, patients with two- or three affected vascular beds had significantly 
higher rates of all-cause and cardiovascular mortality during long-term follow-up.  
 
In Chapter 12, the impact of subclinical increased intimamedia thickness of the common 
carotid artery (CCA-IMT) was evaluated in patients undergoing abdominal aortic- or lower 
extremity artery repair. The optimal predictive value of CCA-IMT, using receiver-operating 
characteristic curve analysis, for the prediction of CV events was calculated to be 1.25 mm 
(sensitivity 70%, specificity 80%). Importantly, an increased CCA-IMT was independently 
associated with 30-day cardiovascular events and long-term cardiovascular mortality. Chapter 
13 evaluates the predictive value of asymptomatic low ankle-brachial index (ABI) towards 
postoperative outcome of patients undergoing abdominal aortic- or carotid artery stenos repair. 
Asymptomatic low ABI has prognostic value towards perioperative myocardial damage and 
long-term mortality, incremental to risk factors imbedded in conventional cardiac risk indices 
such as the Revised Cardiac Risk index. The separate and combined prognostic values of 
asymptomatic low ABI (<0.9) or increased CCA-IMT (>1.25 mm) is evaluated in Chapter 14, 
in a cohort of patients undergoing abdominal aortic aneurysm repair. Although asymptomatic 
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ABI <0.9 and subclinical CCA-IMT >1.25 independently predict 30-day myocardial damage 
and long-term mortality, a combination of these markers is associated with the highest risk 
towards the occurrence of the study endpoints.   
 
 Chapter 15 illustrates that metabolic syndrome, defined according the National 
Cholesterol Education Program’s Adult Treatment Panel III report,4 is highly prevalent in 
vascular surgery patients. Metabolic syndrome was diagnosed in 41% of patients with occlusive 
and 42% of patients with aneurysmatic peripheral arterial disease. Both in occlusive as in 
aneurysmatic peripheral arterial disease patients, metabolic syndrome constituted to be an 
independent predictor of long-term cardiovascular events.  
 
The interrelationship between preoperative anemia and N-terminal Pro-B-type 
natriuretic peptide and its effect in predicting postoperative cardiac events in vascular surgery 
patients is evaluated in Chapter 16. The optimal predictive value of N-terminal Pro-B-type 
natriuretic peptide, using receiver-operating characteristic curve analysis, for the prediction of 
postoperative cardiac events was calculated to be 350 pg/mL. Anemia was defined as serum 
hemoglobin <13 g/dL for men and <12 g/dL for women. Both N-terminal Pro-B-type 
natriuretic peptide and anemia were independently associated with an increased risk for 
postoperative cardiac events. However, N-terminal Pro-B-type natriuretic peptide was less 
predictive in anemic patients.  
 
In Chapter 17, the diagnostic accuracy of a new portable ultrasound scanner 
(Aortascan BVI 9600) developed for automated abdominal aortic aneurysm detection is 
discussed. 150 patients were first scanned with conventional ultrasound, serving as the 
reference technique. An abdominal aortic diameter ≥30 mm defined an aneurysm. The 
Aortascan BVI 9600 automatically detects and calculates the aortic diameter ≥30 mm with a 
90% sensitivity.  
 
 
PART III: Prevention and treatment 
 
In Chapter 18, leading randomized controlled trials addressing the value of preoperative β-
blocker treatment or prophylactic coronary revascularization are discussed. The value of 
preoperative β-blocker treatment has been widely debated. Important factors that may relate to 
the effectiveness of β-blocker therapy are the patients’ underlying cardiac risk and variations of 
treatment protocols in (i) initiation time, (ii) β-blocker type, (iii) starting dose, (iv) dose 
adjustments for heart-rate control, and (v) duration of treatment, as discussed in this chapter. 
Prophylactic coronary revascularization of patients with ≥3 Revised Cardiac Risk factors 
apparently provides insufficient extra protection on top of β-blocker treatment as 
demonstrated. Retrospective data indicate that prophylactic coronary revascularization may be 
the most effective option patients with 1-2 Revised Cardiac Risk factors.  
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Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients 
undergoing major vascular surgery is evaluated in Chapter 19. Included patients in the study 
had ≥3 Revised Cardiac Risk factors + extensive ischemia induced during stress 
echocardiography. Patients were randomized in the following groups: (i) best medical 
treatment or (ii) preoperative coronary revascularization + best medical treatment. Rates for 
survival free of all-cause death, nonfatal myocardial infarction, and coronary revascularization 
were similar in both groups at 49% and 42% for patients allocated to medical treatment or 
coronary revascularization, respectively. Therefore, preoperative coronary revascularization in 
high-risk patients undergoing major vascular surgery was not associated with an improved 
postoperative long-term outcome compared with the best medical treatment. 
 
The aim of Chapter 20 was to assess the influence of (i) different intervals between coronary 
stent placement (drug-eluting or bare metal stents) and noncardiac surgery and (ii) the use of 
dual antiplatelet therapy towards the occurrence of perioperative major adverse cardiac events. 
An inverse relation between the interval from coronary stent placement to noncardiac surgery, 
and the occurrence of perioperative major adverse cardiac events was demonstrated. 
Continuation of dual antiplatelet therapy did not provide complete protection against major 
adverse cardiac events. Based on these results, elective noncardiac surgery should be preferably 
postponed 90 days after placement of a drug-eluting stent and ≥1 year after placement of a 
bare metal stent. 
 
The study described in Chapter 21 was conducted to evaluate the relation between timing of 
β-blocker treatment initiation 0-1, >1-4, and >4 weeks before surgery and (i) preoperative 
heart rate and high-sensitive C-reactive protein levels and (ii) postoperative outcome. The 
results from these studies indicate that β-blocker treatment initiated >1 week before surgery is 
associated with lower preoperative heart rate and improved cardiac outcome after vascular 
surgery, compared with treatment initiated <1 week before surgery. No reduction of median 
hs-CRP levels was observed, also not in patients receiving β-blocker treatment >1 week before 
surgery. The results underline the importance of adequate perioperative heart rate control 
between 60-70 beats per minute, which is discussed in Chapter 22 as well.  
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SAMENVATTING EN CONCLUSIES 
 
Dit proefschrift beschrijft de invloed die asymptomatische aderverkalking, of atherosclerose, 
heeft op de perioperatieve- en lange-termijn resultaat (myocard schade en overleving) van 
patiënten die een perifeer vaatheelkundige ingreep ondergaan. De voorspellende waarde van 
asymptomatische linker ventrikel dysfunctie, asymptomatische verlaagde enkel-arm index en 
een toegenomen intimamedia dikte in de halsslagader op het ontstaan van cardiale complicaties 
en lange-termijn resultaten zijn hiertoe geëvalueerd. Tevens wordt de voorspellende waarde 
van het metabool syndroom en van biomarkers, zoals N-terminal pro-B-type natriuretic 
peptide, besproken. Daarnaast wordt de mogelijkheid tot screening van asymptomatische 
aneurysma’s van de abdominale aorta via het gebruik van een draagbaar echo apparaat 
onderzocht. Het laatste deel van het proefschrift beschrijft de invloed van perioperatief 
bètablokker gebruik en profylactische revascularisatie voorafgaand aan de vaatingreep, op de 
incidentie van perioperatieve cardiale complicaties en de lange-termijn resultaten.  
 
 
Deel I: Linker ventrikel functie 
 
Hoofdstuk 2 beschrijft de meest gebruikte diagnostische testen die gebruikt worden bij de 
preoperatieve inschatting van het cardiale risico tijdens en na de operatie. In perioperatieve 
richtlijnen wordt stress echocardiografie aanbevolen (aanbeveling van klasse 1, niveau van 
bewijs C) bij patiënten met ≥3 ‘Revised Cardiac Risk’ risicofactoren die een ‘high-risk’ perifere 
vaatheelkundige ingreep ondergaan. Daarnaast kan stress echocardiografie worden overwogen 
bij patiënten met 0-2 ‘Revised Cardiac Risk’ risicofactoren die een ‘high-risk’ perifere 
vaatheelkundige ingreep ondergaan (Klasse IIb aanbeveling, niveau van bewijs B) of patiënten 
die een ‘intermediate-risk’ perifere vaatheelkundige ingreep ondergaan (klasse IIb aanbeveling, 
niveau van bewijs C). Verder kan een rust echo worden overwogen bij alle patiënten die een 
‘high-risk’ perifere vaatingreep ondergaan (klasse IIa aanbeveling, het niveau van bewijs C).1 
 
Coronair vaatlijden  is de meest voorkomende oorzaak van aandoeningen van het 
myocard en tevens de oorzaak van systolisch hartfalen bij 70% van de patiënten. 
Echocardiografie speelt een centrale rol in de diagnostiek van coronair vaatlijden, via de 
beoordeling van regionale en globale wandbewegingen van het myocard. Zoals in Hoofdstuk 
3 is beschreven, heeft twee-dimensionale echocardiografie het voordeel (i) veilig, (ii) op grote 
schaal beschikbaar, (iii) niet invasief en (iv) relatief goedkoop te zijn, dit vergeleken met 
cardiale ‘computed tomography’, ‘magnetic resonance imaging’, of nucleaire beeldvormende 
technieken.  
 
Gedurende de periode van 2002 tot en met 2008 zijn 1005 patiënten die een perifere 
vaatingreep in het Erasmus Medisch Centrum ondergingen, onderworpen aan standaard 
preoperatieve evaluatie met behulp van echocardiografie, ongeacht de aanwezigheid van 
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symptomen van hartfalen. Zoals beschreven in Hoofdstuk 4, werd linker ventrikel (LV) 
dysfunctie vastgesteld bij 506 patiënten, dit is 50% van de patiënten. Van deze groep, hadden 
403 patiënten (80%) asymptomatische LV dysfunctie en 103 patiënten (20%) symptomatisch 
hartfalen. De helft van de patiënten met asymptomatische LV dysfunctie had een LV 
ejectiefractie <50%. Een belangrijke constatering is dat medicamenteuze behandeling zoals 
aanbevolen in de richtlijnen van de Europese Vereniging voor Cardiologie,2 met bijvoorbeeld 
ACE-remmers, β-blokkers of diuretica, kon worden opgestart of verbeterd bij één derde van 
de patiënten met LV dysfunctie (zowel symptomatisch als asymptomatisch). De prognostische 
waarde van asymptomatische LV dysfunctie op de postoperatieve resultaten van patiënten die 
een vaatheelkundige ingreep ondergingen wordt besproken in Hoofdstuk 5. Bij patiënten die 
een open open vaatheelkundige ingreep ondergingen, bleek de aanwezigheid van een 
asymptomatische LV dysfunctie gerelateerd te zijn aan een verhoogd risico voor (i) 
cardiovasculaire complicaties (myocardischemie, myocardinfarct en cardiale mortaliteit) 
gedurende de eerste 30 dagen na de ingreep en (ii) een verhoogd risico op cardiovasculair 
overlijden gedurende de lange-termijn follow-up. Echter, bij patiënten die een endovasculaire 
ingreep ondergingen was alleen de aanwezigheid van symptomatisch hartfalen geassocieerd 
met een verhoogd risico voor de hierbovengenoemde studie eindpunten.  
 
Hart-en vaatziekten en chronische longziekten, zoals ‘chronic obstructive pulmonary 
disease’ (COPD), vormen een veel voorkomende co-morbiditeit bij de chirurgische patiënten 
populatie en zijn geassocieerd met een minder goed postoperatief resultaat. In Hoofdstuk 6 
hebben we de hypothese gevormd dat (i) COPD onafhankelijk geassocieerd is met LV 
dysfunctie en (ii) dat de aanwezigheid van een asymptomatische LV dysfunctie bij COPD 
patiënten het risico op postoperatieve sterfte aanzienlijk verhoogd. In deze studie zijn 1005 
patiënten geincludeerd. Met behulp van spirometrie is COPD gediagnosticeerd in ongeveer één 
derde van de patiënten. Echocardiografie toonde dat in meer de helft van de 1005 patiënten 
een LV dysfunctie aanwezig was. Patiënten die zowel milde COPD of matig tot ernstige 
COPD als een asymptomatische LV dysfunctie hadden, hadden een verhoogd risico op 
postoperatieve mortaliteit, vergeleken met COPD patiënten met een normale LV functie. 
 
Een verhoogde ‘high-sensitive C-reactive protein’ (hs-CRP) waarde in het plasma is 
een weerspiegeling van het ontstekingsproces dat samenhangt met atherosclerose. Verhoogde 
hs-CRP waarden zijn geassocieerd met een verhoogd risico op cardiale complicaties, zowel bij 
patiënten mét als bij patiënten zónder coronair vaatlijden. In Hoofdstuk 7 is de prognostische 
waarde van LV dysfunctie, beoordeeld met behulp van de ‘wall motion score index’ (WMSI), 
onderzocht bij patiënten met een normaal of een verhoogd hs-CRP. Uit de resultaten zoals 
beschreven in dit hoofdstuk blijkt dat patiënten met een WMSI >1.5 een verhoogd risico 
hebben op (i) het ontstaan van hartschade binnen 30 dagen na een perifere vaatheelkunde 
ingreep en (ii) mortaliteit gedurende lange-termijn follow-up, zowel bij een hs-CRP >6.5 als 
≤6.5 mg/L. Verder hadden patiënten met een WMSI> 1.5 + hs-CRP >6.5 mg/L het hoogste 
risico op het ontstaan van één van de studie eindpunten. 
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Hoofdstuk 8 beschrijft een studie waarin, bij 54 patiënten, dobutamine stress 
echocardiografie is verricht voorafgaand aan een perifere vaatingreep gevolgd door 
transoesofageale echocardiografie gedurende de operatie. De locatie van 
wandbewegingsstoornissen gedetecteerd gedurende dobutamine stress echocardiografie 
voorafgaand aan de operatie zijn vergeleken met wandbewegingsstoornissen gedetecteerd 
gedurende de operatie. Bij deze patiënten is een zeer goede correlatie gevonden tussen pre- en 
intraoperatieve wandbewegingsstoornissen aanwezig in rust. Echter, de correlatie was slecht 
tussen pre- en intraoperatieve locaties van nieuw ontstane wandbewegingsstoornissen 
gedurende stress.  
 
Hoofdstuk 9 geeft een kort overzicht over de nauwkeurigheid van de drie- vs. 
tweedimensionale ‘speckle tracking’ echocardiografie voor het meten van eind-systolische en 
eind-diastolische LV volumes. Recent is aangetoond dat de inter- en intraobserver variabiliteit 
lager is, en minder verspreid, bij de metingen uitgevoerd met driedimensionale ‘speckle 
tracking’ echocardiografie in vergelijking met metingen verricht met tweedimensionale ‘speckle 
tracking’ echocardiografie.3 Dit zou wellicht kunnen betekenen dat driedimensionale ‘speckle 
tracking’ echocardiografie in de toekomst een aantrekkelijke nieuwe methode is voor de 
beoordeling van LV volume en en misschien ook voor de functie van de LV. 
 
 
Deel II: Asymptomatische atherosclerose bij patiënten met symptomatisch perifeer 
vaatlijden.  
 
Een systematische ‘Medline search’ is verricht in Hoofdstuk 10, gericht op studies 
gepubliceerd tussen 2000 en 2010 met als onderwerp: perioperatieve myocard schade 
gedetecteerd met troponine T of I, bij patiënten die een electief geplande perifere vaatoperatie 
ondergingen. De incidentie van perioperatieve myocard ischemie varieerde van 14-47% en de 
incidentie van perioperatieve myocard infarct (troponine T afgifte + angina pectoris en/of 
veranderingen op het electrocardiogram) varieerde van 1-26%. Hazard ratio’s, die de 
prognostische waarde van troponine T of I ten opzichte van postoperatieve mortaliteit of van 
postoperatieve cardiale complicaties of mortaliteit weergeven, varieerden van 1.9 tot 9.0. 
 
De prevalentie en prognostische implicaties van gegeneraliseerde atherosclerose, bij 
patiënten die een perifere vaatoperatie hebben ondergaan in het Erasmus Medisch Centrum 
gedurende 1990 en 2008, is beschreven in Hoofdstuk 11. Eén, twee en drie aangedane 
vaatbedden waren aanwezig in respectievelijk 1.369 (46%), 1.249 (43%) en 315 (11%) 
patiënten. Patiënten met twee of drie aangedane vaatbedden hadden een beduidend hoger 
risico op sterfte gedurende lange-termijn follow-up, vergeleken met patiënten met één 
aangedaan vaatbed. 
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In Hoofdstuk 12 is het effect van een subklinisch toegenomen intimamedia dikte van 
de halsslagader (CCA-IMT) geëvalueerd bij patiënten die een vaatoperatie hebben ondergaan 
aan de abdominale aorta of de beenslagader. De optimale voorspellende waarde van de CCA-
IMT ten opzichte van het risico op cardiovasculaire complicaties is berekend met behulp van 
‘receiver-operating characteristic curve’ analyses, op 1.25 mm (sensitiviteit 70%, specificiteit 
80%). Een belangrijk gegeven is dat een verhoogde CCA-IMT onafhankelijk geassocieerd was 
met (i) cardiovasculaire complicaties gedurende de eerste 30-dagen na de ingreep en (ii) 
cardiovasculaire mortaliteit gedurende lange-termijn follow-up. In hoofdstuk 13 is de 
voorspellende waarde van een asymptomatisch verlaagde enkel-arm index (ABI) geevalueerd, 
in relatie tot het postoperatieve resultaat van patiënten die een vaatingreep aan de abdominale 
aorta of de halsslagader ondergingen. Een asymptomatische verlaagde ABI had een 
toegevoegde voorspellende waarde ten opzichte van het ontstaan van myocard schade 
gedurende de operatie en mortaliteit gedurende lange-termijn follow-up, als aanvulling op de 
voorspellende waarde van risico factoren gevat in conventionele cardiale risico modellen, zoals 
de ‘Revised Cardiac Risk’ index. De afzonderlijke en gecombineerde prognostische waarden 
van een asymptomatisch verlaagde ABI (<0.9) of een toename van CCA-IMT (>1.25 mm) is 
geëvalueerd in Hoofdstuk 14, bij een groep van patiënten die een perifere vaatingreep 
ondergingen ter herstel van een aneursyma van de abdominale aorta. Hoewel een 
asymptomatisch verlaagde ABI <0.9 en subklinisch toegenomen CCA-IMT >1.25 
onafhankelijk van elkaar (i) het optreden van cardiale complicaties gedurende de eerste 30 
dagen na de ingreep en (ii) de mortaliteit gedurende lange-termijn follow-up voorspellen, is een 
combinatie van deze twee markers geassocieerd met het hoogste risico op het voorkomen van 
de studie eindpunten.  
 
Hoofdstuk 15 illustreert dat het metabool syndroom, gedefinieerd volgens het 
‘National Cholesterol Education Program’s Adult Treatment Panel III report’,4 veel voorkomt 
in de vaatheelkundige patiënten populatie. Het metabool syndroom werd gediagnosticeerd bij 
41% van de patiënten met stenoserend arterieel vaatlijden en bij 42% van de patiënten met 
aneurysmatisch arterieel vaatlijden. Verder was het metabool syndroom een onafhankelijke 
voorspeller van cardiovasculaire complicaties gedurende de lange-termijn follow-up, bij zowel 
patiënten met stenoserend, als patiënten met aneurysmatisch arterieel vaatlijden. 
 
De relatie tussen (i) anemie voorafgaand aan de operatie en (ii) N-terminale pro-B-
type natriuretisch peptide, en de invloed van deze variabelen op het voorspellen van 
postoperatieve cardiale complicaties bij vaatheelkundige patiënten, wordt geëvalueerd in 
Hoofdstuk 16. De optimale voorspellende waarde van de N-terminale pro-B-type 
natriuretisch peptide ten opzichte van het risico op cardiovasculaire complicaties is berekend 
met behulp van ‘receiver-operating characteristic curve’ analyses, op 350 pg/ml. Anemie werd 
gedefinieerd als serum hemoglobine <13 g/dL voor mannen en <12 g/dL voor vrouwen. 
Zowel de N-terminale pro-B-type natriuretisch peptide als anemie waren onafhankelijk 
geassocieerd met een verhoogd risico op postoperatieve cardiale complicaties. Echter, N-
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terminale pro-B-type natriuretisch peptide had een matige voorspellende waarde bij anemische 
patiënten. 
 
In Hoofdstuk 17 wordt de diagnostische nauwkeurigheid van een nieuwe draagbare echo 
scanner (Aortascan BVI 9600), ontwikkeld voor de automatische detectie van aneurysma’s van 
de abdominale aorta, besproken. Hiertoe werden 150 patiënten eerst gescand met 
conventionele echografie, die als de referentie techniek fungeerde. Een abdominale aorta met 
een diameter ≥30 mm was gedefinieerd als een aneurysma. De BVI 9600 Aortascan 
detecteerde de aorta diameter ≥30 mm met een sensitiviteit van 90%.  
 
 
DEEL III: Preventie en behandeling 
 
In Hoofdstuk 18, worden toonaangevende gerandomiseerde onderzoeken besproken die zich 
richten op het nut van preoperatieve bètablokker therapie of profylactische revascularisatie van 
de coronair vaten voorafgaan aan een perifere vaatingreep. In de afgelopen jaren is er 
uitgebreid gediscussieerd over het nut van bètablokker therapie bij perifere vaatoperaties. 
Belangrijke factoren die van invloed kunnen zijn op de effectiviteit van bètablokker therapie 
zijn het cardiale risicoprofiel van de patiënt en de variaties van behandelingsprotocollen in (i) 
start van bètablokker therapie, (ii) type bètablokker, (iii) startdosering, (iv) aanpassen van de 
dosering op geleide van het hart ritme en (v) de duur van de behandeling, zoals besproken in  
dit hoofdstuk. Profylactische revascularisatie van de coronair vaten, bij patiënten met ≥3 
‘Revised Cardiac Risk’ risicofactoren, verschaft onvoldoende bescherming als aanvulling op de 
behandeling met een bètablokker. Uit retrospectieve data blijkt dat profylactische 
revascularisatie van de coronair vaten het meest effectief is bij patiënten met 1-2 ‘Revised 
Cardiac Risk’ risicofactoren.  
 
Het effect van profylactische revascularisatie van de coronair vaten, bij cardiale hoog-
risico patiënten die een vaatingreep ondergaan, wordt geëvalueerd in Hoofdstuk 19. In deze 
studie zijn patiënten geincludeerd met ≥3 ‘Revised Cardiac Risk’ risicofactoren + uitgebreide 
ischemie geïnduceerd gedurende stress echocardiografie. De patiënten werden gerandomiseerd 
in de volgende groepen: (i) de beste medische behandeling of (ii) preoperatieve coronaire 
revascularisatie + beste medische behandeling. Follow-up percentages van patiënten die niet 
overleden waren, geen myocardinfarct hadden gehad of een coronaire revascularisatie hadden 
ondergaan, waren vergelijkbaar in beide groepen, te weten 49% bij patiënten die de beste 
medische behandeling kregen en 42% bij patiënten die preoperatieve coronaire revascularisatie 
+ beste medische behandeling kregen. Het verbeterde postoperatieve of lange-termijn resultaat 
werd vergeleken met de beste medische behandeling. Profylactische revascularisatie van de 
coronair vaten voorafgaand aan een perifere vaatingreep bij hoog-risico patiënten was niet 
geassocieerd met een verbeterd postoperatieve lange-termijn resultaat, in vergelijking met de 
beste medische behandeling. 
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Hoofdstuk 20 heeft tot doel te beoordelen wat de invloed is, op het ontstaan van 
perioperatieve cardiale complicaties, van (i) verschillende intervallen tussen het plaatsen van 
een stent (bare metal of drug-eluting strent) in één van de coronair vaten en het verrichten van 
niet cardiale chirurgie en (ii) het gebruik van gecombineerde aggregatie trombocyten remming. 
De studie toont aan dat een langer interval tussen stent plaatsing en niet cardiale chirurgie 
gerelateerd is aan een lagere hoeveelheid perioperatieve cardiale complicaties. Verder biedt 
voortzetting van gecombineerde aggregatie trombocyten remming geen volledige bescherming 
tegen perioperatieve cardiale complicaties. Op basis van deze resultaten, moet electieve niet 
cardiale chirurgie bij voorkeur 90 dagen worden uitgesteld na plaatsing van een drug-eluting 
stent en ≥1 jaar na plaatsing van een bare metal stent.  
 
De studie beschreven in Hoofdstuk 21 is verricht om te evalueren wat de invloed is 
van het moment van starten met bètablokker therapie 0 tot 1, >1 tot 4, of >4 weken 
voorafgaand aan een perifere vaatingreep op (i) het preoperatief hartritme en de plasma 
waarden van het hs-CRP en (ii) het postoperatieve resultaat. De resultaten van deze studies 
geven aan dat bètablokker therapie gestart >1 week vóór de operatie leidt tot een lager 
hartritme vóór, en een verbeterde cardiale uitkomst ná de vaatheelkundige ingreep, in 
vergelijking tot een behandeling gestart <1 week vóór de operatie. Er werd geen verlaging van 
median hs-CRP waarden waargenomen, ook niet bij patiënten die >1 week voor de 
vaatingreep behandeld werden met een bètablokker. De resultaten van deze studie 
onderstrepen het belang van adequate controle van de hart frequentie tussen de 60-70 slagen 
per minuut, zoals ook besproken wordt in Hoofdstuk 22. 
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